




CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Proposed Grant Awards

February 21, 2024





CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE
FROM: MICHELLE LE BEAU, PH.D., CHIEF SCIENTIFIC OFFICER
SUBJECT: ACADEMIC RESEARCH FY2024 REVIEW CYCLE 1; AND RECRUITMENT AWARD RECOMMENDATIONS FY2024, CYCLE 24.3, CYCLE 24.4 AND CYCLE 24.5.
DATE: FEBRUARY 21, 2024

The Program Integration Committee (PIC) recommendations for FY2024 review cycle 1 and FY24.1 Recruitment Cycles 24.3, 24.4 and 24.5 include **46 awards** from eight grant mechanisms totaling **\$72,689,675**. The applications are ranked by overall score.

The Scientific Review Council (SRC) recommended 53 applications to the PIC; however, because the SRC recommendations exceeded available funds for the second quarter of 2024, the PIC recommended 46 applications to the Oversight Committee. The seven applications not recommended by the PIC include a Recruitment of Rising Star application RR240021 that was withdrawn by the nominating institution prior to the PIC. Table 1 includes the 46 applications recommended by the PIC to the Oversight Committee.

Table 1:

| Grant Mechanism | SRC and PIC Recommendations | |
|---|-----------------------------|---------------------|
| | Awards | Funding |
| Individual Investigator Research Awards | 27 | \$28,250,155 |
| Individual Investigator Research Awards for Childhood and Adolescent Cancers | 5 | \$6,998,170 |
| Individual Investigator Research Awards for Computational Systems Biology of Cancer | 3 | \$3,599,999 |
| Individual Investigator Research Awards for Clinical Translation | 3 | \$5,921,344 |
| Individual Investigator Research Awards for Prevention and Early Detection | 1 | \$1,920,007 |
| Recruitment of Established Investigators | 2 | \$12,000,000 |
| Recruitment of Rising Stars | 2 | \$8,000,000 |
| Recruitment of First-Time, Tenure Track Faculty Members | 3 | \$6,000,000 |
| Total | 46 | \$72,689,675 |

Program Priorities Addressed:

The applications proposed to the Program Integration Committee for funding address the following Academic Research Program Priorities: recruitment of outstanding cancer researchers to Texas, a broad range of innovative, investigator-initiated research projects; computational systems biology and analytic methods, childhood and adolescent cancers, drug discovery, access to innovative clinical trials, and hepatocellular cancer as displayed in Table 2 and Attachment 1.

Table 2

| Program Priorities Addressed by Grant Recommendations[#] | | |
|---|---|-----------------|
| # Awards* | Program Priorities | Funding* |
| 7 | Recruitment of outstanding cancer researchers to Texas | \$26,000,000 |
| 39 | A broad range of innovative, investigator-initiated research projects | \$46,689,675 |
| 5 | Computational Systems Biology and Analytic Methods | \$9,200,000 |
| 7 | Childhood Cancers | \$10,048,170 |
| 2 | Hepatocellular Cancer | \$2,099,385 |
| 3 | Drug Discovery | \$13,050,000 |
| 4 | Expansion of novel clinical trials | \$5,049,682 |
| [#] Table 2 lists the 46 grant awards recommended by Academic Research. [*] Some grant awards address more than one program priority and are double counted. | | |

1. INDIVIDUAL INVESTIGATOR RESEARCH AWARDS (RFA R-24. IIRA) SLATE

Peer Review Recommendations:

The Scientific Review Council recommended 32 Individual Investigator Research Awards (IIRA) totaling \$33,340,622. Due to insufficient funds the Academic Research Program recommends funding 27 IIRAs with scores of 2.6 or better totaling \$28,250,155, as displayed in Table 3.

Purpose of Individual Investigator Research Awards:

Supports applications for innovative research projects addressing critically important questions that will significantly advance knowledge of the causes, prevention, and/or treatment of cancer. Areas of interest include laboratory research, translational studies, and/or clinical investigations. Competitive renewal applications are accepted.

Individual Investigator Research Awards Funding Levels:

Up to \$350,000 per year. Exceptions permitted if extremely well justified; maximum duration: 3 years.

Table 3:

| FY2024 Cycle 1: Recommended IIRA Applications | | | | | | | |
|---|----------|-----------|-------|--|-----------------------|--|-------------|
| Rank | ID | Award RFA | Score | Application Title | PI | PI Organization | Rec. Budget |
| 1 | RP240068 | IIRA | 1.0 | Understanding the Mechanism of Linker Histone Mutations in Malignancy | Soshnev, Alexey | The University of Texas at San Antonio | \$997,770 |
| 2 | RP240291 | IIRA | 1.6 | Targeting MYCN disruption of the molecular clock and tumor metabolism in neuroblastoma oncogenesis. | Barbieri, Eveline | Baylor College of Medicine | \$1,050,000 |
| 3 | RP240289 | IIRA | 1.6 | Real-time, label-free, micro HSI device and transformer-based attention networks for oral cancer imaging | Fei, Baowei | The University of Texas at Dallas | \$1,049,806 |
| 4 | RP240125 | IIRA | 1.8 | Immune-Related Determinants of HPV-Associated Oropharyngeal Cancer Outcomes | Li, Guojun | The University of Texas M. D. Anderson Cancer Center | \$1,049,726 |
| 5 | RP240061 | IIRA | 1.8 | Deciphering Iron Redox Cycles in Ferroptosis-based Cancer Therapy | Lu, Yi | The University of Texas at Austin | \$1,044,608 |
| 6 | RP240091 | IIRA | 1.9 | High resolution high sensitivity photoacoustic imaging molecular guided brain tumor surgery with pilot clinical deployment | Valdes Quevedo, Pablo | The University of Texas Medical Branch at Galveston | \$1,044,967 |
| 7 | RP240095 | IIRA | 2.0 | Targeting chitinase-3-like-1 as a novel therapy for hepatocellular carcinoma | Ju, Cynthia | The University of Texas Health Science Center at Houston | \$1,049,388 |
| 8 | RP240035 | IIRA | 2.0 | Harnessing the metabolic dependencies of mitochondrial NADK2 as a therapeutic strategy for lung cancer | Hoxhaj, Gerta | The University of Texas Southwestern Medical Center | \$1,050,000 |
| 9 | RP240225 | IIRA | 2.0 | PARP16-mediated Ribosome MARYlation and Translation Control in Ovarian Cancer | Kraus, W. Lee | The University of Texas Southwestern Medical Center | \$1,049,743 |
| 10 | RP240259 | IIRA | 2.0 | Targeting Cancer-associated Lactobacillus iners to improve response to cancer therapy | Colbert, Lauren | MDACC/BLI | \$1,049,427 |

| | | | | | | | |
|----|----------|------|-----|---|-------------------|--|-------------|
| 11 | RP240119 | IIRA | 2.0 | Integrating proteolysis-targeting capability into antibodies to augment therapeutic efficacy | Liu, Qingyun | The University of Texas Health Science Center at Houston | \$1,050,000 |
| 12 | RP240326 | IIRA | 2.0 | Translation of gut commensal bacteria peptidoglycan remodeling pathway for chimeric antigen receptor T-cell therapy | Saini, Neeraj | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 13 | RP240311 | IIRA | 2.0 | Treatment planning of ADC therapy for ovarian cancer with molecular photoacoustic-ultrasonic imaging | Bouchard, Richard | The University of Texas M. D. Anderson Cancer Center | \$1,049,859 |
| 14 | RP240117 | IIRA | 2.0 | Identify radiopathomics markers to guide immunotherapy for non-small cell lung cancer | Wu, Jia | The University of Texas M. D. Anderson Cancer Center | \$1,049,906 |
| 15 | RP240183 | IIRA | 2.1 | Restoring TREM2-Dependent Efferocytosis to Inhibit Obesity-Induced Liver Inflammation and Cancer Development | Liang, Shuang | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 16 | RP240263 | IIRA | 2.1 | Identifying the Biological Determinants of Aggressive Meningioma | Patel, Akash | Baylor College of Medicine | \$1,049,370 |
| 17 | RP240392 | IIRA | 2.1 | Identifying Tumor Specific Vulnerabilities in Appendiceal Adenocarcinoma: A Systems Approach | Shen, John Paul | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 18 | RP240133 | IIRA | 2.1 | Modulation of blood-spinal cord barrier for tumor treatment | Qin, Zhenpeng | The University of Texas at Dallas | \$1,050,000 |
| 19 | RP240127 | IIRA | 2.2 | Transposon Restriction, Tumor Suppression and p53 | Abrams, John | The University of Texas Southwestern Medical Center | \$1,039,356 |
| 20 | RP240072 | IIRA | 2.2 | Dissection of CAMKK2's Tumor Cell-intrinsic and -extrinsic Roles in Prostate Cancer | Frigo, Daniel | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 21 | RP240288 | IIRA | 2.3 | Epigenetic mechanism and targeting during response to BRAFi/anti-EGFR therapy in BRAF-mutant colorectal cancers | Kopetz, Scott | The University of Texas M. D. Anderson Cancer Center | \$1,043,909 |

| | | | | | | | |
|----|----------|------|-----|---|-------------------|--|-------------|
| 22 | RP240380 | IIRA | 2.3 | Clonal hematopoiesis for improving lung cancer risk assessment | Cheng, Chao | Baylor College of Medicine | \$1,040,316 |
| 23 | RP240214 | IIRA | 2.5 | Immunoprevention of Breast Cancer Brain Metastasis by Special Dendritic Cell-derived Extracellular Vesicles | Yu, Dihua | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 24 | RP240120 | IIRA | 2.5 | JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC | Zhang, Qing | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 25 | RP240287 | IIRA | 2.5 | Investigating the Impact of Interferon Gamma Signaling on Therapeutic Resistance in Acute Myeloid Leukemia | Abbas, Hussein | The University of Texas M. D. Anderson Cancer Center | \$1,042,256 |
| 26 | RP240104 | IIRA | 2.6 | Characterization and optimization of novel allosteric KRAS inhibitors | Gorfe, Alemayehu | The University of Texas Health Science Center at Houston | \$1,050,000 |
| 27 | RP240320 | IIRA | 2.6 | Benzothiazepines as first-in-class inhibitors for the ribogenesis factor NVL and evaluation in preclinical colorectal cancer models | De Brabander, Jef | The University of Texas Southwestern Medical Center | \$1,049,754 |

2. Individual Investigator Research Awards for Cancer in Children and Adolescents (RFA R-24.1 IIRACCA) Slate

Peer Review Recommendations:

The Scientific Review Council recommended 6 Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA), totaling \$8,398,170. Due to insufficient funds, the Academic Research Program recommends funding 5 IIRACAs totaling \$6,998,170.

Purpose of Individual Investigator Research Awards for Cancer in Children and Adolescents:

Supports applications for innovative research projects addressing questions that will advance knowledge of the causes, prevention, progression, detection, or treatment of cancer in children and adolescents. Laboratory, clinical, or population-based studies are all acceptable. CPRIT expects the outcome of the research to reduce the incidence, morbidity, or mortality from cancer

in children and/or adolescents in the near or long term. Competitive renewal applications accepted.

Individual Investigator Research Awards for Cancer in Children and Adolescents Funding Levels:

Up to \$350,000 per year. Applicants that plan on conducting a clinical trial as part of the project may request up to \$150,000 in additional total costs. Exceptions permitted if extremely well justified; maximum duration: 4 years.

Table 4

| FY2024 Cycle 1: Recommended IIRACCA Applications | | | | | | | |
|--|----------|-----------|-------|---|-------------------|--|-------------|
| Rank | ID | Award RFA | Score | Application Title | PI | PI Organization | Rec. Budget |
| 1 | RP240401 | IIRACCA | 1.9 | Lead Optimization, Target Engagement, and Efficacy Studies of Locally Bioavailable COX-2 inhibitors for Preventing Colon Cancer Progression in FAP Children | Hu, Ming | University of Houston | \$1,400,000 |
| 2 | RP240272 | IIRACCA | 1.9 | The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy for DSRCT | Ludwig, Joseph | The University of Texas M. D. Anderson Cancer Center | \$1,398,788 |
| 3 | RP240054 | IIRACCA | 2.0 | Myeloid Support of Refractory and Aggressive T-ALL at Distinct Tumor Sites | Ehrlich, Lauren | The University of Texas at Austin | \$1,400,000 |
| 4 | RP240237 | IIRACCA | 2.0 | The Role of EWSR1-FLI1-CENP-A Signaling in Chemoresistance in Ewing Sarcoma | Kitagawa, Katsumi | The University of Texas Health Science Center at San Antonio | \$1,400,000 |
| 5 | RP240143 | IIRACCA | 2.6 | Leveraging Passport for Care in a Telehealth Framework to Improve Equitable Access to Survivorship Services | Gramatges, Maria | Baylor College of Medicine | \$1,399,382 |

**3. Individual Investigator Research Awards for Computational Systems
Biology of Cancer
(RFA R-24.1 IIRACSBC) Slate**

Peer Review Recommendations:

The Scientific Review Council recommended 3 Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC), totaling \$3,599,999, as displayed in Table 5.

Purpose of Individual Investigator Research Awards for Computational Systems Biology of Cancer:

Supports applications for projects that integrate innovative computational and mathematical approaches with experimental cancer biology to address challenging questions that will advance current knowledge in etiology, biology, progression, treatment, metastasis, and immunology of cancer.

Individual Investigator Research Awards for Computational Systems Biology of Cancer Funding Levels:

Up to a maximum of \$400,000 per year. Exceptions permitted if extremely well justified; maximum duration: 3 years.

Table 5

| FY2024 Cycle 1: Recommended IIRACSBC Applications | | | | | | | |
|---|----------|-----------|-------|---|---------------|--|-------------|
| Rank | ID | Award RFA | Score | Application Title | PI | PI Organization | Rec. Budget |
| 1 | RP240293 | IIRACSBC | 1.0 | Therapeutic Vulnerabilities and Predictors of Response to Chemo(immuno)therapy in Patients With High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC) | Korkut, Anil | The University of Texas M. D. Anderson Cancer Center | \$1,199,999 |
| 2 | RP240137 | IIRACSBC | 1.1 | Charting TCR-Tumor Antigen Interactions to Foster Novel Immunotherapeutic Approaches for Triple-Negative Breast Cancer | Zhang, Bing | Baylor College of Medicine | \$1,200,000 |
| 3 | RP240131 | IIRACSBC | 2.3 | Computational Methods for CRISPR-Based Lineage Tracing Systems | Liu, Zhandong | Baylor College of Medicine | \$1,200,000 |

4. Individual Investigator Research Awards for Clinical Translation (RFA R-24.1 IIRACT) SLATE

Peer Review Recommendations:

The Scientific Review Council recommended 3 Individual Investigator Research Awards for Clinical Translation (IIRACT) totaling \$5,921,344, as displayed in Table 6.

Purpose of Individual Investigator Research Awards for Clinical Translation:

Supports applications that propose innovative cancer clinical studies that are hypothesis driven and involve patients enrolled prospectively on a clinical trial. Areas of interest include clinical studies of new or repurposed drugs, hormonal therapies, immune therapies, surgery, radiation therapy, stem cell transplantation, combinations of interventions, or therapeutic devices. Clinical trial must be planned to begin when contract is awarded.

Individual Investigator Research Awards for Clinical Translation Funding Levels:

Up to \$500,000 per year. Maximum duration: 4 years. Exceptions permitted if extremely well justified.

Table 6

| FY2024 Cycle 1: Recommended IIRACT Applications | | | | | | | |
|--|-----------|------------------|--------------|--|------------------|---|--------------------|
| Rank | ID | Award RFA | Score | Application Title | PI | PI Organization | Rec. Budget |
| 1 | RP240075 | IIRACT | 1.5 | Combination Therapy Using ATRA and Carfilzomib to Treat Proteasome Inhibitor Refractory Multiple Myeloma | Yi, Qing | The Methodist Hospital Research Institute | \$1,921,388 |
| 2 | RP240184 | IIRACT | 1.9 | Maximizing Antitumor Immunity Through Simultaneous Activation of the Innate and Adaptive Immune System | Hannan, Raquibul | The University of Texas Southwestern Medical Center | \$1,999,993 |
| 3 | RP240233 | IIRACT | 2.1 | Toward Nonoperative Management of Early-Stage ER-Positive Breast Cancer | Rahimi, Asal | The University of Texas Southwestern Medical Center | \$1,999,963 |

**5. Individual Investigator Research Awards for Prevention and Early Detection
(RFA R-24.1 IIRAP) SLATE**

Peer Review Recommendations:

The Scientific Review Council recommended one Individual Investigator Research Award for Prevention and Early Detection, totaling \$1,920,007 as displayed in Table 7. The Academic Research Program recommends funding this application with a score of 2.8, as it was the only IIRAP recommended based on its scientific merit, and priority of the proposed research, namely a randomized controlled trial to test alternative methods for cervical cancer screening, such as self-collection methods in a high-risk Latinx population living along the US-Mexico border.

Purpose of Individual Investigator Research Awards for Prevention and Early Detection:

Supports applications which propose clinical and population-based projects designed to develop effective prevention and early detection interventions to reduce cancer risk, mortality, and morbidity among Texans. Projects that propose such research collaborations with existing CPRIT Prevention Program awardees including the CPRIT funded [*Texas Collaborative Center for Hepatocellular Cancer*](#) are strongly encouraged.

Individual Investigator Research Awards for Prevention and Early Detection Funding Levels:

Up to \$400,000 per year. Exceptions permitted if extremely well justified; maximum duration: 5 years.

Table 7

| FY2024 Cycle 1: Recommended IIRAP Application | | | | | | | |
|---|----------|-----------|-------|--|-------------------------|-----------------------------------|-------------|
| Rank | ID | Award RFA | Score | Application Title | PI | PI Organization | Rec. Budget |
| 1 | RP240208 | IIRAP | 2.8 | Unidos Contra el VPH: Screening Accuracy, Preference, and Uptake of HPV Self-Sampling Among Latinxs Along the US-Mexico Border | Calderon -Mora, Jessica | The University of Texas at Austin | \$1,920,007 |

6. RECRUITMENT OF ESTABLISHED INVESTIGATORS SLATE ***FY24.1, Cycles 24.3, 24.4 and 24.5***

Peer Review Recommendations

The applications were evaluated and scored by the Scientific Review Council (SRC) to determine the candidates' potential to make a significant contribution to the cancer research program of the nominating institution. Review criteria focused on the overall impression of the candidate and his/her potential for continued superb performance as a cancer researcher, scientific merit of the proposed research program, his/her long-term impact on the field of cancer research, and strength of the institutional commitment to the candidate.

Purpose of Recruitment of Established Investigators Awards:

The aim is to recruit outstanding senior research faculty with distinguished professional careers and established cancer research programs to academic institutions in Texas.

Funding levels for Recruitment of Established Investigators Awards:

Up to \$6 million over a period of 5 years.

Recommended Awards:

Three Recruitment of Established Investigators grant applications were submitted and two were recommended by the Scientific Review Council for an Established Investigators Award.

RR240030

Candidate: Anna Malkova, Ph.D.

Funding Mechanism: Recruitment of Established Investigator

Applicant Organization: The University of Texas Health Science Center at San Antonio.

Original Organization of Nominee: University of Iowa

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.3

Recommended Total Budget Award and Duration: \$6,000,000

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas; Drug Discovery and Development

Description:

The University of Texas Health Science Center at San Antonio (UTHSA) is nominating Anna Malkova, PhD, for the CPRIT Established Investigator Award, and appointment as Professor of Biochemistry and Structural Biology with tenure, and the Mays Family Endowed Chair in DNA Repair Genetics, and membership in the Mays Cancer Center. Dr. Malkova leads an internationally acclaimed research program examining the mechanisms and genetics of DNA repair, with a particular focus on the pathways of DNA double-strand break repair and telomere maintenance.

During her post-doctoral fellowship, Dr. Malkova discovered Break-Induced Replication (BIR) - a unique form of recombination-dependent conservative DNA replication that has since become an entire field of study on its own. Over the subsequent two decades, Dr. Malkova has led a

multi-grant funded research program to determine the mechanistic underpinnings of DNA damage repair pathways, particularly BIR, and how dysfunction in these pathways leads to the accumulation of genetic mutations and large-scale gross chromosome rearrangements that are a hallmark of cancer cells.

DNA breaks are induced continuously by agents in our environment and by anti-cancer drugs. Although some DNA break repair pathways are accurate, others such as the BIR pathway are error prone. Dr. Malkova proposes to expand her exceptionally impactful studies to elucidate the mechanism of BIR in both yeast and human cells and to determine how BIR contributes to destabilization of the genome fostering cancer development and progression. Specifically, she will examine the hypothesis that a massive burst of genomic instability during the repair of DNA breaks by the error-prone BIR pathway instigates oncogenic transformation of cells. Through collaborations with colleagues at UTHSA and Baylor College of Medicine, she will identify the entire repertoire of core BIR protein factors in humans, and will use state-of-the-art genetic, biochemical, and structural methods to unravel the mechanistic intricacies of BIR.

In the second phase of her studies, she will test hypotheses regarding the origin and nature of BIR mutation clusters created by APOBEC3 enzymes – cytidine deaminases that create common mutations in the human genome seen in cancer - and the associated mechanisms by which chromosome rearrangements arise during BIR. These studies have high potential to define mutational signatures to serve as a useful biomarker in stratifying patients for specific therapies that target defects in DNA repair, DNA damage checkpoints, and the BIR mechanism itself. Finally, working with the CPRIT-supported Center for Innovative Drug Discovery at UTHSA, she proposes to develop chemical compounds that target key enzymatic components of BIR as chemical biology tools and that could also be developed into novel cancer therapeutics. Together, these multidisciplinary and highly collaborative approaches will lead to elucidation of conserved mechanisms of BIR and will generate actionable information to help lessen the cancer burden in Texas.

RR2440007

Candidate: Xiling Shen, PhD

Funding Mechanism: Recruitment of Established Investigator

Applicant Organization: The University of Texas M. D. Anderson Cancer Center

Original Organization of Nominee: Terasaki Institute

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.3

Recommended Total Budget Award and Duration: \$6,000,000

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas; Hepatocellular Cancer; Computational Systems Biology; Drug Discovery and Development

Description:

The University of Texas MD Anderson Cancer Center (MDACC) is nominating Xiling Shen, PhD, for the CPRIT Established Investigator Award, and appointment as Professor in the Department of Gastrointestinal Medical Oncology at MDACC. Dr. Shen is an exceptional computer scientist and bioengineer focused on interdisciplinary, translational research and academic entrepreneurship that are transforming the cancer field.

Dr. Shen's lab integrates engineering, computational, and biological techniques to study cancer, stem cells, microbiota, metabolism, and the nervous system in the gut. His keen abilities to integrate technical strategies and advantages seamlessly into multidisciplinary basic and clinical work has been instrumental in initiating several translational clinical trials in precision therapy. Examples of his seminal discoveries include (1) demonstrating the role of micro-RNA in normal and cancer stem cell division asymmetry producing one stem cell and one non-stem progenitor cell (Bu et al., *Cell Stem Cell*, 2012, 2016); (2) recognition of the importance of metabolic reprogramming and fructose metabolism in cancer metastasis (Bu et al., *Cell Metabolism*, 2018); and (3) the recognition that KRAS mutations in tumors induces epigenetic and cell fate reprogramming (Murthy et al., *Development Cell*, 2022).

At MDACC, Dr. Shen's interdisciplinary lab will combine their expertise in systems biology and technology development to address several critically unmet needs in cancer research and care, including treatment of minimal residual disease, refractory colorectal cancer (rCRC), hepatocellular carcinoma (HCC), cancer-associated cachexia (CAC), and the cancer microbiome. In Aim 1, he will test the hypothesis that functional drug screens with patient avatars using tumor micro-organosphere (MOS) to identify optimal combinations of treatment is capable of guiding treatment options and providing clinical benefit. The team will develop guided precision oncology for patients with minimal residual disease, rCRC, and HCC and develop a barcode technology to explore the impact of intra-tumoral heterogeneity. The platform has the potential to enable clinicians to find personalized treatments for patients from populations that are underrepresented in clinical trials and have poorer outcomes.

In Aim 2, he will test the hypothesis that neuromodulation of the gut-brain axis will deter cancer-associated cachexia (muscle loss). Based on his discovery that cachexia-inducing tumors cause dysregulation of the vagal nerve and vagal blocking reverses cachexia symptoms in rodent models, the team will test a flexible transcutaneous vagal blocker on a large animal model for cancer and, if successful, design and conduct an investigator-initiated clinical trial in patients. In Aim 3, he will seek to elucidate the role of the microbiome in cancer progression and treatment response by building a cancer-microbiome interactome using statistical "decontamination" methods. Previously, Dr. Shen designed a groundbreaking statistical method to analyze the prevalence of microbial species across sample types. The team will apply this method to develop a web-based microbe set enrichment analysis (MSEA) toolset for the scientific community to investigate the interactions between cancer and microbial cells by mining public datasets such as The Cancer Genome Atlas (TCGA).

Dr. Shen's research aims to improve cancer care via (1) helping clinicians select the right treatment for patients; (2) developing new classes of therapies; and (3) inventing new cancer systems biology tools.

7. RECRUITMENT OF RISING STARS SLATE

FY24.1, Cycles 24.3, 24.4 and 24.5

Peer Review Recommendations

The applications were evaluated and scored by the Scientific Review Council (SRC) to determine the candidates' potential to make a significant contribution to the cancer research program of the nominating institution. Review criteria focused on the overall impression of the candidate and his/her potential for continued superb performance as a cancer researcher, scientific merit of the proposed research program, his/her long-term contribution to and impact on the field of cancer research, and strength of the institutional commitment to the candidate.

Purpose of Recruitment of Rising Stars Awards:

The aim is to recruit outstanding early-stage investigators to Texas, who have demonstrated the promise for continued and enhanced contributions to the field of cancer research.

Funding levels for Recruitment of Rising Stars Awards:

Up to \$4 million over a period of 5 years.

Recommended Awards:

Five Recruitment of Rising Stars grant applications were submitted and three were recommended by the Scientific Review Council for an award. One of the recommended applications RR240021 was withdrawn by the Institution prior to the PIC meeting.

RR240019

Candidate: David Sarlah, PhD

Funding Mechanism: Recruitment of Rising Stars

Applicant Organization: Rice University

Original Organization of Nominee: University of Illinois

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **1.0**

Recommended Total Budget Award and Duration: \$4,000,000

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas

Description:

David Sarlah, PhD has been nominated by Rice University for a CPRIT Rising Star Scholar Award, and appointment as Associate Professor in the Department of Chemistry. He is currently an Associate Professor in the Chemistry Department at the University of Illinois, Urbana-Champaign, and is an internationally recognized leader with groundbreaking discoveries in organic synthesis that have enabled advances in chemical biology, material science, and medicine. He has developed methodologies for synthesizing several potent anticancer natural products, such as pancratistatin, lycoricidine, and narciclasine, as well as several analogs, and has determined their potencies and metabolic properties. His most recent research efforts include the use of cutting-edge informatics tools and artificial intelligence (machine learning) to facilitate the discovery of novel and more efficient reactions.

Compounds from nature (natural products) continue to be one of the most important sources of new lead compounds in the discovery of medicinal agents. However, their structural complexity and limited availability are often obstacles preventing their clinical development. As a synthetic organic chemist situated at the interface of chemistry and biology, Dr. Sarlah proposes three Aims focusing on: (1) mechanistic investigation of complex anticancer terpenoids; (2) synthesis and medicinal chemistry of a promising anticancer natural product; and (3) investigation of the role of the conjugation of carbohydrate molecules on anticancer activities of cytotoxic alkaloids, employing state-of-the-art, top-down approaches, ranging from proteomics to forward chemical genetics and transcriptomics.

Dr. Sarlah envisions his research program to be an iterative process, whereby biological studies can inform future chemical synthesis. Thus, in collaboration with experts in chemical biology and anticancer medicinal chemistry, he is positioned to evaluate newly synthesized compounds rapidly, and to elucidate their precise modes of action in relevant tumor models. This information in turn can aid in the evolutionary design of new drugs inspired by nature with capabilities beyond those of the parent natural products themselves. Dr. Sarlah has already established a number of collaborations with colleagues (including many CPRIT Scholars and grantees) at Rice, TMC, and elsewhere in the US, ensuring that he will advance his compounds to clinical testing rapidly.

RR240015**Candidate:** Stephan Gloeggler, PhD**Funding Mechanism:** Recruitment of Rising Stars**Applicant Organization:** The University of Texas Southwestern Medical Center**Original Organization of Nominee:** Max Planck for Interdisciplinary Sciences**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **2.0****Recommended Total Budget Award and Duration:** \$4,000,000**CPRIT Priorities Addressed:** Recruitment of outstanding cancer researchers to Texas**Description:**

The University of Texas Southwestern Medical Center has nominated Stefan Gloeggler, PhD for a CPRIT Rising Star Scholar Award, appointment as a Professor in the Advanced Imaging Research Center (AIRC) and membership in the Simmons Comprehensive Cancer Center. Dr. Gloeggler is currently an Associate Professor at the Max Planck Institute of Multidisciplinary Sciences in Goettingen, Germany, and is an internationally recognized leader in the field of hyperpolarized MRI contrast agents and polarizer technology development, and molecular imaging technologies for cancer imaging. (Note: hyperpolarized MRI using injected carbon-13 is an example of a sensitive medical imaging technique for probing perfusion and metabolism).

In Texas, Dr. Gloeggler proposes to use a multi-spectral approach to probe multiple aspects of cancer metabolism simultaneously, thus enhancing the specificity and sensitivity of hyperpolarized MRI and allowing him to distinguish different phenotypes of brain cancer and visualize changes induced by cancer therapy or disease progression at very early stages. He will also seek to develop methods for continuous delivery of hyperpolarized contrast agents with long relaxation times to achieve full organ coverage and facilitate routine assessment of metabolic rates in normal and tumor tissue in vivo. Once he has obtained preclinical proof-of-principle that

early treatment responses can be detected using this approach, he intends to seek investigational new drug (IND) approval for human clinical trials and, ultimately, seek FDA approval of a clinical scale polarizer. The tracers developed by this research have the potential to improve patient outcomes by enabling the measurement of early responses of brain tumors to treatment and assessment of treatment efficacy, the rapid identification of tumors that have a high recurrence rate, and the selection of therapeutic strategies. Although initially targeted to brain cancer, his molecular imaging approaches can also be extended to other types of cancer, including breast and prostate cancer, and may ultimately be developed into a cancer screening tool.

8. RECRUITMENT OF FIRST-TIME TENURE TRACK FACULTY MEMBERS FY24.1 Cycles 24.3, 24.4 and 24.5

Peer Review Recommendations

The applications were evaluated and scored by the Scientific Review Council to determine the candidates' potential to make a significant contribution to the cancer research program of the nominating institution. Review criteria focused on the overall impression of the candidate and his/her potential for continued superb performance as a cancer researcher, his/her scientific merit of the proposed research program, his/her long-term contribution to and impact on the field of cancer research, and strength of the institutional commitment to the candidate.

Purpose of First-Time Tenure Track Faculty Recruitment

The aim is to recruit and support very promising emerging investigators, pursuing their first faculty appointment in Texas, who can make outstanding contributions to the field of cancer research.

Funding levels for First-Time Tenure Track Faculty Members Recruitment

Up to \$2 million over a period of up to 5 years.

Recommended Projects:

Four Recruitment of First-Time Tenure Track Faculty Members grant applications were submitted and three were recommended by the Scientific Review Council for an award.

Below is a listing of the candidates with their associated expertise:

RR240013

Candidate: Kevin Mark, PhD

Funding Mechanism: Recruitment of First-Time Tenure Track Faculty Member

Applicant Organization: The University of Texas Southwestern Medical Center

Original Organization of Nominee: University of California, Berkeley

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.2

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas

Description:

The University of Texas Southwestern Medical Center has nominated Dr. Kevin Mark for a CPRIT First-Time, Tenure-Track Faculty Member Award. Dr. Mark is being recruited as an Assistant Professor in the Department of Cell Biology. Dr. Mark, who is nearing the end of his postdoctoral training at the University of California, Berkeley, is a well-trained cancer biologist, with a strong background in stem cell biology, gene regulation, and protein biochemistry, and has been remarkably productive with multiple publications in the top-tier journals.

Many cellular processes rely on protein complexes assembled from multiple proteins, or subunits, allowing cells to respond rapidly to external signals by changing the composition of a complex to modulate its function for different needs. Through a process called ubiquitylation, cells can target specific proteins for rapid elimination, thereby regulating the composition of protein complexes, enabling normal functions as well as an expedited response to environmental stress or other stimuli. Errors in protein degradation can promote tumor development.

During his post-doctoral fellowship, Dr. Mark discovered a new function for a tumor-suppressing ubiquitin ligase, demonstrating that it maintains stem cell pluripotency and that it controls cell identity by a novel mechanism. He found the ligase normally facilitates the degradation of orphan oncogenic transcription factor subunits during stress. In tumors, this pathway can be hijacked, enabling unchecked growth, providing new insight into the long-standing mystery of why tumor cells proliferate even when they encounter adverse growth conditions.

Dr. Mark now proposes to determine how ubiquitylation regulates the multi-subunit protein complexes involved in gene expression and other critical cellular functions. With support from the CPRIT award, his research program seeks to (1) determine how orphan protein ubiquitylation controls chromatin remodeling enzymes to regulate gene expression and promote liver tumorigenesis; (2) determine how the cellular stress response is regulated by orphan transcription factor turnover and how this impacts oncogenesis in the liver; and (3) develop small molecule modulators of ubiquitin ligases as a therapeutic approach for liver cancer. The work proposed here will advance our understanding of how protein degradation processes regulate gene expression and how mutations affecting these pathways contribute to cancer. Moreover, Dr. Mark may identify novel strategies for cancer therapy through the development of small molecules that can inhibit or enhance the interaction of ubiquitin ligases with their substrates.

RR240016

Candidate: Yu Luan, PhD

Funding Mechanism: Recruitment of First-Time Tenure Track Faculty Member

Applicant Organization: The University of Texas Health Science Center at San Antonio

Original Organization of Nominee: Northwestern University

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.3

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas; Computational Biology; Childhood Cancers (ALL)

Description:

Yu Luan, PhD, has been nominated by the University of Texas Health Science Center at San Antonio for a CPRIT First-Time, Tenure-Track Faculty Member Award and appointment as an Assistant Professor on the tenure-track in the Department of Cell Systems and Anatomy, with associate membership in the Greehey Children's Cancer Research Institute. Not only is Dr. Luan an expert in computational analysis of large data sets, he is also a superb programmer in machine learning, which permits his application of machine learning to large cancer genetic data sets, revealing unique insights into how cancer develops and progresses.

Dr. Luan's research addresses acute lymphoblastic leukemia (ALL), one of the most common pediatric cancers in the United States. Philadelphia chromosome-like ALL (Ph-like ALL) is a major subtype of ALL, and is characterized by poor treatment outcomes and a high relapse rate. Ph-like ALL is more prevalent among children of Hispanic heritage and, thus, poses a major health disparity in South Texas. Dr. Luan identified a novel functional genetic variant that likely plays a key role in leukemogenesis, and may explain the increased frequency of ALL in Hispanic children. Specifically, he identified an intron variant (risk A allele) in the *GATA3* gene which encodes a pioneer transcription factor that regulates blood cell development. He found that binding of the NFIC transcription factor to the promoter of the *GATA3* gene increases *GATA3* expression, which in turn reshapes the global chromatin accessibility landscape and 3D chromatin dynamics, likely promoting the genesis and/or survival of leukemia stem cells. Surprisingly, the inherited mutant risk allele is over-represented (more common) in Hispanic patients with Ph-like ALL.

Dr. Luan will apply state-of-the-art genomic analytical tools to delineate the mechanisms by which oncogenic 3D chromatin reorganization mediates the pathogenesis and relapse of pediatric Ph-like ALL. He will conduct a holistic analysis of the variant *GATA3*-dependent alterations in 3D chromatin landscape in the malignant cells from Ph-like ALL patients at the time of disease diagnosis and relapse. He will then test the hypotheses that mutant *GATA3* drives Ph-like ALL pathogenesis in cell and animal models, by mediating changes in 3D chromatin structure and function to help shape the tumor microenvironment and influence the characteristic poor prognosis and frequent disease relapse. Dr. Luan's long-term goals are to elucidate the molecular etiology of Ph-like ALL, to identify novel therapeutic targets for this disease, and to develop therapeutic regimens to improve not only treatment outcomes, but also to minimize relapse.

RR240027**Candidate:** Vishnu Dileep, PhD**Funding Mechanism:** Recruitment of First-Time Tenure Track Faculty Member**Applicant Organization:** Baylor College of Medicine**Original Organization of Nominee:** MIT**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.4**Recommended Total Budget Award and Duration:** \$2,000,000.**CPRIT Priorities Addressed:** Recruitment of outstanding cancer researchers to Texas

Description:

Vishnu Dileep, PhD is being recruited by the Baylor College of Medicine, and is nominated for a CPRIT First-Time, Tenure-Track Faculty Member Award. Dr. Dileep will be appointed as an Assistant Professor in the Department of Molecular and Human Genetics, and as a member of the Dan L. Duncan Comprehensive Cancer Center. Dr. Dileep is currently a postdoctoral fellow in Dr. Li-Huei Tsai's laboratory in the Picower Institute for Learning and Memory at MIT. He is an extremely well-trained and accomplished junior scientist with a stellar publication record, who has already been recognized by the National Institutes of Health with a prestigious K99/R00 Pathway to Independence Award.

Dr. Dileep proposes to combine his expertise in cancer genomics and neuroscience to elucidate the causes of 'chemobrain'. Chemotherapy-induced cognitive impairment, often referred to as 'chemobrain' or 'chemofog' is a common consequence of cancer treatments, leading to persistent cognitive challenges like memory and attention problems even after treatment ends. Despite its prevalence, there are no effective treatment options. The primary roadblock to developing strategies to prevent or cure chemobrain is a significant lack of understanding about how chemotherapy affects brain cells at a molecular level. Several chemotherapy drugs and radiation treatments eliminate cancer cells by causing DNA damage. But these treatments may also inadvertently damage the DNA of healthy cells, including neurons and other brain cells. Yet, the comprehensive effects of chemotherapy drugs on the genome and epigenome (chemical and structural DNA modifications regulating gene activity) and 3D organization of the genome in brain cells are unknown.


Dr. Dileep hypothesizes that DNA damage causes both cell-intrinsic and cell-extrinsic changes in the genome and epigenome of brain cells contributing to chemobrain. Using cutting-edge technologies that measure genome organization, functional assays, mouse and in vitro models of chemobrain, and human samples, he will test this hypothesis by pursuing three major aims: (1) To test whether chemotherapy-induced DNA-double strand breaks disrupt the neuronal genome organization and function; (2) To decipher the impact of various types of DNA damage on the transcriptional state and epigenome of brain cell types in chemotherapy; and (3) To delineate the role of 3D genome organization in abnormal activation of glial cells following chemotherapy. This innovative approach has the potential to uncover a new paradigm in understanding chemobrain through the lens of genome organization, and may open new avenues for therapeutic intervention.

Attachment #1

***Academic Research Program Priorities Addressed by Recommended Awards**

(*Some grant awards address more than one program priority and are double counted.)

| Scale | Recruitment of outstanding cancer researchers to Texas | A broad range of innovative, investigator-initiated research projects | Access to innovative clinical trials | Childhood and Adolescent Cancers | Drug Discovery | Computational biology and analytic methods | Hepatocellular Cancer |
|-------|--|---|--------------------------------------|----------------------------------|----------------|--|-----------------------|
|-------|--|---|--------------------------------------|----------------------------------|----------------|--|-----------------------|





Attachment #2
RFA Descriptions

CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

- **Individual Investigator Research Awards (IIRA)**
Supports applications for innovative research projects addressing critically important questions that will significantly advance knowledge of the causes, prevention, and/or treatment of cancer. Areas of interest include laboratory research, translational studies, and/or clinical investigations. Competitive renewal applications accepted.
Award: Up to \$350,000 per year. Exceptions permitted if extremely well justified; maximum duration: 3 years.
- **Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)**
Supports applications for innovative mathematical and/or computational research projects addressing questions that will advance current knowledge in the (a) mechanisms that tie altered gene expression and downstream molecular mechanisms to functional cancer phenotypes and/or (b) mechanisms that tie tumor morphology to functional cancer phenotypes and/or mechanisms that tie treatment sequence and combination to evolving functional cancer phenotypes (that emerge as a result of treatment selection).
Award: Up to \$400,000 in total costs per year for up to 3 years. Exceptions permitted if extremely well justified.
- **Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)**
Supports applications for innovative research projects addressing questions that will advance knowledge of the causes, prevention, progression, detection, or treatment of cancer in children and adolescents. Laboratory, clinical, or population-based studies are all acceptable. CPRIT expects the outcome of the research to reduce the incidence, morbidity, or mortality from cancer in children and/or adolescents in the near or long term. Competitive renewal applications accepted.
Award: Up to \$350,000 per year. Applicants that plan on conducting a clinical trial as part of the project may request up to \$500,000 in total costs. Exceptions permitted if extremely well justified; maximum duration: 4 years.
- **Individual Investigator Research Awards for Prevention and Early Detection (IIRAP)**
Supports applications which propose clinical and population-based projects designed to develop effective prevention and early detection interventions to reduce cancer risk, mortality, and morbidity among Texans. Projects that propose such research collaborations with existing CPRIT Prevention Program awardees including the CPRIT funded *Texas Collaborative Center for Hepatocellular Cancer*

<https://www.bcm.edu/research/labs-and-centers/research-centers/texas-collaborative-center-for-hepatocellular-cancer>) are strongly encouraged.

Award: Up to \$400,000 per year. Exceptions permitted if extremely well justified; maximum duration: 5 years.

- **Individual Investigator Research Awards for Clinical Translation (IIRACT)**
Supports applications that propose innovative cancer clinical studies that are hypothesis driven and involve patients enrolled prospectively on a clinical trial. Areas of interest include clinical studies of new or repurposed drugs, hormonal therapies, immune therapies, surgery, radiation therapy, stem cell transplantation, combinations of interventions, or therapeutic devices. Clinical trial must be planned to begin when contract is awarded
Award: Up to \$500,000 per year. Maximum duration: 4 years. Exceptions permitted if extremely well justified.
- **Recruitment of Established Investigators (RFA R-24-1 REI):**
Recruits outstanding senior research faculty with distinguished professional careers and established cancer research programs to academic institutions in Texas.
Award: Up to \$6 million over a period of five years.
- **Recruitment of Rising Stars (RFA R-24-1 RRS):**
Recruits outstanding early-stage investigators to Texas, who have demonstrated the promise for continued and enhanced contributions to the field of cancer research.
Award: Up to \$4 million over a period of five years.
- **Recruitment of First-Time Tenure Track Faculty Members (RFA R-24.1. RFT):**
Supports very promising emerging investigators, pursuing their first faculty appointment in Texas, who have the ability to make outstanding contributions to the field of cancer research. Award: Up to \$2 million over a period up to five years.

UC San Diego

SCHOOL OF MEDICINE

January 3, 2024

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Dr. Cummings and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Individual Investigator Research Awards, Individual Investigator Research Awards for Childhood and Adolescent Cancers, Individual Investigator Research Awards for Computational Systems Biology of Cancer, Individual Investigator Research Awards for Clinical Translation, Individual Investigator Research Awards for Prevention and Early Detection, Recruitment of Established Investigators, Recruitment of Rising Stars and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on December 14, 2023 to consider the FY24.1 applications recommended by the peer review panels following their meetings held October 11, 2023 to October 20, 2023. The SRC met on November 16, 2023 to review recruitment applications submitted for Cycle FY24.3-4 and then on December 14, 2023 to review recruitment applications submitted for Cycle FY24.5.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$83,180,142.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

| Recommended for Funding by Mechanism (Ranked by Overall Score) | | | | | | | |
|--|----------|-----------------|-----------------------|---|-----------------|--|--------------------|
| Rank | ID | Award Mechanism | Meeting Overall Score | Application Title | PI | PI Organization | Recommended Budget |
| 1 | RP240068 | IIRA | 1.0 | Understanding the Mechanism of Linker Histone Mutations in Malignancy | Soshnev, Alexey | The University of Texas at San Antonio | \$997,770 |
| 2 | RP240293 | IIRACSBC | 1.0 | Therapeutic Vulnerabilities and Predictors of Response to Chemo(immuno)therapy in Patients With High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC) | Korkut, Anil | The University of Texas M. D. Anderson Cancer Center | \$1,199,999 |
| 3 | RR240019 | RRS | 1.0 | Development of Chemotherapeutics Inspired by Natural Products | Sarlah, David | Rice University | 4,000,000.00 |
| 4 | RP240137 | IIRACSBC | 1.1 | Charting TCR-Tumor Antigen Interactions to Foster Novel Immunotherapeutic Approaches for Triple-Negative Breast Cancer | Zhang, Bing | Baylor College of Medicine | \$1,200,000 |
| 5 | RR240013 | RFTFM | 1.2 | Regulation of gene expression and tumorigenesis by ubiquitin-mediated protein quality control | Mark, Kevin | The University of Texas Southwestern Medical Center | 2,000,000.00 |
| 6 | RR240016 | RFTFM | 1.3 | Impact of Germline Variants on Pediatric Leukemia Progression: Insights from 3D Chromatin Remodeling and Clinical Outcomes | Luan, Yu | The University of Texas Health Science Center at San Antonio | 2,000,000.00 |
| 7 | RR240030 | REI | 1.3 | Break-induced DNA Replication as a Driver of Genomic Instability in Cancer | Malkova, Anna | The University of Texas Health Science Center at San Antonio | 6,000,000.00 |
| 8 | RR240027 | RFTFM | 1.4 | Genomic and Epigenomic Mechanisms of Chemobrain | Dileep, Vishnu | Baylor College of Medicine | 2,000,000.00 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|-----------------------|--|-------------|
| 9 | RP240075 | IIRACT | 1.5 | Combination Therapy Using ATRA and Carfilzomib to Treat Proteasome Inhibitor Refractory Multiple Myeloma | Yi, Qing | The Methodist Hospital Research Institute | \$1,921,388 |
| 10 | RP240291 | IIRA | 1.6 | Targeting MYCN disruption of the molecular clock and tumor metabolism in neuroblastoma oncogenesis. | Barbieri, Eveline | Baylor College of Medicine | \$1,050,000 |
| 11 | RP240289 | IIRA | 1.6 | Real-time, label-free, micro HSI device and transformer-based attention networks for oral cancer imaging | Fei, Baowei | The University of Texas at Dallas | \$1,049,806 |
| 12 | RP240125 | IIRA | 1.8 | Immune-Related Determinants of HPV-Associated Oropharyngeal Cancer Outcomes | Li, Guojun | The University of Texas M. D. Anderson Cancer Center | \$1,049,726 |
| 13 | RP240061 | IIRA | 1.8 | Deciphering Iron Redox Cycles in Ferroptosis-based Cancer Therapy | Lu, Yi | The University of Texas at Austin | \$1,044,608 |
| 14 | RP240091 | IIRA | 1.9 | High resolution high sensitivity photoacoustic imaging molecular guided brain tumor surgery with pilot clinical deployment | Valdes Quevedo, Pablo | The University of Texas Medical Branch at Galveston | \$1,044,967 |
| 15 | RP240401 | IIRACCA | 1.9 | Lead Optimization, Target Engagement, and Efficacy Studies of Locally Bioavailable COX-2 inhibitors for Preventing Colon Cancer Progression in FAP Children | Hu, Ming | University of Houston | \$1,400,000 |
| 16 | RP240272 | IIRACCA | 1.9 | The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy for DSRCT | Ludwig, Joseph | The University of Texas M. D. Anderson Cancer Center | \$1,398,788 |
| 17 | RP240184 | IIRACT | 1.9 | Maximizing Antitumor Immunity Through Simultaneous Activation of the Innate and Adaptive Immune System | Hannan, Raquibul | The University of Texas Southwestern Medical Center | \$1,999,993 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|-------------------|--|-------------|
| 18 | RP240095 | IIRA | 2.0 | Targeting chitinase-3-like-1 as a novel therapy for hepatocellular carcinoma | ju, Cynthia | The University of Texas Health Science Center at Houston | \$1,049,388 |
| 19 | RP240035 | IIRA | 2.0 | Harnessing the metabolic dependencies of mitochondrial NADK2 as a therapeutic strategy for lung cancer | Hoxhaj, Gerta | The University of Texas Southwestern Medical Center | \$1,050,000 |
| 20 | RP240225 | IIRA | 2.0 | PARP16-mediated Ribosome MARYlation and Translation Control in Ovarian Cancer | Kraus, W. Lee | The University of Texas Southwestern Medical Center | \$1,049,743 |
| 21 | RP240259 | IIRA | 2.0 | Targeting Cancer-associated Lactobacillus iners to improve response to cancer therapy | Colbert, Lauren | MDACC/BLI | \$1,049,427 |
| 22 | RP240119 | IIRA | 2.0 | Integrating proteolysis-targeting capability into antibodies to augment therapeutic efficacy | Liu, Qingyun | The University of Texas Health Science Center at Houston | \$1,050,000 |
| 23 | RP240326 | IIRA | 2.0 | Translation of gut commensal bacteria peptidoglycan remodeling pathway for chimeric antigen receptor T-cell therapy | Saini, Neeraj | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 24 | RP240311 | IIRA | 2.0 | Treatment planning of ADC therapy for ovarian cancer with molecular photoacoustic-ultrasonic imaging | Bouchard, Richard | The University of Texas M. D. Anderson Cancer Center | \$1,049,859 |
| 25 | RP240117 | IIRA | 2.0 | Identify radiopathomics markers to guide immunotherapy for non-small cell lung cancer | Wu, Jia | The University of Texas M. D. Anderson Cancer Center | \$1,049,906 |
| 26 | RP240054 | IIRACCA | 2.0 | Myeloid Support of Refractory and Aggressive T-ALL at Distinct Tumor Sites | Ehrlich, Lauren | The University of Texas at Austin | \$1,400,000 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|---------------------|--|--------------|
| 27 | RP240237 | IIRACCA | 2.0 | The Role of EWSR1-FLI1-CENP-A Signaling in Chemoresistance in Ewing Sarcoma | Kitagawa, Katsumi | The University of Texas Health Science Center at San Antonio | \$1,400,000 |
| 28 | RR240015 | RRS | 2.0 | HyperGlio - New tools to fight brain cancer with signal-enhanced magnetic resonance | Gloeggler, Stephan | The University of Texas Southwestern Medical Center | 4,000,000.00 |
| 29 | RR240021 | RRS | 2.0 | Expansion and Single-cell Interrogation of Tumoroid Models for Precise Treatment of Diverse Rectal Cancer Patient Populations | Smith, Jesse Joshua | The University of Texas Southwestern Medical Center | 4,000,000.00 |
| 30 | RP240183 | IIRA | 2.1 | Restoring TREM2-Dependent Efferocytosis to Inhibit Obesity-Induced Liver Inflammation and Cancer Development | Liang, Shuang | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 31 | RP240263 | IIRA | 2.1 | Identifying the Biological Determinants of Aggressive Meningioma | Patel, Akash | Baylor College of Medicine | \$1,049,370 |
| 32 | RP240392 | IIRA | 2.1 | Identifying Tumor Specific Vulnerabilities in Appendiceal Adenocarcinoma: A Systems Approach | Shen, John Paul | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 33 | RP240133 | IIRA | 2.1 | Modulation of blood-spinal cord barrier for tumor treatment | Qin, Zhenpeng | The University of Texas at Dallas | \$1,050,000 |
| 34 | RP240233 | IIRACT | 2.1 | Toward Nonoperative Management of Early-Stage ER-Positive Breast Cancer | Rahimi, Asal | The University of Texas Southwestern Medical Center | \$1,999,963 |
| 35 | RP240127 | IIRA | 2.2 | Transposon Restriction, Tumor Suppression and p53 | Abrams, John | The University of Texas Southwestern Medical Center | \$1,039,356 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|----------|-----|---|------------------|--|--------------|
| 36 | RP240072 | IIRA | 2.2 | Dissection of CAMKK2's Tumor Cell-intrinsic and -extrinsic Roles in Prostate Cancer | Frigo, Daniel | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 37 | RP240288 | IIRA | 2.3 | Epigenetic mechanism and targeting during response to BRAFi/anti-EGFR therapy in BRAF-mutant colorectal cancers | Kopetz, Scott | The University of Texas M. D. Anderson Cancer Center | \$1,043,909 |
| 38 | RP240380 | IIRA | 2.3 | Clonal hematopoiesis for improving lung cancer risk assessment | Cheng, Chao | Baylor College of Medicine | \$1,040,316 |
| 39 | RP240131 | IIRACSBC | 2.3 | Computational Methods for CRISPR-Based Lineage Tracing Systems | Liu, Zhandong | Baylor College of Medicine | \$1,200,000 |
| 40 | RR240007 | REI | 2.3 | Building a multi-modal platform to enable next-generation functional precision oncology | Shen, Xiling | The University of Texas M. D. Anderson Cancer Center | 6,000,000.00 |
| 41 | RP240214 | IIRA | 2.5 | Immunoprevention of Breast Cancer Brain Metastasis by Special Dendritic Cell-derived Extracellular Vesicles | Yu, Dihua | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 42 | RP240120 | IIRA | 2.5 | JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC | ZHANG, QING | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 43 | RP240287 | IIRA | 2.5 | Investigating the Impact of Interferon Gamma Signaling on Therapeutic Resistance in Acute Myeloid Leukemia | Abbas, Hussein | The University of Texas M. D. Anderson Cancer Center | \$1,042,256 |
| 44 | RP240104 | IIRA | 2.6 | Characterization and optimization of novel allosteric KRAS inhibitors | Gorfe, Alemayehu | The University of Texas Health Science Center at Houston | \$1,050,000 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego
SCHOOL OF MEDICINE

| | | | | | | | |
|--|----------|---------|-----|---|------------------------|---|-------------|
| 45 | RP240320 | IIRA | 2.6 | Benzothiazepines as first-in-class inhibitors for the ribogenesis factor NVL and evaluation in preclinical colorectal cancer models | De Brabander, Jef | The University of Texas Southwestern Medical Center | \$1,049,754 |
| 46 | RP240143 | IIRACCA | 2.6 | Leveraging Passport for Care in a Telehealth Framework to Improve Equitable Access to Survivorship Services | Gramatges, Maria | Baylor College of Medicine | \$1,399,382 |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| 51 | RP240208 | IIRAP | 2.8 | Unidos Contra el VPH: Screening Accuracy, Preference, and Uptake of HPV Self-Sampling Among Latinxs Along the US-Mexico Border | Calderon-Mora, Jessica | The University of Texas at Austin | \$1,920,007 |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee.

Individual Investigator Research Awards (IIRA)
Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)
Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)
Individual Investigator Research Awards for Clinical Translation (IIRACT)
Individual Investigator Research Awards for Prevention and Early Detection
Recruitment of Established Investigators (REI)
Recruitment of Rising Stars (RRS)
Recruitment of First-Time, Tenure Track Faculty Members (FTTFM)



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: CPRIT OVERSIGHT COMMITTEE MEMBERS
FROM: RAMONA MAGID, CHIEF PREVENTION OFFICER
SUBJECT: PREVENTION PROGRAM UPDATE
DATE: FEBRUARY 7, 2024

Summary and Recommendation:

The Program Integration Committee (PIC) has completed its review of the recommendations forwarded by the Prevention Review Council (PRC) and recommends awarding 12 projects for FY 2024 Cycle 1 totaling \$25,902,480. The grant recommendations are presented in two slates.

| Grant Mechanism | Number | Amount |
|---|--------|--------------|
| <i>Cancer Screening and Early Detection</i> | 7 | \$14,423,630 |
| <i>Primary Prevention of Cancer</i> | 5 | \$11,478,850 |

Background:

FY 2024 Cycle 1 (24.1)

The Prevention Program released two RFAs, *Primary Prevention of Cancer and Cancer Screening and Early Detection*, on May 5, 2023, for the first cycle of FY 2024. CPRIT received 29 proposals totaling \$46,657,038 by the August 30 deadline. Three applications were administratively withdrawn as they were not responsive to the RFA.

Peer review took place on December 5-6, 2023, and the Prevention Review Council (PRC) met on January 12, 2024, to make recommendations to the Program Integration Committee (PIC). Ms. Magid will present the Prevention Review Council's recommendations to the PIC and the Oversight Committee in February.

Program Priorities Addressed

All the recommended applications address more than one of the Prevention Program priorities. See the attached chart for additional detail.

| Number of Applications Addressing Priorities | | Amount |
|---|---|---------------|
| 12 | Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence | \$25,902,480 |
| 12 | Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence | \$25,902,480 |
| 12 | Prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services | \$25,902,480 |

Prevention Program Slates

Cancer Screening and Early Detection

Mechanism:

This award mechanism seeks to support the delivery of evidence-based clinical services to screen for cancer and pre-cancer in underserved populations who do not have adequate access to cancer early detection interventions and health care, bringing together networks of public health and community partners to carry out programs tailored for their communities. Projects should identify cancers that cause the most burden in the community, have nationally recommended screening methods, and use evidence-based methods to screen for these cancers.

Award: Maximum of \$1M for new projects and \$2.5M for expansion projects; maximum duration of 5 years

Recommended projects (7): \$14,423,630

Sixteen applications were submitted in this mechanism. Seven Cancer Screening and Early Detection projects are recommended.

Project Descriptions

| | | | | | |
|--|---|---------------------|--|-----|-------------|
| PP240017 | Expanding Access to Cervical Cancer Screening through Primary HR-HPV Testing and Self-Sampling: A Multicomponent Intervention for Safety Net Health Systems | Montealegre, Jane R | The University of Texas M. D. Anderson Cancer Center | 2.1 | \$2,499,646 |
| CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services | | | | | |

The overarching goal of the proposed program is to increase cervical cancer screening, early detection, and linkage to treatment in underserved populations that receive care in safety net health systems. To accomplish this goal, a private-public partnership has been formed between two safety net health systems (Harris Health System in Harris County and Su Clinica in the Rio Grande Valley), academic institutions, an industry partner, and the American Cancer Society National Roundtable for Cervical Cancer Screening (ACS NRCCS) to pioneer the implementation of primary HR-HPV testing with self-sampling in Texas and the U.S. Drawing on the successes of past and current CPRIT-funded cervical cancer screening programs, a comprehensive program will be implemented to address barriers along the screening continuum of care. The pillars of the program include: 1) health system changes guided by the ACS NRCCS Implementation Roadmap; 2) provider training and practice facilitation; 3) patient education; 4) patient navigation; and 5) capacity building using Project ECHO® (Extension for Community Healthcare Outcomes) and existing ECHO Network.

| | | | | | |
|--|---|------------------|-----------------------------------|-----|-------------|
| PP240040 | Expanding Intensive Smoking Cessation and Lung Cancer Screening in Vulnerable Adult Patients in Central Texas FQHCs | Attilio, Brandon | The University of Texas at Austin | 2.2 | \$2,000,000 |
| CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services | | | | | |

This project proposes to increase access to low-dose computed tomography (LDCT) scans for high-risk, eligible patients who meet US Preventive Services Task Force eligibility criteria and provide comprehensive, evidence-based intensive cessation services at CommUnityCare and Lone Star Circle of Care(LSCC), both FQHCs. Partnerships have been developed with UT Health Austin, Central Health, Austin Radiological Associates, and the Dell Medical School who will collaborate to continue to improve the current program, leverage the relationships and expertise that have been established, and create new workflows and opportunities as the program expands beyond Travis County, into the surrounding counties through LSCC. These evidence-based interventions will be used: 1) centralized outreach using a well-tested system for assessing eligibility and providing decision support; 2) provider training for in-office identification and referral; 3) use of a well-tested lung cancer screening patient decision aid developed by our team members to facilitate shared decision making and ensure high-quality decisions; 4) multi-disciplinary collaboration among our project team to ensure high-quality CT interpretation and follow-up; and 5) navigation to promote high adherence and completion of work-ups for abnormal scans. Simultaneously, access to effective intensive tobacco cessation counseling will be improved by 1) direct outreach to expand reach; 2) additional provider training to improve in-office assessment and motivation; and 3) referral to intensive counseling and enhanced pharmacological therapy.

| | | | | | |
|--|---|-----------------|---|-----|-------------|
| PP240042 | Cancer Prevention and Outreach for Individuals Disproportionately Affected by Cancer in Medically Underserved Regions (C-CUR) | Esnaola, Nestor | The Methodist Hospital Research Institute | 3.0 | \$1,437,244 |
| CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services | | | | | |

This proposed project seeks to provide breast, cervical, colorectal, and liver cancer prevention education, screening, follow-up diagnostic services, and patient navigation across the continuum of care to underinsured, uninsured, and medically underserved populations. A comprehensive physician and community health worker/promotora-driven navigation program will reduce the time to resolution after abnormal cancer/Hepatitis C virus screening. This project will employ a community-led linkage from the community to the clinical provider approach to making cancer-related preventive services available via Federally Qualified Health Centers in collaboration with the Houston Methodist Neal Cancer Center and Texas A&M Health Science Center to three Legacy Community Health HRSA service areas (1) Greater Fifth Ward Lyons, (2) Santa Clara, and (3) San Jacinto/Baytown.

| | | | | | |
|--|---|----------------|----------------------------|-----|-------------|
| PP240021 | Reducing Racial/Ethnic Disparities in Breast Cancer Screening: Expanding a Comprehensive EHR-Based Patient Navigation Program | Rustveld, Luis | Baylor College of Medicine | 3.1 | \$2,499,998 |
| CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services | | | | | |

This project proposes to increase timely breast cancer screening and follow-up for the diverse patient populations of Baylor College of Medicine (BCM), and CHI St. Luke, expanding on the current CPRIT-funded colorectal cancer screening project. Outreach and education on breast and colorectal cancer prevention and screening guidelines and services for age-eligible community residents served by BCM and CHI St. Luke will be provided. A patient navigator-led navigation workbench integrated into the CHI St. Luke electronic health record (EHR) to document the completion and follow-up of breast cancer screening services will be implemented and continued for colorectal cancer screening services. Several strategies include 1) Harnessing key features of the EHR to better coordinate patient navigation and follow-up of age-eligible patients who are to receive screening and those at high risk for developing breast and colorectal cancers; 2) Implementing a patient navigator (PN) workbench to facilitate identification of gaps in care and integrate care management/coordination to help providers achieve patient cancer screening goals and potentially maximize the likelihood of sustainability beyond the funding period; 3) Providing interactive and culturally/linguistically appropriate PN-led outreach and education, and encourage adoption of healthy lifestyle risk reduction behaviors; and 4) Leveraging of existing culturally/linguistically appropriate multi-media education resources, including monologues, and point of care videos, and other educational materials.

| | | | | | |
|--|---|-----------------|--|-----|-------------|
| PP240012 | Integrated Mammography and Genetic Evaluation Services (IMAGES) | Whitman, Gary J | The University of Texas M. D. Anderson Cancer Center | 3.1 | \$1,499,400 |
| CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services | | | | | |

This project proposes to increase access to screening mammography, genetic evaluation, and navigation services among uninsured women, particularly those who are members of racial or ethnic minority groups and/or reside in under resourced communities. IMAGES combines two ongoing screening programs to address breast cancer disparities and ensure reach and quality of care. Project VALET is a mobile mammography program serving uninsured asymptomatic women ages 40 to 74 years in partnership with area Federally Qualified Health Centers. Project Genetic Health is a current Clinical Cancer Genetics program that provides genetic risk assessment, including family cancer history collection, genetic testing, and genetic counseling to identify individuals at risk of hereditary cancers including hereditary breast and associated cancers. MD Anderson is strongly dedicated to this program and if it is funded, will commit up to an additional \$1 million to provide screening mammograms, diagnostic follow-up, image-guided biopsies, breast MRIs, genetic testing including testing of eligible family members, and counseling and navigation services. IMAGES uses evidence-based interventions and addresses barriers such as access and cost. The program provides appropriate health education materials and on-site community health workers, all fluent in Spanish. Through this program, IMAGES expects to expand Project VALET’s current reach in 23 participating clinics, primarily in Harris County, to 3 additional rural counties, expansion within Fort Bend County and add 2 new clinic systems with multiple locations.

| | | | | | |
|--|---|----------------------|---|-----|-------------|
| PP240019 | Increasing Access to Successful Colorectal Cancer Screening, Pairing Patient Education and Outreach with Navigation | Argenbright, Keith E | The University of Texas Southwestern Medical Center | 3.3 | \$2,487,342 |
| CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services | | | | | |

The proposed program aims to implement a sustainable, large-scale CRC screening program for rural and medically underserved populations across a 67-county wide service area, reducing existing disparities and improving CRC-related health outcomes in these communities. A multicomponent intervention will be utilized to increase CRC screening rates within the service area, combining navigation services and health promotion with mailed Fecal Immunochemical Test (FIT) outreach. Coalition partners affiliated with community health clinics and Federally Qualified Health Centers will

actively refer age-eligible adults who are not adherent to USPSTF recommendations for invitation into the program. Program participation will also be extended to individuals who are not engaged with the healthcare system via self-enrollment in the program, in response to community outreach or education events or through contacting a dedicated 800 number. FIT results, clinical services, and navigation to follow-up care will follow FIT completion, as well as reminder calls for participants who have not completed their FIT. This program will utilize validated survey instruments to assess barriers to CRC screening and colonoscopy completion within the patient population, facilitating the development of targeted interventions that can be utilized to improve screening and colonoscopy completion rates.

| | | | | | |
|--|--|--------------------|-----------------------------------|-----|-------------|
| PP240011 | The Advancing Breast Health among uninsured Women in Central Texas (ABH-CTX) 2 | Shokar, Navkiran K | The University of Texas at Austin | 3.4 | \$2,000,000 |
| CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services | | | | | |

The proposed ABH-CTX 2 program is comprised of a large coalition of partners that have come together to reduce breast cancer burden in 9 Central Texas counties. Through this collaboration, the Addressing Cancer Together Coalition, Dell Medical School, and the Lone Star Circle of Care system have established a successful mobile mammography-based screening program and a diagnosis and treatment pathway for underinsured and uninsured women in the region. The ABH-CTX program integrates clinical recommendations with evidence-based navigation strategies to facilitate completion of mobile screening, diagnostic testing, and connection to treatment for low-income women. Evidence-based culturally tailored health education, new clinical service delivery pathways, and enhanced patient navigation will be added to address additional levels of the socioecological model for health. This project will continue to expand mobile mammography screening while adding 24 new fixed testing sites to meet the need for screening and testing and 17 new clinic referrals sites throughout the nine-county area to reach additional women.

Primary Prevention of Cancer

Mechanism:

This award mechanism focuses on increasing implementation of evidence-based strategies to ensure that all Texans benefit from the cancer prevention knowledge that we currently have. CPRIT seeks to fund multilevel interventions to reduce cancer risk, disease burden, and cancer disparities. Modifiable risk behaviors include tobacco use, obesity, physical inactivity, unhealthy eating, alcohol use, sun exposure, HPV vaccination, Hepatitis B vaccination, and environmental/occupational cancer exposures. Applications should also assess and address social determinants that contribute to cancer burden and disparities (e.g., cultural factors, unmet needs, access barriers). Interventions and communications should be structured to address the unique circumstances of the population to be served.

Award: Maximum of \$1M for new projects and \$2.5M for expansion projects; maximum duration of 5 years

Recommended projects (5): \$11,478,850

Thirteen applications were submitted in this mechanism. Five Primary Prevention of Cancer applications are recommended.

Project Descriptions

| | | | | | |
|----------|---|-------------------|---|-----|-------------|
| PP240022 | Expansion of a multi-pronged intervention to increase HPV vaccination rates among adolescents from rural and medically underserved areas in Texas | Berenson, Abbey B | The University of Texas Medical Branch at Galveston | 2.3 | \$2,494,865 |
|----------|---|-------------------|---|-----|-------------|

CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services

This project proposes to increase HPV vaccination rates among underserved adolescents seen in UTMB clinics in 25 counties. Bilingual PNs will offer in-person counseling to parents of all unvaccinated or partially vaccinated children 9-17 years of age. Same day vaccination appointments and standing orders will be implemented in all clinics. Follow-up appointments will be scheduled before the patient leaves the clinic to ensure completion of all doses. PNs will use multiple systems (text, voice, automated) to remind patients about follow-up visits and immediately reschedule those who miss appointments. Most vaccine costs will be paid by Vaccines for Children, Medicaid or CHIP which will save CPRIT over \$2 million. Members of the health care team, including physicians, nurse practitioners, nurses, and medical assistants, will be educated by giving presentations, in-service training, and lectures across UTMB clinics and on the local, regional, and state level. Community education about the importance of being vaccinated will be provided through health fairs, back-to-school events, and social media.

| | | | | | |
|--|---|--------------|--|-----|-------------|
| PP240041 | Expansion of the evidence-based Adolescent Vaccination Program (AVP) in a safety net clinic system to increase HPV vaccination rates in underserved populations | Shegog, Ross | The University of Texas Health Science Center at Houston | 3.5 | \$1,496,194 |
| CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services | | | | | |

This CPRIT initial expansion project proposes to broaden the use of the evidence-based multi-level Adolescent Vaccination Program (AVP) to safety net clinic settings to increase HPV vaccination among pediatric and adolescent patients ages 9 – 17 in clinic networks that reach underserved populations within Texas. The AVP comprises a suite of recommended evidence-based strategies: immunization champions, provider assessment and feedback, provider reminders, provider continuing education, patient reminder and recall systems, and patient (parent) education. The project will expand the evidence- and system-based AVP to non-profit safety net clinics (e.g., Ibn Sina and VCare clinical networks) to reach large numbers of underserved patients, including a high proportion of Hispanic patients.

| | | | | | |
|--|---|---------------------|--|-----|-------------|
| PP240005 | Preventing Tobacco Related Cancers by Expanding Capacity for Tobacco Use Interventions Within Agencies Serving Women with Behavioral Health Needs | Reitzel, Lorraine R | The University of Texas M. D. Anderson Cancer Center | 4.0 | \$2,487,822 |
| CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services | | | | | |

This project proposes to disseminate and implement Taking Texas Tobacco Free (TTTF), a successful, evidence-based tobacco control intervention for cancer prevention that will provide policy and workflow guidance, specialized training, and resources to agencies serving women with behavioral health needs (WSAs) to bolster their ability to provide tobacco cessation and relapse prevention interventions to their patients. TTTF will work with WSAs to: 1) implement or refresh tobacco-free workplace policies with sustainable plans for enforcement; 2) train employees to increase knowledge and regular provision of tobacco dependence interventions at the point-of-care through developing embedded expertise; 3) provide resources to support program implementation (e.g., nicotine replacement therapies) and change clinical workflows to facilitate regular tobacco intervention (e.g., via provider tools and nudges; fidelity); and 4) establish systems, practices, and policies to maintain this service delivery after active program

implementation, ultimately achieving a reduction of tobacco use rates among engaged employees and the women they serve over time. This work addresses women’s issues and needs affecting tobacco use including pregnancy/postpartum, menopausal, and behavioral health issues; program implementation will incorporate peer support and use a trauma-informed approach to care.

| | | | | | |
|---|-----------------------|---------------------|---|-----|-------------|
| PP240014 | Tiempo De Vacunarte 3 | Molokwu, Jennifer C | Texas Tech University Health Sciences Center at El Paso | 4.1 | \$2,500,000 |
| <p>CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services</p> | | | | | |


This proposed project is a multilevel, multicomponent, culturally tailored, bilingual HPV cancer prevention program aiming to reduce the burden of HPV-associated cancers by providing HPV vaccine to residents 9-45 years old of El Paso, Hudspeth, Culberson, Presidio, and Brewster counties. The program includes outreach, education, and navigation while providing access to no/low-cost HPV vaccine. The proposed project focuses on developing collaborative partnerships and disseminating and implementing effective elements to create sustainable system changes. Service delivery is facilitated through our ongoing collaborations with community organizations, faith groups, schools, and healthcare providers and through new partners who will facilitate recruitment, education, and vaccine administration. Program components include: 1) evidence-based school-based vaccine initiative collaborating with school districts and service providers such as Immunize El Paso to provide onsite services; 2) training and empowering community vaccine champions to improve the capacity to advocate for increased HPV vaccine uptake in the community; 3) expanding collaborative partnerships with private pharmacy providers for service delivery, especially in rural counties; 4) expanding outreach and messaging through social media and new media; and 6) enhancing implementation, adoption, and sustainability of HPV vaccine uptake strategies among collaborating partners.

| | | | | | |
|---|---|----------------|--|-----|-------------|
| PP240030 | All for Them: A multilevel strategy for HPV-related cancer prevention | Cuccaro, Paula | The University of Texas Health Science Center at Houston | 4.3 | \$2,499,969 |
| <p>CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services</p> | | | | | |

The proposed All for Them (AFT) project is a multilevel multicomponent program comprising social marketing, comprehensive adolescent vaccination clinics, and school nurse education strategies aimed at reducing barriers to HPV vaccine series uptake. This project implements AFT among youth living in medically underserved areas in four diverse Texas public school districts and communities in Harris, Chambers, and Tarrant Counties. The parent- and youth-focused social marketing campaign reframes HPV vaccination as cancer prevention and helps parents and high school youth recognize the vaccine as part of routine adolescent healthcare. The social marketing campaign educational messages targeting parent decision-makers to increase HPV vaccine knowledge, positive attitudes, and HPV vaccination for their child. The campaign includes collateral and messages for high school youth of age to consent for the HPV vaccine themselves. This strategy has resulted in over 95% parental acceptance for HPV vaccination for students participating in AFT clinics. Expansion includes community-based vaccination clinics and all-school vaccination clinics open to all middle and high school students and their siblings throughout the year. School nurse education is provided to increase school nurses' knowledge, positive attitudes, effective communication with parents regarding HPV vaccine, and raise awareness about documenting HPV vaccination in students' school health records.

Prevention Program Priorities Addressed by Recommended Awards February 21, 2024

| | | | |
|---|---|--|--|
| <p align="center">Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence</p> | <p align="center">Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence</p> | <p align="center">Prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services</p> | <p align="center">Prevention Program Assessment</p> |
|---|---|--|--|



Note: Some grant awards address more than one program priority and will be double counted.

Dr. David Cummings
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Dr. Cummings and Mr. Roberts,

On behalf of the Prevention Review Council (PRC), I am pleased to provide the PRC's recommendations for the FY2024 Cycle 1 Cancer Screening and Early Detection (CSD) and Primary Prevention of Cancer (PPC) grant awards.

The PRC met on January 12, 2024, to consider the applications recommended by the peer review panel following their December 5-6, 2023, meeting. The PRC recommends 12 projects totaling \$25,902,480.

The projects are numerically ranked in the order the PRC recommends the applications be funded. Recommended funding amounts and the overall evaluation score are stated for each grant application. The average score for recommended applications ranges from 2.1 to 4.3. For the three applications with average scores of 4.0, 4.1 and 4.3 the PRC spent a considerable amount of effort reviewing panel evaluations/scores and concluded that they are quality proposals with the potential for significant impact. The PRC made no changes to the goals, project objectives, or timelines of the applications.

Our recommendations meet the PRC's standards for grant award funding of projects that are evidence-based, deliver programs or services to underserved populations, and focus on primary, secondary, or tertiary prevention. In making these recommendations the PRC continued to consider the available funding, the composition of the current portfolio, and the programmatic priorities in the RFA which include potential for impact and return on investment, geographic distribution, cancer type and type of program. All the recommended grants address one or more of the Prevention Program priorities.

Sincerely,
Stephen W. Wyatt, DMD, MPH
Chair, CPRIT Prevention Review Council

Attachment



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Cycle 24.1 Recommended Prevention Program Awards

| App. ID | Mech | Application Title | PD | Organization | Score | Rank Order | Budget |
|----------|------|---|----------------------|--|-------|------------|-------------|
| PP240017 | CSD | Expanding Access to Cervical Cancer Screening through Primary HR-HPV Testing and Self-Sampling: A Multicomponent Intervention for Safety Net Health Systems | Montealegre, Jane R | The University of Texas M. D. Anderson Cancer Center | 2.1 | 1 | \$2,499,646 |
| PP240040 | CSD | Expanding Intensive Smoking Cessation and Lung Cancer Screening in Vulnerable Adult Patients in Central Texas FQHCs | Altillo, Brandon | The University of Texas at Austin | 2.2 | 2 | \$2,000,000 |
| PP240022 | PPC | Expansion of a multi-pronged intervention to increase HPV vaccination rates among adolescents from rural and medically underserved areas in Texas | Berenson, Abbey B | The University of Texas Medical Branch at Galveston | 2.3 | 3 | \$2,494,865 |
| PP240042 | CSD | Cancer Prevention and Outreach for Individuals Disproportionately Affected by Cancer in Medically Underserved Regions (C-CUR) | Esnaola, Nestor | The Methodist Hospital Research Institute | 3.0 | 4 | \$1,437,244 |
| PP240021 | CSD | Reducing Racial/Ethnic Disparities in Breast Cancer Screening: Expanding a Comprehensive EHR-Based Patient Navigation Program | Rustveld, Luis | Baylor College of Medicine | 3.1 | 5 | \$2,499,998 |
| PP240012 | CSD | Integrated Mammography and Genetic Evaluation Services (IMAGES) | Whitman, Gary J | The University of Texas M. D. Anderson Cancer Center | 3.1 | 6 | \$1,499,400 |
| PP240019 | CSD | Increasing Access to Successful Colorectal Cancer Screening, Pairing Patient Education and Outreach with Navigation | Argenbright, Keith E | The University of Texas Southwestern Medical Center | 3.3 | 7 | \$2,487,342 |
| PP240011 | CSD | The Advancing Breast Health among uninsured Women in Central Texas (ABH-CTX) 2 | Shokar, Navkiran K | The University of Texas at Austin | 3.4 | 8 | \$2,000,000 |
| PP240041 | PPC | Expansion of the evidence-based Adolescent Vaccination Program (AVP) in a safety net clinic system to increase HPV vaccination rates in underserved populations | Shegog, Ross | The University of Texas Health Science Center at Houston | 3.5 | 9 | \$1,496,194 |
| PP240005 | PPC | Preventing Tobacco Related Cancers by Expanding Capacity for Tobacco Use Interventions Within Agencies Serving Women with Behavioral Health Needs | Reitzel, Lorraine R | The University of Texas M. D. Anderson Cancer Center | 4.0 | 10 | \$2,487,822 |
| PP240014 | PPC | Tiempo De Vacunarte 3 | Molokwu, Jennifer C | Texas Tech University Health Sciences Center at El Paso | 4.1 | 11 | \$2,500,000 |
| PP240030 | PPC | All for Them: A multilevel strategy for HPV-related cancer prevention | Cuccaro, Paula | The University of Texas Health Science Center at Houston | 4.3 | 12 | \$2,499,969 |

CSD: Cancer Screening and Early Detection

PPC: Primary Prevention of Cancer



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

February 9, 2024

Dear Oversight Committee Members:

I am pleased to present the Program Integration Committee's (PIC) unanimous recommendation for funding 58 grant applications totaling \$98,592,155. The PIC recommendations for 46 academic research and 12 prevention grant awards are attached.

At the February 7 meeting, the PIC did not recommend seven academic research applications that the Scientific Review Council included in their recommendation. One recruitment application was withdrawn by the nominating institution prior to the PIC meeting and the PIC did not recommend the remaining six applications due to insufficient agency funds available.

Dr. Michelle Le Beau, CPRIT's Chief Scientific Officer, and Ramona Magid, CPRIT's Chief Prevention Officer, have prepared overviews of the recommended academic research and prevention slates to assist your evaluation of the recommended awards. The overviews are intended to provide a comprehensive summary with enough detail to understand the substance of the proposal and the reasons endorsing grant funding. In addition to the full overviews, all the information considered by each Review Council is available by clicking on the appropriate link in the portal. This information includes the application, peer reviewer critiques, and the CEO affidavit for each proposal.

The approval of these grant recommendations is governed by a statutory process that requires two-thirds of the members present and voting to approve each recommendation. Vince Burgess, CPRIT's Chief Compliance Officer, will certify that the review process for the recommended grants followed CPRIT's award process prior to any Oversight Committee action.

The award recommendations will not be considered final until the Oversight Committee meeting on February 21, 2024. Consistent with the non-disclosure agreement that all Oversight Committee members have signed, the recommendations should be kept confidential and not be disclosed to anyone until the award list is publicly announced at the Oversight Committee meeting. I request that Oversight Committee members not print, email, or save to your computer's hard drive any material on the portal. I appreciate your assistance in taking all necessary precautions to protect this information.

If you have any questions or would like more information on the review process or any of the projects recommended for an award, CPRIT's staff, including myself, Dr. Le Beau, and Ms. Magid are always available. Please feel free to contact us directly should you have any questions. The programs that will be supported by the CPRIT awards are an important step in our efforts to mitigate the effects of cancer in Texas.

Thank you for being part of this endeavor.

Sincerely,
Wayne R. Roberts,
Chief Executive Officer

ACADEMIC RESEARCH GRANT AWARD RECOMMENDATIONS

The PIC unanimously recommends approval of 46 academic research grant proposals totaling \$72,689,675. The recommended grant proposals were submitted in response to the following grant mechanisms: *Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Translation; Individual Investigator Research Awards for Prevention and Early Detection; Recruitment of Established Investigators; Recruitment of First-Time, Tenure-Track Faculty Members; and Recruitment of Rising Stars.*

The Scientific Review Council (SRC) provided a prioritized list of 53 grant award recommendations to the presiding officers of the PIC and Oversight Committee on January 3, 2024. On February 7, the PIC recommended 46 applications to the Oversight Committee. The remaining seven applications that the PIC did not recommend include one recruitment application was withdrawn by the applicant prior to the PIC meeting and five Individual Investigator Research Awards (IIRA), and one Individual Investigator Research Award for Cancer in Children and Adolescents (IIRACCA). Dr. Le Beau explained that the SRC's recommendation exceeded the amount of funds available and therefore suggested that the PIC not recommend six applications to the Oversight Committee.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these academic research proposals met the following CPRIT funding priorities:

- Could lead to immediate or long-term medical and scientific breakthroughs in the area of cancer prevention or cures for cancer;
- Strengthen and enhance fundamental science in cancer research;
- Ensure a comprehensive coordinated approach to cancer research;
- Are interdisciplinary or interinstitutional;
- Address federal or other major research sponsors' priorities in emerging scientific or technology Fields in the area of cancer prevention or cures for cancer;
- Are matched with funds available by a private or nonprofit entity and institution or institutions of higher education;
- Are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state;
 - Applicable to *Recruitment of Established Investigators*
- Have a demonstrable economic development benefit to this state;

- Enhance research superiority at institutions of higher education in this state by creating new research superiority, attracting existing research superiority from institutions not located in this state and other research entities, or enhancing existing research superiority by attracting from outside this state additional researchers and resources;
 - Applicable to all except *Recruitment of Established Investigators*
- Address the goals of the Texas Cancer Plan.

| Academic Research Award Recommendations Cycle 24.1 and Recruitment Cycles 24.3-24.5 | | | | | | | |
|---|----------------|--------------|---|-----------------------------------|--|---------------|--------------------|
| <i>IIRA: Individual Investigator Research Awards</i> | | | | | | | |
| <i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i> | | | | | | | |
| <i>IIRACCSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i> | | | | | | | |
| <i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i> | | | | | | | |
| <i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i> | | | | | | | |
| <i>REI: Recruitment of Established Investigators</i> | | | | | | | |
| <i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i> | | | | | | | |
| <i>RRS: Recruitment of Rising Stars</i> | | | | | | | |
| Rank | App. ID | Mech. | Application Title | PI or Scholar Candidate | Organization | Budget | Final Score |
| 1 | RP240068 | IIRA | Understanding the Mechanism of Linker Histone Mutations in Malignancy | Soshne, Alexey | The University of Texas at San Antonio | \$997,770 | 1.0 |
| 2 | RP240293 | IIRA CSBC | Therapeutic Vulnerabilities and Predictors of Response to Chemo(immuno)therapy in Patients With High- Risk, Early-Stage Triple- Negative Breast Cancer (TNBC) | Korkut, Anil | The University of Texas M. D. Anderson Cancer Center | \$1,199,999 | 1.0 |
| 3 | RR240019 | RRS | Development of Chemotherapeutics Inspired by Natural Products | Sarlah, David (scholar candidate) | Rice University | \$4,000,000 | 1.0 |
| 4 | RP240137 | IIRA CSBC | Charting TCR-Tumor Antigen Interactions to Foster Novel Immunotherapeutic Approaches for Triple-Negative Breast Cancer | Zhang, Bing | Baylor College of Medicine | \$1,200,000 | 1.1 |
| 5 | RR240013 | RFTFM | Regulation of gene expression and tumorigenesis by ubiquitin-mediated protein quality control | Mark, Kevin (scholar candidate) | The University of Texas Southwestern Medical Center | \$2,000,000 | 1.2 |

| Academic Research Award Recommendations Cycle 24.1 and Recruitment Cycles 24.3-24.5 | | | | | | | |
|---|----------|---------|--|------------------------------------|--|-------------|-------------|
| <i>IIRA: Individual Investigator Research Awards</i> <i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i> <i>IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i> <i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i> <i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i> <i>REI: Recruitment of Established Investigators</i> <i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i> <i>RRS: Recruitment of Rising Stars</i> | | | | | | | |
| Rank | App. ID | Mech. | Application Title | PI or Scholar Candidate | Organization | Budget | Final Score |
| 6 | RR240016 | RFTFM | Impact of Germline Variants on Pediatric Leukemia Progression: Insights from 3D Chromatin Remodeling and Clinical Outcomes | Luan, Yu (scholar candidate) | The University of Texas Health Science Center at San Antonio | \$2,000,000 | 1.3 |
| 7 | RR240030 | REI | Break-induced DNA Replication as a Driver of Genomic Instability in Cancer | Malkova, Anna (scholar candidate) | The University of Texas Health Science Center at San Antonio | \$6,000,000 | 1.3 |
| 8 | RR240027 | RFTFM | Genomic and Epigenomic Mechanisms of Chemobrain | Dileep, Vishnu (scholar candidate) | Baylor College of Medicine | \$2,000,000 | 1.4 |
| 9 | RP240075 | IIRA CT | Combination Therapy Using ATRA and Carfilzomib to Treat Proteasome Inhibitor Refractory Multiple Myeloma | Yi, Qing | The Methodist Hospital Research Institute | \$1,921,388 | 1.5 |
| 10 | RP240291 | IIRA | Targeting MYCN disruption of the molecular clock and tumor metabolism in neuroblastoma oncogenesis | Barbieri, Eveline | Baylor College of Medicine | \$1,050,000 | 1.6 |
| 11 | RP240289 | IIRA | Real-time, label-free, micro HSI device and transformer-based attention networks for oral cancer imaging | Fei, Baowei | The University of Texas at Dallas | \$1,049,806 | 1.6 |

| Academic Research Award Recommendations Cycle 24.1 and Recruitment Cycles 24.3-24.5 | | | | | | | |
|---|----------------|--------------|---|--------------------------------|--|---------------|--------------------|
| <i>IIRA: Individual Investigator Research Awards</i> | | | | | | | |
| <i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i> | | | | | | | |
| <i>IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i> | | | | | | | |
| <i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i> | | | | | | | |
| <i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i> | | | | | | | |
| <i>REI: Recruitment of Established Investigators</i> | | | | | | | |
| <i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i> | | | | | | | |
| <i>RRS: Recruitment of Rising Stars</i> | | | | | | | |
| Rank | App. ID | Mech. | Application Title | PI or Scholar Candidate | Organization | Budget | Final Score |
| 12 | RP240125 | IIRA | Immune-Related Determinants of HPV-Associated Oropharyngeal Cancer Outcomes | Li, Guojun | The University of Texas M. D. Anderson Cancer Center | \$1,049,726 | 1.8 |
| 13 | RP240061 | IIRA | Deciphering Iron Redox Cycles in Ferroptosis- based Cancer Therapy | Lu, Yi | The University of Texas at Austin | \$1,044,608 | 1.8 |
| 14 | RP240091 | IIRA | High resolution high sensitivity photoacoustic imaging molecular guided brain tumor surgery with pilot clinical deployment | Valdes Quevedo, Pablo | The University of Texas Medical Branch at Galveston | \$1,044,967 | 1.9 |
| 15 | RP240401 | IIRA CCA | Lead Optimization, Target Engagement, and Efficacy Studies of Locally Bioavailable COX-2 inhibitors for Preventing Colon Cancer Progression in FAP Children | Hu, Ming | University of Houston | \$1,400,000 | 1.9 |
| 16 | RP240272 | IIRA CCA | The Epigenetic Impact and Therapeutic Opportunity of AR- Directed Therapy for DSRCT | Ludwig, Joseph | The University of Texas M. D. Anderson Cancer Center | \$1,398,788 | 1.9 |
| 17 | RP240184 | IIRA CT | Maximizing Antitumor Immunity Through Simultaneous Activation of the Innate and Adaptive Immune System | Hannan, Raquibul | The University of Texas Southwestern Medical Center | \$1,999,993 | 1.9 |
| 18 | RP240095 | IIRA | Targeting chitinase-3- like-1 as a novel therapy for hepatocellular carcinoma | Ju, Cynthia | The University of Texas Health Science Center at Houston | \$1,049,388 | 2.0 |

| Academic Research Award Recommendations Cycle 24.1 and Recruitment Cycles 24.3-24.5 | | | | | | | |
|---|----------|-------------|---|-------------------------|--|-------------|-------------|
| <i>IIRA: Individual Investigator Research Awards</i> <i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i> <i>IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i> <i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i> <i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i> <i>REI: Recruitment of Established Investigators</i> <i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i> <i>RRS: Recruitment of Rising Stars</i> | | | | | | | |
| Rank | App. ID | Mech. | Application Title | PI or Scholar Candidate | Organization | Budget | Final Score |
| 19 | RP240035 | IIRA | Harnessing the metabolic dependencies of mitochondrial NADK2 as a therapeutic strategy for lung cancer | Hoxhj, Gerta | The University of Texas Southwestern Medical Center | \$1,050,000 | 2.0 |
| 20 | RP240225 | IIRA | PARP16-mediated Ribosome MARYlation and Translation Control in Ovarian Cancer | Kraus,W. Lee | The University of Texas Southwestern Medical Center | \$1,049,743 | 2.0 |
| 21 | RP240259 | IIRA | Targeting Cancer- associated Lactobacillus iners to improve response to cancer therapy | Colber, Lauren | MDACC/BLI | \$1,049,427 | 2.0 |
| 22 | RP240119 | IIRA | Integrating proteolysis-targeting capability into antibodies to augment therapeutic efficacy | Liu, Qingyn | The University of Texas Health Science Center at Houston | \$1,050,000 | 2.0 |
| 23 | RP240326 | IIRA | Translation of gut commensal bacteria peptidoglycan remodeling pathway for chimeric antigen receptor T-cell therapy | Saini, Neeraj | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 | 2.0 |
| 24 | RP240311 | IIRA | Treatment planning of ADC therapy for ovarian cancer with molecular photoacoustic-ultrasonic imaging | Bouchard, Richard | The University of Texas M. D. Anderson Cancer Center | \$1,049,859 | 2.0 |
| 25 | RP240117 | IIRA | Identify radiopathomics markers to guide immunotherapy for non- small cell lung cancer | Wu, Jia | The University of Texas M. D. Anderson Cancer Center | \$1,049,906 | 2.0 |
| 26 | RP240054 | IIRA CCA | Myeloid Support of Refractory and Aggressive T-ALL at Distinct Tumor Sites | Ehrlic, Lauren | The University of Texas at Austin | \$1,400,000 | 2.0 |

| Academic Research Award Recommendations Cycle 24.1 and Recruitment Cycles 24.3-24.5 | | | | | | | |
|---|----------|-------------|---|--|--|-------------|-------------|
| <i>IIRA: Individual Investigator Research Awards</i> <i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i> <i>IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i> <i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i> <i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i> <i>REI: Recruitment of Established Investigators</i> <i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i> <i>RRS: Recruitment of Rising Stars</i> | | | | | | | |
| Rank | App. ID | Mech. | Application Title | PI or Scholar Candidate | Organization | Budget | Final Score |
| 27 | RP240237 | IIRA CCA | The Role of EWSR1- FLI1- CENP-A Signaling in Chemoresistance in Ewing Sarcoma | Kitagawa, Katsumi | The University of Texas Health Science Center at San Antonio | \$1,400,000 | 2.0 |
| 28 | RR240015 | RRS | HyperGlio - New tools to fight brain cancer with signal-enhanced magnetic resonance | Gloeggler, Stephan (scholar candidate) | The University of Texas Southwestern Medical Center | \$4,000,000 | 2.0 |
| 29 | RP240183 | IIRA | Restoring TREM2- Dependent Efferocytosis to Inhibit Obesity-Induced Liver Inflammation and Cancer Development | Liang, Shuang | The University of Texas Southwestern Medical Center | \$1,049,997 | 2.1 |
| 30 | RP240263 | IIRA | Identifying the Biological Determinants of Aggressive Meningioma | Patel, Akash | Baylor College of Medicine | \$1,049,370 | 2.1 |
| 31 | RP240392 | IIRA | Identifying Tumor Specific Vulnerabilities in Appendiceal Adenocarcinoma: A Systems Approach | Shen, John Paul | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 | 2.1 |
| 32 | RP240133 | IIRA | Modulation of blood- spinal cord barrier for tumor treatment | Qin, Zhenpeg | The University of Texas at Dallas | \$1,050,000 | 2.1 |
| 33 | RP240233 | IIRA CT | Toward Nonoperative Management of Early- Stage ER-Positive Breast Cancer | Rahimi, Asal | The University of Texas Southwestern Medical Center | \$1,999,963 | 2.1 |
| 34 | RP240127 | IIRA | Transposon Restriction, Tumor Suppression and p53 | Abrams, John | The University of Texas Southwestern Medical Center | \$1,039,356 | 2.2 |

| Academic Research Award Recommendations Cycle 24.1 and Recruitment Cycles 24.3-24.5 | | | | | | | |
|---|----------|-----------|---|----------------------------------|--|-------------|-------------|
| <i>IIRA: Individual Investigator Research Awards</i> <i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i> <i>IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i> <i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i> <i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i> <i>REI: Recruitment of Established Investigators</i> <i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i> <i>RRS: Recruitment of Rising Stars</i> | | | | | | | |
| Rank | App. ID | Mech. | Application Title | PI or Scholar Candidate | Organization | Budget | Final Score |
| 35 | RP240072 | IIRA | Dissection of CAMKK2's Tumor Cell- intrinsic and - extrinsic Roles in Prostate Cancer | Frigo, Daniel | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 | 2.2 |
| 36 | RP240288 | IIRA | Epigenetic mechanism and targeting during response to BRAFi/anti- EGFR therapy in BRAF- mutant colorectal cancers | Kopetz, Scott | The University of Texas M. D. Anderson Cancer Center | \$1,043,909 | 2.3 |
| 37 | RP240380 | IIRA | Clonal hematopoiesis for improving lung cancer risk assessment | Cheng, Chao | Baylor College of Medicine | \$1,040,316 | 2.3 |
| 38 | RP240131 | IIRA CSBC | Computational Methods for CRISPR-Based Lineage Tracing Systems | Liu, Zhandong | Baylor College of Medicine | \$1,200,000 | 2.3 |
| 39 | RR240007 | REI | Building a multi-modal platform to enable next-generation functional precision oncology | Shen, Xiling (scholar candidate) | The University of Texas M. D. Anderson Cancer Cent | \$6,000,000 | 2.3 |
| 40 | RP240214 | IIRA | Immunoprevention of Breast Cancer Brain Metastasis by Special Dendritic Cell-derived Extracellular Vesicles | Yu, Dihua | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 | 2.5 |
| 41 | RP240120 | IIRA | JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC | Zhang, Qing | The University of Texas Southwestern Medical Center | \$1,049,997 | 2.5 |
| 42 | RP240287 | IIRA | Investigating the Impact of Interferon Gamma Signaling on Therapeutic Resistance in Acute Myeloid Leukemia | Abbas, Hussein | The University of Texas M. D. Anderson Cancer Center | \$1,042,256 | 2.5 |

| Academic Research Award Recommendations Cycle 24.1 and Recruitment Cycles 24.3-24.5 | | | | | | | |
|---|----------|-------------|---|-------------------------|--|-------------|-------------|
| <i>IIRA: Individual Investigator Research Awards</i> <i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i> <i>IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i> <i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i> <i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i> <i>REI: Recruitment of Established Investigators</i> <i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i> <i>RRS: Recruitment of Rising Stars</i> | | | | | | | |
| Rank | App. ID | Mech. | Application Title | PI or Scholar Candidate | Organization | Budget | Final Score |
| 43 | RP240104 | IIRA | Characterization and optimization of novel allosteric KRAS inhibitors | Gorfe, Alemayehu | The University of Texas Health Science Center at Houston | \$1,050,000 | 2.6 |
| 44 | RP240320 | IIRA | Benzothiazepines as first-in-class inhibitors for the ribogenesis factor NVL and evaluation in preclinical colorectal cancer models | De Brabander, Jef | The University of Texas Southwestern Medical Center | \$1,049,754 | 2.6 |
| 45 | RP240143 | IIRA CCA | Leveraging Passport for Care in a Telehealth Framework to Improve Equitable Access to Survivorship Services | Gramatges, Maria | Baylor College of Medicine | \$1,399,382 | 2.6 |
| 46 | RP240208 | IIRAP | Unidos Contra el VPH: Screening Accuracy, Preference, and Uptake of HPV Self-Sampling Among Latinxs Along the US-Mexico Border | Calderon-Mora, Jessica | The University of Texas at Austin | \$1,920,007 | 2.8 |

PREVENTION GRANT AWARD RECOMMENDATIONS

The PIC unanimously recommends approval of 12 prevention grant proposals totaling \$25,902,480. The recommended grant proposals were submitted in response to the *Cancer Screening and Early Detection* and *Primary Prevention of Cancer* grant mechanisms. The Prevention Review Council (PRC) provided the prioritized list of award recommendations to the presiding officers on January 18, 2024. The PIC approved the award recommendations as presented by the PRC.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these prevention proposals met the following CPRIT funding priorities:

- Ensure a comprehensive coordinated approach to cancer research;
- Are interdisciplinary or interinstitutional;
- Have a demonstrable economic development benefit to this state; and
- Address the goals of the Texas Cancer Plan

| Prevention Award Recommendations | | | | | | | |
|--|----------------|--------------|---|---------------------|--|---------------|--------------------|
| <i>CSD: Cancer Screening and Early Detection</i> | | | | | | | |
| <i>PPC: Primary Prevention of Cancer</i> | | | | | | | |
| Rank | App. ID | Mech. | Application Title | PD | Organization | Budget | Final Score |
| 1 | PP240017 | CDS | Expanding Access to Cervical Cancer Screening through Primary HR-HPV Testing and Self-Sampling: A Multicomponent Intervention for Safety Net Health Systems | Montealegre, Jane R | The University of Texas M. D. Anderson Cancer Center | \$2,499,646 | 2.1 |
| 2 | PP240040 | CSD | Expanding Intensive Smoking Cessation and Lung Cancer Screening in Vulnerable Adult Patients in Central Texas FQHCs | Alttillo, Brandon | The University of Texas at Austin | \$2,000,000 | 2.2 |
| 3 | PP240022 | PPC | Expansion of a multi-pronged intervention to increase HPV vaccination rates among adolescents from rural and medically underserved areas in Texas | Berenson, Abbey B | The University of Texas Medical Branch at Galveston | \$2,494,865 | 2.3 |

| Prevention Award Recommendations | | | | | | | |
|--|----------------|--------------|---|----------------------|--|---------------|--------------------|
| <i>CSD: Cancer Screening and Early Detection</i> | | | | | | | |
| <i>PPC: Primary Prevention of Cancer</i> | | | | | | | |
| Rank | App. ID | Mech. | Application Title | PD | Organization | Budget | Final Score |
| 4 | PP240042 | CSD | Cancer Prevention and Outreach for Individuals Disproportionately Affected by Cancer in Medically Underserved Regions (C-CUR) | Esnaola, Nestor | The Methodist Hospital Research Institute | \$1,437,244 | 3.0 |
| 5 | PP240021 | CSD | Reducing Racial/Ethnic Disparities in Breast Cancer Screening: Expanding a Comprehensive EHR-Based Patient Navigation Program | Rustveld, Luis | Baylor College of Medicine | \$2,499,998 | 3.1 |
| 6 | PP240012 | CSD | Integrated Mammography and Genetic Evaluation Services (IMAGES) | Whitman, Gary J | The University of Texas M. D. Anderson Cancer Center | \$1,499,400 | 3.1 |
| 7 | PP240019 | CSD | Increasing Access to Successful Colorectal Cancer Screening, Pairing Patient Education and Outreach with Navigation | Argenbright, Keith E | The University of Texas Southwestern Medical Center | \$2,487,342 | 3.3 |
| 8 | PP240011 | CSD | The Advancing Breast Health among uninsured Women in Central Texas (ABH-CTX) 2 | Shokar, Navkiran K | The University of Texas at Austin | \$2,000,000 | 3.4 |
| 9 | PP240041 | PPC | Expansion of the evidence-based Adolescent Vaccination Program (AVP) in a safety net clinic system to increase HPV vaccination rates in underserved populations | Shegog, Ross | The University of Texas Health Science Center at Houston | \$1,496,194 | 3.5 |

| Prevention Award Recommendations | | | | | | | |
|--|----------------|--------------|---|---------------------|--|---------------|--------------------|
| <i>CSD: Cancer Screening and Early Detection</i> | | | | | | | |
| <i>PPC: Primary Prevention of Cancer</i> | | | | | | | |
| Rank | App. ID | Mech. | Application Title | PD | Organization | Budget | Final Score |
| 10 | PP240005 | PPC | Preventing Tobacco Related Cancers by Expanding Capacity for Tobacco Use Interventions Within Agencies Serving Women with Behavioral Health Needs | Reitzel, Lorraine R | The University of Texas M. D. Anderson Cancer Center | \$2,487,822 | 4.0 |
| 11 | PP240014 | PPC | Tiempo De Vacunarte 3 | Molokwu, Jennifer C | Texas Tech University Health Sciences Center at El Paso | \$2,500,000 | 4.1 |
| 12 | PP240030 | PPC | All for Them: A multilevel strategy for HPV-related cancer prevention | Cuccaro, Paula | The University of Texas Health Science Center at Houston | \$2,499,969 | 4.3 |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: VINCE BURGESS, CHIEF COMPLIANCE OFFICER
SUBJECT: COMPLIANCE CERTIFICATION – FEBRUARY 2024 AWARDS
DATE: FEBRUARY 16, 2024

Summary and Recommendation:

As CPRIT’s Chief Compliance Officer, I am responsible for reporting to the Oversight Committee regarding the agency’s compliance with applicable statutory and administrative rule requirements during the grant review process. I have reviewed the compliance pedigrees for the grant applications submitted to CPRIT for the:

- Recruitment of Established Investigators
- Recruitment of Rising Stars
- Recruitment of First-Time, Tenure-Track Faculty Members
- Individual Investigator Research Awards
- Individual Investigator Research Awards for Childhood and Adolescent Cancers
- Individual Investigator Research Awards for Computational Systems Biology of Cancer
- Individual Investigator Research Awards for Clinical Translation
- Individual Investigator Research Awards for Prevention and Early Detection
- Cancer Screening and Early Detection
- Primary Prevention of Cancer

I have conferred with staff at CPRIT and General Dynamics Information Technology (GDIT), CPRIT’s contracted third-party grants administrator, regarding the academic research and prevention awards and studied the supporting grant review documentation, including third-party observer reports for the peer review meetings. I am satisfied that the application review process that resulted in the above mechanisms recommended by the Program Integration Committee (PIC) followed applicable laws and agency administrative rules. I certify the academic research and prevention award recommendations for the Oversight Committee’s consideration.

Background:

CPRIT's Chief Compliance Officer must report to the Oversight Committee regarding compliance with the statute and the agency's administrative rules. Among the Chief Compliance Officer's responsibilities is the obligation "to ensure that all grant proposals comply with this chapter and rules adopted under this chapter before the proposals are submitted to the oversight committee for approval." Texas Health & Safety Code § 102.051(c) and (d).

CPRIT uses a compliance pedigree process to formally document compliance for the grant award process. The compliance pedigree tracks the grant application as it moves through the review process and documents compliance with applicable laws and administrative rules. A compliance pedigree is created for each application; the information related to the procedural steps listed on the pedigree is entered and attested to by GDIT employees and CPRIT employees. CPRIT relies on GDIT to accurately record a majority of the information on the pedigree from the pre-receipt stage to final Review Council recommendation. To the greatest extent possible, information reported in the compliance pedigree is imported directly from data contained in CPRIT's Application Receipt System (CARS), the grant application database managed by GDIT. This is done to minimize the opportunity for error caused by manual data entry.

No Prohibited Donations:

Although CPRIT is statutorily authorized to accept gifts and grants pursuant to Texas Health & Safety Code § 102.054, the statute prohibits CPRIT from awarding a grant to an applicant who has made a gift or grant to CPRIT, or a nonprofit organization established to provide support to CPRIT. I note that Texas Health & Safety Code § 102.251(a)(3) specifically addresses "donors from any nonprofit organization established to provide support to the institute compiled from information made available under § 102.262(c)." To the best of my knowledge, there are no nonprofit organizations that have been established to provide support to CPRIT on or after June 14, 2013, the effective date of this statutory change. The only nonprofit organization established to provide support to the Institute was the CPRIT Foundation; however, the CPRIT Foundation ceased operations and changed its name and its purpose prior to June 14, 2013. The institute has received no donations from the CPRIT Foundation made on or after June 14, 2013.

I have reviewed the list of donors to CPRIT maintained by CPRIT (and listed on CPRIT's website) and compared the donors to the list of applicants. No donors to CPRIT have submitted applications for grant awards during the award cycles that are the subject of this report.

Pre-Receipt Compliance:

The activities listed on a compliance pedigree in the pre-receipt stage cover the period beginning with CPRIT's approval and issuance of the Request for Applications (RFA) through the submission of grant applications. For the period covering these RFAs, CPRIT published the

RFAs on the Texas.gov eGrants website. The RFA specifies a deadline and mandates that only those applications submitted electronically through CPRIT's Application Receipt System (CARS) are eligible for consideration. CARS blocks an application from being submitted once the deadline passes. Occasionally, an applicant may have technical difficulties that prevent the applicant from completing the application submission. When this occurs, the applicant may appeal to CPRIT (through the CPRIT Helpdesk that is managed by GDIT) to allow for a submission after the deadline. The program officer considers any requests for extension and may approve an extension for good cause. When a late filing request is approved, the applicant is notified, and CARS is reopened for a brief period – usually two to three hours – the next business day.

Academic Research:

For recruitment cycles 24.3, 24.4 and 24.5, three applications were received for the Recruitment of Established Investigators RFA, six applications were received for the Recruitment of Rising Stars RFA, and four applications were received in response to the Recruitment of First-Time, Tenure Track Faculty Members RFA. One recruitment application was withdrawn by the applicant after the Scientific Review Council (SRC) meeting but prior to the (Program Integration Committee) PIC meeting.

In response to the academic, non-recruitment RFAs for cycle 24.1, CPRIT received 315 applications. Four applications were administratively withdrawn, and one application was voluntarily withdrawn by the applicant.

All academic research RFAs were posted on the Texas.gov eGrants website and all applications were submitted through CARS. Three applicants requested an extension to submit an application after the deadline. The program officer determined that there was good cause for the requests and the deadline was extended.

Prevention:

For prevention cycle 24.1, 16 applications were received for the Cancer Screening and Early Detection RFA and 13 applications were received for the Primary Prevention of Cancer RFA. Three prevention applications were administratively withdrawn for being non-responsive to the RFA.

All prevention RFAs were posted on the Texas.gov eGrants website and all applications were submitted through CARS. Two applicants requested an extension to submit an application after the deadline. The program officer determined that there was good cause for both requests and the deadline was extended.

Receipt, Referral, and Assignment Compliance:

Once applications have been submitted through CARS, GDIT staff reviews the applications for compliance with RFA directions. If an applicant does not comply with the directions, GDIT notifies the program officer, and the program officer makes the final decision whether to administratively withdraw the application. Recruitment grant applications are assigned to the Scientific Review Council members for peer review. All other academic research, product development research, and prevention applications are assigned by the peer review panel chair to their respective peer review panels. Prior to distribution of the applications, reviewers are given summary information about the applicant, including the Project Director and collaborators. Reviewers must sign a conflict of interest agreement and confirm that they do not have a conflict of interest with the application before they are provided with the full application.

The pedigrees attest that a conflict of interest statement was signed by each primary reviewer for each Grant Application.

Academic Research:

Six academic research applications were withdrawn during this cycle: four non-recruitment applications were administratively withdrawn prior to peer review, one non-recruitment application was voluntarily withdrawn by the applicant prior to assignment and one recruitment application was withdrawn by the applicant after the SRC meeting but prior to the PIC meeting.

Prevention:

Three prevention applications were administratively withdrawn prior to peer review assignment.

Peer Review:

Primary reviewers (typically three) must submit written critiques for each of their assigned applications prior to the peer review meeting. Sign out sheets are used to document when a reviewer with a conflict of interest associated with a particular application leaves the room (or disengages from the conference call) during the discussion and scoring of the application.

Following the peer review meeting, each participating peer reviewer must sign a post-review peer review statement certifying that the reviewer knew of and understood CPRIT's conflict of interest policy and followed the policy for this review process. After the peer review meetings, a final score report from the review committee is delivered to the Review Council for additional review.

Academic Research:

For the recruitment awards, the applications are reviewed by the Scientific Review Council (SRC), which assigns two members of the SRC to be primary reviewers. I reviewed the supporting documentation, such as the sign-out sheets, third-party observer reports, and post-review peer reviewer statements. Sign out sheets are used to document when a reviewer with a conflict of

interest associated with a particular application leaves the room (or disengages from the conference call) during the discussion and scoring of the application. No conflicts of interest were declared by the SRC for recruitment cycles 24.3, 24.4 and 24.5.

I reviewed and confirmed that the post review conflict of interest statements were signed by the eight SRC members that attended the 24.3-4 Recruitment Review Panel meeting on November 16, 2023 and the eight SRC members that attended the 24.5 Recruitment Review Panel on December 14, 2023.

Academic research applications (non-recruitment) are reviewed by peer review panels and recommended to the SRC. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in the Individual Investigator Mechanisms in this cycle. This process allows the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments. A total of 228 applications across the five Individual Investigator mechanisms were recommended for full review and of those, 101 applications received a full onsite peer review. As documented by GDIT, reviewers with conflicts of interest did not participate in review of those applications. I reviewed supporting documentation, such as conflict of interest statements (COIs), third-party observer reports, and sign out sheets. All declared COIs left the room or disengaged from the conference call and did not participate in the discussion of relevant applications.

I also reviewed and confirmed that the post review conflict of interest statements were signed by peer review members for each review panel as well as the eight SRC members that attended the Review Council meeting on December 14, 2023.

Prevention:

All Prevention applications, except for the Dissemination of CPRIT-Funded Cancer Control Interventions RFA, are reviewed by peer review panels and then sent to the PRC. For the Dissemination of CPRIT-Funded Cancer Control Interventions RFA, which is not part of the slate of awards in cycle 24.1, the applications are reviewed by the Prevention Review Council (PRC), which assigns two members of the PRC to be primary reviewers.

I reviewed the supporting documentation, such as the sign-out sheets, third-party observer reports, and post-review peer reviewer statements. As documented by GDIT and verified by third-party observer reports, reviewers with conflicts of interest did not participate in review of those applications. All declared COIs left the room or disengaged from the conference call and did not participate in the discussion of relevant applications.

I reviewed and confirmed that the post review conflict of interest statements were signed by the 17 peer review members for Prevention Panel 1 (Day 1) on December 5, 2023, the 18 peer review

members for Prevention Panel 1 (Day 2) on December 6, 2023, and the three PRC members that attended the Review Council meeting on January 12, 2024.

Programmatic Review:

Programmatic review is conducted by the Scientific Review Council, Prevention Review Council, and Product Development Review Council for their respective awards. Each review council creates a final list of grant applications it will recommend to the PIC for grant award slates.

To the extent that any Review Council member identified a conflict of interest, I reviewed documentation confirming that the review council member did not participate in the discussion or vote on the application(s).

I also reviewed the third-party observer reports for each Review Council meeting. The third-party observer reports document that the Review Council discussions were limited to the merits of the applications and established evaluation criteria and that conflicted reviewers, if applicable, exited the room or the conference call when the application was discussed.

For the Academic Research and Prevention awards, I reviewed and confirmed that the Review Council recommendations corresponded to RFAs that had been released. I also confirmed that the pedigrees reflect the date of the Review Council meeting and that the applications were recommended by the Review Council.

Academic Research:

The SRC met on December 14, 2023, to consider 45 applications recommended by the peer review panels following their meetings held on October 11, 13, and 17-20, 2023. After review of these applications, the SRC recommended 45 applications to the Program Integration Committee (PIC) for consideration. In addition, eight academic recruitment applications were recommended to the PIC by the SRC at their meetings on November 16, 2023, and December 14, 2023.

I note that some non-recruitment grant applications are not recommended for funding with scores that are the same as or more favorable than some applications that were recommended within each mechanism. An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. This means that each peer review panel independently sets a cut-off score that determines which applications move forward to the SRC. A panel's cut off score may be different than other the cut off score of other panels. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

Prevention:

Twelve applications were recommended by the peer review panel to the PRC. After review and discussion of these applications, the PRC recommended all 12 applications to the PIC for consideration.

Program Integration Committee (PIC) Review:

Texas Health & Safety Code § 102.051(d) requires the Chief Compliance Officer to attend and observe the PIC meetings to ensure compliance with CPRIT's statute and administrative rules. CPRIT's statute requires that, at the time the PIC's final Grant Award recommendations are formally submitted to the Oversight Committee, the Chief Executive Officer shall prepare a written affidavit for each Grant Application recommended by the PIC containing relevant information related to the Grant Application recommendations.

I attended the February 7, 2024, PIC meeting as an observer and confirm that the PIC review process complied with CPRIT's statute and administrative rules. All five PIC members were present for the meeting.

Fifty-three applications were recommended by the SRC to the PIC; however, one recruitment applicant withdrew after the SRC meeting and prior to the PIC resulting in 52 academic research applications considered by the PIC. In total, the PIC considered 64 applications: 52 academic research and 12 prevention applications. Because the SRC recommendations exceeded available funds, Dr. Le Beau suggested that the PIC not recommend six academic research applications. Therefore, the PIC recommended 46 of the 52 academic research applications to the Oversight Committee. Cumulatively, the PIC unanimously voted to recommend 58 applications to move forward to the Oversight Committee.

I note that of the six applications that the PIC did not recommend, four have scores that are more favorable or the same as an application that was recommended by the PIC to the Oversight Committee. This application was the only Individual Investigator Research Award for Prevention and Early Detection (IIRAP) application during this cycle to receive a recommendation from the SRC to the PIC. The SRC recommended this application to the PIC after the peer review panels scored it with the highest score of all the IIRAP applications reviewed during this cycle.

A review of the CEO affidavits confirms that such affidavits were executed and provided for each grant application recommendation.

**The original certification was dated February 9, 2024. The updated certification contains additional explanation about the PIC's decision not to recommend six academic research applications and how that decision affected the rank order list from the PIC to the OC.*



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2024—Cycle 1
*Individual Investigator Research Awards***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-24.1-IIRA

Individual Investigator Research Awards

**Please also refer to the Instructions for Applicants document,
which will be posted on March 15, 2023**

Application Receipt Opening Date: March 15, 2023

Application Receipt Closing Date: June 14, 2023

FY2024

Fiscal Year Award Period

September 1, 2023–August 31, 2024

TABLE OF CONTENTS

| | |
|--|-----------|
| 1. BRIEF DESCRIPTION OF RFA | 4 |
| 2. ABOUT CPRIT | 4 |
| 2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES | 4 |
| 3. RATIONALE | 5 |
| 4. RESEARCH OBJECTIVES | 6 |
| 5. FUNDING INFORMATION | 6 |
| 6. ELIGIBILITY | 7 |
| 7. RESUBMISSION POLICY | 9 |
| 8. RENEWAL POLICY | 9 |
| 9. RESPONDING TO THIS RFA | 9 |
| 9.1. APPLICATION SUBMISSION GUIDELINES | 9 |
| 9.1.1. <i>Submission Deadline Extension</i> | 10 |
| 9.2. APPLICATION COMPONENTS | 10 |
| 9.2.1. <i>Abstract and Significance (5,000 characters)</i> | 10 |
| 9.2.2. <i>Layperson’s Summary (2,000 characters)</i> | 11 |
| 9.2.3. <i>Specific Aims and Sub-Aims</i> | 11 |
| 9.2.4. <i>Timeline (1 page)</i> | 11 |
| 9.2.5. <i>Specific Aims (1 Page)</i> | 11 |
| 9.2.6. <i>Resubmission Summary (2 pages)</i> | 12 |
| 9.2.7. <i>Renewal Summary (2 pages)</i> | 12 |
| 9.2.8. <i>Research Plan (10 pages)</i> | 12 |
| 9.2.9. <i>Vertebrate Animals (1 page)</i> | 13 |
| 9.2.10. <i>Human Subjects (2 pages)</i> | 13 |
| 9.2.11. <i>Publications/References</i> | 13 |
| 9.2.12. <i>Budget and Justification</i> | 13 |
| 9.2.13. <i>Biographical Sketches (5 pages each)</i> | 14 |
| 9.2.14. <i>Current and Pending Support</i> | 14 |
| 9.2.15. <i>Institutional/Collaborator Support and/or Other Certification (4 pages)</i> | 15 |
| 9.2.16. <i>Previous Summary Statement</i> | 15 |
| 9.3. FORMATTING INSTRUCTIONS | 15 |
| 10. APPLICATION REVIEW | 16 |
| 10.1. PRELIMINARY EVALUATION..... | 16 |
| 10.2. FULL PEER REVIEW | 17 |
| 10.3. CONFIDENTIALITY OF REVIEW | 17 |
| 10.4. REVIEW CRITERIA..... | 18 |
| 10.4.1. <i>Primary Criteria</i> | 18 |
| 10.4.2. <i>Secondary Criteria</i> | 19 |
| 11. KEY DATES | 20 |
| 12. AWARD ADMINISTRATION | 20 |
| 13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS | 21 |
| 14. CONTACT INFORMATION | 22 |
| 14.1. HELPDESK..... | 22 |
| 14.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS | 22 |

RFA VERSION HISTORY

- 2/17/23 RFA released
- 5/16/23 Modified section 9.2.13 – Biographical Sketches; included the following updated language: “Up to 5 additional biographical sketches for key personnel may be provided, these should be concatenated into a single PDF with a 25-page limit.”

1. BRIEF DESCRIPTION OF RFA

- Supports applications for innovative research projects addressing critically important questions that will significantly advance knowledge of the causes, prevention, and/or treatment of cancer.
- Applicants may request a maximum of \$350,000 per year for a 3-year period.
- Multi-Principal Investigators (PIs) (MIs) are allowed under this RFA. See the Information for Applicants (IFA) document for definition and eligibility of MIs.
- Note that CPRIT does not allow the use of the term Co-PI.
- Minimum effort for the PI and/or MIs throughout the project period is required.

2. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

2.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state
- Reducing cancer disparities

The program priorities for academic research adopted by the Oversight Committee include funding projects that address or utilize the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials

3. RATIONALE

The goals of the CPRIT Academic Research Grants Program are to support the discovery of new information about cancer that can lead to prevention, early detection, and cures and to translate new and existing discoveries into practical advances in cancer diagnosis and treatment. CPRIT encourages applications that seek new fundamental knowledge about cancer and cancer development as well as those attempting to develop state-of-the-art technologies, tools, computational models, and/or resources for cancer research, including those with potential commercialization opportunities. This award allows experienced or early-career-stage cancer researchers the opportunity to explore new methods and approaches for investigating a question of importance that has been inadequately addressed or for which there may be an absence of an established paradigm or technical framework. CPRIT will look with special favor on new approaches to be taken or new areas of investigation to be explored by established investigators and on supporting the research programs of the most promising investigators at the beginning of their research careers. Applicants need not be trained specifically in cancer research. Indeed, CPRIT strongly encourages investigators from other fields, including the mathematical and computational modeling, physical, chemical, and engineering sciences, to bring their expertise to bear on the exceptionally challenging problems posed by cancer. CPRIT expects outcomes of supported activities to directly and indirectly benefit subsequent cancer research efforts, cancer

public health policy, and efforts to reduce cancer disparities on the continuum of cancer care—from prevention to early detection, treatment, and survivorship.

To fulfill this vision, applications may address any topic or issue related to cancer, including cancer biology, computational modeling, and systems biology, causation, prevention, detection or screening, treatment, or survivorship. Successful applicants should be working in a research environment capable of supporting potentially high-impact studies. Access to a clinical environment and interaction with translational cancer physician-scientists are highly desirable.

4. RESEARCH OBJECTIVES

CPRIT will foster cancer research in Texas by providing financial support for a wide variety of projects relevant to cancer research. This Request for Applications (RFA) solicits applications for innovative research projects addressing critically important questions that will significantly advance knowledge of the causes, prevention, and/or treatment of cancer. The goal of awards made in response to this RFA is to fund exceptionally innovative research projects with great potential impact that are directed by a single or multiple investigators. Areas of interest include laboratory research, translational studies, and/or clinical investigations. In that cancers arise from a large number of derangements of basic molecular and cellular functions and, in turn, cause many alterations in basic biological processes, almost any aspect of biology may be relevant to cancer research, more or less directly. The *degree of relevance* to cancer research is a critical criterion for evaluation of projects for funding by CPRIT ([section 10.4.1](#)). For example, are alterations in the process in question *primarily* responsible for oncogenesis or secondary manifestations of malignant transformation? Will understanding the process or interfering with it offer selective and useful insight into prevention, diagnosis, or treatment of cancer? *Successful applicants for funding from CPRIT will have addressed these questions satisfactorily.*

5. FUNDING INFORMATION

Applicants may request a maximum of \$350,000 in total costs per year for up to 3 years for research. Exceptions to these limits may be requested if extremely well justified (see [section 9.2.12](#)). Funds may be used for salary and fringe benefits, research supplies, equipment, subject participation costs, and travel to scientific/technical meetings or collaborating institutions. Requests for funds to support construction and/or renovation will not be approved under this

funding mechanism. State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount.

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism; these entities must use the appropriate award mechanism(s) under CPRIT's Product Development Research Program.
- The PI must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and must be a full-time resident of Texas during the time the research that is the subject of the grant is conducted.
- This award mechanism allows MIs for projects that require a team science approach (see the IFA for guidelines on CPRIT rules for MI awards).
- For applications that include 1 PI, the PI is required to maintain a minimum 15% level of effort throughout the entire award period. For applications that include MIs, each PI is required to maintain a minimum 10% effort throughout the entire award period.
- A PI may not submit applications to this RFA and to RFA R-24.1-IIRACSBC, RFA R-24.1-IIRACCA, RFA R-24.1-IIRACT, or RFA R-24.1-IIRAP.
- A PI may submit only 1 application, either a new, resubmission or renewal application under this RFA during this funding cycle.
- A PI may be a part of only 1 application, whether as a single applicant or as part of an MI application, under this RFA and RFA R-24.1-IIRACSBC, RFA R-24.1-IIRACCA, RFA R-24.1-IIRACT, or RFA R-24.1-IIRAP.
- An individual may serve as a PI on no more than 3 active CPRIT Academic Research grants. Recruitment Grants and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers MIRA Project Co-PIs equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be March 1, 2024).

- Applications that address prevention and early detection population-based studies, cancers in children and adolescents, computational systems biology of cancer, or innovative clinical trials should be submitted under the appropriate targeted RFA.
- Collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity) has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, regardless of whether these individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 12](#) and [section 13](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted **once** and must follow all resubmission guidelines. More than 1 resubmission is not permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the PI for a project or a change of title of the project that was previously submitted to CPRIT or omission or modification of an aim does not constitute a new application; the application would be considered a resubmission. This policy is in effect for all applications submitted to date. See [section 9.2.6](#).

8. RENEWAL POLICY

An application funded by CPRIT under this mechanism may be submitted for a competitive renewal. This policy is in effect for all awards submitted to date. See [section 9.2.7](#). Competitive renewals are not subject to preliminary evaluation. Renewal applications move directly to the full peer review phase. See [section 10.2](#).

9. RESPONDING TO THIS RFA

9.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on March 15, 2023, and must be submitted by 4 PM central time on June 14, 2023. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

9.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

9.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the IFA for details that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

9.2.1. Abstract and Significance (5,000 characters)

It is the responsibility of the applicant to capture CPRIT's attention primarily with the Abstract and Significance statement alone. Therefore, applicants are advised to prepare this section wisely. **Based on the Abstract and Significance statement (and the Specific Aims page, Budget and Justification and Biographical Sketches), applications that are judged to offer only modest contributions to the field of cancer research or that do not sufficiently capture the reviewers' interest may be excluded from further peer review (see [section 10.1](#)).**

Applicants should not waste this valuable space by stating obvious facts (eg, that cancer is a significant problem; that better diagnostic and therapeutic approaches are needed urgently; or that the type of cancer of interest to the PI is important, vexing, or deadly).

Clearly explain the question or problem to be addressed and the approach to its answer or solution. The specific aims of the application must be obvious from the abstract although they need not be restated verbatim from the research plan.

Clearly address how the proposed project, if successful, will have a major impact on cancer. Indicate whether this research will address cancers associated with disparities. Summarize how

the proposed research creates new paradigms or challenges existing ones. Indicate whether this research plan represents a new direction for the PI.

9.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detection, prevention, treatment, or survivorship. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. **Do not include any proprietary information in the layperson's summary.** The layperson's summary will also be used by advocate reviewers ([section 10.2](#)) in evaluating the significance and impact of the proposed work.

9.2.3. Specific Aims and Sub-Aims

Please provide a description of the Aims and Sub-aims and milestones to be achieved for each year of the project. Provide 2-3 sentences describing activities to be performed and anticipated milestones. These Aims will also be used during the submission and evaluation of progress reports and assessment of project success.

9.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications.

If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

9.2.5. Specific Aims (1 Page)

Please provide a 1-page summary of the aims of the proposal. The Specific Aims page should identify the problem, or gap in our current knowledge. It should present a hypothesis and briefly describe the aims and approaches. Address the proposal's innovation, novel approaches and

significance and impact on the field and cancer research. Please also refer to the template located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.6. Resubmission Summary (2 pages)

Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

Note: An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to need considerable attention. Applicants may prepare a fresh research plan or modify the original research plan and mark the changes. However, **all resubmitted applications should be carefully reconstructed**; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes.

9.2.7. Renewal Summary (2 pages)

Applicants preparing a renewal must describe and demonstrate that appropriate/adequate progress has been made on the current funded award to warrant further funding. Publications and manuscripts in press that have resulted from work performed during the initial funded period should be listed in the renewal summary.

9.2.8. Research Plan (10 pages)

Background: Present the rationale behind the proposed project, emphasizing the pressing problem in cancer research that will be addressed.

Hypothesis and Specific Aims: Concisely state the hypothesis and/or specific aims to be tested or addressed by the research described in the application. Describe the significance, innovation, and potential impact of the research.

Research Strategy: Describe the experimental design, including methods, anticipated results, potential problems or pitfalls, and alternative approaches. Preliminary data that support the proposed hypothesis are encouraged but not required.

9.2.9. Vertebrate Animals (1 page)

If vertebrate animals will be used, provide a detailed plan of the protocols that will be followed and justification for the number of animals used with reference to biostatistical input for sample selection and evaluation. Certification of approval by the institutional IACUC of the proposed animal use will be required before funding can occur.

9.2.10. Human Subjects (2 pages)

If human subjects or human biological samples will be used, provide a detailed plan for recruitment of subjects and/or the acquisition of samples that will meet the time constraints of this award mechanism. Certification of approval of these plans by the institutional IRB will be required before funding can occur.

9.2.11. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

9.2.12. Budget and Justification

Provide a compelling and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, supplies, equipment, patient care costs, animal care costs, and other expenses. Applicants are advised not to interpret the maximum allowable request under this award as a suggestion that they should expand their anticipated budget to this level. Reasonable budgets clearly work in favor of the applicant.

However, if there is a highly specific and defensible need to request more than the maximum amount in any year(s) of the proposed budget, include a special and clearly labeled section in the budget justification that explains the request. Poorly justified requests of this type will likely have a negative impact on the overall evaluation of the application.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding

indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.

- The maximum annual salary (also referred to as direct salary or institutional base salary) that an individual may request under a CPRIT award for FY 2024 is \$200,000; CPRIT FY 2024 is from September 1, 2023, through August 31, 2024. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

9.2.13. Biographical Sketches (5 pages each)

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research. A biographical sketch must be provided for the PI and, if applicable, any additional PIs (if an MI application), as required by the online application receipt system. Up to 5 additional biographical sketches for key personnel may be provided, these should be concatenated into a single PDF with a 25-page limit. Each biographical sketch must not exceed 5 pages. The NIH biosketch format is appropriate.

9.2.14. Current and Pending Support

Describe the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project, and, if relevant, a statement of overlap with the current application. At a minimum, current and pending support of the PI and, if applicable, any additional PIs (if an MI application) must be provided. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.15. Institutional/Collaborator Support and/or Other Certification (4 pages)

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 4 pages may be provided.

9.2.16. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or that do not meet the eligibility requirements listed above will be administratively rejected without review.

9.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters

are also acceptable as long as the journal information is stated. Include URLs of publications referenced in the application.

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45-67.

- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

10. APPLICATION REVIEW

10.1. Preliminary Evaluation

To ensure the timely and thorough review of only the most innovative and cutting-edge research with the greatest potential for advancement of cancer research, all eligible applications may be preliminarily evaluated by CPRIT Scientific Research Program panel members for scientific merit and impact.

This preliminary evaluation will be based on a subset of material presented in the application—namely, Abstract and Significance, Specific Aims page, Budget and Justification, and Biographical Sketches. Applications that do not sufficiently capture the reviewers' interest at this stage will not be considered for further review. Such applications will have been judged to offer only modest contributions to the field of cancer research and will be excluded from further peer review.

The applicant will be notified of the decision to disapprove the application after the preliminary evaluation stage has concluded. Due to the volume of applications to be reviewed, comments made by reviewers at the preliminary evaluation stage may be limited.

10.2. Full Peer Review

Applications that pass preliminary evaluation will undergo further review using a 2-stage peer review process: (1) Full peer review and (2) Prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 10.4](#). In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by the Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

10.3. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules ([Texas Administrative Code RULE §703.9](#)).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee Member, a PIC Member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Research Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

10.4. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

10.4.1. Primary Criteria

Primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

Significance and Impact: Will the results of this research, if successful, significantly change the research of others or the opportunities for better cancer prevention, diagnosis, or treatment for patients? Is the application innovative? Does the applicant propose new paradigms or challenge existing ones? Does the project develop state-of-the-art technologies, methods, tools, or resources for cancer research or address important underexplored or unexplored areas? If the research project is successful, will it lead to truly substantial advances in the field rather than add modest increments of insight? Projects that modestly extend current lines of research will not be considered for this award. Projects that represent straightforward extensions of ongoing work, especially work traditionally funded by other mechanisms, will not be competitive.

Research Plan: Is the proposed work presented as a self-contained research project? Does the proposed research have a clearly defined hypothesis or goal that is supported by sufficient preliminary data and/or scientific rationale? Are the methods appropriate, and are potential experimental obstacles and unexpected results discussed?

Applicant Investigator: Does the investigator(s) demonstrate the required creativity and expertise to make a significant contribution to the research? Applicants' credentials will be evaluated in a career stage-specific fashion. Have early-career-stage investigators received excellent training, and do their accomplishments to date offer great promise for a successful career? Has the applicant(s) devoted a sufficient amount of their time (percent effort) to this project?

Relevance: Does the proposed research have a high degree of relevance to cancer research? This is a critical criterion for evaluation of projects for CPRIT support.

10.4.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research.

Secondary criteria include the following:

Research Environment: Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the proposed research? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support of the research team and the project?

Vertebrate Animals and/or Human Subjects: Is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed?

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

11. KEY DATES

RFA

RFA release February 17, 2023

Application

Online application opens March 15, 2023, 7 AM central time

Application due June 14, 2023, 4 PM central time

Application review June 2023–February 2024

Award

Award notification February 2024

Anticipated start date March 1, 2024

12. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT’s electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT’s electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT’s Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT’s Administrative Rules related to

contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12.](#)

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20.](#)

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. A grant recipient that is a public or private institution of higher education, as defined by §61.003, Texas Education Code, may credit toward the Grant Recipient's Matching Funds obligation the dollar amount equivalent to the difference between the indirect cost rate authorized by the federal government for research grants awarded to the Grant Recipient and the 5% indirect cost limit imposed by §102.203(c), Texas Health and Safety Code. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11,](#) for specific requirements regarding demonstration of available funding. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted.

14. CONTACT INFORMATION

14.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

14.2. Scientific and Programmatic Questions

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Director of Academic Research.

Tel: 512-305-8491

Email: research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel - Basic Cancer

Research-1 (24.1_AR_BCR-1)

Observation Report

Report No. 2023-10-20 24.1_AR_BCR-1
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel - Basic Cancer Research-1
(24.1_AR_BCR-1)
Panel Date: October 20, 2023
Report Date: October 26, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel - Basic Cancer Research-1 (24.1_AR_BCR-1) meeting. The meeting was chaired by Eric Fearson and conducted via videoconference on October 20, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and twenty-three (23) applications were not discussed
- Panelists: One (1) panel chair, thirteen (13) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were five (5) Conflict of Interest (COI) identified prior to and/or during the meeting. Two (2) applications with COIs were discussed and two (2) applications with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel – Basic Cancer Research (24.1 ACR-BCR-2) Observation Report

Report No. 2023-10-11 24.1_ACR-BCR-2
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel – Basic Cancer Research
(24.1 _ACR-BCR-2)
Panel Date: October 11, 2023
Report Date: October 16, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel – Basic Cancer Research (24.1_ACR-BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on October 11, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and thirty (30) applications were not discussed
- Panelists: One (1) panel chair, Nineteen (19) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Eight (8)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were nine (9) Conflicts of Interest (COI) identified prior to and/or during the meeting. COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel - Basic Cancer

Research (24.1 ACR CPR)

Observation Report

Report No. 2023-10-13 24.1_ACR CPR
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel - Basic Cancer Research
(24.1 _ACR CPR)
Panel Date: October 13, 2023
Report Date: October 16, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel - Basic Cancer Research (24.1_ACR CPR) meeting. The meeting was chaired by Elena Martinez and conducted via videoconference on October 13, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Ten (10) applications were discussed and eleven (11) applications were not discussed
- Panelists: One (1) panel chair, twelve (12) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Seven (7)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflict of Interest (COI) identified prior to and/or during the meeting. Two (2) applications with COIs were discussed and one (1) application with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
24.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (24.1_ACR-CTCR)
Observation Report

Report No. 2023-10-17 24.1_ACR-CTCR
Program Name: Academic Research
Panel Name: 24.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (24.1_ACR-CTCR)
Panel Date: October 17, 2023
Report Date: October 23, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Clinical and Translational Cancer Research (C/TCR) (24.1_ACR-CTCR) meeting. The meeting was chaired by Richard O'Reilly and Margaret Tempero and conducted via videoconference on October 17, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty-one (21) applications were discussed and thirty-five (35) applications were not discussed
- Panelists: Two (2) panel chair, seventeen (17) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflict of Interest (COI) identified prior to and/or during the meeting. Two (2) applications with COIs were discussed and two (2) applications with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel – Imaging Technology and Informatics (24.1 ACR ITI) Observation Report

Report No. 2023-10-19 24.1_ACR-ITI
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel – Imaging Technology and Informatics (24.1 _ACR-ITI)
Panel Date: October 19, 2023
Report Date: October 26, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel – Imaging Technology and Informatics (24.1_ACR-ITI) meeting. The meeting was co-chaired by Anna Wu, Henry VanBrocklin, and Jason Lewis, in lieu of Martin Pomper and conducted via videoconference on October 19, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Sixteen (16) applications were discussed and thirteen (13) applications were not discussed
- Panelists: Three (3) panel chairs, thirteen (13) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were twelve (12) Conflicts of Interest (COI) identified prior to and/or during the meeting. Four (4) applications with a COI were discussed and three (3) applications with a COI were not discussed. COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Scientific Review Council (24.1 SRC) Observation Report

Report No. 2023-12-14 24.1_SRC
Program Name: Academic Research
Panel Name: 24.1 Academic Research Scientific Review Council (24.1 _SRC)
Panel Date: December 14, 2023
Report Date: January 17, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Scientific Review Council (24.1_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 14, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Forty- five (45) applications were discussed
- Panelists: One (1) panel chair, and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 24.1

Awards Announced at the February 21, 2024, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 24.1 include: *Individual Investigator Research Awards*; *Individual Investigator Research Awards for Cancer in Children and Adolescents*; *Individual Investigator Research Awards for Computational Systems Biology of Cancer*; *Individual Investigator Research Awards for Clinical Translation*; and *Individual Investigator Research Awards for Prevention and Early Detection*. Applications submitted in response to these five award mechanisms went through preliminary evaluation as allowed by TAC § 703.6(e)(1).

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|--|------------------------|--|------------------------------------|
| Applications considered by the PIC and Oversight Committee: | | | |
| RP240127 | John Abrams | The University of Texas Southwestern Medical Center | Benjamin Greenbaum |
| RP240072 | Daniel Frigo | The University of Texas M. D. Anderson Cancer Center | Steffi Oesterreich |
| RP240125 | Guojun Li | The University of Texas M. D. Anderson Cancer Center | Electra Paskett; Thomas Brandon |
| RP240272 | Joseph Ludwig | The University of Texas M. D. Anderson Cancer Center | Richard O'Reilly |
| RP240117 | Jia Wu | The University of Texas M. D. Anderson Cancer Center | Charles Kahn; Maryellen Giger |

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|---|------------------------|--|-------------------------------|
| RP240311 | Richard Bouchard | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger; Weibo Cai |
| RP240291 | Eveline Barbieri | Baylor College of Medicine | Craig Rosenfeld |
| Applications not considered by the PIC or Oversight Committee: | | | |
| RP240101 ^a | Sang Eun Lee | The University of Texas Health Science Center at San Antonio | Alan Tomkinson; John Petrini |
| RP240118 | Elizabeth Goldsmith | The University of Texas Southwestern Medical Center | Alan Tomkinson |
| RP240236 | Katharina Schlacher | The University of Texas M. D. Anderson Cancer Center | John Petrini |
| RP240270 | Giulio Draetta | The University of Texas M. D. Anderson Cancer Center | Eileen White; Nabeel Bardeesy |
| RP240364 | Christopher Amos | Baylor College of Medicine | Alan Tomkinson |
| RP240399 | Jonathan Sessler | The University of Texas at Austin | Nabeel Bardeesy |
| RP240368 | Zhaoyong Hu | Baylor College of Medicine | Steffi Oesterreich |
| RP240106 | Michelle Hildebrandt | The University of Texas M. D. Anderson Cancer Center | Electra Paskett |
| RP240240 | Maria Swartz | The University of Texas M. D. Anderson Cancer Center | Electra Paskett |
| RP240112 | Jianjun Zhang | The University of Texas M. D. Anderson Cancer Center | Antoni Ribas |
| RP240340 | Kareem Azab | The University of Texas Southwestern Medical Center | John DiPersio |
| RP240354 | Charles Reynolds | Texas Tech University Health Sciences Center | W. Martin Kast |

^a The PIC did not recommend this application to the Oversight Committee.

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|-----------------------------------|------------------------|--|--|
| RP240044 | Jingfei Ma | The University of Texas M. D. Anderson Cancer Center | Charles Kahn; David Mankoff; Martin Pomper |
| RP240056 | David Fuentes | The University of Texas M. D. Anderson Cancer Center | David Mankoff; Maryellen Giger |
| RP240066 | Xiankai Sun | The University of Texas Southwestern Medical Center | Anna Wu |
| RP240088 | Hongyu Wang | The University of Texas Health Science Center at Houston | Charles Kahn |
| RP240141 | Jian Gu | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger |
| RP240018 | Lan Zhou | The Methodist Hospital Research Institute | Eric Fearon; Weiping Zou |
| RP240299 | Wen Jiang | The University of Texas M. D. Anderson Cancer Center | Kristin Swanson |
| RP240396 | Leonidas Bleris | The University of Texas at Dallas | Alexander Anderson |
| RP240409 | Tae Jin Lee | The University of Texas Health Science Center at Houston | Kristin Swanson |
| RP240177 (preliminary evaluation) | Hays Rye | Texas AgriLife Research | Benjamin Raphael |
| RP240410 (preliminary evaluation) | Murugesan Palaniappan | Baylor College of Medicine | Steffi Oesterreich |
| RP240140 (preliminary evaluation) | Sang Cho | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger |
| RP240221 (preliminary evaluation) | Tinsu Pan | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger |

De-Identified Overall Evaluation Scores

Individual Investigator Research Awards

Academic Research Cycle 24.1

Final Scores for Fully Reviewed Applications

Some Individual Investigator Research Awards grant applications are not recommended for funding with scores that are the same as or more favorable than applications that were recommended. An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding.

This comprehensive list of Individual Investigator Research Awards de-identified application scores created for the purpose of this CEO affidavit packet combines the information for all Academic Research review panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not. Within each panel, no application with a less favorable score was recommended ahead of an application with a more favorable score.

| Application ID | Final Overall Evaluation Score |
|----------------|--------------------------------|
| RP240068* | 1.0 |
| RP240291* | 1.6 |
| RP240289* | 1.6 |
| RP240125* | 1.8 |
| RP240061* | 1.8 |
| RP240091* | 1.9 |
| RP240095* | 2.0 |
| RP240035* | 2.0 |
| RP240225* | 2.0 |
| RP240259* | 2.0 |
| RP240119* | 2.0 |
| RP240326* | 2.0 |
| RP240311* | 2.0 |
| RP240117* | 2.0 |
| RP240183* | 2.1 |
| RP240263* | 2.1 |
| RP240392* | 2.1 |

* Recommended for funding.

^ The SRC recommended this application to the PIC; however, due to insufficient funding, the PIC did not recommend this application to the Oversight Committee.

| Application ID | Final Overall Evaluation Score |
|----------------|--------------------------------|
| RP240133* | 2.1 |
| RP240127* | 2.2 |
| RP240072* | 2.2 |
| RP240288* | 2.3 |
| RP240380* | 2.3 |
| RP240214* | 2.5 |
| RP240120* | 2.5 |
| RP240287* | 2.5 |
| RP240104* | 2.6 |
| RP240320* | 2.6 |
| Na | 2.6 |
| nb^ | 2.7 |
| nc^ | 2.7 |
| Nd | 2.7 |
| Ne | 2.7 |
| nf^ | 2.8 |
| ng^ | 2.8 |
| nh | 2.8 |
| ni | 2.8 |
| nj^ | 2.9 |
| Nk | 2.9 |
| Nl | 2.9 |
| Nm | 2.9 |
| Nn | 3.0 |
| No | 3.0 |
| Np | 3.0 |
| Nq | 3.1 |
| Nr | 3.2 |
| Ns | 3.3 |
| Nt | 3.3 |
| Nu | 3.3 |
| Nv | 3.3 |
| Nw | 3.3 |
| Nx | 3.3 |
| Ny | 3.3 |
| Nz | 3.3 |
| Oa | 3.3 |

* Recommended for funding.

^ The SRC recommended this application to the PIC; however, due to insufficient funding, the PIC did not recommend this application to the Oversight Committee.

| Application ID | Final Overall Evaluation Score |
|----------------|--------------------------------|
| Ob | 3.3 |
| Oc | 3.3 |
| Od | 3.3 |
| Oe | 3.3 |
| Of | 3.3 |
| Og | 3.4 |
| Oh | 3.4 |
| Oi | 3.4 |
| Oj | 3.4 |
| Ok | 3.5 |
| Ol | 3.5 |
| Om | 3.5 |
| On | 3.5 |
| Oo | 3.6 |
| Op | 3.6 |
| Oq | 3.7 |
| Or | 3.7 |
| Os | 3.7 |
| Ot | 3.7 |
| Ou | 3.7 |
| Ov | 3.7 |
| Ow | 3.7 |
| Ox | 3.7 |
| Oy | 3.7 |
| Oz | 3.7 |
| Pa | 3.7 |
| Pb | 3.7 |
| Pc | 3.7 |
| Pd | 3.7 |
| Pe | 3.7 |
| Pf | 3.7 |
| Pg | 3.7 |
| Ph | 3.7 |
| Pi | 3.8 |
| Pj | 3.8 |
| Pk | 3.8 |
| Pl | 4.0 |

* Recommended for funding.

^ The SRC recommended this application to the PIC; however, due to insufficient funding, the PIC did not recommend this application to the Oversight Committee.

| Application ID | Final Overall Evaluation Score |
|----------------|--------------------------------|
| Pm | 4.0 |
| Pn | 4.0 |
| Po | 4.0 |
| Pp | 4.0 |
| Pq | 4.0 |
| Pr | 4.0 |
| Ps | 4.0 |
| Pt | 4.0 |
| Pu | 4.0 |
| Pv | 4.0 |
| Pw | 4.0 |
| Px | 4.0 |
| Py | 4.0 |
| Pz | 4.0 |
| Qa | 4.0 |
| Qb | 4.0 |
| Qc | 4.0 |
| Qd | 4.0 |
| Qe | 4.0 |
| Qf | 4.0 |
| Qg | 4.0 |
| Qh | 4.0 |
| Qi | 4.0 |
| Qj | 4.0 |
| Qk | 4.0 |
| Ql | 4.0 |
| Qm | 4.0 |
| Qn | 4.0 |
| Qo | 4.0 |
| Qp | 4.1 |
| Qq | 4.2 |
| Qr | 4.2 |
| Qs | 4.2 |
| Qt | 4.3 |
| Qu | 4.3 |
| Qv | 4.3 |
| Qw | 4.3 |

* Recommended for funding.

^ The SRC recommended this application to the PIC; however, due to insufficient funding, the PIC did not recommend this application to the Oversight Committee.

| Application ID | Final Overall Evaluation Score |
|----------------|--------------------------------|
| Qx | 4.3 |
| Qy | 4.3 |
| Qz | 4.3 |
| Ra | 4.3 |
| Rb | 4.3 |
| Rc | 4.3 |
| Rd | 4.3 |
| Re | 4.3 |
| Rf | 4.3 |
| Rg | 4.3 |
| Rh | 4.3 |
| Ri | 4.5 |
| Rj | 4.5 |
| Rk | 4.7 |
| Rl | 4.7 |
| Rm | 4.7 |
| Rn | 4.7 |
| Ro | 4.7 |
| Rp | 4.7 |
| Rq | 4.7 |
| Rr | 4.7 |
| Rs | 4.7 |
| Rt | 4.7 |
| Ru | 4.7 |
| Rv | 4.7 |
| Rw | 4.7 |
| Rx | 4.7 |
| Ry | 4.7 |
| Rz | 4.7 |
| Sa | 4.8 |
| Sb | 5.0 |
| Sc | 5.0 |
| Sd | 5.0 |
| Se | 5.0 |
| Sf | 5.0 |
| Sg | 5.3 |
| Sh | 5.3 |

* Recommended for funding.

^ The SRC recommended this application to the PIC; however, due to insufficient funding, the PIC did not recommend this application to the Oversight Committee.

| Application ID | Final Overall Evaluation Score |
|----------------|--------------------------------|
| Su | 5.3 |
| Sj | 5.3 |
| Sk | 5.3 |
| Sl | 5.3 |
| Sm | 5.6 |
| Sn | 5.7 |
| So | 6.0 |

* Recommended for funding.

^ The SRC recommended this application to the PIC; however, due to insufficient funding, the PIC did not recommend this application to the Oversight Committee.

Individual Investigator Research Awards

Academic Research Cycle 24.1

Final Scores for Preliminary Evaluation

These are the final overall evaluation scores for applications receiving preliminary evaluation that did not move forward to full review. The final overall evaluation score is an average of the preliminary evaluation scores assigned to each application by the primary reviewers.

| Application ID | Final Overall Score |
|----------------|---------------------|
| Da | 4.33 |
| Db | 4.33 |
| Dc | 4.33 |
| Dd | 4.33 |
| De | 4.33 |
| Df | 4.33 |
| Dg | 4.33 |
| Dh | 4.33 |
| Di | 4.33 |
| Dj | 4.67 |
| Dk | 4.67 |
| Dl | 4.67 |
| Dm | 4.67 |
| Dn | 4.67 |
| Do | 4.67 |
| Dp | 4.67 |
| Dq | 4.67 |
| Dr | 4.67 |
| Ds | 4.67 |
| Dt | 4.67 |
| Du | 4.67 |
| Dv | 4.67 |
| Dw | 4.67 |
| Dx | 4.67 |
| Dy | 4.67 |
| Dz | 4.67 |
| Ea | 4.67 |
| Be | 4.67 |

| Application ID | Final Overall Score |
|----------------|---------------------|
| Ec | 5.00 |
| Ed | 5.00 |
| Ee | 5.00 |
| Ef | 5.00 |
| Eg | 5.00 |
| Eh | 5.00 |
| Ei | 5.00 |
| Ej | 5.00 |
| Ek | 5.33 |
| El | 5.33 |
| Em | 5.33 |
| En | 5.33 |
| Eo | 5.33 |
| Ep | 5.33 |
| Eq | 5.33 |
| Es | 5.33 |
| Et | 5.67 |
| Eu | 5.67 |
| Ev | 5.67 |
| Ew | 6.00 |
| Ex | 6.00 |
| Ey | 6.00 |
| Ez | 6.00 |
| Fa | 6.00 |
| Fb | 6.33 |
| Fc | 6.67 |

Final Overall Evaluation Scores and Rank Order Scores

UC San Diego

SCHOOL OF MEDICINE

January 3, 2024

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Dr. Cummings and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Individual Investigator Research Awards, Individual Investigator Research Awards for Childhood and Adolescent Cancers, Individual Investigator Research Awards for Computational Systems Biology of Cancer, Individual Investigator Research Awards for Clinical Translation, Individual Investigator Research Awards for Prevention and Early Detection, Recruitment of Established Investigators, Recruitment of Rising Stars and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on December 14, 2023 to consider the FY24.1 applications recommended by the peer review panels following their meetings held October 11, 2023 to October 20, 2023. The SRC met on November 16, 2023 to review recruitment applications submitted for Cycle FY24.3-4 and then on December 14, 2023 to review recruitment applications submitted for Cycle FY24.5.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$83,180,142.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

| Recommended for Funding by Mechanism (Ranked by Overall Score) | | | | | | | |
|--|----------|-----------------|-----------------------|---|-----------------|--|--------------------|
| Rank | ID | Award Mechanism | Meeting Overall Score | Application Title | PI | PI Organization | Recommended Budget |
| 1 | RP240068 | IIRA | 1.0 | Understanding the Mechanism of Linker Histone Mutations in Malignancy | Soshnev, Alexey | The University of Texas at San Antonio | \$997,770 |
| 2 | RP240293 | IIRACSBC | 1.0 | Therapeutic Vulnerabilities and Predictors of Response to Chemo(immuno)therapy in Patients With High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC) | Korkut, Anil | The University of Texas M. D. Anderson Cancer Center | \$1,199,999 |
| 3 | RR240019 | RRS | 1.0 | Development of Chemotherapeutics Inspired by Natural Products | Sarlah, David | Rice University | 4,000,000.00 |
| 4 | RP240137 | IIRACSBC | 1.1 | Charting TCR-Tumor Antigen Interactions to Foster Novel Immunotherapeutic Approaches for Triple-Negative Breast Cancer | Zhang, Bing | Baylor College of Medicine | \$1,200,000 |
| 5 | RR240013 | RFTFM | 1.2 | Regulation of gene expression and tumorigenesis by ubiquitin-mediated protein quality control | Mark, Kevin | The University of Texas Southwestern Medical Center | 2,000,000.00 |
| 6 | RR240016 | RFTFM | 1.3 | Impact of Germline Variants on Pediatric Leukemia Progression: Insights from 3D Chromatin Remodeling and Clinical Outcomes | Luan, Yu | The University of Texas Health Science Center at San Antonio | 2,000,000.00 |
| 7 | RR240030 | REI | 1.3 | Break-induced DNA Replication as a Driver of Genomic Instability in Cancer | Malkova, Anna | The University of Texas Health Science Center at San Antonio | 6,000,000.00 |
| 8 | RR240027 | RFTFM | 1.4 | Genomic and Epigenomic Mechanisms of Chemobrain | Dileep, Vishnu | Baylor College of Medicine | 2,000,000.00 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|-----------------------|--|-------------|
| 9 | RP240075 | IIRACT | 1.5 | Combination Therapy Using ATRA and Carfilzomib to Treat Proteasome Inhibitor Refractory Multiple Myeloma | Yi, Qing | The Methodist Hospital Research Institute | \$1,921,388 |
| 10 | RP240291 | IIRA | 1.6 | Targeting MYCN disruption of the molecular clock and tumor metabolism in neuroblastoma oncogenesis. | Barbieri, Eveline | Baylor College of Medicine | \$1,050,000 |
| 11 | RP240289 | IIRA | 1.6 | Real-time, label-free, micro HSI device and transformer-based attention networks for oral cancer imaging | Fei, Baowei | The University of Texas at Dallas | \$1,049,806 |
| 12 | RP240125 | IIRA | 1.8 | Immune-Related Determinants of HPV-Associated Oropharyngeal Cancer Outcomes | Li, Guojun | The University of Texas M. D. Anderson Cancer Center | \$1,049,726 |
| 13 | RP240061 | IIRA | 1.8 | Deciphering Iron Redox Cycles in Ferroptosis-based Cancer Therapy | Lu, Yi | The University of Texas at Austin | \$1,044,608 |
| 14 | RP240091 | IIRA | 1.9 | High resolution high sensitivity photoacoustic imaging molecular guided brain tumor surgery with pilot clinical deployment | Valdes Quevedo, Pablo | The University of Texas Medical Branch at Galveston | \$1,044,967 |
| 15 | RP240401 | IIRACCA | 1.9 | Lead Optimization, Target Engagement, and Efficacy Studies of Locally Bioavailable COX-2 inhibitors for Preventing Colon Cancer Progression in FAP Children | Hu, Ming | University of Houston | \$1,400,000 |
| 16 | RP240272 | IIRACCA | 1.9 | The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy for DSRCT | Ludwig, Joseph | The University of Texas M. D. Anderson Cancer Center | \$1,398,788 |
| 17 | RP240184 | IIRACT | 1.9 | Maximizing Antitumor Immunity Through Simultaneous Activation of the Innate and Adaptive Immune System | Hannan, Raquibul | The University of Texas Southwestern Medical Center | \$1,999,993 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|-------------------|--|-------------|
| 18 | RP240095 | IIRA | 2.0 | Targeting chitinase-3-like-1 as a novel therapy for hepatocellular carcinoma | ju, Cynthia | The University of Texas Health Science Center at Houston | \$1,049,388 |
| 19 | RP240035 | IIRA | 2.0 | Harnessing the metabolic dependencies of mitochondrial NADK2 as a therapeutic strategy for lung cancer | Hoxhaj, Gerta | The University of Texas Southwestern Medical Center | \$1,050,000 |
| 20 | RP240225 | IIRA | 2.0 | PARP16-mediated Ribosome MARYlation and Translation Control in Ovarian Cancer | Kraus, W. Lee | The University of Texas Southwestern Medical Center | \$1,049,743 |
| 21 | RP240259 | IIRA | 2.0 | Targeting Cancer-associated Lactobacillus iners to improve response to cancer therapy | Colbert, Lauren | MDACC/BLI | \$1,049,427 |
| 22 | RP240119 | IIRA | 2.0 | Integrating proteolysis-targeting capability into antibodies to augment therapeutic efficacy | Liu, Qingyun | The University of Texas Health Science Center at Houston | \$1,050,000 |
| 23 | RP240326 | IIRA | 2.0 | Translation of gut commensal bacteria peptidoglycan remodeling pathway for chimeric antigen receptor T-cell therapy | Saini, Neeraj | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 24 | RP240311 | IIRA | 2.0 | Treatment planning of ADC therapy for ovarian cancer with molecular photoacoustic-ultrasonic imaging | Bouchard, Richard | The University of Texas M. D. Anderson Cancer Center | \$1,049,859 |
| 25 | RP240117 | IIRA | 2.0 | Identify radiopathomics markers to guide immunotherapy for non-small cell lung cancer | Wu, Jia | The University of Texas M. D. Anderson Cancer Center | \$1,049,906 |
| 26 | RP240054 | IIRACCA | 2.0 | Myeloid Support of Refractory and Aggressive T-ALL at Distinct Tumor Sites | Ehrlich, Lauren | The University of Texas at Austin | \$1,400,000 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660

T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|---------------------|--|--------------|
| 27 | RP240237 | IIRACCA | 2.0 | The Role of EWSR1-FLI1-CENP-A Signaling in Chemoresistance in Ewing Sarcoma | Kitagawa, Katsumi | The University of Texas Health Science Center at San Antonio | \$1,400,000 |
| 28 | RR240015 | RRS | 2.0 | HyperGlio - New tools to fight brain cancer with signal-enhanced magnetic resonance | Gloeggler, Stephan | The University of Texas Southwestern Medical Center | 4,000,000.00 |
| 29 | RR240021 | RRS | 2.0 | Expansion and Single-cell Interrogation of Tumoroid Models for Precise Treatment of Diverse Rectal Cancer Patient Populations | Smith, Jesse Joshua | The University of Texas Southwestern Medical Center | 4,000,000.00 |
| 30 | RP240183 | IIRA | 2.1 | Restoring TREM2-Dependent Efferocytosis to Inhibit Obesity-Induced Liver Inflammation and Cancer Development | Liang, Shuang | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 31 | RP240263 | IIRA | 2.1 | Identifying the Biological Determinants of Aggressive Meningioma | Patel, Akash | Baylor College of Medicine | \$1,049,370 |
| 32 | RP240392 | IIRA | 2.1 | Identifying Tumor Specific Vulnerabilities in Appendiceal Adenocarcinoma: A Systems Approach | Shen, John Paul | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 33 | RP240133 | IIRA | 2.1 | Modulation of blood-spinal cord barrier for tumor treatment | Qin, Zhenpeng | The University of Texas at Dallas | \$1,050,000 |
| 34 | RP240233 | IIRACT | 2.1 | Toward Nonoperative Management of Early-Stage ER-Positive Breast Cancer | Rahimi, Asal | The University of Texas Southwestern Medical Center | \$1,999,963 |
| 35 | RP240127 | IIRA | 2.2 | Transposon Restriction, Tumor Suppression and p53 | Abrams, John | The University of Texas Southwestern Medical Center | \$1,039,356 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|----------|-----|---|------------------|--|--------------|
| 36 | RP240072 | IIRA | 2.2 | Dissection of CAMKK2's Tumor Cell-intrinsic and -extrinsic Roles in Prostate Cancer | Frigo, Daniel | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 37 | RP240288 | IIRA | 2.3 | Epigenetic mechanism and targeting during response to BRAFi/anti-EGFR therapy in BRAF-mutant colorectal cancers | Kopetz, Scott | The University of Texas M. D. Anderson Cancer Center | \$1,043,909 |
| 38 | RP240380 | IIRA | 2.3 | Clonal hematopoiesis for improving lung cancer risk assessment | Cheng, Chao | Baylor College of Medicine | \$1,040,316 |
| 39 | RP240131 | IIRACSBC | 2.3 | Computational Methods for CRISPR-Based Lineage Tracing Systems | Liu, Zhandong | Baylor College of Medicine | \$1,200,000 |
| 40 | RR240007 | REI | 2.3 | Building a multi-modal platform to enable next-generation functional precision oncology | Shen, Xiling | The University of Texas M. D. Anderson Cancer Center | 6,000,000.00 |
| 41 | RP240214 | IIRA | 2.5 | Immunoprevention of Breast Cancer Brain Metastasis by Special Dendritic Cell-derived Extracellular Vesicles | Yu, Dihua | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 42 | RP240120 | IIRA | 2.5 | JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC | ZHANG, QING | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 43 | RP240287 | IIRA | 2.5 | Investigating the Impact of Interferon Gamma Signaling on Therapeutic Resistance in Acute Myeloid Leukemia | Abbas, Hussein | The University of Texas M. D. Anderson Cancer Center | \$1,042,256 |
| 44 | RP240104 | IIRA | 2.6 | Characterization and optimization of novel allosteric KRAS inhibitors | Gorfe, Alemayehu | The University of Texas Health Science Center at Houston | \$1,050,000 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego
SCHOOL OF MEDICINE

| | | | | | | | |
|--|----------|---------|-----|---|------------------------|---|-------------|
| 45 | RP240320 | IIRA | 2.6 | Benzothiazepines as first-in-class inhibitors for the ribogenesis factor NVL and evaluation in preclinical colorectal cancer models | De Brabander, Jef | The University of Texas Southwestern Medical Center | \$1,049,754 |
| 46 | RP240143 | IIRACCA | 2.6 | Leveraging Passport for Care in a Telehealth Framework to Improve Equitable Access to Survivorship Services | Gramatges, Maria | Baylor College of Medicine | \$1,399,382 |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| 51 | RP240208 | IIRAP | 2.8 | Unidos Contra el VPH: Screening Accuracy, Preference, and Uptake of HPV Self-Sampling Among Latinxs Along the US-Mexico Border | Calderon-Mora, Jessica | The University of Texas at Austin | \$1,920,007 |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee.

Individual Investigator Research Awards (IIRA)
Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)
Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)
Individual Investigator Research Awards for Clinical Translation (IIRACT)
Individual Investigator Research Awards for Prevention and Early Detection
Recruitment of Established Investigators (REI)
Recruitment of Rising Stars (RRS)
Recruitment of First-Time, Tenure Track Faculty Members (FTTFM)



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2024—Cycle 1**
*Individual Investigator Research Awards for
Cancer in Children and Adolescents*

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-24.1-IIRACCA

**Individual Investigator Research Awards
for Cancer in Children and Adolescents**

**Please also refer to the Instructions for Applicants document,
which will be posted on March 15, 2023**

Application Receipt Opening Date: March 15, 2023

Application Receipt Closing Date: June 14, 2023

FY2024

Fiscal Year Award Period

September 1, 2023–August 31, 2024

TABLE OF CONTENTS

| | |
|--|-----------|
| 1. BRIEF DESCRIPTION OF RFA..... | 4 |
| 2. ABOUT CPRIT..... | 4 |
| 2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES..... | 4 |
| 3. RATIONALE..... | 5 |
| 4. RESEARCH OBJECTIVES..... | 6 |
| 5. FUNDING INFORMATION..... | 7 |
| 6. ELIGIBILITY..... | 7 |
| 7. RESUBMISSION POLICY..... | 9 |
| 8. RENEWAL POLICY..... | 10 |
| 9. RESPONDING TO THIS RFA..... | 10 |
| 9.1. APPLICATION SUBMISSION GUIDELINES..... | 10 |
| 9.1.1. <i>Submission Deadline Extension</i> | 10 |
| 9.2. APPLICATION COMPONENTS..... | 11 |
| 9.2.1. <i>Abstract and Significance (5,000 characters)</i> | 11 |
| 9.2.2. <i>Layperson’s Summary (2,000 characters)</i> | 11 |
| 9.2.3. <i>Specific Aims and Sub-Aims</i> | 12 |
| 9.2.4. <i>Timeline (1 page)</i> | 12 |
| 9.2.5. <i>Specific Aims (1 Page)</i> | 12 |
| 9.2.6. <i>Resubmission Summary (2 Pages)</i> | 12 |
| 9.2.7. <i>Renewal Summary (2 pages)</i> | 13 |
| 9.2.8. <i>Research Plan (10 pages)</i> | 13 |
| 9.2.9. <i>Vertebrate Animals (1 page)</i> | 13 |
| 9.2.10. <i>Human Subjects (2 pages)</i> | 13 |
| 9.2.11. <i>Publications/References</i> | 14 |
| 9.2.12. <i>Budget and Justification</i> | 14 |
| 9.2.13. <i>Biographical Sketches (5 pages each)</i> | 15 |
| 9.2.14. <i>Current and Pending Support</i> | 15 |
| 9.2.15. <i>Institutional/Collaborator Support and/or Other Certification (4 pages)</i> | 16 |
| 9.2.16. <i>Previous Summary Statement</i> | 16 |
| 9.3. FORMATTING INSTRUCTIONS..... | 16 |
| 10. APPLICATION REVIEW..... | 17 |
| 10.1. PRELIMINARY EVALUATION..... | 17 |
| 10.2. FULL PEER REVIEW..... | 18 |
| 10.3. CONFIDENTIALITY OF REVIEW..... | 18 |
| 10.4. REVIEW CRITERIA..... | 19 |
| 10.4.1. <i>Primary Criteria</i> | 20 |
| 10.4.2. <i>Secondary Criteria</i> | 21 |
| 11. KEY DATES..... | 21 |
| 12. AWARD ADMINISTRATION..... | 21 |
| 13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS..... | 22 |
| 14. CONTACT INFORMATION..... | 23 |
| 14.1. HELPDESK..... | 23 |
| 14.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS..... | 23 |

RFA VERSION HISTORY

- 2/17/23 RFA released
- 5/16/23 Modified section 9.2.13 – Biographical Sketches; included the following updated language: “Up to 5 additional biographical sketches for key personnel may be provided, these should be concatenated into a single PDF with a 25-page limit.”

1. BRIEF DESCRIPTION OF RFA

- Supports applications for innovative research projects addressing questions that will advance knowledge of the causes, prevention, progression, detection, treatment or survivorship of cancer in children and adolescents.
- Applicants may request a maximum of \$350,000 per year for a period of up to 4 years. Applicants who plan on conducting a clinical trial as part of the project may request up to \$150,000 in additional total costs per year for the time frame that the trial is active.
- Multi-Principal Investigators (PIs) (MIs) are allowed under this RFA. See the Information for Applicants (IFA) document for definition and eligibility of MIs.
- Note that CPRIT does not allow the use of the term Co-PI.
- Minimum effort for the PI and/or MIs throughout the project period is required.

2. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

2.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state.
- Reducing cancer disparities.

The program priorities for academic research adopted by the Oversight Committee include funding projects that address or utilize the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials

3. RATIONALE

In recent decades, great strides have been made in reducing mortality from childhood cancers. Most of these gains have been realized in childhood leukemia and lymphoma. However, improvements in survival have been less robust in other types of childhood cancers, which make up more than 40% of total cancer cases in children and adolescents aged 0 to 19 years. Furthermore, the overall incidence of pediatric cancer has increased at an annual rate of 0.6% since 1975, with most of the increases being seen in acute lymphoblastic leukemia, brain and central nervous system tumors, non-Hodgkin lymphoma, and testicular germ cell tumors. Reasons for increases in these tumor types are unknown, indicating that information on the etiology of these cancers is urgently needed. Because of the high rates of survival for certain childhood and adolescent cancers, there are increasing numbers of survivors of such cancers living today. These individuals have a high rate of late effects from the cancer or its treatment, including the occurrence of additional cancers. Clearly, more effective, less-toxic treatments are needed for these diseases. However, few new therapies have been developed in recent years.

Several reasons account for the paucity of new treatments, including the lack of interest on the part of pharmaceutical companies in developing treatments for cancers that account for only 1% of all cancer cases and the difficulty of collecting sufficient numbers of tumors for laboratory studies.

Because cancers in children and adolescents differ from those in adults with regard to genetic alterations and biological behavior, application of adult therapies to these cancers may not be successful. Therefore, this area of investigation represents an opportunity for CPRIT to deploy funding in an area of critical need that is not heavily represented in other funding portfolios.

4. RESEARCH OBJECTIVES

This Request for Applications (RFA) solicits applications for innovative research projects addressing questions that will advance current knowledge of the causes, prevention, progression, detection, or treatment of cancer in children and adolescents. Applications may address any topic related to these areas as well as projects dealing with the causes or amelioration of late effects of cancer treatment. Laboratory, clinical, or population-based studies are all acceptable. CPRIT expects the outcome of the research to reduce the incidence, morbidity, or mortality from cancer in children and/or adolescents in the near or long term. Applications that seek to apply or develop state-of-the-art approaches, technologies, tools, treatments, and/or resources are encouraged, particularly those with potential for commercialization. Applications that address cancer disparities will be looked on with special favor. Successful applicants should be working in a research environment capable of supporting potentially high-impact studies.

The subject of applications may include, but is not limited to, the following:

- Causes of cancer in children and adolescents, including genetic factors or prenatal exposure to environmental agents;
- Identification of risk factors for cancer development;
- New methods for diagnosing cancers in children and/or adolescents;
- Development of new therapies, including targeted therapies, immunotherapies, and new drugs;
- Identification of patients at risk of developing late effects of cancer treatment;
- Improvements in quality of life for survivors of childhood and adolescent cancers; and

- Identification of the determinants for cancer outcomes and mitigation to reduce cancer disparities.

The *degree of relevance* to reducing the burden of cancer in these populations is a critical criterion for evaluation of projects for funding by CPRIT ([section 10.4.1](#)).

5. FUNDING INFORMATION

Applicants may request a maximum of \$350,000 per year for a period of up to 4 years. Applicants who plan on conducting a clinical trial as part of the project may request up to \$150,000 in additional total costs per year for the time frame that the trial is active. Note that an individual detailed budget for conducting a clinical trial is required. If a clinical trial is proposed, the budget justification must include a timeline for the clinical trial initiation and accrual targets. Applicants should provide documentation that the proposed trial is feasible with the project timeline. Exceptions to these limits may be requested if extremely well justified. Funds may be used for salary and fringe benefits, research supplies, equipment, subject participation costs, and travel to scientific/technical meetings or collaborating institutions. Requests for funds to support construction and/or renovation will not be approved under this funding mechanism. State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount.

Please see [section 9.2.12](#) and the IFA for additional information.

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism; these entities must use the appropriate award mechanism(s) under CPRIT's Product Development Research Program.
- The PI must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and be a full-time resident of Texas during the time the research that is the subject of the grant is conducted.

- This award mechanism allows MIs for projects that require a team science approach (see the IFA for guidelines on CPRIT rules for MI awards).
- For applications that include 1 PI, the PI is required to maintain a minimum 15% level of effort throughout the entire award period. For applications that include MIs, each PI is required to maintain a minimum 10% effort throughout the entire award period.
- A PI may not submit applications to this RFA and to RFA R-24.1-IIRA, RFA 24.1-IIRACSBC, RFA R-24.1-IIRACT, or RFA R-24.1-IIRAP.
- A PI may submit only 1 application, either a new, resubmission or renewal application under this RFA during this funding cycle.
- A PI may be a part of only 1 application, whether as a single applicant or as part of an MI application, under this RFA and RFA R-24.1-IIRA, RFA R-24.1-IIRACSBC, RFA R-24.1-IIRACT, or RFA R-24.1-IIRAP.
- An individual may serve as a PI on no more than 3 active CPRIT Academic Research grants. Recruitment Grants and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers MIRA Project Co-PIs equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be March 1, 2024).
- Applications that address prevention, early detection, or population-based studies, computational oncology studies of cancer, or innovative clinical trials should be submitted under the appropriate targeted RFA.
- Collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.

- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, regardless of whether those individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 12](#) and [section 13](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted **once** and must follow all resubmission guidelines. More than 1 resubmission is not permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the PI for a project or a change of title of the project that was previously submitted to CPRIT or omission or modification of an aim do not constitute a new application; the application would be considered a resubmission. This policy is in effect for all applications submitted to date. See [section 9.2.6](#).

8. RENEWAL POLICY

An application funded by CPRIT under this mechanism may be submitted for a competitive renewal. An application originally funded by CPRIT as an IIRA that is appropriate for the IIRACCA mechanism may be submitted under this RFA for a competitive renewal. See [section 9.2.7](#). Competitive renewals are not subject to preliminary evaluation. Renewal applications move directly to the full peer review phase. See [section 10.2](#).

9. RESPONDING TO THIS RFA

9.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on March 15, 2023, and must be submitted by 4 PM central time on June 14, 2023. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

9.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#), within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

9.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the IFA for details that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

9.2.1. Abstract and Significance (5,000 characters)

It is the responsibility of the applicant to capture CPRIT's attention primarily with the Abstract and Significance statement alone. Therefore, applicants are advised to prepare this section wisely. **Based on the Abstract and Significance statement (and the Specific Aims page, Budget and Justification and Biographical Sketches), applications that are judged to offer only modest contributions to the field of cancer research or that do not sufficiently capture the reviewers' interest may be excluded from further peer review (see [section 10.1](#)).**

Applicants should not waste this valuable space by stating obvious facts (eg, that cancer is a significant problem; that better diagnostic and therapeutic approaches are needed urgently; or that the type of cancer of interest to the PI is important, vexing, or deadly).

Clearly explain the question or problem to be addressed and the approach to its answer or solution. The specific aims of the application must be obvious from the abstract although they need not be restated verbatim from the research plan.

Clearly address how the proposed project, if successful, will have a major impact on cancer. Indicate whether this research will address cancers associated with disparities. Summarize how the proposed research creates new paradigms or challenges existing ones. Indicate whether this research plan represents a new direction for the PI.

9.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detection, prevention, treatment, or survivorship. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for

funding. **Do not include any proprietary information in the layperson's summary.** The layperson's summary will also be used by advocate reviewers ([section 10.2](#)) in evaluating the significance and impact of the proposed work.

9.2.3. Specific Aims and Sub-Aims

Please provide a description of the Aims and Sub-aims and milestones to be achieved for each year of the project. Provide 2-3 sentences describing activities to be performed and anticipated milestones. These Aims will also be used during the submission and evaluation of progress reports and assessment of project success.

9.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications.

If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

9.2.5. Specific Aims (1 Page)

Please provide a 1-page summary of the aims of the proposal. The Specific Aims page should identify the problem, or gap in our current knowledge. It should present a hypothesis and briefly describe the aims and approaches. Address the proposal's innovation, novel approaches and significance and impact on the field and cancer research. Please also refer to the template located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.6. Resubmission Summary (2 Pages)

Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

Note: An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to need considerable attention. Applicants may

prepare a fresh research plan or modify the original research plan and mark the changes. However, **all resubmitted applications should be carefully reconstructed**; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes.

9.2.7. Renewal Summary (2 pages)

Applicants preparing a renewal must describe and demonstrate that appropriate/adequate progress has been made on the current funded award to warrant further funding. Publications and manuscripts in press that have resulted from work performed during the initial funded period should be listed in the renewal summary.

9.2.8. Research Plan (10 pages)

Background: Present the rationale behind the proposed project, emphasizing the pressing problem in cancer research that will be addressed.

Hypothesis and Specific Aims: Concisely state the hypothesis and/or specific aims to be tested or addressed by the research described in the application. Describe the significance, innovation, and potential impact of the research.

Research Strategy: Describe the experimental design, including methods, anticipated results, potential problems or pitfalls, and alternative approaches. Preliminary data that support the proposed hypothesis are encouraged but not required.

9.2.9. Vertebrate Animals (1 page)

If vertebrate animals will be used, provide a detailed plan of the protocols that will be followed and justification for the number of animals used with reference to biostatistical input for sample selection and evaluation. Certification of approval by the institutional IACUC of the proposed animal use will be required before funding can occur.

9.2.10. Human Subjects (2 pages)

If human subjects or human biological samples will be used, provide a detailed plan for recruitment of subjects and/or the acquisition of samples that will meet the time constraints of this award mechanism. Certification of approval of these plans by the institutional IRB will be required before funding can occur.

9.2.11. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

9.2.12. Budget and Justification

Provide a compelling and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, supplies, equipment, costs associated with the conduct of a clinical trial, animal care costs, and other expenses. Do not exceed \$350,000 per year for a period of up to 4 years. Applicants who plan on conducting a clinical trial as part of the project may request up to \$150,000 in additional total costs per year during the time frame that the clinical trial is active and must not exceed \$500,000 per year during that time frame. While there will be 1 budget for the entire project, an individual budget and budget justification for the conduct of a clinical trial **must be included**. The justification should include the statistical considerations that led to the clinical trial design, accrual milestones, and validation of biomarkers. Applicants are advised not to interpret the maximum allowable time and funding under this award as a suggestion that they should expand their anticipated work and budget to this level. Reasonable budgets clearly work in favor of the applicant.

However, if there is a highly specific and defensible need to request more than the maximum amount in any year(s) of the proposed budget, include a special and clearly labeled section in the budget justification that explains the request. Poorly justified requests of this type will likely have a negative impact on the overall evaluation of the application.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees;

maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.

- The maximum annual salary (also referred to as direct salary or institutional base salary) that an individual may request under a CPRIT award for FY 2024 is \$200,000; CPRIT FY 2024 is from September 1, 2023, through August 31, 2024. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.
- Funds can be used to pay for costs that a cancer clinical trial participant may have associated with their participation in a clinical trial, including: 1) transportation, including car mileage, parking, bus fare, taxi or ride hailing fare exclusive of tips, and commercial economy class airfare within the borders of the State of Texas; 2) lodging.

9.2.13. Biographical Sketches (5 pages each)

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research.

A biographical sketch must be provided for the PI and, if applicable, any additional PIs (if an MI application), as required by the online application receipt system. Up to 5 additional biographical sketches for key personnel may be provided, these should be concatenated into a single PDF with a 25-page limit. Each biographical sketch must not exceed 5 pages. The NIH biosketch format is appropriate.

9.2.14. Current and Pending Support

Describe the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project and, if relevant, a statement of overlap with the current application. At a minimum, current and pending support of the PI and, if applicable, any additional PIs (if an MI application), must be provided. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.15. Institutional/Collaborator Support and/or Other Certification (4 pages)

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 4 pages may be provided.

9.2.16. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

Applications that are missing 1 or more of these components, exceed the specified page, word, or budget limits, or that do not meet the eligibility requirements listed above will be administratively rejected without review.

9.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters

are also acceptable as long as the journal information is stated. Include URLs of publications referenced in the application.

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45-67.

- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

10. APPLICATION REVIEW

10.1. Preliminary Evaluation

To ensure the timely and thorough review of only the most innovative and cutting-edge research with the greatest potential for advancement of cancer research, all eligible applications may be preliminarily evaluated by CPRIT Scientific Research Program panel members for scientific merit and impact.

This preliminary evaluation will be based on a subset of material presented in the application—namely, Abstract and Significance, Specific Aims page, Budget and Justification, and Biographical Sketches. Applications that do not sufficiently capture the reviewers' interest at this stage will not be considered for further review. Such applications will have been judged to offer only modest contributions to the field of cancer research and will be excluded from further peer review.

The applicant will be notified of the decision to disapprove the application after the preliminary evaluation stage has concluded. Due to the volume of applications to be reviewed, comments made by reviewers at the preliminary evaluation stage may be limited.

10.2. Full Peer Review

Applications that pass preliminary evaluation will undergo further review using a 2-stage peer review process: (1) Full peer review and (2) Prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 10.4](#). In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by the Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC.

The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

10.3. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, ([Texas Administrative Code RULE §703.9](#)).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee Member, a PIC Member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Research Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

10.4. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

10.4.1. Primary Criteria

Primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

Significance and Impact: Will the results of this research, if successful, significantly change the research of others or the opportunities for better cancer prevention, diagnosis, or treatment for patients? Is the application innovative? Does the applicant propose new paradigms or challenge existing ones? Does the project develop state-of-the-art technologies, methods, tools, or resources for cancer research or address important underexplored or unexplored areas? If the research project is successful, will it lead to truly substantial advances in the field rather than add modest increments of insight? Projects that modestly extend current lines of research will not be considered for this award. Projects that represent straightforward extensions of ongoing work, especially work traditionally funded by other mechanisms, will not be competitive.

Research Plan: Is the proposed work presented as a self-contained research project? Does the proposed research have a clearly defined hypothesis or goal that is supported by sufficient preliminary data and/or scientific rationale? Are the methods appropriate, and are potential experimental obstacles and unexpected results discussed?

Applicant Investigator: Does the investigator(s) demonstrate the required creativity and expertise to make a significant contribution to the research? Applicants' credentials will be evaluated in a career stage-specific fashion. Have early-career-stage investigators received excellent training, and do their accomplishments to date offer great promise for a successful career? Has the applicant(s) devoted a sufficient amount of their time (percent effort) to this project?

Relevance: Does the proposed research address cancer in children or adolescents? Is it likely to make an impact on these diseases? This is a critical criterion for evaluation of projects for CPRIT support.

10.4.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research.

Secondary criteria include the following:

Research Environment: Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the proposed research? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support of the research team and the project?

Vertebrate Animals and/or Human Subjects: Is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed?

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

11. KEY DATES

RFA

RFA release February 17, 2023

Application

Online application opens March 15, 2023, 7 AM central time

Application due June 14, 2023, 4 PM central time

Application review June 2023–February 2024

Award

Award notification February 2024

Anticipated start date March 1, 2024

12. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a

grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT's administrative rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. A grant recipient that is a public or private institution of higher education, as defined by §61.003, Texas Education Code, may credit toward the Grant Recipient's Matching Funds obligation the dollar amount equivalent to the difference between the indirect cost rate authorized by the federal government for research grants awarded to the Grant Recipient and the 5% indirect cost limit imposed by §102.203(c), Texas Health and

Safety Code. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted.

14. CONTACT INFORMATION

14.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

14.2. Scientific and Programmatic Questions

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Director of Academic Research.

Tel: 512-305-8491

Email: research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel - Basic Cancer

Research-1 (24.1_AR_BCR-1)

Observation Report

Report No. 2023-10-20 24.1_AR_BCR-1
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel - Basic Cancer Research-1
(24.1_AR_BCR-1)
Panel Date: October 20, 2023
Report Date: October 26, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel - Basic Cancer Research-1 (24.1_AR_BCR-1) meeting. The meeting was chaired by Eric Fearson and conducted via videoconference on October 20, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and twenty-three (23) applications were not discussed
- Panelists: One (1) panel chair, thirteen (13) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were five (5) Conflict of Interest (COI) identified prior to and/or during the meeting. Two (2) applications with COIs were discussed and two (2) applications with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the closing text.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel – Basic Cancer

Research (24.1 ACR-BCR-2) Observation Report

Report No. 2023-10-11 24.1_ACR-BCR-2
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel – Basic Cancer Research
(24.1 _ACR-BCR-2)
Panel Date: October 11, 2023
Report Date: October 16, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel – Basic Cancer Research (24.1_ACR-BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on October 11, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and thirty (30) applications were not discussed
- Panelists: One (1) panel chair, Nineteen (19) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Eight (8)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were nine (9) Conflicts of Interest (COI) identified prior to and/or during the meeting. COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel - Basic Cancer

Research (24.1 ACR CPR)

Observation Report

Report No. 2023-10-13 24.1_ACR CPR
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel - Basic Cancer Research
(24.1 _ACR CPR)
Panel Date: October 13, 2023
Report Date: October 16, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel - Basic Cancer Research (24.1_ACR CPR) meeting. The meeting was chaired by Elena Martinez and conducted via videoconference on October 13, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Ten (10) applications were discussed and eleven (11) applications were not discussed
- Panelists: One (1) panel chair, twelve (12) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Seven (7)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflict of Interest (COI) identified prior to and/or during the meeting. Two (2) applications with COIs were discussed and one (1) application with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the closing text.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
24.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (24.1_ACR-CTCR)
Observation Report

Report No. 2023-10-17 24.1_ACR-CTCR
Program Name: Academic Research
Panel Name: 24.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (24.1_ACR-CTCR)
Panel Date: October 17, 2023
Report Date: October 23, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Clinical and Translational Cancer Research (C/TCR) (24.1_ACR-CTCR) meeting. The meeting was chaired by Richard O'Reilly and Margaret Tempero and conducted via videoconference on October 17, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty-one (21) applications were discussed and thirty-five (35) applications were not discussed
- Panelists: Two (2) panel chair, seventeen (17) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflict of Interest (COI) identified prior to and/or during the meeting. Two (2) applications with COIs were discussed and two (2) applications with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel – Imaging Technology and Informatics (24.1 ACR ITI) Observation Report

Report No. 2023-10-19 24.1_ACR-ITI
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel – Imaging Technology and Informatics (24.1 _ACR-ITI)
Panel Date: October 19, 2023
Report Date: October 26, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel – Imaging Technology and Informatics (24.1_ACR-ITI) meeting. The meeting was co-chaired by Anna Wu, Henry VanBrocklin, and Jason Lewis, in lieu of Martin Pomper and conducted via videoconference on October 19, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Sixteen (16) applications were discussed and thirteen (13) applications were not discussed
- Panelists: Three (3) panel chairs, thirteen (13) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were twelve (12) Conflicts of Interest (COI) identified prior to and/or during the meeting. Four (4) applications with a COI were discussed and three (3) applications with a COI were not discussed. COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Scientific Review Council (24.1 SRC) Observation Report

Report No. 2023-12-14 24.1_SRC
Program Name: Academic Research
Panel Name: 24.1 Academic Research Scientific Review Council (24.1 _SRC)
Panel Date: December 14, 2023
Report Date: January 17, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Scientific Review Council (24.1_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 14, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Forty- five (45) applications were discussed
- Panelists: One (1) panel chair, and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 24.1

Awards Announced at the February 21, 2024, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 24.1 include: *Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Translation; and Individual Investigator Research Awards for Prevention and Early Detection.* Applications submitted in response to these five award mechanisms went through preliminary evaluation as allowed by TAC § 703.6(e)(1).

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT’s third party grant administrator, and by CPRIT.

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|--|------------------------|--|------------------------------------|
| Applications considered by the PIC and Oversight Committee: | | | |
| RP240127 | John Abrams | The University of Texas Southwestern Medical Center | Benjamin Greenbaum |
| RP240072 | Daniel Frigo | The University of Texas M. D. Anderson Cancer Center | Steffi Oesterreich |
| RP240125 | Guojun Li | The University of Texas M. D. Anderson Cancer Center | Electra Paskett; Thomas Brandon |
| RP240272 | Joseph Ludwig | The University of Texas M. D. Anderson Cancer Center | Richard O'Reilly |
| RP240117 | Jia Wu | The University of Texas M. D. Anderson Cancer Center | Charles Kahn; Maryellen Giger |

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|---|------------------------|--|-------------------------------|
| RP240311 | Richard Bouchard | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger; Weibo Cai |
| RP240291 | Eveline Barbieri | Baylor College of Medicine | Craig Rosenfeld |
| Applications not considered by the PIC or Oversight Committee: | | | |
| RP240101 ^a | Sang Eun Lee | The University of Texas Health Science Center at San Antonio | Alan Tomkinson; John Petrini |
| RP240118 | Elizabeth Goldsmith | The University of Texas Southwestern Medical Center | Alan Tomkinson |
| RP240236 | Katharina Schlacher | The University of Texas M. D. Anderson Cancer Center | John Petrini |
| RP240270 | Giulio Draetta | The University of Texas M. D. Anderson Cancer Center | Eileen White; Nabeel Bardeesy |
| RP240364 | Christopher Amos | Baylor College of Medicine | Alan Tomkinson |
| RP240399 | Jonathan Sessler | The University of Texas at Austin | Nabeel Bardeesy |
| RP240368 | Zhaoyong Hu | Baylor College of Medicine | Steffi Oesterreich |
| RP240106 | Michelle Hildebrandt | The University of Texas M. D. Anderson Cancer Center | Electra Paskett |
| RP240240 | Maria Swartz | The University of Texas M. D. Anderson Cancer Center | Electra Paskett |
| RP240112 | Jianjun Zhang | The University of Texas M. D. Anderson Cancer Center | Antoni Ribas |
| RP240340 | Kareem Azab | The University of Texas Southwestern Medical Center | John DiPersio |
| RP240354 | Charles Reynolds | Texas Tech University Health Sciences Center | W. Martin Kast |

^a The PIC did not recommend this application to the Oversight Committee.

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|-----------------------------------|------------------------|--|--|
| RP240044 | Jingfei Ma | The University of Texas M. D. Anderson Cancer Center | Charles Kahn; David Mankoff; Martin Pomper |
| RP240056 | David Fuentes | The University of Texas M. D. Anderson Cancer Center | David Mankoff; Maryellen Giger |
| RP240066 | Xiankai Sun | The University of Texas Southwestern Medical Center | Anna Wu |
| RP240088 | Hongyu Wang | The University of Texas Health Science Center at Houston | Charles Kahn |
| RP240141 | Jian Gu | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger |
| RP240018 | Lan Zhou | The Methodist Hospital Research Institute | Eric Fearon; Weiping Zou |
| RP240299 | Wen Jiang | The University of Texas M. D. Anderson Cancer Center | Kristin Swanson |
| RP240396 | Leonidas Bleris | The University of Texas at Dallas | Alexander Anderson |
| RP240409 | Tae Jin Lee | The University of Texas Health Science Center at Houston | Kristin Swanson |
| RP240177 (preliminary evaluation) | Hays Rye | Texas AgriLife Research | Benjamin Raphael |
| RP240410 (preliminary evaluation) | Murugesan Palaniappan | Baylor College of Medicine | Steffi Oesterreich |
| RP240140 (preliminary evaluation) | Sang Cho | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger |
| RP240221 (preliminary evaluation) | Tinsu Pan | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger |

De-Identified Overall Evaluation Scores

Individual Investigator Research Awards for Cancer in Children and Adolescents

Academic Research Cycle 24.1

Final Scores for Fully Reviewed Applications

| Application ID | Final Overall Evaluation Score |
|----------------|--------------------------------|
| RP240401* | 1.9 |
| RP240272* | 1.9 |
| RP240054* | 2.0 |
| RP240237* | 2.0 |
| RP240143* | 2.6 |
| lv | 2.8 |
| lw^ | 2.9 |
| Lx | 3.0 |
| Ly | 3.4 |
| Lz | 3.6 |
| Ma | 3.7 |
| Mb | 3.7 |
| Mc | 3.7 |
| Md | 3.7 |
| Me | 4.0 |
| Mf | 4.0 |
| Mg | 4.0 |
| Mh | 4.0 |
| Mi | 4.3 |
| Mj | 4.5 |
| Mk | 4.7 |
| Ml | 4.7 |
| Mm | 5.0 |
| Mn | 5.2 |
| Mo | 5.3 |
| Mp | 7.0 |

* Recommended for funding.

^ The SRC recommended this application to the PIC; however, due to insufficient funding, the PIC did not recommend this application to the Oversight Committee.

Individual Investigator Research Awards for Cancer in Children and Adolescents

Academic Research Cycle 24.1

Final Scores for Preliminary Evaluation

These are the final overall evaluation scores for applications receiving preliminary evaluation that did not move forward to full review. The final overall evaluation score is an average of the preliminary evaluation scores assigned to each application by the primary reviewers.

| Application ID | Final Overall Score |
|----------------|---------------------|
| Aa | 5.00 |
| Ab | 5.33 |
| Ac | 5.33 |
| Ad | 5.33 |
| Ae | 5.67 |
| Af | 6.00 |
| Ag | 6.00 |
| Ah | 6.33 |
| Ai | 7.00 |

Final Overall Evaluation Scores and Rank Order Scores

UC San Diego

SCHOOL OF MEDICINE

January 3, 2024

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Dr. Cummings and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Individual Investigator Research Awards, Individual Investigator Research Awards for Childhood and Adolescent Cancers, Individual Investigator Research Awards for Computational Systems Biology of Cancer, Individual Investigator Research Awards for Clinical Translation, Individual Investigator Research Awards for Prevention and Early Detection, Recruitment of Established Investigators, Recruitment of Rising Stars and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on December 14, 2023 to consider the FY24.1 applications recommended by the peer review panels following their meetings held October 11, 2023 to October 20, 2023. The SRC met on November 16, 2023 to review recruitment applications submitted for Cycle FY24.3-4 and then on December 14, 2023 to review recruitment applications submitted for Cycle FY24.5.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$83,180,142.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

| Recommended for Funding by Mechanism (Ranked by Overall Score) | | | | | | | |
|--|----------|-----------------|-----------------------|---|-----------------|--|--------------------|
| Rank | ID | Award Mechanism | Meeting Overall Score | Application Title | PI | PI Organization | Recommended Budget |
| 1 | RP240068 | IIRA | 1.0 | Understanding the Mechanism of Linker Histone Mutations in Malignancy | Soshnev, Alexey | The University of Texas at San Antonio | \$997,770 |
| 2 | RP240293 | IIRACSBC | 1.0 | Therapeutic Vulnerabilities and Predictors of Response to Chemo(immuno)therapy in Patients With High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC) | Korkut, Anil | The University of Texas M. D. Anderson Cancer Center | \$1,199,999 |
| 3 | RR240019 | RRS | 1.0 | Development of Chemotherapeutics Inspired by Natural Products | Sarlah, David | Rice University | 4,000,000.00 |
| 4 | RP240137 | IIRACSBC | 1.1 | Charting TCR-Tumor Antigen Interactions to Foster Novel Immunotherapeutic Approaches for Triple-Negative Breast Cancer | Zhang, Bing | Baylor College of Medicine | \$1,200,000 |
| 5 | RR240013 | RFTFM | 1.2 | Regulation of gene expression and tumorigenesis by ubiquitin-mediated protein quality control | Mark, Kevin | The University of Texas Southwestern Medical Center | 2,000,000.00 |
| 6 | RR240016 | RFTFM | 1.3 | Impact of Germline Variants on Pediatric Leukemia Progression: Insights from 3D Chromatin Remodeling and Clinical Outcomes | Luan, Yu | The University of Texas Health Science Center at San Antonio | 2,000,000.00 |
| 7 | RR240030 | REI | 1.3 | Break-induced DNA Replication as a Driver of Genomic Instability in Cancer | Malkova, Anna | The University of Texas Health Science Center at San Antonio | 6,000,000.00 |
| 8 | RR240027 | RFTFM | 1.4 | Genomic and Epigenomic Mechanisms of Chemobrain | Dileep, Vishnu | Baylor College of Medicine | 2,000,000.00 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|-----------------------|--|-------------|
| 9 | RP240075 | IIRACT | 1.5 | Combination Therapy Using ATRA and Carfilzomib to Treat Proteasome Inhibitor Refractory Multiple Myeloma | Yi, Qing | The Methodist Hospital Research Institute | \$1,921,388 |
| 10 | RP240291 | IIRA | 1.6 | Targeting MYCN disruption of the molecular clock and tumor metabolism in neuroblastoma oncogenesis. | Barbieri, Eveline | Baylor College of Medicine | \$1,050,000 |
| 11 | RP240289 | IIRA | 1.6 | Real-time, label-free, micro HSI device and transformer-based attention networks for oral cancer imaging | Fei, Baowei | The University of Texas at Dallas | \$1,049,806 |
| 12 | RP240125 | IIRA | 1.8 | Immune-Related Determinants of HPV-Associated Oropharyngeal Cancer Outcomes | Li, Guojun | The University of Texas M. D. Anderson Cancer Center | \$1,049,726 |
| 13 | RP240061 | IIRA | 1.8 | Deciphering Iron Redox Cycles in Ferroptosis-based Cancer Therapy | Lu, Yi | The University of Texas at Austin | \$1,044,608 |
| 14 | RP240091 | IIRA | 1.9 | High resolution high sensitivity photoacoustic imaging molecular guided brain tumor surgery with pilot clinical deployment | Valdes Quevedo, Pablo | The University of Texas Medical Branch at Galveston | \$1,044,967 |
| 15 | RP240401 | IIRACCA | 1.9 | Lead Optimization, Target Engagement, and Efficacy Studies of Locally Bioavailable COX-2 inhibitors for Preventing Colon Cancer Progression in FAP Children | Hu, Ming | University of Houston | \$1,400,000 |
| 16 | RP240272 | IIRACCA | 1.9 | The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy for DSRCT | Ludwig, Joseph | The University of Texas M. D. Anderson Cancer Center | \$1,398,788 |
| 17 | RP240184 | IIRACT | 1.9 | Maximizing Antitumor Immunity Through Simultaneous Activation of the Innate and Adaptive Immune System | Hannan, Raquibul | The University of Texas Southwestern Medical Center | \$1,999,993 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|-------------------|--|-------------|
| 18 | RP240095 | IIRA | 2.0 | Targeting chitinase-3-like-1 as a novel therapy for hepatocellular carcinoma | ju, Cynthia | The University of Texas Health Science Center at Houston | \$1,049,388 |
| 19 | RP240035 | IIRA | 2.0 | Harnessing the metabolic dependencies of mitochondrial NADK2 as a therapeutic strategy for lung cancer | Hoxhaj, Gerta | The University of Texas Southwestern Medical Center | \$1,050,000 |
| 20 | RP240225 | IIRA | 2.0 | PARP16-mediated Ribosome MARYlation and Translation Control in Ovarian Cancer | Kraus, W. Lee | The University of Texas Southwestern Medical Center | \$1,049,743 |
| 21 | RP240259 | IIRA | 2.0 | Targeting Cancer-associated Lactobacillus iners to improve response to cancer therapy | Colbert, Lauren | MDACC/BLI | \$1,049,427 |
| 22 | RP240119 | IIRA | 2.0 | Integrating proteolysis-targeting capability into antibodies to augment therapeutic efficacy | Liu, Qingyun | The University of Texas Health Science Center at Houston | \$1,050,000 |
| 23 | RP240326 | IIRA | 2.0 | Translation of gut commensal bacteria peptidoglycan remodeling pathway for chimeric antigen receptor T-cell therapy | Saini, Neeraj | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 24 | RP240311 | IIRA | 2.0 | Treatment planning of ADC therapy for ovarian cancer with molecular photoacoustic-ultrasonic imaging | Bouchard, Richard | The University of Texas M. D. Anderson Cancer Center | \$1,049,859 |
| 25 | RP240117 | IIRA | 2.0 | Identify radiopathomics markers to guide immunotherapy for non-small cell lung cancer | Wu, Jia | The University of Texas M. D. Anderson Cancer Center | \$1,049,906 |
| 26 | RP240054 | IIRACCA | 2.0 | Myeloid Support of Refractory and Aggressive T-ALL at Distinct Tumor Sites | Ehrlich, Lauren | The University of Texas at Austin | \$1,400,000 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660

T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|---------------------|--|--------------|
| 27 | RP240237 | IIRACCA | 2.0 | The Role of EWSR1-FLI1-CENP-A Signaling in Chemoresistance in Ewing Sarcoma | Kitagawa, Katsumi | The University of Texas Health Science Center at San Antonio | \$1,400,000 |
| 28 | RR240015 | RRS | 2.0 | HyperGlio - New tools to fight brain cancer with signal-enhanced magnetic resonance | Gloeggler, Stephan | The University of Texas Southwestern Medical Center | 4,000,000.00 |
| 29 | RR240021 | RRS | 2.0 | Expansion and Single-cell Interrogation of Tumoroid Models for Precise Treatment of Diverse Rectal Cancer Patient Populations | Smith, Jesse Joshua | The University of Texas Southwestern Medical Center | 4,000,000.00 |
| 30 | RP240183 | IIRA | 2.1 | Restoring TREM2-Dependent Efferocytosis to Inhibit Obesity-Induced Liver Inflammation and Cancer Development | Liang, Shuang | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 31 | RP240263 | IIRA | 2.1 | Identifying the Biological Determinants of Aggressive Meningioma | Patel, Akash | Baylor College of Medicine | \$1,049,370 |
| 32 | RP240392 | IIRA | 2.1 | Identifying Tumor Specific Vulnerabilities in Appendiceal Adenocarcinoma: A Systems Approach | Shen, John Paul | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 33 | RP240133 | IIRA | 2.1 | Modulation of blood-spinal cord barrier for tumor treatment | Qin, Zhenpeng | The University of Texas at Dallas | \$1,050,000 |
| 34 | RP240233 | IIRACT | 2.1 | Toward Nonoperative Management of Early-Stage ER-Positive Breast Cancer | Rahimi, Asal | The University of Texas Southwestern Medical Center | \$1,999,963 |
| 35 | RP240127 | IIRA | 2.2 | Transposon Restriction, Tumor Suppression and p53 | Abrams, John | The University of Texas Southwestern Medical Center | \$1,039,356 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|----------|-----|---|------------------|--|--------------|
| 36 | RP240072 | IIRA | 2.2 | Dissection of CAMKK2's Tumor Cell-intrinsic and -extrinsic Roles in Prostate Cancer | Frigo, Daniel | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 37 | RP240288 | IIRA | 2.3 | Epigenetic mechanism and targeting during response to BRAFi/anti-EGFR therapy in BRAF-mutant colorectal cancers | Kopetz, Scott | The University of Texas M. D. Anderson Cancer Center | \$1,043,909 |
| 38 | RP240380 | IIRA | 2.3 | Clonal hematopoiesis for improving lung cancer risk assessment | Cheng, Chao | Baylor College of Medicine | \$1,040,316 |
| 39 | RP240131 | IIRACSBC | 2.3 | Computational Methods for CRISPR-Based Lineage Tracing Systems | Liu, Zhandong | Baylor College of Medicine | \$1,200,000 |
| 40 | RR240007 | REI | 2.3 | Building a multi-modal platform to enable next-generation functional precision oncology | Shen, Xiling | The University of Texas M. D. Anderson Cancer Center | 6,000,000.00 |
| 41 | RP240214 | IIRA | 2.5 | Immunoprevention of Breast Cancer Brain Metastasis by Special Dendritic Cell-derived Extracellular Vesicles | Yu, Dihua | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 42 | RP240120 | IIRA | 2.5 | JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC | ZHANG, QING | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 43 | RP240287 | IIRA | 2.5 | Investigating the Impact of Interferon Gamma Signaling on Therapeutic Resistance in Acute Myeloid Leukemia | Abbas, Hussein | The University of Texas M. D. Anderson Cancer Center | \$1,042,256 |
| 44 | RP240104 | IIRA | 2.6 | Characterization and optimization of novel allosteric KRAS inhibitors | Gorfe, Alemayehu | The University of Texas Health Science Center at Houston | \$1,050,000 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego
SCHOOL OF MEDICINE

| | | | | | | | |
|--|----------|---------|-----|---|------------------------|---|-------------|
| 45 | RP240320 | IIRA | 2.6 | Benzothiazepines as first-in-class inhibitors for the ribogenesis factor NVL and evaluation in preclinical colorectal cancer models | De Brabander, Jef | The University of Texas Southwestern Medical Center | \$1,049,754 |
| 46 | RP240143 | IIRACCA | 2.6 | Leveraging Passport for Care in a Telehealth Framework to Improve Equitable Access to Survivorship Services | Gramatges, Maria | Baylor College of Medicine | \$1,399,382 |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| 51 | RP240208 | IIRAP | 2.8 | Unidos Contra el VPH: Screening Accuracy, Preference, and Uptake of HPV Self-Sampling Among Latinxs Along the US-Mexico Border | Calderon-Mora, Jessica | The University of Texas at Austin | \$1,920,007 |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee.

Individual Investigator Research Awards (IIRA)
Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)
Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)
Individual Investigator Research Awards for Clinical Translation (IIRACT)
Individual Investigator Research Awards for Prevention and Early Detection
Recruitment of Established Investigators (REI)
Recruitment of Rising Stars (RRS)
Recruitment of First-Time, Tenure Track Faculty Members (FTTFM)



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2024—Cycle 1**

***Individual Investigator Research Awards for
Computational Systems Biology of Cancer***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-24.1-IIRACSB

**Individual Investigator Research Awards for
Computational Systems Biology of Cancer**

**Please also refer to the Instructions for Applicants document,
which will be posted on March 15, 2023**

Application Receipt Opening Date: March 15, 2023

Application Receipt Closing Date: June 14, 2023

FY 2024

Fiscal Year Award Period
September 1, 2023–August 31, 2024

TABLE OF CONTENTS

| | |
|--|-----------|
| 1. BRIEF DESCRIPTION OF RFA | 4 |
| 2. ABOUT CPRIT | 4 |
| 2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES..... | 4 |
| 3. RATIONALE | 5 |
| 4. RESEARCH OBJECTIVES | 6 |
| 5. FUNDING INFORMATION | 7 |
| 6. ELIGIBILITY | 7 |
| 7. RESUBMISSION POLICY | 9 |
| 8. RENEWAL POLICY | 9 |
| 9. RESPONDING TO THIS RFA | 10 |
| 9.1. APPLICATION SUBMISSION GUIDELINES..... | 10 |
| 9.1.1. <i>Submission Deadline Extension</i> | 10 |
| 9.2. APPLICATION COMPONENTS..... | 10 |
| 9.2.1. <i>Abstract and Significance (5,000 characters)</i> | 10 |
| 9.2.2. <i>Layperson’s Summary (2,000 characters)</i> | 11 |
| 9.2.3. <i>Aims and Sub-Aims</i> | 11 |
| 9.2.4. <i>Timeline (1 page)</i> | 12 |
| 9.2.5. <i>Specific Aims (1 page)</i> | 12 |
| 9.2.6. <i>Resubmission Summary (2 pages)</i> | 12 |
| 9.2.7. <i>Renewal Summary (2 pages)</i> | 12 |
| 9.2.8. <i>Research Plan (10 pages)</i> | 13 |
| 9.2.9. <i>Vertebrate Animals (1 page)</i> | 13 |
| 9.2.10. <i>Human Subjects (2 pages)</i> | 13 |
| 9.2.11. <i>Publications/References</i> | 13 |
| 9.2.12. <i>Budget and Justification</i> | 13 |
| 9.2.13. <i>Biographical Sketches (5 pages each)</i> | 14 |
| 9.2.14. <i>Current and Pending Support</i> | 15 |
| 9.2.15. <i>Institutional/Collaborator Support and/or Other Certification (4 pages)</i> | 15 |
| 9.2.16. <i>Previous Summary Statement</i> | 15 |
| 9.3. FORMATTING INSTRUCTIONS..... | 15 |
| 10. APPLICATION REVIEW | 16 |
| 10.1. PRELIMINARY EVALUATION..... | 16 |
| 10.2. FULL PEER REVIEW..... | 17 |
| 10.3. CONFIDENTIALITY OF REVIEW..... | 17 |
| 10.4. REVIEW CRITERIA..... | 18 |
| 10.4.1. <i>Primary Criteria</i> | 19 |
| 10.4.2. <i>Secondary Criteria</i> | 20 |
| 11. KEY DATES | 20 |
| 12. AWARD ADMINISTRATION | 20 |
| 13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS | 21 |
| 14. CONTACT INFORMATION | 22 |
| 14.1. HELPDESK..... | 22 |
| 14.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS..... | 22 |

RFA VERSION HISTORY

- 2/17/23 RFA released
- 5/16/23 Modified section 9.2.13 – Biographical Sketches; included the following updated language: “Up to 5 additional biographical sketches for key personnel may be provided, these should be concatenated into a single PDF with a 25-page limit.”

1. BRIEF DESCRIPTION OF RFA

- Supports applications for projects that integrate innovative computational and mathematical approaches with experimental cancer biology to address challenging questions that will advance current knowledge in the etiology, biology, progression, treatment, metastasis, and immunology of cancer.
- Applicants may request a maximum of \$400,000 per year for a period of up to 3 years.
- Multi-Principal Investigators (PIs) (MIs) are allowed under this RFA. See Information for Applicants for definition and eligibility of MIs.
- Note that CPRIT does not allow the use of the term Co-PI.
- Minimum effort for the PI and/or MIs throughout the project period is required.

2. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

2.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state
- Reducing cancer disparities.

The program priorities for academic research adopted by the Oversight Committee include funding projects that address or utilize the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials

3. RATIONALE

Cancer is a complex multiscale disease involving the interaction of dynamic processes at the molecular, cellular, and multicellular levels. These interactive processes adapt and evolve in response to both intracellular and extracellular cues, and across temporal and spatial scales, making cancer difficult to prevent and treat as well as to predict the effects of therapy. Cancer systems biology has emerged as a powerful field that employs multidimensional data as well as mathematical and computational modeling to address these complexities in cancer biology and to predict integrated mechanisms underlying cancer initiation, progression, metastasis, prognosis, and treatment response. The historic focus on single genetic alterations has now expanded to embrace a broader view of the changing cancer ecosystem and evolving patterns of genotypes and phenotypes associated with progression and therapeutic intervention, facilitated by an explosion in the quantity of experimental data available from high-throughput technologies, such as genomics/epigenomics, transcriptomics, metabolomics, and proteomics. Systems analyses and predictive modeling are proving to be valuable tools to convert these large data sets, spanning different length and time scales, into predictions that can then be experimentally tested or validated in a disease-relevant context, thereby enabling cancer biologists and oncologists to understand and predict how one alteration effects an entire tumor system, increasing our understanding of tumor biology, treatment options, and patient outcomes.

4. RESEARCH OBJECTIVES

This Request for Applications (RFA) solicits applications for innovative research projects in cancer systems biology. CPRIT has adopted the National Cancer Institute's (NCI) definition of cancer systems biology as “a holistic approach to the study of the complexities of cancer through the explicit integration of experimental biology and computational and mathematical methods to build predictive models of cancer that are tested and validated in a disease-relevant context” (<https://www.cancer.gov/about-nci/organization/dcb/research-programs/csbc>). Examples of projects responsive to this RFA include, but are not limited to, scientific proposals addressing the following:

- Developing integrated models of genetic/epigenetic, chemical, cytoplasmic/network, microenvironment, and structural features across space and time scales to understand the mechanisms of cancer initiation, progression, metastasis, and therapeutic response;
- Characterization of cellular interactions and their impact on local, systemic, and evolving cellular behaviors that underlie cancer processes, such as initiation, progression, and metastasis;
- Delineation of the interactions between tumor and nontumor components, eg, tumor-immune cell interactions, and involvement in mediating the response or resistance to therapy;
- Integration of the biology underlying normal physiological processes, such as development, aging, metabolism, immunity, or chronic inflammation, to inform cancer development, progression, metastasis, or treatment response;
- Elucidation of the mechanism(s) by which external factors, such as the microbiome, affect tumor biology, including therapeutic response;
- Application of systems biology approaches, eg, network and multiscale modeling, to discover targetable molecular or cellular mechanisms and to test biologically informed therapies, sequences of therapies and combinations of therapies that incorporate variables such as toxicities, dose, and timing; and
- Integration of molecular and cellular oncogenic processes with population-level risk factors, such as obesity or chronic inflammation, or environmental factors that may differentially impact patient populations and influence cancer disparities.

Partnering of mathematical or computational scientists with cancer biologists or oncologists is highly recommended to form a truly interdisciplinary team that can both develop and validate models leading to a deeper integrated understanding of cancer progression and treatment.

NCI established the Cancer Systems Biology Consortium ([CSBC](#)) to support computational systems biology approaches to cancer research in recognition of the potential for the integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research. The CSBC website includes descriptions of the CSBC portfolio of NCI-funded projects that are examples of the type of applications this RFA seeks to attract. Applications that propose projects focused on purely bioinformatic analyses of omics data or propose correlative studies without a mathematical or computational model are not responsive to this RFA. CPRIT expects the outcomes of activities supported by this RFA to lead to new insights into cancer biology or clinical outcomes in the long term. The degree of relevance to reducing the burden of cancer is a critical criterion for evaluation of projects for funding by CPRIT ([section 10.4.1](#)).

5. FUNDING INFORMATION

Applicants may request a maximum of \$400,000 in total costs per year for up to 3 years. Exceptions to these limits may be requested if extremely well justified (see [section 9.2.12](#)). Funds may be used for salary and fringe benefits, research supplies, equipment, and travel to scientific/technical meetings or collaborating institutions. Requests for funds to support construction and/or renovation will not be approved under this funding mechanism. State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount.

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism; these entities must use the appropriate award mechanism(s) under CPRIT's Product Development Research Program.

- The PI must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and must be a full-time resident of Texas during the time the research that is the subject of the grant is conducted.
- This award mechanism allows MIs for projects that require a team science approach (see the IFA for guidelines on CPRIT rules for MI awards).
- For applications that include 1 PI, the PI is required to maintain a minimum 15% level of effort throughout the entire award period. For applications that include MIs, each PI is required to maintain a minimum 10% effort throughout the entire award period.
- A PI may not submit applications to this RFA and to RFA R-24.1-IIRA, RFA R-24.1-IIRACCA, RFA R-24.1-IIRACT, or RFA R-24.1-IIRAP during this funding cycle.
- A PI may submit only 1 application, either a new, resubmission or renewal application under this RFA during this funding cycle.
- A PI may be a part of only one application, whether as a single applicant or as part of an MI application, under this RFA and RFA R-24.1-IIRA, RFA R-24.1-IIRACCA, RFA R-24.1-IIRACT, or RFA R-24.1-IIRAP.
- An individual may serve as a PI on no more than 3 active CPRIT Academic Research grants. Recruitment Grants and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers MIRA Project Co-PIs equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be March 1, 2024).
- Collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member or key personnel listed on the grant application, or any officer or director of the

grant applicant's organization or institution is related to a CPRIT Oversight Committee member.

- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, regardless of whether those individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 12](#) and [section 13](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted **once** if the proposed project meets the IIRACSBC research objectives (see [section 4](#)) and follows all resubmission guidelines. More than 1 resubmission is not permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the PI for a project or a change of title of the project that was previously submitted to CPRIT does not constitute a new application; the application would be considered a resubmission. This policy is in effect for all applications submitted to date. See [section 9.2.6](#).

8. RENEWAL POLICY

An application originally funded by CPRIT as an IIRA or IIRACB mechanism may be submitted under this RFA for a competitive renewal if the proposed project meets the IIRACSBC research objectives. See [section 4](#) and [section 9.2.7](#). Competitive renewals are not subject to preliminary evaluation. Renewal applications move directly to the full peer review phase. See [section 10.2](#).

9. RESPONDING TO THIS RFA

9.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on March 15, 2023, and must be submitted by 4 PM central time on June 14, 2023. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

9.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grant applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

9.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the IFA for details that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

9.2.1. Abstract and Significance (5,000 characters)

It is the responsibility of the applicant to capture CPRIT's attention primarily with the Abstract and Significance statement alone. Therefore, applicants are advised to prepare this section

wisely. **Based on the Abstract and Significance statement (and the Specific Aims page, Budget and Justification and Biographical Sketches), applications that are judged to offer only modest contributions to the field of cancer research or that do not sufficiently capture the reviewers' interest may be excluded from further peer review (see [section 10.1](#)).**

Applicants should not waste this valuable space by stating obvious facts (eg, that cancer is a significant problem; that better diagnostic and therapeutic approaches are needed urgently; or that the type of cancer of interest to the PI is important, vexing, or deadly).

Clearly explain the question or problem to be addressed and the approach to its answer or solution. The specific aims of the application must be obvious from the abstract although they need not be restated verbatim from the research plan.

Clearly address how the proposed project, if successful, will have a major impact on cancer. Indicate whether this research will address cancers associated with disparities. Summarize how the proposed research creates new paradigms or challenges existing ones. Indicate whether this research plan represents a new direction for the PI.

9.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detection, prevention, treatment, or survivorship. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. **Do not include any proprietary information in the layperson's summary.** The layperson's summary will also be used by advocate reviewers ([section 10.2](#)) in evaluating the significance and impact of the proposed work.

9.2.3. Aims and Sub-Aims

Please provide a description of the Aims and Sub-aims and milestones to be achieved for each year of the project. Provide 2-3 sentences describing activities to be performed and anticipated milestones. These Aims will also be used during the submission and evaluation of progress reports and assessment of project success.

9.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications.

If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

9.2.5. Specific Aims (1 page)

Please provide a 1-page summary of the aims of the proposal. The Specific Aims page should identify the problem, or gap in our current knowledge. It should present a hypothesis and briefly describe the aims and approaches. Address the proposal's innovation, novel approaches and significance and impact on the field and cancer research. Please also refer to the template located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.6. Resubmission Summary (2 pages)

Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

Note: An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to need considerable attention. Applicants may prepare a fresh research plan or modify the original research plan and mark the changes. However, **all resubmitted applications should be carefully reconstructed**; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes.

9.2.7. Renewal Summary (2 pages)

Applicants preparing a renewal must describe and demonstrate that appropriate/adequate progress has been made on the current funded award to warrant further funding. Publications and manuscripts in press that have resulted from work performed during the initial funded period should be listed in the renewal summary.

9.2.8. Research Plan (10 pages)

Background: Present the rationale behind the proposed project, emphasizing the pressing problem in cancer research that will be addressed.

Hypothesis and Specific Aims: Concisely state the hypothesis and/or specific aims to be tested or addressed by the research described in the application. Describe the significance, innovation, and potential impact of the research.

Research Strategy: Describe the experimental design, including methods, anticipated results, potential problems or pitfalls, and alternative approaches. Preliminary data that support the proposed hypothesis are encouraged but not required.

9.2.9. Vertebrate Animals (1 page)

If vertebrate animals will be used, provide a detailed plan of the protocols that will be followed and justification for the number of animals used with reference to biostatistical input for sample selection and evaluation. Certification of approval by the institutional IACUC of the proposed animal use will be required before funding can occur.

9.2.10. Human Subjects (2 pages)

If human subjects or human biological samples will be used, provide a detailed plan for recruitment of subjects and/or the acquisition of samples that will meet the time constraints of this award mechanism. Certification of approval of these plans by the institutional IRB will be required before funding can occur.

9.2.11. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

9.2.12. Budget and Justification

Provide a compelling and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, supplies, equipment, patient care costs, animal care costs, and other expenses. Applicants may request a maximum of \$400,000 in total costs per year for up to 3 years. Applicants are advised not to interpret the maximum allowable time and funding under this award as a suggestion that they should expand their anticipated work and budget to this level. Reasonable budgets clearly work in favor of the applicant.

However, if there is a highly specific and defensible need to request more than the maximum amount in any year(s) of the proposed budget, include a special and clearly labeled section in the budget justification that explains the request. Poorly justified requests of this type will likely have a negative impact on the overall evaluation of the application.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.
- The maximum annual salary (also referred to as direct salary or institutional base salary) that an individual may request under a CPRIT award for FY 2024 is \$200,000; CPRIT FY 2024 is from September 1, 2023, through August 31, 2024. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

9.2.13. Biographical Sketches (5 pages each)

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research. A biographical sketch must be provided for the PI and, if applicable, any additional PIs (if an MI application), as required by the online application receipt system. Up to 5 additional biographical sketches for key personnel may be provided, these should be concatenated into a single PDF with

a 25-page limit. Each biographical sketch must not exceed 5 pages. The NIH biosketch format is appropriate.

9.2.14. Current and Pending Support

Describe the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project, and, if relevant, a statement of overlap with the current application. At a minimum, current and pending support of the PI and, if applicable, any additional PIs (if an MI application), must be provided. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.15. Institutional/Collaborator Support and/or Other Certification (4 pages)

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 4 pages may be provided.

9.2.16. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

Applications that are missing 1 or more of these components, exceed the specified page, word, or budget limits, or that do not meet the eligibility requirements listed above will be administratively rejected without review.

9.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions

- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable as long as the journal information is stated. Include URLs of publications referenced in the application.
Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45-67.
- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

10. APPLICATION REVIEW

10.1. Preliminary Evaluation

To ensure the timely and thorough review of only the most innovative and cutting-edge research with the greatest potential for advancement of cancer research, all eligible applications may be preliminarily evaluated by CPRIT Scientific Research Program panel members for scientific merit and impact.

This preliminary evaluation will be based on a subset of material presented in the application—namely, Abstract and Significance, Specific Aims page, Budget and

Justification, and Biographical Sketches. Applications that do not sufficiently capture the reviewers' interest at this stage will not be considered for further review. Such applications will have been judged to offer only modest contributions to the field of cancer research and will be excluded from further peer review.

The applicant will be notified of the decision to disapprove the application after the preliminary evaluation stage has concluded. Due to the volume of applications to be reviewed, comments made by reviewers at the preliminary evaluation stage may be limited.

10.2. Full Peer Review

Applications that pass preliminary evaluation will undergo further review using a 2-stage peer review process: (1) Full peer review and (2) Prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 10.4](#). In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by the Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

10.3. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, (Texas Administrative Code [RULE §703.9](#)).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee Member, a PIC Member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Research Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

10.4. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

10.4.1. Primary Criteria

Primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

Significance and Impact: Will the results of this research, if successful, significantly change the research of others or the opportunities for better cancer prevention, diagnosis, or treatment for patients? Is the application innovative? Does the applicant propose new paradigms or challenge existing ones? Does the project develop state-of-the-art technologies, methods, tools, or resources for cancer research or address important underexplored or unexplored areas? If the research project is successful, will it lead to truly substantial advances in the field rather than add modest increments of insight? Projects that modestly extend current lines of research will not be considered for this award. Projects that represent straightforward extensions of ongoing work, especially work traditionally funded by other mechanisms, will not be competitive.

Research Plan: Is the proposed work presented as a self-contained research project? Does the proposed research have a clearly defined hypothesis or goal that is supported by sufficient preliminary data and/or scientific rationale? Are the methods appropriate, and are potential experimental obstacles and unexpected results discussed?

Applicant Investigator: Does the investigator(s) demonstrate the required experience and creativity to make a significant contribution to the research? Does the applicant investigator(s) demonstrate the required expertise to make a significant contribution in both mathematical or computational sciences and oncology, or are there appropriate collaborators or consultants with expertise in oncology or cancer biology? It is highly encouraged that applicant investigators engage such collaborators. Applicants' credentials will be evaluated in a career stage-specific fashion. Have early-career-stage investigators received excellent training, and do their accomplishments to date offer great promise for a successful career? Has the applicant(s) devoted a sufficient amount of their time (percent effort) to this project?

Relevance: Does the proposed research address a significant problem related to cancer? Is it likely to make an impact on this disease? This is a critical criterion for evaluation of projects for CPRIT support.

10.4.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research.

Secondary criteria include the following:

Research Environment: Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the proposed research? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support of the research team and the project?

Vertebrate Animals and/or Human Subjects: Is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed?

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

11. KEY DATES

RFA

RFA release February 17, 2023

Application

Online application opens March 15, 2023, 7 AM central time

Application due June 14, 2023, 4 PM central time

Application review June 2023–February 2024

Award

Award notification February 2024

Anticipated start date March 1, 2024

12. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to

exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT's administrative rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. A grant recipient that is a public or private institution of higher education, as defined by §61.003, Texas Education Code, may credit toward the Grant Recipient's Matching Funds obligation the dollar amount equivalent to the difference between the indirect cost rate authorized by the federal government for research grants awarded to the Grant Recipient and the 5% indirect cost limit imposed by §102.203(c), Texas Health and Safety Code. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding. The

demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted.

14. CONTACT INFORMATION

14.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time.

Tel: 866-941-7146

Email: Help@CPRITGrants.org

14.2. Scientific and Programmatic Questions

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Director of Research.

Tel: 512-305-8491

Email: research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel - Basic Cancer

Research-1 (24.1_AR_BCR-1)

Observation Report

Report No. 2023-10-20 24.1_AR_BCR-1
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel - Basic Cancer Research-1
(24.1_AR_BCR-1)
Panel Date: October 20, 2023
Report Date: October 26, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel - Basic Cancer Research-1 (24.1_AR_BCR-1) meeting. The meeting was chaired by Eric Fearson and conducted via videoconference on October 20, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and twenty-three (23) applications were not discussed
- Panelists: One (1) panel chair, thirteen (13) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were five (5) Conflict of Interest (COI) identified prior to and/or during the meeting. Two (2) applications with COIs were discussed and two (2) applications with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel – Basic Cancer

Research (24.1 ACR-BCR-2) Observation Report

Report No. 2023-10-11 24.1_ACR-BCR-2
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel – Basic Cancer Research
(24.1 _ACR-BCR-2)
Panel Date: October 11, 2023
Report Date: October 16, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel – Basic Cancer Research (24.1_ACR-BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on October 11, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and thirty (30) applications were not discussed
- Panelists: One (1) panel chair, Nineteen (19) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Eight (8)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were nine (9) Conflicts of Interest (COI) identified prior to and/or during the meeting. COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel - Basic Cancer

Research (24.1 ACR CPR)

Observation Report

Report No. 2023-10-13 24.1_ACR CPR
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel - Basic Cancer Research
(24.1 _ACR CPR)
Panel Date: October 13, 2023
Report Date: October 16, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel - Basic Cancer Research (24.1_ACR CPR) meeting. The meeting was chaired by Elena Martinez and conducted via videoconference on October 13, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Ten (10) applications were discussed and eleven (11) applications were not discussed
- Panelists: One (1) panel chair, twelve (12) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Seven (7)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflict of Interest (COI) identified prior to and/or during the meeting. Two (2) applications with COIs were discussed and one (1) application with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
24.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (24.1_ACR-CTCR)
Observation Report

Report No. 2023-10-17 24.1_ACR-CTCR
Program Name: Academic Research
Panel Name: 24.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (24.1_ACR-CTCR)
Panel Date: October 17, 2023
Report Date: October 23, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Clinical and Translational Cancer Research (C/TCR) (24.1_ACR-CTCR) meeting. The meeting was chaired by Richard O'Reilly and Margaret Tempero and conducted via videoconference on October 17, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty-one (21) applications were discussed and thirty-five (35) applications were not discussed
- Panelists: Two (2) panel chair, seventeen (17) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflict of Interest (COI) identified prior to and/or during the meeting. Two (2) applications with COIs were discussed and two (2) applications with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel – Imaging Technology and Informatics (24.1 ACR ITI) Observation Report

Report No. 2023-10-19 24.1_ACR-ITI
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel – Imaging Technology and Informatics (24.1 _ACR-ITI)
Panel Date: October 19, 2023
Report Date: October 26, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel – Imaging Technology and Informatics (24.1_ACR-ITI) meeting. The meeting was co-chaired by Anna Wu, Henry VanBrocklin, and Jason Lewis, in lieu of Martin Pomper and conducted via videoconference on October 19, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Sixteen (16) applications were discussed and thirteen (13) applications were not discussed
- Panelists: Three (3) panel chairs, thirteen (13) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were twelve (12) Conflicts of Interest (COI) identified prior to and/or during the meeting. Four (4) applications with a COI were discussed and three (3) applications with a COI were not discussed. COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Scientific Review Council (24.1 SRC) Observation Report

Report No. 2023-12-14 24.1_SRC
Program Name: Academic Research
Panel Name: 24.1 Academic Research Scientific Review Council (24.1 _SRC)
Panel Date: December 14, 2023
Report Date: January 17, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Scientific Review Council (24.1_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 14, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Forty- five (45) applications were discussed
- Panelists: One (1) panel chair, and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 24.1

Awards Announced at the February 21, 2024, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 24.1 include: *Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Translation; and Individual Investigator Research Awards for Prevention and Early Detection.* Applications submitted in response to these five award mechanisms went through preliminary evaluation as allowed by TAC § 703.6(e)(1).

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT’s third party grant administrator, and by CPRIT.

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|--|------------------------|--|------------------------------------|
| Applications considered by the PIC and Oversight Committee: | | | |
| RP240127 | John Abrams | The University of Texas Southwestern Medical Center | Benjamin Greenbaum |
| RP240072 | Daniel Frigo | The University of Texas M. D. Anderson Cancer Center | Steffi Oesterreich |
| RP240125 | Guojun Li | The University of Texas M. D. Anderson Cancer Center | Electra Paskett; Thomas Brandon |
| RP240272 | Joseph Ludwig | The University of Texas M. D. Anderson Cancer Center | Richard O'Reilly |
| RP240117 | Jia Wu | The University of Texas M. D. Anderson Cancer Center | Charles Kahn; Maryellen Giger |

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|---|------------------------|--|-------------------------------|
| RP240311 | Richard Bouchard | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger; Weibo Cai |
| RP240291 | Eveline Barbieri | Baylor College of Medicine | Craig Rosenfeld |
| Applications not considered by the PIC or Oversight Committee: | | | |
| RP240101 ^a | Sang Eun Lee | The University of Texas Health Science Center at San Antonio | Alan Tomkinson; John Petrini |
| RP240118 | Elizabeth Goldsmith | The University of Texas Southwestern Medical Center | Alan Tomkinson |
| RP240236 | Katharina Schlacher | The University of Texas M. D. Anderson Cancer Center | John Petrini |
| RP240270 | Giulio Draetta | The University of Texas M. D. Anderson Cancer Center | Eileen White; Nabeel Bardeesy |
| RP240364 | Christopher Amos | Baylor College of Medicine | Alan Tomkinson |
| RP240399 | Jonathan Sessler | The University of Texas at Austin | Nabeel Bardeesy |
| RP240368 | Zhaoyong Hu | Baylor College of Medicine | Steffi Oesterreich |
| RP240106 | Michelle Hildebrandt | The University of Texas M. D. Anderson Cancer Center | Electra Paskett |
| RP240240 | Maria Swartz | The University of Texas M. D. Anderson Cancer Center | Electra Paskett |
| RP240112 | Jianjun Zhang | The University of Texas M. D. Anderson Cancer Center | Antoni Ribas |
| RP240340 | Kareem Azab | The University of Texas Southwestern Medical Center | John DiPersio |
| RP240354 | Charles Reynolds | Texas Tech University Health Sciences Center | W. Martin Kast |

^a The PIC did not recommend this application to the Oversight Committee.

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|-----------------------------------|------------------------|--|--|
| RP240044 | Jingfei Ma | The University of Texas M. D. Anderson Cancer Center | Charles Kahn; David Mankoff; Martin Pomper |
| RP240056 | David Fuentes | The University of Texas M. D. Anderson Cancer Center | David Mankoff; Maryellen Giger |
| RP240066 | Xiankai Sun | The University of Texas Southwestern Medical Center | Anna Wu |
| RP240088 | Hongyu Wang | The University of Texas Health Science Center at Houston | Charles Kahn |
| RP240141 | Jian Gu | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger |
| RP240018 | Lan Zhou | The Methodist Hospital Research Institute | Eric Fearon; Weiping Zou |
| RP240299 | Wen Jiang | The University of Texas M. D. Anderson Cancer Center | Kristin Swanson |
| RP240396 | Leonidas Bleris | The University of Texas at Dallas | Alexander Anderson |
| RP240409 | Tae Jin Lee | The University of Texas Health Science Center at Houston | Kristin Swanson |
| RP240177 (preliminary evaluation) | Hays Rye | Texas AgriLife Research | Benjamin Raphael |
| RP240410 (preliminary evaluation) | Murugesan Palaniappan | Baylor College of Medicine | Steffi Oesterreich |
| RP240140 (preliminary evaluation) | Sang Cho | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger |
| RP240221 (preliminary evaluation) | Tinsu Pan | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger |

De-Identified Overall Evaluation Scores

Individual Investigator Research Awards for Computational Systems Biology of Cancer

Academic Research Cycle 24.1

Final Scores for Fully Reviewed Applications

| Application ID | Final Overall Evaluation Score |
|----------------|--------------------------------|
| RP240293* | 1.0 |
| RP240137* | 1.1 |
| RP240131* | 2.3 |
| Ta | 2.6 |
| Tb | 3.4 |
| Tc | 3.7 |
| Td | 3.7 |
| Te | 3.7 |
| Tf | 3.9 |
| Tg | 4.0 |
| Th | 4.0 |
| Ti | 4.3 |
| Tj | 4.7 |
| Tk | 5.0 |
| Tl | 6.0 |

* Recommended for funding.

Individual Investigator Research Awards for Computational Systems Biology of Cancer

Academic Research Cycle 24.1

Final Scores for Preliminary Evaluation

These are the final overall evaluation scores for applications receiving preliminary evaluation that did not move forward to full review. The final overall evaluation score is an average of the preliminary evaluation scores assigned to each application by the primary reviewers.

| Application ID | Final Overall Score |
|----------------|---------------------|
| ba | 4.67 |
| bb | 5.33 |
| bc | 6.33 |

Final Overall Evaluation Scores and Rank Order Scores

UC San Diego

SCHOOL OF MEDICINE

January 3, 2024

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Dr. Cummings and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Individual Investigator Research Awards, Individual Investigator Research Awards for Childhood and Adolescent Cancers, Individual Investigator Research Awards for Computational Systems Biology of Cancer, Individual Investigator Research Awards for Clinical Translation, Individual Investigator Research Awards for Prevention and Early Detection, Recruitment of Established Investigators, Recruitment of Rising Stars and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on December 14, 2023 to consider the FY24.1 applications recommended by the peer review panels following their meetings held October 11, 2023 to October 20, 2023. The SRC met on November 16, 2023 to review recruitment applications submitted for Cycle FY24.3-4 and then on December 14, 2023 to review recruitment applications submitted for Cycle FY24.5.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$83,180,142.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

| Recommended for Funding by Mechanism (Ranked by Overall Score) | | | | | | | |
|--|----------|-----------------|-----------------------|---|-----------------|--|--------------------|
| Rank | ID | Award Mechanism | Meeting Overall Score | Application Title | PI | PI Organization | Recommended Budget |
| 1 | RP240068 | IIRA | 1.0 | Understanding the Mechanism of Linker Histone Mutations in Malignancy | Soshnev, Alexey | The University of Texas at San Antonio | \$997,770 |
| 2 | RP240293 | IIRACSBC | 1.0 | Therapeutic Vulnerabilities and Predictors of Response to Chemo(immuno)therapy in Patients With High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC) | Korkut, Anil | The University of Texas M. D. Anderson Cancer Center | \$1,199,999 |
| 3 | RR240019 | RRS | 1.0 | Development of Chemotherapeutics Inspired by Natural Products | Sarlah, David | Rice University | 4,000,000.00 |
| 4 | RP240137 | IIRACSBC | 1.1 | Charting TCR-Tumor Antigen Interactions to Foster Novel Immunotherapeutic Approaches for Triple-Negative Breast Cancer | Zhang, Bing | Baylor College of Medicine | \$1,200,000 |
| 5 | RR240013 | RFTFM | 1.2 | Regulation of gene expression and tumorigenesis by ubiquitin-mediated protein quality control | Mark, Kevin | The University of Texas Southwestern Medical Center | 2,000,000.00 |
| 6 | RR240016 | RFTFM | 1.3 | Impact of Germline Variants on Pediatric Leukemia Progression: Insights from 3D Chromatin Remodeling and Clinical Outcomes | Luan, Yu | The University of Texas Health Science Center at San Antonio | 2,000,000.00 |
| 7 | RR240030 | REI | 1.3 | Break-induced DNA Replication as a Driver of Genomic Instability in Cancer | Malkova, Anna | The University of Texas Health Science Center at San Antonio | 6,000,000.00 |
| 8 | RR240027 | RFTFM | 1.4 | Genomic and Epigenomic Mechanisms of Chemobrain | Dileep, Vishnu | Baylor College of Medicine | 2,000,000.00 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|-----------------------|--|-------------|
| 9 | RP240075 | IIRACT | 1.5 | Combination Therapy Using ATRA and Carfilzomib to Treat Proteasome Inhibitor Refractory Multiple Myeloma | Yi, Qing | The Methodist Hospital Research Institute | \$1,921,388 |
| 10 | RP240291 | IIRA | 1.6 | Targeting MYCN disruption of the molecular clock and tumor metabolism in neuroblastoma oncogenesis. | Barbieri, Eveline | Baylor College of Medicine | \$1,050,000 |
| 11 | RP240289 | IIRA | 1.6 | Real-time, label-free, micro HSI device and transformer-based attention networks for oral cancer imaging | Fei, Baowei | The University of Texas at Dallas | \$1,049,806 |
| 12 | RP240125 | IIRA | 1.8 | Immune-Related Determinants of HPV-Associated Oropharyngeal Cancer Outcomes | Li, Guojun | The University of Texas M. D. Anderson Cancer Center | \$1,049,726 |
| 13 | RP240061 | IIRA | 1.8 | Deciphering Iron Redox Cycles in Ferroptosis-based Cancer Therapy | Lu, Yi | The University of Texas at Austin | \$1,044,608 |
| 14 | RP240091 | IIRA | 1.9 | High resolution high sensitivity photoacoustic imaging molecular guided brain tumor surgery with pilot clinical deployment | Valdes Quevedo, Pablo | The University of Texas Medical Branch at Galveston | \$1,044,967 |
| 15 | RP240401 | IIRACCA | 1.9 | Lead Optimization, Target Engagement, and Efficacy Studies of Locally Bioavailable COX-2 inhibitors for Preventing Colon Cancer Progression in FAP Children | Hu, Ming | University of Houston | \$1,400,000 |
| 16 | RP240272 | IIRACCA | 1.9 | The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy for DSRCT | Ludwig, Joseph | The University of Texas M. D. Anderson Cancer Center | \$1,398,788 |
| 17 | RP240184 | IIRACT | 1.9 | Maximizing Antitumor Immunity Through Simultaneous Activation of the Innate and Adaptive Immune System | Hannan, Raquibul | The University of Texas Southwestern Medical Center | \$1,999,993 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|-------------------|--|-------------|
| 18 | RP240095 | IIRA | 2.0 | Targeting chitinase-3-like-1 as a novel therapy for hepatocellular carcinoma | ju, Cynthia | The University of Texas Health Science Center at Houston | \$1,049,388 |
| 19 | RP240035 | IIRA | 2.0 | Harnessing the metabolic dependencies of mitochondrial NADK2 as a therapeutic strategy for lung cancer | Hoxhaj, Gerta | The University of Texas Southwestern Medical Center | \$1,050,000 |
| 20 | RP240225 | IIRA | 2.0 | PARP16-mediated Ribosome MARYlation and Translation Control in Ovarian Cancer | Kraus, W. Lee | The University of Texas Southwestern Medical Center | \$1,049,743 |
| 21 | RP240259 | IIRA | 2.0 | Targeting Cancer-associated Lactobacillus iners to improve response to cancer therapy | Colbert, Lauren | MDACC/BLI | \$1,049,427 |
| 22 | RP240119 | IIRA | 2.0 | Integrating proteolysis-targeting capability into antibodies to augment therapeutic efficacy | Liu, Qingyun | The University of Texas Health Science Center at Houston | \$1,050,000 |
| 23 | RP240326 | IIRA | 2.0 | Translation of gut commensal bacteria peptidoglycan remodeling pathway for chimeric antigen receptor T-cell therapy | Saini, Neeraj | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 24 | RP240311 | IIRA | 2.0 | Treatment planning of ADC therapy for ovarian cancer with molecular photoacoustic-ultrasonic imaging | Bouchard, Richard | The University of Texas M. D. Anderson Cancer Center | \$1,049,859 |
| 25 | RP240117 | IIRA | 2.0 | Identify radiopathomics markers to guide immunotherapy for non-small cell lung cancer | Wu, Jia | The University of Texas M. D. Anderson Cancer Center | \$1,049,906 |
| 26 | RP240054 | IIRACCA | 2.0 | Myeloid Support of Refractory and Aggressive T-ALL at Distinct Tumor Sites | Ehrlich, Lauren | The University of Texas at Austin | \$1,400,000 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660

T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|---------------------|--|--------------|
| 27 | RP240237 | IIRACCA | 2.0 | The Role of EWSR1-FLI1-CENP-A Signaling in Chemoresistance in Ewing Sarcoma | Kitagawa, Katsumi | The University of Texas Health Science Center at San Antonio | \$1,400,000 |
| 28 | RR240015 | RRS | 2.0 | HyperGlio - New tools to fight brain cancer with signal-enhanced magnetic resonance | Gloeggler, Stephan | The University of Texas Southwestern Medical Center | 4,000,000.00 |
| 29 | RR240021 | RRS | 2.0 | Expansion and Single-cell Interrogation of Tumoroid Models for Precise Treatment of Diverse Rectal Cancer Patient Populations | Smith, Jesse Joshua | The University of Texas Southwestern Medical Center | 4,000,000.00 |
| 30 | RP240183 | IIRA | 2.1 | Restoring TREM2-Dependent Efferocytosis to Inhibit Obesity-Induced Liver Inflammation and Cancer Development | Liang, Shuang | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 31 | RP240263 | IIRA | 2.1 | Identifying the Biological Determinants of Aggressive Meningioma | Patel, Akash | Baylor College of Medicine | \$1,049,370 |
| 32 | RP240392 | IIRA | 2.1 | Identifying Tumor Specific Vulnerabilities in Appendiceal Adenocarcinoma: A Systems Approach | Shen, John Paul | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 33 | RP240133 | IIRA | 2.1 | Modulation of blood-spinal cord barrier for tumor treatment | Qin, Zhenpeng | The University of Texas at Dallas | \$1,050,000 |
| 34 | RP240233 | IIRACT | 2.1 | Toward Nonoperative Management of Early-Stage ER-Positive Breast Cancer | Rahimi, Asal | The University of Texas Southwestern Medical Center | \$1,999,963 |
| 35 | RP240127 | IIRA | 2.2 | Transposon Restriction, Tumor Suppression and p53 | Abrams, John | The University of Texas Southwestern Medical Center | \$1,039,356 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|----------|-----|---|------------------|--|--------------|
| 36 | RP240072 | IIRA | 2.2 | Dissection of CAMKK2's Tumor Cell-intrinsic and -extrinsic Roles in Prostate Cancer | Frigo, Daniel | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 37 | RP240288 | IIRA | 2.3 | Epigenetic mechanism and targeting during response to BRAFi/anti-EGFR therapy in BRAF-mutant colorectal cancers | Kopetz, Scott | The University of Texas M. D. Anderson Cancer Center | \$1,043,909 |
| 38 | RP240380 | IIRA | 2.3 | Clonal hematopoiesis for improving lung cancer risk assessment | Cheng, Chao | Baylor College of Medicine | \$1,040,316 |
| 39 | RP240131 | IIRACSBC | 2.3 | Computational Methods for CRISPR-Based Lineage Tracing Systems | Liu, Zhandong | Baylor College of Medicine | \$1,200,000 |
| 40 | RR240007 | REI | 2.3 | Building a multi-modal platform to enable next-generation functional precision oncology | Shen, Xiling | The University of Texas M. D. Anderson Cancer Center | 6,000,000.00 |
| 41 | RP240214 | IIRA | 2.5 | Immunoprevention of Breast Cancer Brain Metastasis by Special Dendritic Cell-derived Extracellular Vesicles | Yu, Dihua | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 42 | RP240120 | IIRA | 2.5 | JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC | ZHANG, QING | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 43 | RP240287 | IIRA | 2.5 | Investigating the Impact of Interferon Gamma Signaling on Therapeutic Resistance in Acute Myeloid Leukemia | Abbas, Hussein | The University of Texas M. D. Anderson Cancer Center | \$1,042,256 |
| 44 | RP240104 | IIRA | 2.6 | Characterization and optimization of novel allosteric KRAS inhibitors | Gorfe, Alemayehu | The University of Texas Health Science Center at Houston | \$1,050,000 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego
SCHOOL OF MEDICINE

| | | | | | | | |
|--|----------|---------|-----|---|------------------------|---|-------------|
| 45 | RP240320 | IIRA | 2.6 | Benzothiazepines as first-in-class inhibitors for the ribogenesis factor NVL and evaluation in preclinical colorectal cancer models | De Brabander, Jef | The University of Texas Southwestern Medical Center | \$1,049,754 |
| 46 | RP240143 | IIRACCA | 2.6 | Leveraging Passport for Care in a Telehealth Framework to Improve Equitable Access to Survivorship Services | Gramatges, Maria | Baylor College of Medicine | \$1,399,382 |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| 51 | RP240208 | IIRAP | 2.8 | Unidos Contra el VPH: Screening Accuracy, Preference, and Uptake of HPV Self-Sampling Among Latinxs Along the US-Mexico Border | Calderon-Mora, Jessica | The University of Texas at Austin | \$1,920,007 |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee.

Individual Investigator Research Awards (IIRA)
Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)
Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)
Individual Investigator Research Awards for Clinical Translation (IIRACT)
Individual Investigator Research Awards for Prevention and Early Detection
Recruitment of Established Investigators (REI)
Recruitment of Rising Stars (RRS)
Recruitment of First-Time, Tenure Track Faculty Members (FTTFM)



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2024—Cycle 1
*Individual Investigator Research Awards for
Clinical Translation***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS

RFA R-24.1-IIRACT

Individual Investigator Research Awards for Clinical Translation

**Please also refer to the Instructions for Applicants document,
which will be posted on March 15, 2023**

Application Receipt Opening Date: March 15, 2023

Application Receipt Closing Date: June 14, 2023

FY 2024

Fiscal Year Award Period

September 1, 2023–August 31, 2024

TABLE OF CONTENTS

| | |
|--|-----------|
| 1. BRIEF DESCRIPTION OF RFA | 5 |
| 2. ABOUT CPRIT | 5 |
| 2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES..... | 5 |
| 3. RATIONALE | 6 |
| 4. RESEARCH OBJECTIVES | 7 |
| 5. FUNDING INFORMATION | 8 |
| 6. ELIGIBILITY | 8 |
| 7. RESUBMISSION POLICY | 10 |
| 8. RENEWAL POLICY | 11 |
| 9. RESPONDING TO THIS RFA | 11 |
| 9.1. APPLICATION SUBMISSION GUIDELINES..... | 11 |
| 9.1.1. <i>Submission Deadline Extension</i> | 11 |
| 9.2. APPLICATION COMPONENTS..... | 11 |
| 9.2.1. <i>Abstract and Significance (5,000 characters)</i> | 12 |
| 9.2.2. <i>Layperson's Summary (2,000 characters)</i> | 12 |
| 9.2.3. <i>Specific Aims and Sub-Aims</i> | 13 |
| 9.2.4. <i>Timeline (1 page)</i> | 13 |
| 9.2.5. <i>Specific Aims (1 page)</i> | 13 |
| 9.2.6. <i>Resubmission Summary (2 pages)</i> | 13 |
| 9.2.7. <i>Renewal Summary (2 Pages)</i> | 14 |
| 9.2.8. <i>Summary Checklist (1 Page)</i> | 14 |
| 9.2.9. <i>Research Plan (11 pages)</i> | 14 |
| 9.2.10. <i>Vertebrate Animals (1 page)</i> | 15 |
| 9.2.11. <i>Human Subjects (2 pages)</i> | 15 |
| 9.2.12. <i>Protocol Documentation</i> | 15 |
| 9.2.13. <i>Investigational New Drug Application (IND)/Investigational Device Exemption (IDE)</i> | 15 |
| 9.2.14. <i>Publications/References</i> | 15 |
| 9.2.15. <i>Budget and Justification</i> | 15 |
| 9.2.16. <i>Biographical Sketches (5 pages each)</i> | 17 |
| 9.2.17. <i>Current and Pending Support</i> | 17 |
| 9.2.18. <i>Institutional/Collaborator Support and/or Other Certification (4 pages)</i> | 17 |
| 9.2.19. <i>Previous Summary Statement</i> | 17 |
| 9.3. FORMATTING INSTRUCTIONS..... | 18 |
| 10. APPLICATION REVIEW | 19 |
| 10.1. PRELIMINARY EVALUATION..... | 19 |
| 10.2. FULL PEER REVIEW..... | 19 |
| 10.3. CONFIDENTIALITY OF REVIEW..... | 20 |
| 10.4. REVIEW CRITERIA..... | 21 |
| 10.4.1. <i>Primary Criteria</i> | 21 |
| 10.4.2. <i>Secondary Criteria</i> | 22 |
| 11. KEY DATES | 22 |
| 12. AWARD ADMINISTRATION | 23 |
| 13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS | 23 |

| | |
|---|-----------|
| 14. CONTACT INFORMATION | 24 |
| 14.1. HELPDESK..... | 24 |
| 14.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS | 24 |

RFA VERSION HISTORY

- 2/17/23 RFA released
- 5/16/23 Modified section 9.2.16 – Biographical Sketches; included the following updated language: “Up to 5 additional biographical sketches for key personnel may be provided, these should be concatenated into a single PDF with a 25-page limit.”

1. BRIEF DESCRIPTION OF RFA

- Supports applications that propose innovative cancer clinical studies that are hypothesis driven and involve patients enrolled prospectively on a clinical trial. Applications must provide documentation that the proposed trial will be ready to commence immediately upon award of the CPRIT contract and the trial goals are feasible within the project timeline.
- Applicants are required to complete a checklist (required template provided in CARS under [Current Funding Opportunities](#))
- Applicants may request a maximum of \$500,000 per year for a period of up to 4 years.
- Multi-Principal Investigators (PIs) (MIs) are allowed under this RFA. See the Information for Applicants (IFA) document for definition and eligibility of MIs.
- Note that CPRIT does not allow the use of the term Co-PI.

Minimum effort for the PI and/or MIs throughout the project period is required.

2. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for, cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and

Develop and implement the Texas Cancer Plan.

2.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state
- Reducing cancer disparities.

The program priorities for academic research adopted by the Oversight Committee include funding projects that address or utilize the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer

Expanding access to innovative clinical trials

3. RATIONALE

This Individual Investigator Research Awards for Clinical Translation (IIRACT) mechanism will support applications that propose innovative cancer clinical studies that are hypothesis-driven and involve patients enrolled prospectively on a clinical trial. Areas of interest include clinical studies of new or repurposed drugs, hormonal therapies, immune therapies, surgery, radiation therapy, stem cell transplantation, combinations of interventions, or therapeutic devices. Such clinical trials offer important opportunities to incorporate biomarkers, pharmacokinetic and pharmacodynamic monitoring, and/or imaging studies to provide more precise knowledge about what works, in whom, and in which types of cancer and to guide subsequent clinical development of a novel cancer therapy.

The research supported by this mechanism is important because current clinical development of novel cancer therapeutics remains slow and expensive with many late-stage failures. Only 5% of cancer therapeutics that enter clinical evaluation will be approved, and the approval process is often measured in decades. There is an urgent need to accelerate and enhance the efficiency of this process by improving the clinical evaluation of novel cancer therapeutics through adoption

of modern trial designs that incorporate biomarkers. Such trials will build on advances in basic discovery that have identified the critical targets involved in the hallmarks of cancer and have led to mechanism-based therapeutics. Trials that are designed to determine if predictors of response and efficacy identified in preclinical models also occur in patients have the potential to accelerate therapeutic development and approvals. They also guide the development of diagnostic tests to identify those patients most likely to benefit from these new treatments. Well-conducted early-phase studies will also inform reasons for treatment failure and feed back to preclinical studies designed to overcome barriers to success identified in patients.

4. RESEARCH OBJECTIVES

The goal of the IIRACT Award is to promote clinical research that will lead to a better understanding of the clinical efficacy of a cancer therapy or diagnostic device. Applications submitted under this mechanism should propose innovative clinical studies that are hypothesis-driven and involve patients enrolled prospectively on a clinical trial.

Clinical studies of new or repurposed drugs, hormonal therapies, immune therapies, surgery, radiation therapy, stem cell transplantation, combinations of interventions, or therapeutic devices are all responsive to this Request for Applications (RFA).

Applications that propose the development and validation of a biomarker prior to use of that biomarker in a prospective clinical trial are not responsive to this RFA and should be directed to the CPRIT Individual Investigator Research Award mechanism RFA R-24.1-IIRA.

Early-phase clinical trials of agents or combinations of agents for which there are robust nonclinical data that suggest there may be clinical activity are responsive to the RFA, even if there is no biomarker, as long as the early-phase clinical trial will lead to determining if the activity observed in the laboratory can be replicated in patients.

Additional examples of the types of studies appropriate for the IIRACT award include, but are not limited to, phase 1 or small phase 2 trials of new agents, repurposed agents, radiation therapy, surgery, or combinations of interventions where the trial design incorporates biomarker and/or imaging strategies to determine one or more of the following: presence of the drug target, target inhibition, biological pathway inhibition, or pathophysiological alteration by the investigational drug or device

5. FUNDING INFORMATION

Applicants may request a maximum of \$500,000 per year for a period of up to 4 years. Exceptions to these limits may be requested if extremely well justified (see [section 9.2.15](#)). Funds may be used for salary and fringe benefits, research supplies, equipment, subject participation costs including diagnostic or interventional procedures associated with participation in a clinical trial and not considered routine patient care, and travel to scientific/technical meetings or collaborating institutions. Requests for funds to support construction and/or renovation will not be approved under this funding mechanism. State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount. The budget justification must include a timeline for the clinical trial initiation and accrual targets. Applications must provide documentation that the proposed trial will be ready to commence immediately upon award of the CPRIT contract and the trial goals are feasible within the project timeline. For example, drug access through an industry or CTEP arrangement should be documented. When indicated, an approved investigational new drug application (IND) or investigational device exemption (IDE) for devices from the Food and Drug Administration (FDA) should be cited, or if no IND is yet available for the agent(s), then a pre-IND meeting would have been held with the FDA, and the summary letter from that pre-IND meeting would be included as an attachment (see [section 9.2.13](#)).

Please see [section 9.2.15](#) and the IFA for additional information.

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism; these entities must use the appropriate award mechanism(s) under CPRIT's Product Development Research Program.
- The PI must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and must be a full-time resident of Texas during the time the research that is the subject of the grant is conducted.
- This award mechanism allows MIs for projects that require a team science approach (see the IFA for guidelines on CPRIT rules for MI awards).

- For applications that include 1 PI, the PI is required to maintain a minimum 15% level of effort throughout the entire award period. For applications that include MIs, each PI is required to maintain a minimum 10% effort throughout the entire award period.
- A PI may not submit applications to this RFA and to RFA R-24.1-IIRA, RFA R-24.1-IIRACSBC, RFA R-24.1-IIRACCA, or RFA R-24.1-IIRAP.
- A PI may submit only 1 application, either a new, resubmission or renewal application under this RFA during this funding cycle
- A PI may be a part of only one application, whether as a single applicant or as part of an MI application, under this RFA and RFA R-24.1-IIRA, RFA R-24.1-IIRACCA, RFA R-24.1-IIRACSBC, or RFA R-24.1-IIRAP.
- An individual may serve as a PI on no more than 3 active CPRIT Academic Research grants. Recruitment Grants and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers MIRA Project Co-PIs equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be March 1, 2024).
- Applications that address prevention and early detection, cancers in children and adolescents, or computational systems biology of cancer should be submitted under the appropriate targeted RFA. As noted in section 4, applications that propose the development and validation of a biomarker prior to use of that biomarker in a prospective clinical trial are not responsive to this RFA and should be directed to the CPRIT Individual Investigator Research Award mechanism RFA R-24.1-IIRA.
- Collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.

- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, regardless of whether those individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.

CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 12](#) and [section 13](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted **once** and must follow all resubmission guidelines and be eligible for this mechanism under the criteria in Section 4. If a previously submitted application does not meet the new criteria for this mechanism outlined in Section 4 it must be resubmitted under the IIRA mechanism. More than 1 resubmission is not permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the PI for a project or a change of title of the project that was previously submitted to CPRIT or omission or modification of an aim does not constitute a new application; the application would be considered a resubmission. This policy is in effect for all applications submitted to date. See [section 9.2.6](#).

8. RENEWAL POLICY

An application originally funded by CPRIT as an IIRA, IIRACCA, IIRACSBC, or IIRAP that is appropriate for the IIRACT mechanism may be submitted under this RFA for a competitive renewal. See [section 9.2.7](#). Competitive renewals are not subject to preliminary evaluation. Renewal applications move directly to the full peer review phase. See [section 10.2](#).

9. RESPONDING TO THIS RFA

9.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on March 15, 2023, and must be submitted by 4 PM central time on June 14, 2023. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

9.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grant applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

9.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the IFA for details that will be available when

the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

9.2.1. Abstract and Significance (5,000 characters)

It is the responsibility of the applicant to capture CPRIT's attention primarily with the Abstract and Significance statement alone. Therefore, applicants are advised to prepare this section wisely. **Based on the Abstract and Significance statement (and the Specific Aims page, Budget and Justification and Biographical Sketches), applications that are judged to offer only modest contributions to the field of cancer research or that do not sufficiently capture the reviewers' interest may be excluded from further peer review (see [section 10.1](#)).**

Applicants should not waste this valuable space by stating obvious facts (eg, that cancer is a significant problem; that better diagnostic and therapeutic approaches are needed urgently; or that the type of cancer of interest to the PI is important, vexing, or deadly).

Clearly explain the question or problem to be addressed and the approach to its answer or solution. The specific aims of the application must be obvious from the abstract although they need not be restated verbatim from the research plan. Indicate whether this proposed clinical research addresses cancers with disparities and/or whether the trial will enroll patients from underserved populations.

Clearly address how the proposed project, if successful, will have a major impact on cancer. Summarize how the proposed research creates new paradigms or challenges existing ones or may lead to changes in practice. Indicate whether this research plan represents a new direction for the PI.

9.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detections, prevention, or treatment. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. **Do not include any proprietary information in the layperson's summary.** The layperson's summary

will also be used by advocate reviewers ([section 10.2](#)) in evaluating the significance and impact of the proposed work.

9.2.3. Specific Aims and Sub-Aims

Please provide a description of the Aims and Sub-aims and milestones to be achieved for each year of the project. Provide 2-3 sentences describing activities to be performed and anticipated milestones. These Aims will also be used during the submission and evaluation of progress reports and assessment of project success.

9.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications.

If a clinical trial is proposed as a component of this application, the timeline must include clearly defined patient accrual milestones.

If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

9.2.5. Specific Aims (1 page)

Please provide a 1-page summary of the aims of the proposal. The Specific Aims page should identify the problem, or gap in our current knowledge. It should present a hypothesis and briefly describe the aims and approaches. Address the proposal's innovation, novel approaches and significance and impact on the field and cancer research. Please also refer to the template located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.6. Resubmission Summary (2 pages)

Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

Note: An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to need considerable attention. Applicants may prepare a fresh research plan or modify the original research plan and mark the changes. However, **all resubmitted applications should be carefully reconstructed**; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes.

9.2.7. Renewal Summary (2 Pages)

Applicants preparing a renewal must describe and demonstrate that appropriate/adequate progress has been made on the current funded award to warrant further funding. Publications and manuscripts in press that have resulted from work performed during the initial funded period should be listed in the renewal summary.

9.2.8. Summary Checklist (1 Page)

Applicants are required to complete a summary checklist. The required template is provided in CARS under [*Current Funding Opportunities*](#).

9.2.9. Research Plan (11 pages)

Background: Present the rationale behind the proposed project, emphasizing the pressing problem in cancer research that will be addressed. Describe the innovation and potential impact of the research.

Hypothesis and Specific Aims: Concisely state the hypothesis and/or specific aims to be tested or addressed by the research described in the application.

Research Strategy: Describe the experimental design, including methods, anticipated results, potential problems or pitfalls, and alternative approaches. Preliminary data that support the proposed hypothesis are encouraged but not required. This section has been lengthened to allow the applicant to present the statistical considerations used to determine a trial design, accrual milestones, and biomarker validation. Describe the population of eligible patients and plans to enroll unique populations, eg, underserved populations.

9.2.10. Vertebrate Animals (1 page)

If vertebrate animals will be used, provide a detailed plan of the protocols that will be followed and justification for the number of animals used with reference to biostatistical input for sample selection and evaluation. Certification of approval by the institutional IACUC of the proposed animal use will be required before funding can occur.

9.2.11. Human Subjects (2 pages)

For the use of human subjects or human biological samples, provide a detailed plan for recruitment of subjects and/or the acquisition of samples that will meet the time constraints of this award mechanism. Certification of approval of these plans by the institutional IRB will be required before funding can occur.

9.2.12. Protocol Documentation

Provide a full protocol of the clinical trial (if one is planned); a PDF copy of the full protocol can be attached.

9.2.13. Investigational New Drug Application (IND)/Investigational Device Exemption (IDE)

If a clinical trial is proposed that requires an IND or IDE, provide evidence of an approved IND or IDE for devices from the FDA. If no IND is yet available for the agent(s), then provide a summary letter from a pre-IND meeting held with the FDA. If the drug or device is to be provided through an industry or CTEP mechanism, provide documentation that the drug or device will be available.

9.2.14. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

9.2.15. Budget and Justification

Provide a compelling and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, supplies, equipment, costs associated with the conduct of a clinical trial, animal care costs, and other expenses. While there will be 1 budget for the entire project, an individual budget and budget justification for the conduct of a clinical trial

must be included. The justification should include the statistical considerations that led to the clinical trial design, accrual milestones, and validation of biomarkers. Applicants are advised not to interpret the maximum allowable request under this award as a suggestion that they should expand their anticipated budget to this level. However, if there is a highly specific and defensible need to request more than the maximum amount in any year(s) of the proposed budget, include a special and clearly labeled section in the budget justification that explains the request.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.
- The maximum annual salary (also referred to as direct salary or institutional base salary) that an individual may request under a CPRIT award for FY 2024 is \$200,000; CPRIT FY 2024 is from September 1, 2023, through August 31, 2024. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.
- Funds can be used to pay for costs that a cancer clinical trial participant may have associated with their participation in a clinical trial, including: 1) transportation, including car mileage, parking, bus fare, taxi or ride hailing fare exclusive of tips, and commercial economy class airfare within the borders of the State of Texas; 2) lodging.

9.2.16. Biographical Sketches (5 pages each)

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research. A biographical sketch must be provided for the PI and, if applicable, any additional PIs (if an MI application), as required by the online application receipt system. Up to 5 additional biographical sketches for key personnel may be provided, these should be concatenated into a single PDF with a 25-page limit. Each biographical sketch must not exceed 5 pages. The NIH biosketch format is appropriate.

9.2.17. Current and Pending Support

Describe the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project, and, if relevant, a statement of overlap with the current application. At a minimum, current and pending support of the PI and, if applicable, any additional PIs (if an MI application), must be provided. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.18. Institutional/Collaborator Support and/or Other Certification (4 pages)

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 4 pages may be provided.

9.2.19. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

Applications that are missing 1 or more of these components, exceed the specified page, word, or budget limits, or that do not meet the eligibility requirements listed above will be administratively rejected without review.

9.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable as long as the journal information is stated. Include URLs of publications referenced in the application.
Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45-67.
- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.

All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

10. APPLICATION REVIEW

10.1. Preliminary Evaluation

To ensure the timely and thorough review of only the most innovative and cutting-edge research with the greatest potential for advancement of cancer research, all eligible applications may be preliminarily evaluated by CPRIT Scientific Research Program panel members for scientific merit and impact.

This preliminary evaluation will be based on a subset of material presented in the application—namely, Abstract and Significance, Specific Aims page, Budget and Justification, and Biographical Sketches. Applications that do not sufficiently capture the reviewers' interest at this stage will not be considered for further review. Such applications will have been judged to offer only modest contributions to the field of cancer research and will be excluded from further peer review.

The applicant will be notified of the decision to disapprove the application after the preliminary evaluation stage has concluded. Due to the volume of applications to be reviewed, comments made by reviewers at the preliminary evaluation stage may be limited.

10.2. Full Peer Review

Applications that pass preliminary evaluation will undergo further review using a 2-stage peer review process: (1) Full peer review and (2) Prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 10.4](#). In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by the Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of

the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

10.3. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in [Texas Administrative Code RULE §703.9](#)

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee Member, a PIC Member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Research Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

10.4. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

10.4.1. Primary Criteria

Primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

Significance and Impact: Will the results of this research, if successful, significantly change the research of others or the opportunities for better cancer prevention, diagnosis, or treatment for patients? Is the application innovative? Does the applicant propose new paradigms or challenge existing ones? Does the project develop state-of-the-art technologies, methods, tools, or resources for cancer research or address important underexplored or unexplored areas? If the research project is successful, will it lead to truly substantial advances in the field rather than add modest increments of insight? Projects that modestly extend current lines of research will not be considered for this award. Projects that represent straightforward extensions of ongoing work, especially work traditionally funded by other mechanisms, will not be competitive.

Research Plan: Is the proposed work presented as a self-contained research project? Does the proposed research have a clearly defined hypothesis or goal that is supported by sufficient preliminary data and/or scientific rationale? Are the methods appropriate, and are potential experimental obstacles and unexpected results discussed?

Applicant Investigator: Does the investigator(s) demonstrate the required creativity and expertise to make a significant contribution to the research? Applicants' credentials will be evaluated in a career stage-specific fashion. Have early-career-stage investigators received excellent training, and do their accomplishments to date offer great promise for a successful

career? Has the applicant(s) devoted a sufficient amount of his or her time (percent effort) to this project?

Relevance: Does the proposed research have a high degree of relevance to cancer research? This is a critical criterion for evaluation of projects for CPRIT support.

10.4.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research.

Secondary criteria include the following:

Research Environment: Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the proposed research? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support of the research team and the project?

Vertebrate Animals and/or Human Subjects: Is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed?

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

11. KEY DATES

RFA

RFA release February 17, 2023

Application

Online application opens March 15, 2023, 7 AM central time

Application due June 14, 2023, 4 PM central time

Application review June 2023–February 2024

Award

Award notification February 2024

Anticipated start date March 1, 2024

12. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to

the research that is the subject of the award. A grant recipient that is a public or private institution of higher education, as defined by §61.003, Texas Education Code, may credit toward the Grant Recipient's Matching Funds obligation the dollar amount equivalent to the difference between the indirect cost rate authorized by the federal government for research grants awarded to the Grant Recipient and the 5% indirect cost limit imposed by §102.203(c), Texas Health and Safety Code. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted.

14. CONTACT INFORMATION

14.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

14.2. Scientific and Programmatic Questions

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Director of Academic Research.

Tel: 512-305-8491

Email: research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel - Basic Cancer

Research-1 (24.1_AR_BCR-1)

Observation Report

Report No. 2023-10-20 24.1_AR_BCR-1
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel - Basic Cancer Research-1
(24.1_AR_BCR-1)
Panel Date: October 20, 2023
Report Date: October 26, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel - Basic Cancer Research-1 (24.1_AR_BCR-1) meeting. The meeting was chaired by Eric Fearson and conducted via videoconference on October 20, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and twenty-three (23) applications were not discussed
- Panelists: One (1) panel chair, thirteen (13) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were five (5) Conflict of Interest (COI) identified prior to and/or during the meeting. Two (2) applications with COIs were discussed and two (2) applications with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel – Basic Cancer

Research (24.1 ACR-BCR-2) Observation Report

Report No. 2023-10-11 24.1_ACR-BCR-2
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel – Basic Cancer Research
(24.1 _ACR-BCR-2)
Panel Date: October 11, 2023
Report Date: October 16, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel – Basic Cancer Research (24.1_ACR-BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on October 11, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and thirty (30) applications were not discussed
- Panelists: One (1) panel chair, Nineteen (19) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Eight (8)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were nine (9) Conflicts of Interest (COI) identified prior to and/or during the meeting. COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to read 'Mara Ash', with a long horizontal flourish extending to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel - Basic Cancer

Research (24.1 ACR CPR)

Observation Report

Report No. 2023-10-13 24.1_ACR CPR
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel - Basic Cancer Research
(24.1 _ACR CPR)
Panel Date: October 13, 2023
Report Date: October 16, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel - Basic Cancer Research (24.1_ACR CPR) meeting. The meeting was chaired by Elena Martinez and conducted via videoconference on October 13, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Ten (10) applications were discussed and eleven (11) applications were not discussed
- Panelists: One (1) panel chair, twelve (12) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Seven (7)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflict of Interest (COI) identified prior to and/or during the meeting. Two (2) applications with COIs were discussed and one (1) application with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
24.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (24.1_ACR-CTCR)
Observation Report

Report No. 2023-10-17 24.1_ACR-CTCR
Program Name: Academic Research
Panel Name: 24.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (24.1_ACR-CTCR)
Panel Date: October 17, 2023
Report Date: October 23, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Clinical and Translational Cancer Research (C/TCR) (24.1_ACR-CTCR) meeting. The meeting was chaired by Richard O'Reilly and Margaret Tempero and conducted via videoconference on October 17, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty-one (21) applications were discussed and thirty-five (35) applications were not discussed
- Panelists: Two (2) panel chair, seventeen (17) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflict of Interest (COI) identified prior to and/or during the meeting. Two (2) applications with COIs were discussed and two (2) applications with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the closing text.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel – Imaging Technology and Informatics (24.1 ACR ITI) Observation Report

Report No. 2023-10-19 24.1_ACR-ITI
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel – Imaging Technology and Informatics (24.1 _ACR-ITI)
Panel Date: October 19, 2023
Report Date: October 26, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel – Imaging Technology and Informatics (24.1_ACR-ITI) meeting. The meeting was co-chaired by Anna Wu, Henry VanBrocklin, and Jason Lewis, in lieu of Martin Pomper and conducted via videoconference on October 19, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Sixteen (16) applications were discussed and thirteen (13) applications were not discussed
- Panelists: Three (3) panel chairs, thirteen (13) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were twelve (12) Conflicts of Interest (COI) identified prior to and/or during the meeting. Four (4) applications with a COI were discussed and three (3) applications with a COI were not discussed. COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Scientific Review Council (24.1 SRC) Observation Report

Report No. 2023-12-14 24.1_SRC
Program Name: Academic Research
Panel Name: 24.1 Academic Research Scientific Review Council (24.1 _SRC)
Panel Date: December 14, 2023
Report Date: January 17, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Scientific Review Council (24.1_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 14, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Forty- five (45) applications were discussed
- Panelists: One (1) panel chair, and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 24.1

Awards Announced at the February 21, 2024, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 24.1 include: *Individual Investigator Research Awards*; *Individual Investigator Research Awards for Cancer in Children and Adolescents*; *Individual Investigator Research Awards for Computational Systems Biology of Cancer*; *Individual Investigator Research Awards for Clinical Translation*; and *Individual Investigator Research Awards for Prevention and Early Detection*. Applications submitted in response to these five award mechanisms went through preliminary evaluation as allowed by TAC § 703.6(e)(1).

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|--|------------------------|--|------------------------------------|
| Applications considered by the PIC and Oversight Committee: | | | |
| RP240127 | John Abrams | The University of Texas Southwestern Medical Center | Benjamin Greenbaum |
| RP240072 | Daniel Frigo | The University of Texas M. D. Anderson Cancer Center | Steffi Oesterreich |
| RP240125 | Guojun Li | The University of Texas M. D. Anderson Cancer Center | Electra Paskett; Thomas Brandon |
| RP240272 | Joseph Ludwig | The University of Texas M. D. Anderson Cancer Center | Richard O'Reilly |
| RP240117 | Jia Wu | The University of Texas M. D. Anderson Cancer Center | Charles Kahn; Maryellen Giger |

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|---|------------------------|--|-------------------------------|
| RP240311 | Richard Bouchard | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger; Weibo Cai |
| RP240291 | Eveline Barbieri | Baylor College of Medicine | Craig Rosenfeld |
| Applications not considered by the PIC or Oversight Committee: | | | |
| RP240101 ^a | Sang Eun Lee | The University of Texas Health Science Center at San Antonio | Alan Tomkinson; John Petrini |
| RP240118 | Elizabeth Goldsmith | The University of Texas Southwestern Medical Center | Alan Tomkinson |
| RP240236 | Katharina Schlacher | The University of Texas M. D. Anderson Cancer Center | John Petrini |
| RP240270 | Giulio Draetta | The University of Texas M. D. Anderson Cancer Center | Eileen White; Nabeel Bardeesy |
| RP240364 | Christopher Amos | Baylor College of Medicine | Alan Tomkinson |
| RP240399 | Jonathan Sessler | The University of Texas at Austin | Nabeel Bardeesy |
| RP240368 | Zhaoyong Hu | Baylor College of Medicine | Steffi Oesterreich |
| RP240106 | Michelle Hildebrandt | The University of Texas M. D. Anderson Cancer Center | Electra Paskett |
| RP240240 | Maria Swartz | The University of Texas M. D. Anderson Cancer Center | Electra Paskett |
| RP240112 | Jianjun Zhang | The University of Texas M. D. Anderson Cancer Center | Antoni Ribas |
| RP240340 | Kareem Azab | The University of Texas Southwestern Medical Center | John DiPersio |
| RP240354 | Charles Reynolds | Texas Tech University Health Sciences Center | W. Martin Kast |

^a The PIC did not recommend this application to the Oversight Committee.

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|--------------------------------------|------------------------|--|--|
| RP240044 | Jingfei Ma | The University of Texas M. D. Anderson Cancer Center | Charles Kahn; David Mankoff; Martin Pomper |
| RP240056 | David Fuentes | The University of Texas M. D. Anderson Cancer Center | David Mankoff; Maryellen Giger |
| RP240066 | Xiankai Sun | The University of Texas Southwestern Medical Center | Anna Wu |
| RP240088 | Hongyu Wang | The University of Texas Health Science Center at Houston | Charles Kahn |
| RP240141 | Jian Gu | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger |
| RP240018 | Lan Zhou | The Methodist Hospital Research Institute | Eric Fearon; Weiping Zou |
| RP240299 | Wen Jiang | The University of Texas M. D. Anderson Cancer Center | Kristin Swanson |
| RP240396 | Leonidas Bleris | The University of Texas at Dallas | Alexander Anderson |
| RP240409 | Tae Jin Lee | The University of Texas Health Science Center at Houston | Kristin Swanson |
| RP240177 (preliminary evaluation) | Hays Rye | Texas AgriLife Research | Benjamin Raphael |
| RP240410 (preliminary evaluation) | Murugesan Palaniappan | Baylor College of Medicine | Steffi Oesterreich |
| RP240140 (preliminary evaluation) | Sang Cho | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger |
| RP240221 (preliminary evaluation) | Tinsu Pan | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger |

De-Identified Overall Evaluation Scores

Individual Investigator Research Awards for Clinical Translation

Academic Research Cycle 24.1

Final Scores for Fully Reviewed Applications

| Application ID | Final Overall Evaluation Score |
|----------------|--------------------------------|
| RP240075* | 1.5 |
| RP240184* | 1.9 |
| RP240233* | 2.1 |
| La | 2.7 |
| Lb | 3.3 |
| Lc | 3.3 |
| Ld | 3.7 |
| Le | 3.7 |
| Lf | 3.7 |
| Lg | 4.0 |
| Lh | 4.0 |
| Li | 4.3 |
| Lj | 4.3 |
| Lk | 4.4 |
| Ll | 4.7 |
| Lm | 5.3 |

* Recommended for funding.

Individual Investigator Research Awards for Clinical Translation

Academic Research Cycle 24.1

Final Scores for Preliminary Evaluation

These are the final overall evaluation scores for applications receiving preliminary evaluation that did not move forward to full review. The final overall evaluation score is an average of the preliminary evaluation scores assigned to each application by the primary reviewers.

| Application ID | Final Overall Score |
|----------------|---------------------|
| ca | 5.00 |

Final Overall Evaluation Scores and Rank Order Scores

UC San Diego

SCHOOL OF MEDICINE

January 3, 2024

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Dr. Cummings and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Individual Investigator Research Awards, Individual Investigator Research Awards for Childhood and Adolescent Cancers, Individual Investigator Research Awards for Computational Systems Biology of Cancer, Individual Investigator Research Awards for Clinical Translation, Individual Investigator Research Awards for Prevention and Early Detection, Recruitment of Established Investigators, Recruitment of Rising Stars and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on December 14, 2023 to consider the FY24.1 applications recommended by the peer review panels following their meetings held October 11, 2023 to October 20, 2023. The SRC met on November 16, 2023 to review recruitment applications submitted for Cycle FY24.3-4 and then on December 14, 2023 to review recruitment applications submitted for Cycle FY24.5.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$83,180,142.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

| Recommended for Funding by Mechanism (Ranked by Overall Score) | | | | | | | |
|--|----------|-----------------|-----------------------|---|-----------------|--|--------------------|
| Rank | ID | Award Mechanism | Meeting Overall Score | Application Title | PI | PI Organization | Recommended Budget |
| 1 | RP240068 | IIRA | 1.0 | Understanding the Mechanism of Linker Histone Mutations in Malignancy | Soshnev, Alexey | The University of Texas at San Antonio | \$997,770 |
| 2 | RP240293 | IIRACSBC | 1.0 | Therapeutic Vulnerabilities and Predictors of Response to Chemo(immuno)therapy in Patients With High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC) | Korkut, Anil | The University of Texas M. D. Anderson Cancer Center | \$1,199,999 |
| 3 | RR240019 | RRS | 1.0 | Development of Chemotherapeutics Inspired by Natural Products | Sarlah, David | Rice University | 4,000,000.00 |
| 4 | RP240137 | IIRACSBC | 1.1 | Charting TCR-Tumor Antigen Interactions to Foster Novel Immunotherapeutic Approaches for Triple-Negative Breast Cancer | Zhang, Bing | Baylor College of Medicine | \$1,200,000 |
| 5 | RR240013 | RFTFM | 1.2 | Regulation of gene expression and tumorigenesis by ubiquitin-mediated protein quality control | Mark, Kevin | The University of Texas Southwestern Medical Center | 2,000,000.00 |
| 6 | RR240016 | RFTFM | 1.3 | Impact of Germline Variants on Pediatric Leukemia Progression: Insights from 3D Chromatin Remodeling and Clinical Outcomes | Luan, Yu | The University of Texas Health Science Center at San Antonio | 2,000,000.00 |
| 7 | RR240030 | REI | 1.3 | Break-induced DNA Replication as a Driver of Genomic Instability in Cancer | Malkova, Anna | The University of Texas Health Science Center at San Antonio | 6,000,000.00 |
| 8 | RR240027 | RFTFM | 1.4 | Genomic and Epigenomic Mechanisms of Chemobrain | Dileep, Vishnu | Baylor College of Medicine | 2,000,000.00 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|-----------------------|--|-------------|
| 9 | RP240075 | IIRACT | 1.5 | Combination Therapy Using ATRA and Carfilzomib to Treat Proteasome Inhibitor Refractory Multiple Myeloma | Yi, Qing | The Methodist Hospital Research Institute | \$1,921,388 |
| 10 | RP240291 | IIRA | 1.6 | Targeting MYCN disruption of the molecular clock and tumor metabolism in neuroblastoma oncogenesis. | Barbieri, Eveline | Baylor College of Medicine | \$1,050,000 |
| 11 | RP240289 | IIRA | 1.6 | Real-time, label-free, micro HSI device and transformer-based attention networks for oral cancer imaging | Fei, Baowei | The University of Texas at Dallas | \$1,049,806 |
| 12 | RP240125 | IIRA | 1.8 | Immune-Related Determinants of HPV-Associated Oropharyngeal Cancer Outcomes | Li, Guojun | The University of Texas M. D. Anderson Cancer Center | \$1,049,726 |
| 13 | RP240061 | IIRA | 1.8 | Deciphering Iron Redox Cycles in Ferroptosis-based Cancer Therapy | Lu, Yi | The University of Texas at Austin | \$1,044,608 |
| 14 | RP240091 | IIRA | 1.9 | High resolution high sensitivity photoacoustic imaging molecular guided brain tumor surgery with pilot clinical deployment | Valdes Quevedo, Pablo | The University of Texas Medical Branch at Galveston | \$1,044,967 |
| 15 | RP240401 | IIRACCA | 1.9 | Lead Optimization, Target Engagement, and Efficacy Studies of Locally Bioavailable COX-2 inhibitors for Preventing Colon Cancer Progression in FAP Children | Hu, Ming | University of Houston | \$1,400,000 |
| 16 | RP240272 | IIRACCA | 1.9 | The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy for DSRCT | Ludwig, Joseph | The University of Texas M. D. Anderson Cancer Center | \$1,398,788 |
| 17 | RP240184 | IIRACT | 1.9 | Maximizing Antitumor Immunity Through Simultaneous Activation of the Innate and Adaptive Immune System | Hannan, Raquibul | The University of Texas Southwestern Medical Center | \$1,999,993 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|-------------------|--|-------------|
| 18 | RP240095 | IIRA | 2.0 | Targeting chitinase-3-like-1 as a novel therapy for hepatocellular carcinoma | ju, Cynthia | The University of Texas Health Science Center at Houston | \$1,049,388 |
| 19 | RP240035 | IIRA | 2.0 | Harnessing the metabolic dependencies of mitochondrial NADK2 as a therapeutic strategy for lung cancer | Hoxhaj, Gerta | The University of Texas Southwestern Medical Center | \$1,050,000 |
| 20 | RP240225 | IIRA | 2.0 | PARP16-mediated Ribosome MARYlation and Translation Control in Ovarian Cancer | Kraus, W. Lee | The University of Texas Southwestern Medical Center | \$1,049,743 |
| 21 | RP240259 | IIRA | 2.0 | Targeting Cancer-associated Lactobacillus iners to improve response to cancer therapy | Colbert, Lauren | MDACC/BLI | \$1,049,427 |
| 22 | RP240119 | IIRA | 2.0 | Integrating proteolysis-targeting capability into antibodies to augment therapeutic efficacy | Liu, Qingyun | The University of Texas Health Science Center at Houston | \$1,050,000 |
| 23 | RP240326 | IIRA | 2.0 | Translation of gut commensal bacteria peptidoglycan remodeling pathway for chimeric antigen receptor T-cell therapy | Saini, Neeraj | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 24 | RP240311 | IIRA | 2.0 | Treatment planning of ADC therapy for ovarian cancer with molecular photoacoustic-ultrasonic imaging | Bouchard, Richard | The University of Texas M. D. Anderson Cancer Center | \$1,049,859 |
| 25 | RP240117 | IIRA | 2.0 | Identify radiopathomics markers to guide immunotherapy for non-small cell lung cancer | Wu, Jia | The University of Texas M. D. Anderson Cancer Center | \$1,049,906 |
| 26 | RP240054 | IIRACCA | 2.0 | Myeloid Support of Refractory and Aggressive T-ALL at Distinct Tumor Sites | Ehrlich, Lauren | The University of Texas at Austin | \$1,400,000 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|---------------------|--|--------------|
| 27 | RP240237 | IIRACCA | 2.0 | The Role of EWSR1-FLI1-CENP-A Signaling in Chemoresistance in Ewing Sarcoma | Kitagawa, Katsumi | The University of Texas Health Science Center at San Antonio | \$1,400,000 |
| 28 | RR240015 | RRS | 2.0 | HyperGlio - New tools to fight brain cancer with signal-enhanced magnetic resonance | Gloeggler, Stephan | The University of Texas Southwestern Medical Center | 4,000,000.00 |
| 29 | RR240021 | RRS | 2.0 | Expansion and Single-cell Interrogation of Tumoroid Models for Precise Treatment of Diverse Rectal Cancer Patient Populations | Smith, Jesse Joshua | The University of Texas Southwestern Medical Center | 4,000,000.00 |
| 30 | RP240183 | IIRA | 2.1 | Restoring TREM2-Dependent Efferocytosis to Inhibit Obesity-Induced Liver Inflammation and Cancer Development | Liang, Shuang | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 31 | RP240263 | IIRA | 2.1 | Identifying the Biological Determinants of Aggressive Meningioma | Patel, Akash | Baylor College of Medicine | \$1,049,370 |
| 32 | RP240392 | IIRA | 2.1 | Identifying Tumor Specific Vulnerabilities in Appendiceal Adenocarcinoma: A Systems Approach | Shen, John Paul | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 33 | RP240133 | IIRA | 2.1 | Modulation of blood-spinal cord barrier for tumor treatment | Qin, Zhenpeng | The University of Texas at Dallas | \$1,050,000 |
| 34 | RP240233 | IIRACT | 2.1 | Toward Nonoperative Management of Early-Stage ER-Positive Breast Cancer | Rahimi, Asal | The University of Texas Southwestern Medical Center | \$1,999,963 |
| 35 | RP240127 | IIRA | 2.2 | Transposon Restriction, Tumor Suppression and p53 | Abrams, John | The University of Texas Southwestern Medical Center | \$1,039,356 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|----------|-----|---|------------------|--|--------------|
| 36 | RP240072 | IIRA | 2.2 | Dissection of CAMKK2's Tumor Cell-intrinsic and -extrinsic Roles in Prostate Cancer | Frigo, Daniel | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 37 | RP240288 | IIRA | 2.3 | Epigenetic mechanism and targeting during response to BRAFi/anti-EGFR therapy in BRAF-mutant colorectal cancers | Kopetz, Scott | The University of Texas M. D. Anderson Cancer Center | \$1,043,909 |
| 38 | RP240380 | IIRA | 2.3 | Clonal hematopoiesis for improving lung cancer risk assessment | Cheng, Chao | Baylor College of Medicine | \$1,040,316 |
| 39 | RP240131 | IIRACSBC | 2.3 | Computational Methods for CRISPR-Based Lineage Tracing Systems | Liu, Zhandong | Baylor College of Medicine | \$1,200,000 |
| 40 | RR240007 | REI | 2.3 | Building a multi-modal platform to enable next-generation functional precision oncology | Shen, Xiling | The University of Texas M. D. Anderson Cancer Center | 6,000,000.00 |
| 41 | RP240214 | IIRA | 2.5 | Immunoprevention of Breast Cancer Brain Metastasis by Special Dendritic Cell-derived Extracellular Vesicles | Yu, Dihua | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 42 | RP240120 | IIRA | 2.5 | JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC | ZHANG, QING | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 43 | RP240287 | IIRA | 2.5 | Investigating the Impact of Interferon Gamma Signaling on Therapeutic Resistance in Acute Myeloid Leukemia | Abbas, Hussein | The University of Texas M. D. Anderson Cancer Center | \$1,042,256 |
| 44 | RP240104 | IIRA | 2.6 | Characterization and optimization of novel allosteric KRAS inhibitors | Gorfe, Alemayehu | The University of Texas Health Science Center at Houston | \$1,050,000 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego
SCHOOL OF MEDICINE

| | | | | | | | |
|--|----------|---------|-----|---|------------------------|---|-------------|
| 45 | RP240320 | IIRA | 2.6 | Benzothiazepines as first-in-class inhibitors for the ribogenesis factor NVL and evaluation in preclinical colorectal cancer models | De Brabander, Jef | The University of Texas Southwestern Medical Center | \$1,049,754 |
| 46 | RP240143 | IIRACCA | 2.6 | Leveraging Passport for Care in a Telehealth Framework to Improve Equitable Access to Survivorship Services | Gramatges, Maria | Baylor College of Medicine | \$1,399,382 |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| 51 | RP240208 | IIRAP | 2.8 | Unidos Contra el VPH: Screening Accuracy, Preference, and Uptake of HPV Self-Sampling Among Latinxs Along the US-Mexico Border | Calderon-Mora, Jessica | The University of Texas at Austin | \$1,920,007 |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee.

Individual Investigator Research Awards (IIRA)
Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)
Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)
Individual Investigator Research Awards for Clinical Translation (IIRACT)
Individual Investigator Research Awards for Prevention and Early Detection
Recruitment of Established Investigators (REI)
Recruitment of Rising Stars (RRS)
Recruitment of First-Time, Tenure Track Faculty Members (FTTFM)



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2024—Cycle 1**
*Individual Investigator Research Awards for
Prevention and Early Detection*

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-24.1-IIRAP

Individual Investigator Research Awards
for Prevention and Early Detection

**Please also refer to the Instructions for Applicants document,
which will be posted on March 15, 2023**

Application Receipt Opening Date: March 15, 2023

Application Receipt Closing Date: June 14, 2023

FY 2024

Fiscal Year Award Period

September 1, 2023–August 31, 2024

TABLE OF CONTENTS

| | |
|---|-----------|
| 1. BRIEF DESCRIPTION OF RFA | 4 |
| 2. KEY POINTS | 4 |
| 3. ABOUT CPRIT | 5 |
| 3.1. ACADEMIC RESEARCH PROGRAM PRIORITIES..... | 5 |
| 4. RATIONALE | 6 |
| 5. RESEARCH OBJECTIVES | 7 |
| 6. FUNDING INFORMATION | 8 |
| 7. ELIGIBILITY | 8 |
| 8. RESUBMISSION POLICY | 10 |
| 9. RENEWAL POLICY | 11 |
| 10. RESPONDING TO THIS RFA | 11 |
| 10.1. APPLICATION SUBMISSION GUIDELINES | 11 |
| 10.1.1. <i>Submission Deadline Extension</i> | 11 |
| 10.2. APPLICATION COMPONENTS | 12 |
| 10.2.1. <i>Abstract and Significance (5,000 characters)</i> | 12 |
| 10.2.2. <i>Layperson’s Summary (2,000 characters)</i> | 13 |
| 10.2.3. <i>Aims and Sub-Aims</i> | 13 |
| 10.2.4. <i>Timeline (1 page)</i> | 13 |
| 10.2.5. <i>Specific Aims (1 page)</i> | 13 |
| 10.2.6. <i>Resubmission Summary (2 pages)</i> | 14 |
| 10.2.7. <i>Renewal Summary (2 pages)</i> | 14 |
| 10.2.8. <i>Research Plan (10 pages)</i> | 14 |
| 10.2.9. <i>Vertebrate Animals (1 page)</i> | 14 |
| 10.2.10. <i>Human Subjects (2 pages)</i> | 15 |
| 10.2.11. <i>Publications/References</i> | 15 |
| 10.2.12. <i>Budget and Justification</i> | 15 |
| 10.2.13. <i>Biographical Sketches (5 pages each)</i> | 16 |
| 10.2.14. <i>Current and Pending Support</i> | 16 |
| 10.2.15. <i>Institutional/Collaborator Support and/or Other Certification (4 pages)</i> | 17 |
| 10.2.16. <i>Previous Summary Statement</i> | 17 |
| 10.3. FORMATTING INSTRUCTIONS | 17 |
| 11. APPLICATION REVIEW | 18 |
| 11.1. PRELIMINARY EVALUATION..... | 18 |
| 11.2. FULL PEER REVIEW | 19 |
| 11.3. CONFIDENTIALITY OF REVIEW | 19 |
| 11.4. REVIEW CRITERIA..... | 20 |
| 11.4.1. <i>Primary Criteria</i> | 20 |
| 11.4.2. <i>Secondary Criteria</i> | 21 |
| 12. KEY DATES | 22 |
| 13. AWARD ADMINISTRATION | 22 |
| 14. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS | 23 |
| 15. CONTACT INFORMATION | 24 |
| 15.1. HELPDESK..... | 24 |
| 15.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS | 24 |

RFA VERSION HISTORY

- 2/17/23 RFA released
- 5/16/23 Modified section 10.2.13 – Biographical Sketches; included the following updated language: “Up to 5 additional biographical sketches for key personnel may be provided, these should be concatenated into a single PDF with a 25-page limit.”

1. BRIEF DESCRIPTION OF RFA

- Supports applications which propose clinical and population-based projects designed to develop effective prevention and early detection interventions to reduce cancer risk, mortality, and morbidity among Texans.
- Applicants may request up to a maximum of \$400,000 per year for a period of up to 5 years.
- Multi-Principal Investigators (PIs) (MIs) are allowed under this RFA. See the Information for Applicants (IFA) document for applicants for definition and eligibility of MIs.
- Note that CPRIT does not allow the use of the term Co-PI.
- Minimum effort for the PI and/or MIs throughout the project period is required.

2. KEY POINTS

This new version of the Individual Investigator Research Award for Prevention and Early Detection invites clinical and population-based projects designed to develop effective prevention, early detection, or behavioral interventions to reduce cancer risk, mortality, and morbidity among Texans. Examples of projects responsive to this RFA include those planning clinical or population-based projects:

- (1) To identify risk factors for cancers affecting Texans including social, environmental, and behavioral factors, genetic markers, and health disparities.
- (2) To validate biomarkers, genomic technologies, or imaging methods in Texas populations at high risk for cancer that will lead to detection of cancers at an early stage.
- (3) To develop and validate innovative interventions for the prevention or early detection of cancers with particular emphasis on Texans at highest risk for cancer.
- (4) To increase implementation and/or dissemination of evidence-based interventions for the prevention and/or early detection of cancers among all Texans as well as Texas populations at high risk for cancer.
- (5) To conduct health services research in Texas populations at highest risk for cancer to identify the most effective ways to address the disparities (eg, through systems change, outreach, access) and delivery of early detection and preventive care.

Basic research using laboratory and/or animal models designed to identify underlying mechanisms causing cancer ***is not responsive*** to this RFA and should be directed to other CPRIT mechanisms supporting basic discovery research.

Basic and clinical research to discover or to evaluate chemoprevention strategies ***is not responsive*** to this RFA and should be directed to other CPRIT mechanisms supporting basic discovery research or clinical translational research.

Applicants may request up to \$400,000 per year in CPRIT funds over 5 years.

3. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer.
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

3.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state
- Reducing cancer disparities

The program priorities for academic research adopted by the Oversight Committee include funding projects that address or utilize the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials

4. RATIONALE

Nowhere is there greater potential to reduce the burden of cancer than by reducing its incidence. It is estimated that more than half of all cancer deaths could be prevented. It is also well established that early detection of cancer improves cancer mortality. The goal of this RFA is to promote research to develop effective cancer prevention and early detection approaches for Texans.

Many opportunities exist to make greater progress in reducing cancer mortality in Texas through cancer prevention and early detection. Large numbers of Texans at average risk for cancers for which there are proven prevention and early detection strategies fail to take advantage of these strategies. This is particularly true among the medically underserved and hard to reach populations where numerous barriers inhibit the adoption and implementation of proven strategies for prevention or early detection. Early detection and prevention can improve mortality in individuals with an inherited predisposition to cancer. Yet testing for inherited cancer syndromes in appropriate populations is vastly underused. Novel technologies and noninvasive approaches (eg, liquid biopsies, novel imaging strategies) to detect cancer biomarkers are undergoing rapid advances that offer opportunities to improve surveillance of individuals at high risk for cancer. Behavioral sciences research informs the development and uptake of cancer-reducing strategies, eg, tobacco cessation strategies and obesity control. Greater attention to

implementation of evidence-based identification of at-risk individuals may empower them to make and act upon informed, cancer-preventing health decisions.

5. RESEARCH OBJECTIVES

This Request for Applications (RFA) solicits clinical and population-based projects designed to improve current methods and develop new strategies for the prevention and early detection of cancer among Texans. Examples of projects responsive to this RFA include those planning clinical or population-based projects to do the following:

- (1) To identify social, environmental, and behavioral factors, genetic markers, and health disparities that underlie cancer risk and predisposition among Texans at high risk for cancer.
- (2) To validate biomarkers, genomic technologies, or imaging methods in populations at risk for cancer that will lead to detection of cancers at an early stage.
- (3) To develop and validate innovative interventions for the prevention or early detection of cancers with particular emphasis on Texans at highest risk for cancer.
- (4) To conduct behavioral science studies that inform the development of interventions to reduce cancer risk, eg, conducting obesity research, increasing uptake of screening or cancer vaccinations, or reducing use of combustible tobacco and vaping products, particularly in populations with cancer disparities.
- (5) To increase implementation and/or dissemination of evidence-based interventions for the prevention and/or early detection of cancers among all Texans as well as those populations at high risk.
- (6) To conduct health services research in populations at highest risk to identify the most effective ways to address the disparities (eg, through systems change, outreach, access) and delivery of early detection and preventive care.

Basic research using laboratory and/or animal models designed to identify underlying mechanisms causing cancer ***is not responsive*** to this RFA and should be directed to other CPRIT mechanisms supporting basic discovery research.

Basic and clinical research to discover or to evaluate chemoprevention strategies ***is not responsive*** to this RFA and should be directed to other CPRIT mechanisms supporting basic discovery research or clinical translational research.

The *degree of relevance* to reducing the burden of cancer in Texas is a critical criterion for evaluation of projects for funding by CPRIT ([section 11.4.1](#)). Although CPRIT is required to spend 10% of its budget on cancer prevention, CPRIT's Cancer Prevention Program focuses exclusively on the delivery of evidence-based interventions to underserved populations and does not fund prevention research. **Thus, there is a unique opportunity for respondents to this RFA in CPRIT's Academic Research Program to develop collaborations with CPRIT Prevention Program grantees who have developed community-based partnerships and can provide access to Texas populations for research designed to improve current practices. Projects that propose such research collaborations with existing CPRIT Prevention Program awardees including the CPRIT funded *Texas Collaborative Center for Hepatocellular Cancer* (<https://www.bcm.edu/research/labs-and-centers/research-centers/texas-collaborative-center-for-hepatocellular-cancer>) are strongly encouraged.**

6. FUNDING INFORMATION

Applicants may request a maximum up to \$400,000 in total costs per year for up to 5 years for clinical or population-based research, including implementation or dissemination research designed to accelerate the adoption and deployment of sustainable, evidence-based cancer prevention and screening interventions at multiple levels and in different clinical and community settings. Exceptions to these limits may be requested if extremely well justified (see [section 10.2.12](#)). Funds may be used for salary and fringe benefits, research supplies, equipment, subject participation costs, and travel to scientific/technical meetings or collaborating institutions. Requests for funds to support construction and/or renovation will not be approved under this funding mechanism. State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount.

7. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism.

A public or private company is not eligible for funding under this award mechanism; these entities must use the appropriate award mechanism(s) under CPRIT's Product Development Research Program.

- The PI must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and be a full-time resident of Texas during the time the research that is the subject of the grant is conducted.
- This award mechanism allows MIs for projects that require a team science approach (see the IFA for guidelines on CPRIT rules for MI awards).
- For applications that include 1 PI, the PI is required to maintain a minimum 15% level of effort throughout the entire award period. For applications that include MIs, each PI is required to maintain a minimum 10% effort throughout the entire award period.
- A PI may not submit applications to this RFA and to RFA R-24.1-IIRA, RFA R-24.1-IIRACCA, RFA R-24.1-IIRACSBC, or RFA R-24.1-IIRACT.
- A PI may submit only 1 application, either a new, resubmission or renewal application under this RFA during this funding cycle
- A PI may be a part of only one application, whether as a single applicant or as part of an MI application, under this RFA and RFA R-24.1-IIRA, RFA R-24.1-IIRACCA, RFA R-24.1-IIRACSBC, or RFA R-24.1-IIRACT.
- An individual may serve as a PI on no more than 3 active CPRIT Academic Research grants. Recruitment Grants and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers MIRA Project Co-PIs equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be March 1, 2024).
- Applications that address basic or animal-based projects, cancers in children and adolescents, computational systems biology of cancer, or innovative clinical trials should be submitted under the appropriate targeted RFA.
- Collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.

- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member, or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, regardless of whether those individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 13](#) and [section 14](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

8. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted once and must follow all resubmission guidelines and be eligible for this mechanism under the criteria in Section 5. If a previously submitted application does not meet the new criteria for this mechanism outlined in Section 5, it must be resubmitted under the IIRA mechanism. More than 1 resubmission is not permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the

PI for a project or a change of title of the project that was previously submitted to CPRIT or omission or modification of an aim do not constitute a new application; the application would be considered a resubmission. This policy is in effect for all applications submitted to date. See [section 10.2.6](#).

9. RENEWAL POLICY

An application funded by CPRIT under this mechanism may be submitted for a competitive renewal. An application originally funded by CPRIT as an IIRA that is now appropriate for the IIRAP mechanism may be submitted under this RFA for a competitive renewal. See [section 10.2.7](#). An application originally funded by CPRIT under this mechanism that does not meet the new criteria outlined in Section 5 must be submitted under the IIRA mechanism. Competitive renewals are not subject to preliminary evaluation. Renewal applications move directly to the full peer review phase. See [section 11.2](#).

10. RESPONDING TO THIS RFA

10.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on March 15, 2023, and must be submitted by 4 PM central time on June 14, 2023. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

10.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants

applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#), within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

10.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the IFA for details that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 7](#) will be administratively withdrawn without review.

10.2.1. Abstract and Significance (5,000 characters)

It is the responsibility of the applicant to capture CPRIT's attention primarily with the Abstract and Significance statement alone. Therefore, applicants are advised to prepare this section wisely. **Based on the Abstract and Significance statement (and the Specific Aims Page, Budget and Justification and Biographical Sketches), applications that are judged to offer only modest contributions to the field of cancer research or that do not sufficiently capture the reviewers' interest may be excluded from further peer review (see [section 11.1](#)).**

Applicants should not waste this valuable space by stating obvious facts (eg, that cancer is a significant problem; that better diagnostic and therapeutic approaches are needed urgently; or that the type of cancer of interest to the PI is important, vexing, or deadly).

Clearly explain the question or problem to be addressed and the approach to its answer or solution. The specific aims of the application must be obvious from the abstract although they need not be restated verbatim from the research plan.

Clearly address how the proposed project, if successful, will have a major impact on cancer. Indicate whether this research addresses the identification, or mitigation, of cancer disparities. Summarize how the proposed research creates new paradigms or challenges existing ones. Indicate whether this research plan represents a new direction for the PI.

10.2.2. Layperson’s Summary (2,000 characters)

Provide a layperson’s summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detection, prevention, or treatment. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. **Do not include any proprietary information in the layperson’s summary.** The layperson’s summary will also be used by advocate reviewers ([section 11.2](#)) in evaluating the significance and impact of the proposed work.

10.2.3. Aims and Sub-Aims

Please provide a description of the Aims and Sub-aims and milestones to be achieved for each year of the project. Provide 2-3 sentences describing activities to be performed and anticipated milestones. These Aims will also be used during the submission and evaluation of progress reports and assessment of project success.

10.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications.

If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

10.2.5. Specific Aims (1 page)

Please provide a 1-page summary of the aims of the proposal. The Specific Aims page should identify the problem, or gap in our current knowledge. It should present a hypothesis and briefly describe the aims and approaches. Address the proposal’s innovation, novel approaches and significance and impact on the field and cancer research. Please also refer to the template located in [Current Funding Opportunities](#) for Academic Research in CARS.

10.2.6. Resubmission Summary (2 pages)

Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

Note: An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to need considerable attention. Applicants may prepare a fresh research plan or modify the original research plan and mark the changes. However, **all resubmitted applications should be carefully reconstructed**; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes.

10.2.7. Renewal Summary (2 pages)

Applicants preparing a renewal must describe and demonstrate that appropriate/adequate progress has been made on the current funded award to warrant further funding. Publications and manuscripts in press that have resulted from work performed during the initial funded period should be listed in the renewal summary.

10.2.8. Research Plan (10 pages)

Background: Present the rationale behind the proposed project, emphasizing the pressing problem in cancer research that will be addressed.

Hypothesis and Specific Aims: Concisely state the hypothesis and/or specific aims to be tested or addressed by the research described in the application. Describe the significance, innovation, and potential impact of the research.

Research Strategy: Describe the experimental design, including methods, anticipated results, potential problems or pitfalls, and alternative approaches. Preliminary data that support the proposed hypothesis are encouraged but not required.

10.2.9. Vertebrate Animals (1 page)

If vertebrate animals will be used, provide a detailed plan of the protocols that will be followed and justification for the number of animals used with reference to biostatistical input for sample

selection and evaluation. Certification of approval by the institutional IACUC of the proposed animal use will be required before funding can occur.

10.2.10. Human Subjects (2 pages)

If human subjects or human biological samples will be used, provide a detailed plan for recruitment of subjects and/or the acquisition of samples that will meet the time constraints of this award mechanism. Certification of approval of these plans by the institutional IRB will be required before funding can occur.

10.2.11. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

10.2.12. Budget and Justification

Provide a compelling and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, supplies, equipment, patient care costs, animal care costs, and other expenses. Do not exceed \$400,000 per year for studies, including implementation research designed to accelerate the adoption and deployment of sustainable, evidence-based cancer prevention and screening interventions at multiple levels and in different clinical and community settings. Applicants are advised not to interpret the maximum allowable request under this award as a suggestion that they should expand their anticipated budget to this level. Reasonable budgets clearly work in favor of the applicant.

However, if there is a highly specific and defensible need to request more than the maximum amount in any year(s) of the proposed budget, include a special and clearly labeled section in the budget justification that explains the request. Poorly justified requests of this type will likely have a negative impact on the overall evaluation of the application.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding

indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.

- The maximum annual salary (also referred to as direct salary or institutional base salary) that an individual may request under a CPRIT award for FY 2024 is \$200,000; CPRIT FY 2024 is from September 1, 2023, through August 31, 2024. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.
- Funds can be used to pay for costs that a cancer clinical trial participant may have associated with their participation in a clinical trial, including: 1) transportation, including car mileage, parking, bus fare, taxi or ride hailing fare exclusive of tips, and commercial economy class airfare within the borders of the State of Texas; 2) lodging.

10.2.13. Biographical Sketches (5 pages each)

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research. A biographical sketch must be provided for the PI and, if applicable, any additional PIs (if an MI application), as required by the online application receipt system. Up to 5 additional biographical sketches for key personnel may be provided, these should be concatenated into a single PDF with a 25-page limit. Each biographical sketch must not exceed 5 pages. The NIH biosketch format is appropriate.

10.2.14. Current and Pending Support

Describe the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project and, if relevant, a statement of overlap with the

current application. At a minimum, current and pending support of the PI and, if applicable, any additional PIs (if an MI application), must be provided. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

10.2.15. Institutional/Collaborator Support and/or Other Certification (4 pages)

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 4 pages may be provided.

10.2.16. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or that do not meet the eligibility requirements listed above will be administratively rejected without review.

10.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.

- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable if the journal information is stated. Include URLs of publications referenced in the application.

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45-67.

- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

11. APPLICATION REVIEW

11.1. Preliminary Evaluation

To ensure the timely and thorough review of only the most innovative and cutting-edge research with the greatest potential for advancement of cancer research, all eligible applications may be preliminarily evaluated by CPRIT Scientific Research Program panel members for scientific merit and impact.

This preliminary evaluation will be based on a subset of material presented in the application—namely, Abstract and Significance, Specific Aims page, Budget and Justification, and Biographical Sketches. Applications that do not sufficiently capture the reviewers' interest at this stage will not be considered for further review. Such applications will have been judged to offer only modest contributions to the field of cancer research and will be excluded from further peer review.

The applicant will be notified of the decision to disapprove the application after the preliminary evaluation stage has concluded. Due to the volume of applications to be reviewed, comments made by reviewers at the preliminary evaluation stage may be limited.

11.2. Full Peer Review

Applications that pass preliminary evaluation will undergo further review using a 2-stage peer review process: (1) Full peer review and (2) Prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 11.4](#). In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all the peer review panels and programmatic priorities. Applications approved by the Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

11.3. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules (Texas Administrative Code [RULE §703.9](#)).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee Member, a PIC Member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Research Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

11.4. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

11.4.1. Primary Criteria

Primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

Significance and Impact: Will the results of this research, if successful, significantly change the research of others or the opportunities for better cancer prevention or early detection? Is the application innovative? Does the applicant propose new paradigms or challenge existing ones? Does the project develop state-of-the-art technologies, methods, tools, or resources for cancer research or address important underexplored or unexplored areas? If the research project is successful, will it lead to truly substantial advances in the field rather than add modest increments of insight? Projects that modestly extend current lines of research will not be considered for this award. Projects that represent straightforward extensions of ongoing work, especially work traditionally funded by other mechanisms, will not be competitive.

Research Plan: Is the proposed work presented as a self-contained research project? Does the proposed research have a clearly defined hypothesis or goal that is supported by sufficient preliminary data and/or scientific rationale? Are the methods appropriate, and are potential experimental obstacles and unexpected results discussed?

Applicant Investigator: Does the investigator(s) demonstrate the required creativity and expertise to make a significant contribution to the research? Applicants' credentials will be evaluated in a career stage-specific fashion. Have early-career-stage investigators received excellent training, and do their accomplishments to date offer great promise for a successful career? Has the applicant(s) devoted a sufficient amount of their time (percent effort) to this project?

Relevance: Does the proposed research have a high degree of relevance to cancer prevention research or early detection for Texans? This is a critical criterion for evaluation of projects for CPRIT support.

11.4.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research.

Secondary criteria include the following:

Research Environment: Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the proposed research? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support of the research team and the project?

Vertebrate Animals and/or Human Subjects: Is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed?

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

12. KEY DATES

RFA

RFA release February 17, 2023

Application

Online application opens March 15, 2023, 7 AM central time

Application due June 14, 2023, 4 PM central time

Application review June 2023–February 2024

Award

Award notification February 2024

Anticipated start date March 1, 2024

13. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT’s electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT’s electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT's administrative rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

14. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. A grant recipient that is a public or private institution of higher education, as defined by §61.003, Texas Education Code, may credit toward the Grant Recipient's Matching Funds obligation the dollar amount equivalent to the difference between the indirect cost rate authorized by the federal government for research grants awarded to the Grant Recipient and the 5% indirect cost limit imposed by §102.203(c), Texas Health and Safety Code. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted.

15. CONTACT INFORMATION

15.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not able to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

15.2. Scientific and Programmatic Questions

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Director of Academic Research.

Tel: 512-305-8491

Email: research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel - Basic Cancer

Research-1 (24.1_AR_BCR-1)

Observation Report

Report No. 2023-10-20 24.1_AR_BCR-1
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel - Basic Cancer Research-1
(24.1_AR_BCR-1)
Panel Date: October 20, 2023
Report Date: October 26, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel - Basic Cancer Research-1 (24.1_AR_BCR-1) meeting. The meeting was chaired by Eric Fearson and conducted via videoconference on October 20, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and twenty-three (23) applications were not discussed
- Panelists: One (1) panel chair, thirteen (13) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were five (5) Conflict of Interest (COI) identified prior to and/or during the meeting. Two (2) applications with COIs were discussed and two (2) applications with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel – Basic Cancer

Research (24.1 ACR-BCR-2) Observation Report

Report No. 2023-10-11 24.1_ACR-BCR-2
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel – Basic Cancer Research
(24.1 _ACR-BCR-2)
Panel Date: October 11, 2023
Report Date: October 16, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel – Basic Cancer Research (24.1_ACR-BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on October 11, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and thirty (30) applications were not discussed
- Panelists: One (1) panel chair, Nineteen (19) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Eight (8)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were nine (9) Conflicts of Interest (COI) identified prior to and/or during the meeting. COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel - Basic Cancer

Research (24.1 ACR CPR)

Observation Report

Report No. 2023-10-13 24.1_ACR CPR
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel - Basic Cancer Research
(24.1 _ACR CPR)
Panel Date: October 13, 2023
Report Date: October 16, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel - Basic Cancer Research (24.1_ACR CPR) meeting. The meeting was chaired by Elena Martinez and conducted via videoconference on October 13, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Ten (10) applications were discussed and eleven (11) applications were not discussed
- Panelists: One (1) panel chair, twelve (12) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Seven (7)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflict of Interest (COI) identified prior to and/or during the meeting. Two (2) applications with COIs were discussed and one (1) application with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the closing text.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
24.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (24.1_ACR-CTCR)
Observation Report

Report No. 2023-10-17 24.1_ACR-CTCR
Program Name: Academic Research
Panel Name: 24.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (24.1_ACR-CTCR)
Panel Date: October 17, 2023
Report Date: October 23, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Clinical and Translational Cancer Research (C/TCR) (24.1_ACR-CTCR) meeting. The meeting was chaired by Richard O'Reilly and Margaret Tempero and conducted via videoconference on October 17, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty-one (21) applications were discussed and thirty-five (35) applications were not discussed
- Panelists: Two (2) panel chair, seventeen (17) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflict of Interest (COI) identified prior to and/or during the meeting. Two (2) applications with COIs were discussed and two (2) applications with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Review Panel – Imaging Technology and Informatics (24.1 ACR ITI) Observation Report

Report No. 2023-10-19 24.1_ACR-ITI
Program Name: Academic Research
Panel Name: 24.1 Academic Research Review Panel – Imaging Technology and Informatics (24.1 _ACR-ITI)
Panel Date: October 19, 2023
Report Date: October 26, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Review Panel – Imaging Technology and Informatics (24.1_ACR-ITI) meeting. The meeting was co-chaired by Anna Wu, Henry VanBrocklin, and Jason Lewis, in lieu of Martin Pomper and conducted via videoconference on October 19, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Sixteen (16) applications were discussed and thirteen (13) applications were not discussed
- Panelists: Three (3) panel chairs, thirteen (13) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were twelve (12) Conflicts of Interest (COI) identified prior to and/or during the meeting. Four (4) applications with a COI were discussed and three (3) applications with a COI were not discussed. COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Academic Research Scientific Review Council (24.1 SRC) Observation Report

Report No. 2023-12-14 24.1_SRC
Program Name: Academic Research
Panel Name: 24.1 Academic Research Scientific Review Council (24.1 _SRC)
Panel Date: December 14, 2023
Report Date: January 17, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Academic Research Scientific Review Council (24.1_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 14, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Forty- five (45) applications were discussed
- Panelists: One (1) panel chair, and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 24.1

Awards Announced at the February 21, 2024, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 24.1 include: *Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Translation; and Individual Investigator Research Awards for Prevention and Early Detection.* Applications submitted in response to these five award mechanisms went through preliminary evaluation as allowed by TAC § 703.6(e)(1).

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|--|------------------------|--|------------------------------------|
| Applications considered by the PIC and Oversight Committee: | | | |
| RP240127 | John Abrams | The University of Texas Southwestern Medical Center | Benjamin Greenbaum |
| RP240072 | Daniel Frigo | The University of Texas M. D. Anderson Cancer Center | Steffi Oesterreich |
| RP240125 | Guojun Li | The University of Texas M. D. Anderson Cancer Center | Electra Paskett; Thomas Brandon |
| RP240272 | Joseph Ludwig | The University of Texas M. D. Anderson Cancer Center | Richard O'Reilly |
| RP240117 | Jia Wu | The University of Texas M. D. Anderson Cancer Center | Charles Kahn; Maryellen Giger |

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|---|------------------------|--|-------------------------------|
| RP240311 | Richard Bouchard | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger; Weibo Cai |
| RP240291 | Eveline Barbieri | Baylor College of Medicine | Craig Rosenfeld |
| Applications not considered by the PIC or Oversight Committee: | | | |
| RP240101 ^a | Sang Eun Lee | The University of Texas Health Science Center at San Antonio | Alan Tomkinson; John Petrini |
| RP240118 | Elizabeth Goldsmith | The University of Texas Southwestern Medical Center | Alan Tomkinson |
| RP240236 | Katharina Schlacher | The University of Texas M. D. Anderson Cancer Center | John Petrini |
| RP240270 | Giulio Draetta | The University of Texas M. D. Anderson Cancer Center | Eileen White; Nabeel Bardeesy |
| RP240364 | Christopher Amos | Baylor College of Medicine | Alan Tomkinson |
| RP240399 | Jonathan Sessler | The University of Texas at Austin | Nabeel Bardeesy |
| RP240368 | Zhaoyong Hu | Baylor College of Medicine | Steffi Oesterreich |
| RP240106 | Michelle Hildebrandt | The University of Texas M. D. Anderson Cancer Center | Electra Paskett |
| RP240240 | Maria Swartz | The University of Texas M. D. Anderson Cancer Center | Electra Paskett |
| RP240112 | Jianjun Zhang | The University of Texas M. D. Anderson Cancer Center | Antoni Ribas |
| RP240340 | Kareem Azab | The University of Texas Southwestern Medical Center | John DiPersio |
| RP240354 | Charles Reynolds | Texas Tech University Health Sciences Center | W. Martin Kast |

^a The PIC did not recommend this application to the Oversight Committee.

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|-----------------------------------|------------------------|--|--|
| RP240044 | Jingfei Ma | The University of Texas M. D. Anderson Cancer Center | Charles Kahn; David Mankoff; Martin Pomper |
| RP240056 | David Fuentes | The University of Texas M. D. Anderson Cancer Center | David Mankoff; Maryellen Giger |
| RP240066 | Xiankai Sun | The University of Texas Southwestern Medical Center | Anna Wu |
| RP240088 | Hongyu Wang | The University of Texas Health Science Center at Houston | Charles Kahn |
| RP240141 | Jian Gu | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger |
| RP240018 | Lan Zhou | The Methodist Hospital Research Institute | Eric Fearon; Weiping Zou |
| RP240299 | Wen Jiang | The University of Texas M. D. Anderson Cancer Center | Kristin Swanson |
| RP240396 | Leonidas Bleris | The University of Texas at Dallas | Alexander Anderson |
| RP240409 | Tae Jin Lee | The University of Texas Health Science Center at Houston | Kristin Swanson |
| RP240177 (preliminary evaluation) | Hays Rye | Texas AgriLife Research | Benjamin Raphael |
| RP240410 (preliminary evaluation) | Murugesan Palaniappan | Baylor College of Medicine | Steffi Oesterreich |
| RP240140 (preliminary evaluation) | Sang Cho | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger |
| RP240221 (preliminary evaluation) | Tinsu Pan | The University of Texas M. D. Anderson Cancer Center | Maryellen Giger |

De-Identified Overall Evaluation Scores

Individual Investigator Research Awards for Prevention and Early Detection

Academic Research Cycle 24.1

Final Scores for Fully Reviewed Applications

| Application ID | Final Overall Evaluation Score |
|----------------|--------------------------------|
| RP240208* | 2.8 |
| Ln | 3.1 |
| Lo | 3.9 |
| Lp | 4.0 |
| Lq | 4.0 |
| Lr | 4.0 |
| Ls | 4.7 |
| Lt | 5.0 |
| Lu | 6.0 |

* Recommended for funding.

Individual Investigator Research Awards for Prevention and Early Detection

Academic Research Cycle 24.1

Final Scores for Preliminary Evaluation

These are the final overall evaluation scores for applications receiving preliminary evaluation that did not move forward to full review. The final overall evaluation score is an average of the preliminary evaluation scores assigned to each application by the primary reviewers.

| Application ID | Final Overall Score |
|----------------|---------------------|
| Cb | 4.33 |
| Cc | 4.33 |
| Cd | 4.67 |
| Ce | 5.00 |
| Cf | 5.33 |
| Cg | 5.67 |

Final Overall Evaluation Scores and Rank Order Scores

UC San Diego

SCHOOL OF MEDICINE

January 3, 2024

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Dr. Cummings and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Individual Investigator Research Awards, Individual Investigator Research Awards for Childhood and Adolescent Cancers, Individual Investigator Research Awards for Computational Systems Biology of Cancer, Individual Investigator Research Awards for Clinical Translation, Individual Investigator Research Awards for Prevention and Early Detection, Recruitment of Established Investigators, Recruitment of Rising Stars and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on December 14, 2023 to consider the FY24.1 applications recommended by the peer review panels following their meetings held October 11, 2023 to October 20, 2023. The SRC met on November 16, 2023 to review recruitment applications submitted for Cycle FY24.3-4 and then on December 14, 2023 to review recruitment applications submitted for Cycle FY24.5.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$83,180,142.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

| Recommended for Funding by Mechanism (Ranked by Overall Score) | | | | | | | |
|--|----------|-----------------|-----------------------|---|-----------------|--|--------------------|
| Rank | ID | Award Mechanism | Meeting Overall Score | Application Title | PI | PI Organization | Recommended Budget |
| 1 | RP240068 | IIRA | 1.0 | Understanding the Mechanism of Linker Histone Mutations in Malignancy | Soshnev, Alexey | The University of Texas at San Antonio | \$997,770 |
| 2 | RP240293 | IIRACSBC | 1.0 | Therapeutic Vulnerabilities and Predictors of Response to Chemo(immuno)therapy in Patients With High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC) | Korkut, Anil | The University of Texas M. D. Anderson Cancer Center | \$1,199,999 |
| 3 | RR240019 | RRS | 1.0 | Development of Chemotherapeutics Inspired by Natural Products | Sarlah, David | Rice University | 4,000,000.00 |
| 4 | RP240137 | IIRACSBC | 1.1 | Charting TCR-Tumor Antigen Interactions to Foster Novel Immunotherapeutic Approaches for Triple-Negative Breast Cancer | Zhang, Bing | Baylor College of Medicine | \$1,200,000 |
| 5 | RR240013 | RFTFM | 1.2 | Regulation of gene expression and tumorigenesis by ubiquitin-mediated protein quality control | Mark, Kevin | The University of Texas Southwestern Medical Center | 2,000,000.00 |
| 6 | RR240016 | RFTFM | 1.3 | Impact of Germline Variants on Pediatric Leukemia Progression: Insights from 3D Chromatin Remodeling and Clinical Outcomes | Luan, Yu | The University of Texas Health Science Center at San Antonio | 2,000,000.00 |
| 7 | RR240030 | REI | 1.3 | Break-induced DNA Replication as a Driver of Genomic Instability in Cancer | Malkova, Anna | The University of Texas Health Science Center at San Antonio | 6,000,000.00 |
| 8 | RR240027 | RFTFM | 1.4 | Genomic and Epigenomic Mechanisms of Chemobrain | Dileep, Vishnu | Baylor College of Medicine | 2,000,000.00 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|-----------------------|--|-------------|
| 9 | RP240075 | IIRACT | 1.5 | Combination Therapy Using ATRA and Carfilzomib to Treat Proteasome Inhibitor Refractory Multiple Myeloma | Yi, Qing | The Methodist Hospital Research Institute | \$1,921,388 |
| 10 | RP240291 | IIRA | 1.6 | Targeting MYCN disruption of the molecular clock and tumor metabolism in neuroblastoma oncogenesis. | Barbieri, Eveline | Baylor College of Medicine | \$1,050,000 |
| 11 | RP240289 | IIRA | 1.6 | Real-time, label-free, micro HSI device and transformer-based attention networks for oral cancer imaging | Fei, Baowei | The University of Texas at Dallas | \$1,049,806 |
| 12 | RP240125 | IIRA | 1.8 | Immune-Related Determinants of HPV-Associated Oropharyngeal Cancer Outcomes | Li, Guojun | The University of Texas M. D. Anderson Cancer Center | \$1,049,726 |
| 13 | RP240061 | IIRA | 1.8 | Deciphering Iron Redox Cycles in Ferroptosis-based Cancer Therapy | Lu, Yi | The University of Texas at Austin | \$1,044,608 |
| 14 | RP240091 | IIRA | 1.9 | High resolution high sensitivity photoacoustic imaging molecular guided brain tumor surgery with pilot clinical deployment | Valdes Quevedo, Pablo | The University of Texas Medical Branch at Galveston | \$1,044,967 |
| 15 | RP240401 | IIRACCA | 1.9 | Lead Optimization, Target Engagement, and Efficacy Studies of Locally Bioavailable COX-2 inhibitors for Preventing Colon Cancer Progression in FAP Children | Hu, Ming | University of Houston | \$1,400,000 |
| 16 | RP240272 | IIRACCA | 1.9 | The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy for DSRCT | Ludwig, Joseph | The University of Texas M. D. Anderson Cancer Center | \$1,398,788 |
| 17 | RP240184 | IIRACT | 1.9 | Maximizing Antitumor Immunity Through Simultaneous Activation of the Innate and Adaptive Immune System | Hannan, Raquibul | The University of Texas Southwestern Medical Center | \$1,999,993 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660

T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|-------------------|--|-------------|
| 18 | RP240095 | IIRA | 2.0 | Targeting chitinase-3-like-1 as a novel therapy for hepatocellular carcinoma | ju, Cynthia | The University of Texas Health Science Center at Houston | \$1,049,388 |
| 19 | RP240035 | IIRA | 2.0 | Harnessing the metabolic dependencies of mitochondrial NADK2 as a therapeutic strategy for lung cancer | Hoxhaj, Gerta | The University of Texas Southwestern Medical Center | \$1,050,000 |
| 20 | RP240225 | IIRA | 2.0 | PARP16-mediated Ribosome MARYlation and Translation Control in Ovarian Cancer | Kraus, W. Lee | The University of Texas Southwestern Medical Center | \$1,049,743 |
| 21 | RP240259 | IIRA | 2.0 | Targeting Cancer-associated Lactobacillus iners to improve response to cancer therapy | Colbert, Lauren | MDACC/BLI | \$1,049,427 |
| 22 | RP240119 | IIRA | 2.0 | Integrating proteolysis-targeting capability into antibodies to augment therapeutic efficacy | Liu, Qingyun | The University of Texas Health Science Center at Houston | \$1,050,000 |
| 23 | RP240326 | IIRA | 2.0 | Translation of gut commensal bacteria peptidoglycan remodeling pathway for chimeric antigen receptor T-cell therapy | Saini, Neeraj | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 24 | RP240311 | IIRA | 2.0 | Treatment planning of ADC therapy for ovarian cancer with molecular photoacoustic-ultrasonic imaging | Bouchard, Richard | The University of Texas M. D. Anderson Cancer Center | \$1,049,859 |
| 25 | RP240117 | IIRA | 2.0 | Identify radiopathomics markers to guide immunotherapy for non-small cell lung cancer | Wu, Jia | The University of Texas M. D. Anderson Cancer Center | \$1,049,906 |
| 26 | RP240054 | IIRACCA | 2.0 | Myeloid Support of Refractory and Aggressive T-ALL at Distinct Tumor Sites | Ehrlich, Lauren | The University of Texas at Austin | \$1,400,000 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|---------------------|--|--------------|
| 27 | RP240237 | IIRACCA | 2.0 | The Role of EWSR1-FLI1-CENP-A Signaling in Chemoresistance in Ewing Sarcoma | Kitagawa, Katsumi | The University of Texas Health Science Center at San Antonio | \$1,400,000 |
| 28 | RR240015 | RRS | 2.0 | HyperGlio - New tools to fight brain cancer with signal-enhanced magnetic resonance | Gloeggler, Stephan | The University of Texas Southwestern Medical Center | 4,000,000.00 |
| 29 | RR240021 | RRS | 2.0 | Expansion and Single-cell Interrogation of Tumoroid Models for Precise Treatment of Diverse Rectal Cancer Patient Populations | Smith, Jesse Joshua | The University of Texas Southwestern Medical Center | 4,000,000.00 |
| 30 | RP240183 | IIRA | 2.1 | Restoring TREM2-Dependent Efferocytosis to Inhibit Obesity-Induced Liver Inflammation and Cancer Development | Liang, Shuang | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 31 | RP240263 | IIRA | 2.1 | Identifying the Biological Determinants of Aggressive Meningioma | Patel, Akash | Baylor College of Medicine | \$1,049,370 |
| 32 | RP240392 | IIRA | 2.1 | Identifying Tumor Specific Vulnerabilities in Appendiceal Adenocarcinoma: A Systems Approach | Shen, John Paul | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 33 | RP240133 | IIRA | 2.1 | Modulation of blood-spinal cord barrier for tumor treatment | Qin, Zhenpeng | The University of Texas at Dallas | \$1,050,000 |
| 34 | RP240233 | IIRACT | 2.1 | Toward Nonoperative Management of Early-Stage ER-Positive Breast Cancer | Rahimi, Asal | The University of Texas Southwestern Medical Center | \$1,999,963 |
| 35 | RP240127 | IIRA | 2.2 | Transposon Restriction, Tumor Suppression and p53 | Abrams, John | The University of Texas Southwestern Medical Center | \$1,039,356 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|----------|-----|---|------------------|--|--------------|
| 36 | RP240072 | IIRA | 2.2 | Dissection of CAMKK2's Tumor Cell-intrinsic and -extrinsic Roles in Prostate Cancer | Frigo, Daniel | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 37 | RP240288 | IIRA | 2.3 | Epigenetic mechanism and targeting during response to BRAFi/anti-EGFR therapy in BRAF-mutant colorectal cancers | Kopetz, Scott | The University of Texas M. D. Anderson Cancer Center | \$1,043,909 |
| 38 | RP240380 | IIRA | 2.3 | Clonal hematopoiesis for improving lung cancer risk assessment | Cheng, Chao | Baylor College of Medicine | \$1,040,316 |
| 39 | RP240131 | IIRACSBC | 2.3 | Computational Methods for CRISPR-Based Lineage Tracing Systems | Liu, Zhandong | Baylor College of Medicine | \$1,200,000 |
| 40 | RR240007 | REI | 2.3 | Building a multi-modal platform to enable next-generation functional precision oncology | Shen, Xiling | The University of Texas M. D. Anderson Cancer Center | 6,000,000.00 |
| 41 | RP240214 | IIRA | 2.5 | Immunoprevention of Breast Cancer Brain Metastasis by Special Dendritic Cell-derived Extracellular Vesicles | Yu, Dihua | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 42 | RP240120 | IIRA | 2.5 | JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC | ZHANG, QING | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 43 | RP240287 | IIRA | 2.5 | Investigating the Impact of Interferon Gamma Signaling on Therapeutic Resistance in Acute Myeloid Leukemia | Abbas, Hussein | The University of Texas M. D. Anderson Cancer Center | \$1,042,256 |
| 44 | RP240104 | IIRA | 2.6 | Characterization and optimization of novel allosteric KRAS inhibitors | Gorfe, Alemayehu | The University of Texas Health Science Center at Houston | \$1,050,000 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego
SCHOOL OF MEDICINE

| | | | | | | | |
|--|----------|---------|-----|---|------------------------|---|-------------|
| 45 | RP240320 | IIRA | 2.6 | Benzothiazepines as first-in-class inhibitors for the ribogenesis factor NVL and evaluation in preclinical colorectal cancer models | De Brabander, Jef | The University of Texas Southwestern Medical Center | \$1,049,754 |
| 46 | RP240143 | IIRACCA | 2.6 | Leveraging Passport for Care in a Telehealth Framework to Improve Equitable Access to Survivorship Services | Gramatges, Maria | Baylor College of Medicine | \$1,399,382 |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| 51 | RP240208 | IIRAP | 2.8 | Unidos Contra el VPH: Screening Accuracy, Preference, and Uptake of HPV Self-Sampling Among Latinxs Along the US-Mexico Border | Calderon-Mora, Jessica | The University of Texas at Austin | \$1,920,007 |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee.

Individual Investigator Research Awards (IIRA)
Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)
Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)
Individual Investigator Research Awards for Clinical Translation (IIRACT)
Individual Investigator Research Awards for Prevention and Early Detection
Recruitment of Established Investigators (REI)
Recruitment of Rising Stars (RRS)
Recruitment of First-Time, Tenure Track Faculty Members (FTTFM)



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit

Supporting Information

Academic Research Recruitment
FY 2024—Cycles 3 through 5
Recruitment of Established Investigators

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-24.1-REI

Recruitment of Established Investigators

**Please also refer to the Instructions for Applicants document, which will be
posted on June 21, 2023**

Application Receipt Dates:

June 21, 2023-June 20, 2024

FY 2024

Fiscal Year Award Period

September 1, 2023-August 31, 2024

TABLE OF CONTENTS

| | |
|--|-----------|
| 1. ABOUT CPRIT | 4 |
| 1.1. ACADEMIC RESEARCH PROGRAM PRIORITIES | 4 |
| 2. RATIONALE | 5 |
| 3. RECRUITMENT OBJECTIVES | 6 |
| 4. INSTITUTIONAL COMMITMENT | 7 |
| 5. FUNDING INFORMATION | 8 |
| 6. ELIGIBILITY | 9 |
| 7. RESUBMISSION POLICY | 11 |
| 8. RESPONDING TO THIS RFA | 11 |
| 8.1. APPLICATION SUBMISSION GUIDELINES | 11 |
| 8.2. APPLICATION COMPONENTS | 12 |
| 8.2.1. <i>Summary of Nomination (2,500 characters)</i> | 12 |
| 8.2.2. <i>Layperson's Summary (2,000 characters)</i> | 12 |
| 8.2.3. <i>Summary of Specific Aims and Sub Aims (2,000 characters)</i> | 12 |
| 8.2.4. <i>Specific Aims and Sub Aims</i> | 13 |
| 8.2.5. <i>Institutional Commitment (3 pages)</i> | 13 |
| 8.2.6. <i>Letter of Support from Department Chair (up to 2 pages)</i> | 15 |
| 8.2.7. <i>Curriculum Vitae (CV)</i> | 16 |
| 8.2.8. <i>Research (4 pages)</i> | 16 |
| 8.2.9. <i>Publications/References (1 Page)</i> | 16 |
| 8.2.10. <i>Research Collaboration/Synergy Plan (2 pages)</i> | 17 |
| 8.2.11. <i>Publications</i> | 17 |
| 8.2.12. <i>Timeline (1 page)</i> | 17 |
| 8.2.13. <i>Current and Pending Support</i> | 17 |
| 8.2.14. <i>Research Environment (1 page)</i> | 17 |
| 8.2.15. <i>Descriptive Biography (Up to 2 pages)</i> | 18 |
| 9. APPLICATION REVIEW | 18 |
| 9.1. REVIEW PROCESS..... | 18 |
| 9.1.1. <i>Confidentiality of Review</i> | 19 |
| 9.2. REVIEW CRITERIA..... | 19 |
| 10. KEY DATES | 21 |
| 11. AWARD ADMINISTRATION | 21 |
| 12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS | 22 |
| 13. CONTACT INFORMATION | 23 |
| 13.1. HELPDESK..... | 23 |
| 13.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS | 23 |

RFA VERSION HISTORY

6/21/23 RFA release

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas
- Develop and implement the Texas Cancer Plan

1.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

To accomplish CPRIT's long-term vision, the Oversight Committee has identified these 2024 priorities:

- Investing in the cancer research capacity of Texas institutions through recruitment of cancer scholars, investment in core facilities, and investment in individual investigator awards in all regions of the state;
- Building the Texas cancer life science ecosystem across Texas by bridging discovery and translational research into early-stage company products with high impact on cancer patient care and creating economic development for the State of Texas; and
- Increasing the capacity for Texas to have a significant impact on cancer prevention and early detection, ultimately decreasing cancer incidence and mortality.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state

- Reducing cancer disparities

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions and population research addressing cancer disparities
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access

2. RATIONALE

The aim of this award mechanism is to bolster cancer research in Texas by providing financial support to attract world-class research scientists with distinguished professional careers to Texas universities and cancer research institutes to establish research programs that add research talent to the state. This award will support established academic leaders whose body of work has made an outstanding contribution to cancer research. Awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research, thereby advancing cancer research and prevention efforts and promoting economic development in the State of Texas.

The recruitment of outstanding scientists will greatly enhance programs of scientific excellence in cancer research and will position Texas as a leader in the fight against cancer. Applications may address any research topic related to cancer biology, causation, prevention, detection or screening, treatment, or survivorship. Principal Investigators (PIs) with research programs addressing CPRIT's priority areas for research are encouraged. These areas include implementation research to accelerate the adoption and deployment of evidence-based

prevention and screening interventions, research including population-based research addressing cancer disparities, computational oncology and analytic methods, childhood and adolescent cancers, hepatocellular cancer, and expansion of access to innovative clinical trials.

3. RECRUITMENT OBJECTIVES

The goal of this award mechanism is to recruit exceptional faculty to universities and/or cancer research institutions in the State of Texas. This award honors outstanding senior investigators with proven track records of research accomplishments combined with excellence in leadership and teaching. All PIs should be recognized research or clinical investigators, held in the highest esteem by professional colleagues nationally and internationally, whose contributions have had a significant influence on their discipline and, likely, beyond. They must have clearly established themselves as exemplary faculty members with exceptional accomplishments in teaching and advising and/or basic, translational, population-based, or clinical cancer research activities. It is expected that the PI will contribute significantly to and have a major impact on the institution's overall cancer research initiative. PIs will be leaders capable of initiating and developing creative ideas leading to novel solutions related to cancer prevention and control, detection, diagnosis, treatment, and/or survivorship. They are also expected to maintain and lead a strong research group and have a stellar, high-impact publication portfolio, as well as continue to secure external funding. Furthermore, recipients will lead and inspire undergraduate and graduate students interested in pursuing research careers and will engage in collegial and collaborative relationships with others within and beyond their traditional discipline in an effort to expand the boundaries of cancer research.

Funding will be given for exceptional PIs who will continue to develop new research methods and techniques in the life, population-based, physical, engineering, or computational sciences and apply them to solving outstanding problems in cancer research that have been inadequately addressed or for which there may be an absence of an established paradigm or technical framework.

Ideal PIs will have specific expertise in cancer-related areas needed to address an institutional priority. PIs should be at the career level of a full professor or equivalent. This funding mechanism considers expertise, accomplishments, and breadth of experience as vital metrics for

guiding CPRIT's investment in that person's originality, insight, and potential for continued contribution. Relevance to cancer research and to CPRIT's priority areas are important evaluation criteria for CPRIT funding.

Applications nominating individuals who carry out patient-oriented research and who have demonstrated exceptional ability to lead innovative discovery campaigns through conduct of clinical trials are appropriate for this mechanism and encouraged.

Additionally, prevention and population health research that addresses the burden of cancer in Texas is a priority for CPRIT. Applications nominating individuals who have demonstrated exceptional ability to lead innovative research programs involving any component across the continuum of cancer prevention and control research are appropriate for this mechanism and are highly encouraged.

Applications that include purposeful collaborations with institutions eligible for a CPRIT Texas Regional Excellence in Cancer Award are highly encouraged.

Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of "CPRIT Scholar in Cancer Research," and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

4. INSTITUTIONAL COMMITMENT

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research to Texas. The funds provided by CPRIT for the Recruitment of an Established Investigator (REI) Award must be complemented by a strong financial institutional commitment to the recruitment. The institutional commitment should be clearly documented in the application (see [section 8.2.5](#)) and include the amount and sources of salary support and all additional financial support that will be available to the PI's research program through the course of the CPRIT award. The financial commitments made to the PI by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

5. FUNDING INFORMATION

This award is up to 5 years and is not renewable. Grant support will be awarded based upon the breadth and nature of the research program proposed. Grant funds of up to \$6,000,000 (total costs) for the 5-year period may be requested. Applicants are encouraged to tailor the budget as appropriate to the exigencies of the project; grant funds totaling less than \$6,000,000 for the term of the award are acceptable if warranted by the scope of the research. Exceptions exceeding this limit will be entertained only if there is compelling written justification. The award request may include indirect costs of up to 5% of the total award amount (5.263% of the direct costs). CPRIT will make every effort to be flexible in the timing for disbursement of funds; recipients will be asked at the beginning of each year for an estimate of their needs for the year. Funds may not be carried over beyond 5 years except under extraordinary circumstances with strong justification for a no-cost extension. In addition, funds for extraordinary equipment needs may be awarded in the first year of the grant if very well justified and a detailed justification is provided along with an institutional plan should the additional funds not be approved. Scholars may request funds for travel for 2 project staff to attend CPRIT's conference.

Funds from this award mechanism may be used for salary support of this PI but may not be used to construct or renovate laboratory space.

Note that the annual salary (also referred to as direct salary or institutional base salary) that an individual may be reimbursed from a CPRIT award for FY 2024 is limited to a maximum of \$200,000. In other words, an individual may request salary proportional to the percent of effort up to a maximum of \$200,000. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

Note: In the event of insufficient funds, specific recruitment categories may be eliminated (example REI/RRS/RFTTFM) and nominations for specific categories may be closed for the remaining cycles of the fiscal year. Additionally, depending on the availability of funds, review cycles may be reduced, and/or the number of applications per institution may be capped, and

recommended nominations submitted in response to this Request for Applications (RFA) during the current receipt period may be announced and awarded either in the current fiscal year (prior to August 31, 2024) or in the first quarter of the next fiscal year (starting September 1, 2024).

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism.
- PIs must be nominated by the president, provost, vice president for research, or appropriate dean of a Texas-based public or private institution of higher education, including academic health institutions. The application must be submitted on behalf of a specific PI.
- A PI may be nominated by only 1 institution. If more than 1 institution is interested in a given PI, negotiations as to which institution will nominate him or her must be concluded before the nomination is made.
- No annual limit on the number of grant submissions by institutions has been set.
- A PI who has already accepted a position at the recruiting institution prior to the time that the Scientific Review Council reviews the PI for a recruitment award is not eligible for a recruitment award, as an investment by CPRIT is obviously not necessary. No award is final until approved by the Oversight Committee at a public meeting. However, in recognition of the timeline involved with recruiting highly sought-after PIs who are often considering multiple offers, CPRIT's Academic Research program staff will notify the nominating institution of the Scientific Review Council's review decision following the Review Council meeting. If a position is offered to the PI during the period following the Scientific Review Council's review decision but prior to the Oversight Committee's final approval, the institution does so at its own risk. There is no guarantee that the recruitment award will be approved by the Oversight Committee.
- The PI must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, **and reside in Texas for the duration of the appointment**. The PI must devote at least 70% time to research activities. PIs whose major responsibilities are clinical care, teaching, or administration are not eligible.

- At the time of the application, the PI should hold an appointment at the rank of professor (or equivalent) at an accredited academic institution, research institution, industry, government agency, or private foundation. The PI must not reside in Texas at the time the application is submitted.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the nominator, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not the individuals will receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.

CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 11](#) and [section 12](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

Resubmissions will not be accepted for the REI award mechanism. Any nomination for the REI that was previously submitted to CPRIT and reviewed but was not recommended for funding may not be resubmitted. A nomination for the REI that was previously submitted to CPRIT for any of the recruitment RFA mechanisms and reviewed and recommended for funding but declined by the PI may be submitted in response to this RFA if the PI meets the eligibility criteria described in [section 6](#) and the application is not in the same fiscal year as the previous application. If a nomination was administratively rejected prior to review, it can be resubmitted in the following cycles. Applications being resubmitted according to the criteria permitted by this section should be submitted as a new application (refer to the *Instructions for Applicants* [IFA] document for more details).

8. RESPONDING TO THIS RFA

8.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application is submitted. PIs must be nominated by the institution's president, provost, vice president for research, or appropriate dean. The individual submitting the application (nominator) must create a user account in the system (which includes the nominator's credentials and email address) to start and submit an application. Furthermore, the Application Signing Official, who is the person authorized to sign and submit the application for the organization, and the Grants Contract/Office of Sponsored Projects Official, who is the individual who will manage the grant contract if an award is made, also must create a user account in CARS.

Dependent upon available funding, applications will be accepted on a continuous basis throughout FY24.

In order to manage the timely review of nominations, it is anticipated that applications submitted by 11:59 PM central time on the 20th of each month will be reviewed by the 15th day of the

following month. For an application to be considered for review during the cycle, that application must be submitted on or before 11:59 PM central time. In the event that the closing date falls on Saturday or Sunday, applications may be submitted on or before 11:59 PM central time the following Monday. CPRIT will not extend the submission deadline. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

8.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. For details, please refer to the *IFA* document that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

8.2.1. Summary of Nomination (2,500 characters)

Provide a brief summary of the nomination. Include the PI's name, organization from which the PI is being recruited, and the department and/or entity within the nominator's organization where the PI will hold the faculty position.

8.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. **This section must be completed by the PI.** Describe, in simple, nontechnical terms, the overall aims of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detection, prevention, treatment, or survivorship. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. Do not include any proprietary information in the layperson's summary.

8.2.3. Summary of Specific Aims and Sub Aims (2,000 characters)

Please provide a summary of the aims of the proposal. **This section must be completed by the PI.** The Specific Aims Summary should identify the problem or gap in our current knowledge. It should present a hypothesis and briefly describe the aims and approaches and address the

proposal's innovation, novel approaches, and significance and impact on the field and cancer research.

8.2.4. Specific Aims and Sub Aims

List specific aims and sub aims to be achieved during this award. **This section must be completed by the PI.** These aims/sub aims will also be used during the submission and evaluation of progress reports and assessment of project success. Refer to the template for specific aims and sub aims document located in [Current Funding Opportunities](#) for Academic Research in CARS.

8.2.5. Institutional Commitment (3 pages)

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research to Texas. The funds provided by CPRIT for the REI faculty should be complemented by a strongly documented institutional commitment to the recruitment. The financial commitments made to the PI by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

The following guidelines should be followed when documenting the institutional commitment to the PI:

- The institutional commitment should be clearly documented in the form of a letter signed by the applicant institution's president, provost, or appropriate dean and include the amount and sources of salary support and all additional financial support that will be available to the PI's research program through the course of the CPRIT award. The financial commitments made to the PI by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.
- The institutional commitment letter must include the following statement regarding the institution's financial commitment required to meet the 50% match.
 - This institutional financial commitment will not be offset by funds from an investigator-initiated award received by the PI. If an award dictates that such funds

must be used for salary, the corresponding amount of institutional funds committed to pay the PI's salary will be redirected to allow the PI to use them for program support.

- Institutional commitment as described above must be presented in a table (example below), that clearly identifies the salary amount, sources of salary, and any additional research support from institutional sources over the course of the CPRIT award. Sources of support for the PI's full salary, including summer salary, for the duration of the award must be documented. If the PI is expected to provide salary support from grants during the award period, the institutional commitment must identify the source for salary support in the event grant support is not available. Note that a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the PI.
- Include a brief job description for the PI should recruitment be successful.
- Describe the institutional environment and any professional commitments to the PI including, but not limited to, dedicated personnel, access to students, space assignment, and access to shared equipment, and discuss all other agreements between the institution and the PI.
- Institutions may provide additional information in support of a PI's research plan to demonstrate how the institutional commitment, through development of strategic collaborations, will foster a PI's cancer research. This additional information is highly encouraged when proposing a PI with exceptional expertise and/or talent that can be directed to cancer research such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research.
- Note that Texas law allows an institution of higher learning to use its federal indirect cost rate credit to comply with the requirement to demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award (see [section 12](#)). However, a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the PI.

Example of an acceptable Institutional Commitment table:

PI's Name, Institutional Commitments

| | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|------------------------|--------|--------|--------|--------|--------|
| Salary/Benefits | | | | | |
| Research Support | | | | | |
| Administrative Support | | | | | |
| Moving Expenses | | | | | |

Total =

Note: CPRIT acknowledges that the institutional commitments by category may change during the course of the award; however, the total financial commitment to the PI must remain equal to or greater than 50% of the CPRIT award.

8.2.6. Letter of Support from Department Chair (up to 2 pages)

Provide the letter of support from and signed by the chair of the department to which the PI is being recruited. The following information should be included in the letter:

Recruitment Activities: CPRIT is committed to increasing the life sciences infrastructure in Texas via the recruitment of exceptional cancer researchers, as well as expanding research resources. The letter should provide a description of the recruitment activities, strategies, and priorities that have led to the nomination of this PI. Provide the necessary context by describing the institution’s vision for the cancer programs, how the work of the nominee contributes to achieving these goals—including impact on diversity, equity, and inclusion, if applicable—and the expected impact of the recruitment on the institution (or department) and the burden of cancer in Texas (if applicable).

Caliber of PI: The letter should include a description of the caliber of the PI and justification of nomination of the PI by the institution. CPRIT recognizes that there is variability in the metrics of impact applicable across the continuum of cancer research. For example, in some disciplines, research findings—although highly impactful on the field—are less likely to be published in the highest ranked journals, ie, *Science*, *Cell*, or *Nature* series. Thus, it is incumbent on the institution to describe the impact of a nominee’s work, including paradigm-shifting, practice-changing, or influence on public policy, population health behavior, or cancer disparities.

Description of PI Duties and Certification of 70% Time Commitment to Research: While scholars may engage in direct patient care activities and/or have some administrative or teaching duties, at least 70% of the PI's time must be available for research. Breach of this requirement will constitute grounds for discontinuation of funding. The certification that 70% time will be spent on research must be included.

8.2.7. Curriculum Vitae (CV)

Provide a complete CV and list of publications for the PI.

8.2.8. Research (4 pages)

Summarize the key elements of the PI's research accomplishments and provide an overview of the proposed research by outlining the background and rationale, hypotheses and aims, strategies, specific aims, and projected impact of the focus of the research program. Highlight the innovative aspects of this effort and place it into context with regard to what pressing problem in cancer will be addressed. **This section of the application must be prepared by the PI.**

References cited in this section should be listed in the Publications/References section (see [section 8.2.9](#)).

PIs for CPRIT Scholar Awards must include the following signed statement at the end of this section. **Applications that do not contain this signed statement will be returned without review.**

“I understand that I do not need to have made a commitment to <nominating institution> before this application has been submitted. However, I also understand that only 1 Texas institution may nominate me for a CPRIT Recruitment Award, and this is the nomination that I have endorsed. I understand that requests to change the recruiting institution during the recruitment process are not allowed after the application is submitted to CPRIT.”

8.2.9. Publications/References (1 Page)

Provide a concise and relevant list of publications/references cited in the Research section of the application. Any appropriate citation format is acceptable; official journal abbreviations should be used.

8.2.10. Research Collaboration/Synergy Plan (2 pages)

Institutions may provide additional information in support of a PI's research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a PI's cancer research. This additional information is highly encouraged when proposing a PI with exceptional expertise and/or talent that can be directed to cancer research, such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research. Biographical sketches of collaborators established in the research collaborative plan must be uploaded as part of the application. This will be in addition to the 2-page synergy plan (see IFA).

8.2.11. Publications

Provide the 5 most significant publications that have resulted from the PI's research efforts. Publications should be uploaded as PDFs of full-text articles. Only articles that have been published or that have been accepted for publication ("in press") should be submitted.

8.2.12. Timeline (1 page)

Provide a general outline of anticipated major award outcomes to be tracked. Timelines will be reviewed during the evaluation of annual progress reports. If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

8.2.13. Current and Pending Support

State the funding source, duration, and title of all current and pending research support held by the PI. If the PI has no current or pending funding, a document stating this must be submitted. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

8.2.14. Research Environment (1 page)

Briefly describe the research environment available to support the PI's research program, including core facilities, training programs, and collaborative opportunities.

8.2.15. Descriptive Biography (Up to 2 pages)

Provide a brief descriptive biography of the PI, including his or her accomplishments, education and training, professional experience, awards and honors, publications relevant to cancer research, and a brief overview of the PI's specific aims, if selected, to receive the award. **This section of the application must be prepared by the PI.** If the application is approved for funding, this section will be made publicly available on CPRIT's website. PIs are advised not to include information that they consider confidential or proprietary when preparing this section.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or do not meet the eligibility requirements listed above will be administratively withdrawn without review.

9. APPLICATION REVIEW

9.1. Review Process

All eligible applications will be evaluated and scored by the CPRIT Scientific Review Council using the criteria listed in this RFA. Applications may be submitted continuously in response to this RFA but will generally be reviewed on a monthly basis by the CPRIT Scientific Review Council. Council members may seek additional ad hoc evaluations of PIs. Scientific Review Council members will review applications and provide an individual Overall Evaluation Score that conveys the members' recommendation related to the proposed recruitment. Applications recommended by the Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review, prioritization, and recommendation to the CPRIT Oversight Committee for approval and funding. Approval is based on an application receiving a positive vote from at least two-thirds of the members of the Oversight Committee. The review process is described more fully in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703.](#)

The decision of the Scientific Review Council not to recommend an application is final, and such applications may not be resubmitted for a recruitment award. Notification of review decisions is sent to the nominator.

9.1.1. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Review Council members are non-Texas residents.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed conflict of interest as set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, or a Scientific Review Council member.

Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of the Department of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant applicant from further consideration for a grant award.

9.2. Review Criteria

Applications will be assessed based on evaluation of the quality of the PI and his or her potential for continued superb performance as a cancer researcher. **Also, of critical importance is the strength of the institutional commitment to the PI. Recruitment efforts are not likely to be successful unless there is a strong commitment from both CPRIT and the host institution.** It is not necessary that a PI agrees to accept the recruitment offer at the time an application is submitted. However, applicant institutions should have an expectation that the recruitment will

be successful if an award is granted by CPRIT. It is the expectation that the nominating institution provides CPRIT with a status of the award acceptance as soon as status is known.

Review criteria will focus on the overall impression of the PI, his/her proposed research program, and his/her long-term contribution to, and impact on, the field of cancer research.

Questions to be considered by the reviewers are as follows:

Quality of the PI: Has the PI made significant, transformative, and sustained contributions to basic, translational, clinical, or population-based cancer research? Is the PI an established and nationally and/or internationally recognized leader in the field? Has the PI demonstrated excellence in leadership and teaching? Has the PI provided mentorship, inspiration, and/or professional training opportunities to junior scientists and students? Does the PI have a strong record of research funding? Does the PI have a publication history in high-impact journals within cancer research broadly, or within their specialty field, if applicable? Does the PI show evidence of collaborative interaction with others?

Scientific Merit of Proposed Research: Is the research plan comprehensive and well thought out? Does the proposed research program demonstrate innovation, creativity, and feasibility? Will it expand the boundaries of cancer research beyond traditional methodology by incorporating novel and interdisciplinary techniques? Does the research program integrate with and/or increase collaborative research efforts and relationships at the nominating institution?

Relevance of PI's Research: Is the proposed research likely to have a significant impact on reducing the burden of cancer in the near term, or address unique aspects of the burden of cancer in Texas? Does the research contribute to basic, translational, clinical, or population-based cancer research?

Research Environment: Does the institution have the necessary facilities, expertise, and resources to support the PI's research program? Is there evidence of strong institutional support? Will the PI be free of major administrative/clinical responsibilities so that he or she can focus on maintaining and enhancing his or her research program?

10. KEY DATES

RFA

RFA Release June 21, 2023

11. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Awards made under this RFA are not transferable to another institution. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov.

Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research specific aims and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be

required as appropriate. CPRIT requires funding acknowledgement to include the award grant ID on all print and visual materials that are funded in whole or in part by CPRIT grants. Examples of print and visual materials include, but are not limited to, publications, brochures, pamphlets, project websites, videos, and media materials. Grantees must have written approval from CPRIT prior to the purchase of any equipment. If the equipment is clearly defined in the grantee's budget submitted with the initiating award requirements, then approval of the grant award constitutes "prior approval" for the purchase. Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of "CPRIT Scholar in Cancer Research," and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must be made at the time the award contract is executed and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#), for specific requirements regarding the demonstration of available funding.

13. CONTACT INFORMATION

13.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff members are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

13.2. Scientific and Programmatic Questions

Questions regarding the CPRIT Program, including questions regarding this or other funding opportunities, should be directed to the CPRIT Director of Academic Research.

Email: Research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)
Academic Research Review Panel – Recruitment Review
Panel 24.3-4 (REC 24.3-4)
Observation Report

Report No. 2023-11-16 REC_24.3-4
Program Name: Academic Research
Panel Name: Academic Research Review Panel – Recruitment Review Panel
24.3-4 (REC_24.3-4)
Panel Date: November 16, 2023
Report Date: November 17, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the Academic Research Review Panel – Recruitment Review Panel 24.3-4 (REC_24.3-4) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on November 16, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer(s) participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Nine (9) applications were discussed
- Panelists: One (1) panel chair, and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Three (3)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.5 Academic Research Recruitment Review Panel (24.5

REC) Observation Report

Report No. 2023-12-14 24.5_REC
Program Name: Academic Research
Panel Name: 24.5 Academic Research Recruitment Review Panel (24.5 _REC)
Panel Date: December 14, 2023
Report Date: January 17, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.5 Academic Research Recruitment Review Panel (24.5_REC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 14, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Five (5) applications were discussed; one (1) application was provisionally approved in the 24.3-4_REC meeting
- Panelists: One (1) panel chair, and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COIs) identified prior to the meeting. However, application RR240007 from 24.3-4_REC was discussed during this meeting. No additional information pertaining to COIs or the discussion of this application was received prior to, during or after the meeting. Please note, 24.3-4_REC meeting information indicated no COI's existed for this application, and panel members were the same for both meetings.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Recruitment Cycles 24.3-24.5

Awards Announced at the February 21, 2024, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Recruitment Cycles 24.3 through 24.5 include: *Recruitment of Established Investigators*, *Recruitment of First-Time, Tenure-Track Faculty Members*; and *Recruitment of Rising Stars*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|--|------------------------|--------------|----------------------------|
| Applications considered by the PIC and Oversight Committee: | | | |
| No reported COIs. | | | |
| Applications not considered by the PIC and Oversight Committee: | | | |
| No reported COIs. | | | |

De-Identified Overall Evaluation Scores

Recruitment of Established Investigators

Academic Research Recruitment Cycles 24.3-24.5

| Application ID | Final Overall Evaluation Score |
|----------------|--------------------------------|
| RR240030* | 1.3 |
| RR240007* | 2.3 |
| aa | 4.2 |

* Recommended for funding.

Final Overall Evaluation Scores and Rank Order Scores

UC San Diego

SCHOOL OF MEDICINE

January 3, 2024

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Dr. Cummings and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Individual Investigator Research Awards, Individual Investigator Research Awards for Childhood and Adolescent Cancers, Individual Investigator Research Awards for Computational Systems Biology of Cancer, Individual Investigator Research Awards for Clinical Translation, Individual Investigator Research Awards for Prevention and Early Detection, Recruitment of Established Investigators, Recruitment of Rising Stars and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on December 14, 2023 to consider the FY24.1 applications recommended by the peer review panels following their meetings held October 11, 2023 to October 20, 2023. The SRC met on November 16, 2023 to review recruitment applications submitted for Cycle FY24.3-4 and then on December 14, 2023 to review recruitment applications submitted for Cycle FY24.5.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$83,180,142.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

| Recommended for Funding by Mechanism (Ranked by Overall Score) | | | | | | | |
|--|----------|-----------------|-----------------------|---|-----------------|--|--------------------|
| Rank | ID | Award Mechanism | Meeting Overall Score | Application Title | PI | PI Organization | Recommended Budget |
| 1 | RP240068 | IIRA | 1.0 | Understanding the Mechanism of Linker Histone Mutations in Malignancy | Soshnev, Alexey | The University of Texas at San Antonio | \$997,770 |
| 2 | RP240293 | IIRACSBC | 1.0 | Therapeutic Vulnerabilities and Predictors of Response to Chemo(immuno)therapy in Patients With High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC) | Korkut, Anil | The University of Texas M. D. Anderson Cancer Center | \$1,199,999 |
| 3 | RR240019 | RRS | 1.0 | Development of Chemotherapeutics Inspired by Natural Products | Sarlah, David | Rice University | 4,000,000.00 |
| 4 | RP240137 | IIRACSBC | 1.1 | Charting TCR-Tumor Antigen Interactions to Foster Novel Immunotherapeutic Approaches for Triple-Negative Breast Cancer | Zhang, Bing | Baylor College of Medicine | \$1,200,000 |
| 5 | RR240013 | RFTFM | 1.2 | Regulation of gene expression and tumorigenesis by ubiquitin-mediated protein quality control | Mark, Kevin | The University of Texas Southwestern Medical Center | 2,000,000.00 |
| 6 | RR240016 | RFTFM | 1.3 | Impact of Germline Variants on Pediatric Leukemia Progression: Insights from 3D Chromatin Remodeling and Clinical Outcomes | Luan, Yu | The University of Texas Health Science Center at San Antonio | 2,000,000.00 |
| 7 | RR240030 | REI | 1.3 | Break-induced DNA Replication as a Driver of Genomic Instability in Cancer | Malkova, Anna | The University of Texas Health Science Center at San Antonio | 6,000,000.00 |
| 8 | RR240027 | RFTFM | 1.4 | Genomic and Epigenomic Mechanisms of Chemobrain | Dileep, Vishnu | Baylor College of Medicine | 2,000,000.00 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|-----------------------|--|-------------|
| 9 | RP240075 | IIRACT | 1.5 | Combination Therapy Using ATRA and Carfilzomib to Treat Proteasome Inhibitor Refractory Multiple Myeloma | Yi, Qing | The Methodist Hospital Research Institute | \$1,921,388 |
| 10 | RP240291 | IIRA | 1.6 | Targeting MYCN disruption of the molecular clock and tumor metabolism in neuroblastoma oncogenesis. | Barbieri, Eveline | Baylor College of Medicine | \$1,050,000 |
| 11 | RP240289 | IIRA | 1.6 | Real-time, label-free, micro HSI device and transformer-based attention networks for oral cancer imaging | Fei, Baowei | The University of Texas at Dallas | \$1,049,806 |
| 12 | RP240125 | IIRA | 1.8 | Immune-Related Determinants of HPV-Associated Oropharyngeal Cancer Outcomes | Li, Guojun | The University of Texas M. D. Anderson Cancer Center | \$1,049,726 |
| 13 | RP240061 | IIRA | 1.8 | Deciphering Iron Redox Cycles in Ferroptosis-based Cancer Therapy | Lu, Yi | The University of Texas at Austin | \$1,044,608 |
| 14 | RP240091 | IIRA | 1.9 | High resolution high sensitivity photoacoustic imaging molecular guided brain tumor surgery with pilot clinical deployment | Valdes Quevedo, Pablo | The University of Texas Medical Branch at Galveston | \$1,044,967 |
| 15 | RP240401 | IIRACCA | 1.9 | Lead Optimization, Target Engagement, and Efficacy Studies of Locally Bioavailable COX-2 inhibitors for Preventing Colon Cancer Progression in FAP Children | Hu, Ming | University of Houston | \$1,400,000 |
| 16 | RP240272 | IIRACCA | 1.9 | The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy for DSRCT | Ludwig, Joseph | The University of Texas M. D. Anderson Cancer Center | \$1,398,788 |
| 17 | RP240184 | IIRACT | 1.9 | Maximizing Antitumor Immunity Through Simultaneous Activation of the Innate and Adaptive Immune System | Hannan, Raquibul | The University of Texas Southwestern Medical Center | \$1,999,993 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|-------------------|--|-------------|
| 18 | RP240095 | IIRA | 2.0 | Targeting chitinase-3-like-1 as a novel therapy for hepatocellular carcinoma | ju, Cynthia | The University of Texas Health Science Center at Houston | \$1,049,388 |
| 19 | RP240035 | IIRA | 2.0 | Harnessing the metabolic dependencies of mitochondrial NADK2 as a therapeutic strategy for lung cancer | Hoxhaj, Gerta | The University of Texas Southwestern Medical Center | \$1,050,000 |
| 20 | RP240225 | IIRA | 2.0 | PARP16-mediated Ribosome MARYlation and Translation Control in Ovarian Cancer | Kraus, W. Lee | The University of Texas Southwestern Medical Center | \$1,049,743 |
| 21 | RP240259 | IIRA | 2.0 | Targeting Cancer-associated Lactobacillus iners to improve response to cancer therapy | Colbert, Lauren | MDACC/BLI | \$1,049,427 |
| 22 | RP240119 | IIRA | 2.0 | Integrating proteolysis-targeting capability into antibodies to augment therapeutic efficacy | Liu, Qingyun | The University of Texas Health Science Center at Houston | \$1,050,000 |
| 23 | RP240326 | IIRA | 2.0 | Translation of gut commensal bacteria peptidoglycan remodeling pathway for chimeric antigen receptor T-cell therapy | Saini, Neeraj | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 24 | RP240311 | IIRA | 2.0 | Treatment planning of ADC therapy for ovarian cancer with molecular photoacoustic-ultrasonic imaging | Bouchard, Richard | The University of Texas M. D. Anderson Cancer Center | \$1,049,859 |
| 25 | RP240117 | IIRA | 2.0 | Identify radiopathomics markers to guide immunotherapy for non-small cell lung cancer | Wu, Jia | The University of Texas M. D. Anderson Cancer Center | \$1,049,906 |
| 26 | RP240054 | IIRACCA | 2.0 | Myeloid Support of Refractory and Aggressive T-ALL at Distinct Tumor Sites | Ehrlich, Lauren | The University of Texas at Austin | \$1,400,000 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|---------------------|--|--------------|
| 27 | RP240237 | IIRACCA | 2.0 | The Role of EWSR1-FLI1-CENP-A Signaling in Chemoresistance in Ewing Sarcoma | Kitagawa, Katsumi | The University of Texas Health Science Center at San Antonio | \$1,400,000 |
| 28 | RR240015 | RRS | 2.0 | HyperGlio - New tools to fight brain cancer with signal-enhanced magnetic resonance | Gloeggler, Stephan | The University of Texas Southwestern Medical Center | 4,000,000.00 |
| 29 | RR240021 | RRS | 2.0 | Expansion and Single-cell Interrogation of Tumoroid Models for Precise Treatment of Diverse Rectal Cancer Patient Populations | Smith, Jesse Joshua | The University of Texas Southwestern Medical Center | 4,000,000.00 |
| 30 | RP240183 | IIRA | 2.1 | Restoring TREM2-Dependent Efferocytosis to Inhibit Obesity-Induced Liver Inflammation and Cancer Development | Liang, Shuang | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 31 | RP240263 | IIRA | 2.1 | Identifying the Biological Determinants of Aggressive Meningioma | Patel, Akash | Baylor College of Medicine | \$1,049,370 |
| 32 | RP240392 | IIRA | 2.1 | Identifying Tumor Specific Vulnerabilities in Appendiceal Adenocarcinoma: A Systems Approach | Shen, John Paul | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 33 | RP240133 | IIRA | 2.1 | Modulation of blood-spinal cord barrier for tumor treatment | Qin, Zhenpeng | The University of Texas at Dallas | \$1,050,000 |
| 34 | RP240233 | IIRACT | 2.1 | Toward Nonoperative Management of Early-Stage ER-Positive Breast Cancer | Rahimi, Asal | The University of Texas Southwestern Medical Center | \$1,999,963 |
| 35 | RP240127 | IIRA | 2.2 | Transposon Restriction, Tumor Suppression and p53 | Abrams, John | The University of Texas Southwestern Medical Center | \$1,039,356 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|----------|-----|---|------------------|--|--------------|
| 36 | RP240072 | IIRA | 2.2 | Dissection of CAMKK2's Tumor Cell-intrinsic and -extrinsic Roles in Prostate Cancer | Frigo, Daniel | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 37 | RP240288 | IIRA | 2.3 | Epigenetic mechanism and targeting during response to BRAFi/anti-EGFR therapy in BRAF-mutant colorectal cancers | Kopetz, Scott | The University of Texas M. D. Anderson Cancer Center | \$1,043,909 |
| 38 | RP240380 | IIRA | 2.3 | Clonal hematopoiesis for improving lung cancer risk assessment | Cheng, Chao | Baylor College of Medicine | \$1,040,316 |
| 39 | RP240131 | IIRACSBC | 2.3 | Computational Methods for CRISPR-Based Lineage Tracing Systems | Liu, Zhandong | Baylor College of Medicine | \$1,200,000 |
| 40 | RR240007 | REI | 2.3 | Building a multi-modal platform to enable next-generation functional precision oncology | Shen, Xiling | The University of Texas M. D. Anderson Cancer Center | 6,000,000.00 |
| 41 | RP240214 | IIRA | 2.5 | Immunoprevention of Breast Cancer Brain Metastasis by Special Dendritic Cell-derived Extracellular Vesicles | Yu, Dihua | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 42 | RP240120 | IIRA | 2.5 | JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC | ZHANG, QING | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 43 | RP240287 | IIRA | 2.5 | Investigating the Impact of Interferon Gamma Signaling on Therapeutic Resistance in Acute Myeloid Leukemia | Abbas, Hussein | The University of Texas M. D. Anderson Cancer Center | \$1,042,256 |
| 44 | RP240104 | IIRA | 2.6 | Characterization and optimization of novel allosteric KRAS inhibitors | Gorfe, Alemayehu | The University of Texas Health Science Center at Houston | \$1,050,000 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego
SCHOOL OF MEDICINE

| | | | | | | | |
|--|----------|---------|-----|---|------------------------|---|-------------|
| 45 | RP240320 | IIRA | 2.6 | Benzothiazepines as first-in-class inhibitors for the ribogenesis factor NVL and evaluation in preclinical colorectal cancer models | De Brabander, Jef | The University of Texas Southwestern Medical Center | \$1,049,754 |
| 46 | RP240143 | IIRACCA | 2.6 | Leveraging Passport for Care in a Telehealth Framework to Improve Equitable Access to Survivorship Services | Gramatges, Maria | Baylor College of Medicine | \$1,399,382 |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| 51 | RP240208 | IIRAP | 2.8 | Unidos Contra el VPH: Screening Accuracy, Preference, and Uptake of HPV Self-Sampling Among Latinxs Along the US-Mexico Border | Calderon-Mora, Jessica | The University of Texas at Austin | \$1,920,007 |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee.

Individual Investigator Research Awards (IIRA)
Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)
Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)
Individual Investigator Research Awards for Clinical Translation (IIRACT)
Individual Investigator Research Awards for Prevention and Early Detection
Recruitment of Established Investigators (REI)
Recruitment of Rising Stars (RRS)
Recruitment of First-Time, Tenure Track Faculty Members (FTTFM)



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research Recruitment
FY 2024—Cycles 3 through 5
*Recruitment of First-Time,
Tenure-Track Faculty Members***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-24.1-RFT

**Recruitment of First-Time, Tenure-Track
Faculty Members**

**Please also refer to the Instructions for Applicants document,
which will be posted on June 21, 2023**

**Application Receipt Dates:
June 21, 2023-June 20, 2024**

FY 2024
Fiscal Year Award Period
September 1, 2023-August 31, 2024

TABLE OF CONTENTS

| | |
|--|-----------|
| 1. ABOUT CPRIT | 4 |
| 1.1. ACADEMIC RESEARCH PROGRAM PRIORITIES | 4 |
| 2. RATIONALE | 5 |
| 3. RECRUITMENT OBJECTIVES | 6 |
| 4. INSTITUTIONAL COMMITMENT | 7 |
| 5. FUNDING INFORMATION | 7 |
| 6. ELIGIBILITY | 8 |
| 7. RESUBMISSION POLICY | 10 |
| 8. RESPONDING TO THIS RFA | 10 |
| 8.1. APPLICATION SUBMISSION GUIDELINES | 10 |
| 8.2. APPLICATION COMPONENTS | 11 |
| 8.2.1. <i>Summary of Nomination (2,000 characters)</i> | 11 |
| 8.2.2. <i>Layperson's Summary (2,000 characters)</i> | 11 |
| 8.2.3. <i>Summary of Specific Aims and Sub Aims (2,000 characters)</i> | 12 |
| 8.2.4. <i>Specific Aims and Sub Aims</i> | 12 |
| 8.2.5. <i>Institutional Commitment (3 pages)</i> | 12 |
| 8.2.6. <i>Letter of Support from Department Chair (up to 2 pages)</i> | 14 |
| 8.2.7. <i>Curriculum Vitae (CV)</i> | 15 |
| 8.2.8. <i>Research (4 pages)</i> | 15 |
| 8.2.9. <i>Publications/References (1 page)</i> | 16 |
| 8.2.10. <i>Research Collaboration/Synergy Plan (2 pages)</i> | 16 |
| 8.2.11. <i>Publications</i> | 16 |
| 8.2.12. <i>Timeline (1 page)</i> | 16 |
| 8.2.13. <i>Current and Pending Support</i> | 17 |
| 8.2.14. <i>Letters of Recommendation</i> | 17 |
| 8.2.15. <i>Research Environment (1 page)</i> | 17 |
| 8.2.16. <i>Descriptive Biography (Up to 2 pages)</i> | 17 |
| 9. APPLICATION REVIEW | 17 |
| 9.1. REVIEW PROCESS..... | 17 |
| 9.1.1. <i>Confidentiality of Review</i> | 18 |
| 9.2. REVIEW CRITERIA..... | 19 |
| 10. KEY DATES | 20 |
| 11. AWARD ADMINISTRATION | 20 |
| 12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS | 21 |
| 13. CONTACT INFORMATION | 22 |
| 13.1. HELPDESK..... | 22 |
| 13.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS | 22 |

RFA VERSION HISTORY

6/21/23 RFA release

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas
- Develop and implement the Texas Cancer Plan

1.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

To accomplish CPRIT's long-term vision, the Oversight Committee has identified these 2024 priorities:

- Investing in the cancer research capacity of Texas institutions through recruitment of cancer scholars, investment in core facilities, and investment in individual investigator awards in all regions of the state;
- Building the Texas cancer life science ecosystem across Texas by bridging discovery and translational research into early-stage company products with high impact on cancer patient care and creating economic development for the State of Texas; and
- Increasing the capacity for Texas to have a significant impact on cancer prevention and early detection, ultimately decreasing cancer incidence and mortality.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state
- Reducing cancer disparities

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions and population research addressing cancer disparities
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access

2. RATIONALE

The aim of this award mechanism is to bolster cancer research in Texas by providing financial support to attract very promising investigators who are pursuing their first faculty appointment at the level of assistant professor (first-time, tenure-track faculty members). These individuals must have demonstrated academic excellence, innovation during predoctoral and/or postdoctoral research training, commitment to pursuing cancer research, and exceptional potential for achieving future impact in basic, translational, population-based, or clinical research. Awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research, thereby advancing cancer research and prevention efforts, and promoting economic development in the State of Texas.

The recruitment of outstanding scientists will greatly enhance programs of scientific excellence in cancer research and will position Texas as a leader in the fight against cancer. Applications may address any research topic related to cancer biology, causation, prevention, detection or screening, treatment, or survivorship. Principal Investigators (PIs) with research programs addressing CPRIT's priority areas for research are encouraged. These include implementation research to accelerate the adoption and deployment of evidence-based prevention and screening

interventions, computational oncology and analytic methods, research including population-based research addressing cancer disparities, childhood and adolescent cancers, hepatocellular cancer, and expansion of access to innovative clinical trials.

3. RECRUITMENT OBJECTIVES

The goal of this award mechanism is to recruit exceptional faculty to universities and/or cancer research institutions in the State of Texas. All PIs are expected to have completed their doctoral and fellowship training and to have clearly demonstrated truly superior ability as evidenced by their accomplishments during training, proposed research plan, publication record, and letters of recommendation. This CPRIT-supported initiative is designed to enhance innovative programs of excellence by providing research support for promising, early-stage investigators **seeking their first tenure-track position.**

CPRIT will provide start-up funding for newly independent investigators, with the goal of augmenting and expanding the institution's efforts in cancer research. PIs will be expected to develop research projects within the sponsoring institution. Projects should be appropriate for a newly independent investigator and should foster the development of preliminary data that can be used to prepare applications for future independent research project grants to further both the investigator's research career and the CPRIT mission. The institution will be expected to work with each newly recruited research faculty member to design and execute a faculty career development plan consistent with his or her research emphasis. Relevance to cancer research and to CPRIT's priority areas are important evaluation criteria for CPRIT funding.

Applications nominating individuals who are well prepared to pursue careers in patient-oriented research and who have demonstrated exceptional potential to lead innovative discovery campaigns through conduct of clinical trials are appropriate for this mechanism and are encouraged.

Additionally, population research that addresses the burden of cancer in Texas is a priority for CPRIT. Applications nominating individuals who have demonstrated exceptional ability to lead innovative research programs involving any component across the continuum of cancer prevention and control research are appropriate for this mechanism and are highly encouraged.

Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of “CPRIT Scholar in Cancer Research,” and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

4. INSTITUTIONAL COMMITMENT

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world’s best talent in cancer research to Texas. The funds provided by CPRIT for the Recruitment of a First-Time, Tenure-Track Faculty Member (RFTTFM) Award must therefore be complemented by a strong institutional commitment to the PI’s career development that includes financial commitments that are in addition to the CPRIT award. The institutional commitment should be clearly documented in the application (see [section 8.2.5](#)) and include the amount and sources of salary support and all additional financial support that will be available to the PI’s research program through the course of the CPRIT award. The financial commitments made to the PI for his or her research program by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

5. FUNDING INFORMATION

This award is up to 5 years and is not renewable, although individuals may apply for other future CPRIT funding as appropriate. Grant funds of up to \$2,000,000 (total costs) for the 5-year period may be requested. Applicants are encouraged to tailor the budget as appropriate to the exigencies of the project; grant funds totaling less than \$2,000,000 for the term of the award are acceptable if warranted by the scope of the research. Funding is to be used by the PI to support his or her research program. The award request may include indirect costs of up to 5% of the total award amount (5.263% of the direct costs). CPRIT will make every effort to be flexible in the timing for disbursement of funds; recipients will be asked at the beginning of each year for an estimate of their needs for the year. Funds may not be carried over beyond 5 years except under extraordinary circumstances with strong justification for a no-cost extension. In addition, funds for extraordinary equipment needs may be awarded in the first year of the grant if very well justified and a detailed justification is provided along with an institutional plan should the

additional funds not be approved. Scholars may request funds for travel for 2 project staff to attend CPRIT's conference.

Funds from this CPRIT award may not be used for salary support of this PI or to construct or renovate laboratory space.

Note: In the event of insufficient funds, specific recruitment categories may be eliminated (example REI/RRS/RFTTFM) and nominations for specific categories may be closed for the remaining cycles of the fiscal year. Additionally, depending on the availability of funds, review cycles may be reduced, and/or the number of applications per institution may be capped, and recommended nominations submitted in response to this Request for Applications (RFA) during the current receipt period may be announced and awarded either in the current fiscal year (prior to August 31, 2024) or in the first quarter of the next fiscal year (starting September 1, 2024).

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism.
- PIs must be nominated by the president, provost, vice president for research, or appropriate dean of a Texas-based public or private institution of higher education, including academic health institutions. The application must be submitted on behalf of a specific PI.
- A PI may be nominated by only 1 institution. If more than 1 institution is interested in a given PI, negotiations as to which institution will nominate him or her must be concluded before the nomination is made.
- No annual limit on the number of grant submissions by institutions has been set.
- A PI who has already accepted a position as a tenure-track assistant professor at the recruiting institution prior to the time that the Scientific Review Council reviews the PI for a recruitment award is not eligible for a recruitment award, as an investment by CPRIT is obviously not necessary. No award is final until approved by the Oversight Committee at a public meeting. However, in recognition of the timeline involved with recruiting highly sought-after PIs who are often considering multiple offers, CPRIT's Academic Research program staff will notify the nominating institution of the Scientific

Review Council's review decision following the Scientific Review Council meeting. If a position is offered to the PI during the period following the Scientific Review Council's review decision but prior to the Oversight Committee's final approval, the institution does so at its own risk. There is no guarantee that the recruitment award will be approved by the Oversight Committee.

- The PI must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, **and reside in Texas for the duration of the appointment.** The PI must devote at least 70% time to research activities. PIs whose major responsibilities are clinical care, teaching, or administration are not eligible.
- At the time of the application, the PI must **not** hold an appointment at the rank of assistant professor or above (or equivalent) at an accredited academic institution, research institution, industry, government agency, or private foundation. PIs holding non-tenure-track appointments at the rank of assistant professor are **not** eligible for this award. Examples of such appointments include research assistant professor, adjunct research assistant professor, assistant professor (non-tenure track).
- The PI may or may not reside in Texas at the time the application is submitted and may be nominated for a faculty position at the Texas institution where he or she is completing postdoctoral training or at another Texas institution.
- Applications nominating a PI for a faculty position at the Texas institution where he or she is completing postdoctoral training that do not clearly demonstrate a subsequent career pathway to independence for the PI will not be looked upon with favor.
- Successful PIs will be offered tenure-track academic positions at the rank of assistant professor.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant nominator, any senior member, or key personnel listed on the grant application, or any officer or

director of the grant applicant's institution or organization is related to a CPRIT Oversight Committee member.

- The applicant must report whether the applicant institution or organization, the nominator, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not the individuals will receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.

CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 11](#) and [section 12](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

Resubmissions will not be accepted for the RFTTFM Award mechanism. Any nomination for the RFTTFM Award that was previously submitted to CPRIT and reviewed but was not recommended for funding may not be resubmitted. If a nomination was administratively rejected prior to review, it can be resubmitted in the following cycles.

8. RESPONDING TO THIS RFA

8.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application is submitted. PIs must be nominated by the institution's president, provost, vice president for research, or appropriate dean. The individual submitting the application (nominator) must create a user account in the system

(which includes the nominator's credentials and email address) to start and submit an application. Furthermore, the Application Signing Official, who is the person authorized to sign and submit the application for the organization, and the Grants Contract/Office of Sponsored Projects Official, who is the individual who will manage the grant contract if an award is made, also must create a user account in CARS.

Dependent upon available funding, applications will be accepted on a continuous basis throughout FY24.

In order to manage the timely review of nominations, it is anticipated that applications submitted by 11:59 PM central time on the 20th of each month and will be reviewed by the 15th day of the following month. For an application to be considered for review during the cycle, that application must be submitted on or before 11:59 PM central time. In the event that the closing date falls on Saturday or Sunday, applications may be submitted on or before 11:59 PM central time the following Monday. CPRIT will not extend the submission deadline. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

8.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. For details, please refer to the Instructions for Applicants (IFA) document that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

8.2.1. Summary of Nomination (2,000 characters)

Provide a brief summary of the nomination. Include the PI's name, organization from which the PI is being recruited, and also the department and/or entity within the nominator's organization where the PI will hold the faculty position.

8.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. **This section must be completed by the PI.** Describe, in simple, nontechnical terms, the overall aims of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detection, prevention, treatment, or survivorship.

The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. Do not include any proprietary information in the layperson's summary.

8.2.3. Summary of Specific Aims and Sub Aims (2,000 characters)

Please provide a summary of the aims of the proposal. **This section must be completed by the PI.** The specific aims summary should identify the problem or gap in our current knowledge. It should present a hypothesis and briefly describe the aims and approaches and address the proposal's innovation, novel approaches, and significance and impact on the field and cancer research.

8.2.4. Specific Aims and Sub Aims

List specific aims and sub aims to be achieved during this award. **This section must be completed by the PI.** These aims/sub aims will also be used during the submission and evaluation of progress reports and assessment of project success. Refer to the template specific aims and sub aims document located in [Current Funding Opportunities](#) for Academic Research in CARS.

8.2.5. Institutional Commitment (3 pages)

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research to Texas. The funds provided by CPRIT for the RFTTFM Award must therefore be complemented by a strongly documented institutional commitment to the PI's career development that includes financial commitments that are in addition to the CPRIT award.

The following guidelines should be followed when documenting the institutional commitment to the PI:

- The institutional commitment should be clearly documented in the form of a letter signed by the applicant institution's president, provost, or appropriate dean and include the amount and sources of salary support and all additional financial support that will be available to the PI's research program through the course of the CPRIT award. The financial commitments made to the PI by the recruiting institution are required to be

equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

- The institutional commitment letter must include the following statement regarding the institution's financial commitment required to meet the 50% match.
 - This institutional financial commitment will not be offset by funds from a career transition award (K99/R00) or an investigator-initiated award received by the PI. If an award dictates that such funds must be used for salary, the corresponding amount of institutional funds committed to pay the PI's salary will be redirected to allow the PI to use them for program support.
- Institutional commitment as described above must be presented in a table (example below) that clearly identifies the salary amount, sources of salary, and any additional research support from institutional sources over the course of the CPRIT award. Sources of support for the PI's full salary, including summer salary, for the duration of the award must be documented. If the PI is expected to provide salary support from grants during the award period, the institutional commitment must identify the source for salary support in the event grant support is not available. Note that a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the PI.
- Include a brief job description for the PI should recruitment be successful.
- Describe the institutional environment and any professional commitments to the PI including, but not limited to, dedicated personnel, access to students, space assignment, and access to shared equipment, and discuss all other agreements between the institution and the PI.
- Institutions may provide additional information in support of a PI's research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a PI's cancer research. This additional information is highly encouraged when proposing a PI with exceptional expertise and/or talent that can be directed to cancer research such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research.
- Note that Texas law allows an institution of higher learning to use its federal indirect cost rate credit to comply with the requirement to demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the

award (see [section 12](#)). However, a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the PI.

Example of an acceptable Institutional Commitment table:

PI's Name, Institutional Commitments

| | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|------------------------|--------|--------|--------|--------|--------|
| Salary/Benefits | | | | | |
| Research Support | | | | | |
| Administrative Support | | | | | |
| Moving Expenses | | | | | |

Total =

Note: CPRIT acknowledges that the institutional commitments by category may change during the course of the award; however, the total financial commitment to the PI must remain equal to or greater than 50% of the CPRIT award.

8.2.6. Letter of Support from Department Chair (up to 2 pages)

Provide the letter of support from and signed by the chair of the department to which the PI is being recruited. The following information should be included in the letter:

Recruitment Activities: CPRIT is committed to increasing the life sciences infrastructure in Texas via the recruitment of exceptional cancer researchers, as well as expanding research resources. The letter should provide a description of the recruitment activities, strategies, and priorities that have led to the nomination of this PI. Provide the necessary context by describing the institution’s vision for the cancer programs, how the work of the nominee contributes to achieving these goals—including impact on diversity, equity, and inclusion, if applicable—and the expected impact of the recruitment on the institution (or department) and the burden of cancer in Texas (if applicable).

Caliber of PI: The letter should include a description of the caliber of the PI and justification of the nomination of the PI by the institution. CPRIT recognizes that there is variability in the metrics of impact applicable across the continuum of cancer research. For example, in some disciplines, research findings—although highly impactful on the field—are less likely to be published in the highest ranked journals, ie, *Science*, *Cell*, or *Nature* series. Thus, it is incumbent

upon the institution to describe the impact of a nominee's work, including paradigm-shifting, practice-changing, or influence on public policy, population health behavior, or cancer disparities.

Description of PI Duties and Certification of 70% Time Commitment to Research: While scholars may engage in direct patient care activities and/or have some administrative or teaching duties, at least 70% of the PI's time must be available for research. Breach of this requirement will constitute grounds for discontinuation of funding. The certification that 70% time will be spent on research must be included.

The letter of support from the department chair must also do the following:

1. Describe how the PI will be independent and autonomous in developing his or her research program at the institution.
2. Present a plan for mentoring that includes the design and execution of a faculty career development plan for the PI.

8.2.7. Curriculum Vitae (CV)

Provide a complete CV and list of publications for the PI. Only articles that have been published or that have been accepted for publication ("in press") should be cited.

8.2.8. Research (4 pages)

Summarize the key elements of the PI's research accomplishments and provide an overview of the proposed research by outlining the background and rationale, hypotheses and aims, strategies, specific aims, and projected impact of the focus of the research program. Highlight the innovative aspects of this effort and place it into context with regard to what pressing problem in cancer will be addressed. **This section of the application must be prepared by the PI. References cited in this section should be included in the Publications/References section (see 8.2.9).**

PIs for CPRIT Scholar Awards must include the following signed statement at the end of this section. **Applications that do not contain this signed statement will be returned without review.**

“I understand that I do not need to have made a commitment to *<nominating institution>* before this application has been submitted. However, I also understand that only 1 Texas institution may nominate me for a CPRIT Recruitment Award, and this is the nomination that I have endorsed. I understand that requests to change the recruiting institution during the recruitment process are not allowed after the application is submitted to CPRIT.”

8.2.9. Publications/References (1 page)

Provide a concise and relevant list of publications/references cited in the Research section of the application. Any appropriate citation format is acceptable; official journal abbreviations should be used.

8.2.10. Research Collaboration/Synergy Plan (2 pages)

Institutions may provide additional information in support of a PI’s research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a PI’s cancer research. This additional information is highly encouraged when proposing a PI with exceptional expertise and/or talent that can be directed to cancer research, such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research. Biographical sketches of collaborators established in the research collaborative plan must be uploaded as part of the application. This will be in addition to the 2-page synergy plan (see IFA).

8.2.11. Publications

Provide the 3 most significant publications that have resulted from the PI’s research efforts. Publications should be uploaded as PDFs of full-text articles. Only articles that have been published or that have been accepted for publication (“in press”) should be submitted.

8.2.12. Timeline (1 page)

Provide a general outline of anticipated major award outcomes to be tracked. Timelines will be reviewed during the evaluation of annual progress reports. If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

8.2.13. Current and Pending Support

State the funding source, duration, and title of all current and pending research support held by the PI. If the PI has no current or pending funding, a document stating this must be submitted. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

8.2.14. Letters of Recommendation

Provide 3 letters of recommendation from individuals who are in a position to detail the PI's academic and scientific research accomplishments, potential for high-impact research, and ability to make a significant contribution to the field of cancer research.

8.2.15. Research Environment (1 page)

Clearly and concisely describe the research environment available to support the PI's research program, including core facilities, training programs, and collaborative opportunities.

8.2.16. Descriptive Biography (Up to 2 pages)

Provide a brief descriptive biography of the PI, including his or her accomplishments, education and training, professional experience, awards and honors, publications relevant to cancer research, and a brief overview of the PI's specific aims, if selected, to receive the award. **This section of the application must be prepared by the PI.** If the application is approved for funding, this section will be made publicly available on CPRIT's website. PIs are advised not to include information that they consider confidential or proprietary when preparing this section.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or do not meet the eligibility requirements listed above will be administratively withdrawn without review.

9. APPLICATION REVIEW

9.1. Review Process

All eligible applications will be evaluated and scored by the CPRIT Scientific Review Council using the criteria listed in this RFA. Applications may be submitted continuously in response to this RFA but will generally be reviewed on a monthly basis by the CPRIT Scientific Review

Council. Council members may seek additional ad hoc evaluations of PIs. Scientific Review Council members will review applications and provide an individual Overall Evaluation Score that conveys the members' recommendation related to the proposed recruitment. Applications recommended by the Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review, prioritization, and recommendation to the CPRIT Oversight Committee for approval and funding. Approval is based on an application receiving a positive vote from at least two-thirds of the members of the Oversight Committee. The review process is described more fully in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

The decision of the Scientific Review Council not to recommend an application is final, and such applications may not be resubmitted for a recruitment award. Notification of review decisions is sent to the nominator.

9.1.1. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Review Council members are non-Texas residents.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed conflict of interest as set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, or a Scientific Review Council member.

Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer,

and the Commissioner of the Department of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant applicant from further consideration for a grant award.

9.2. Review Criteria

Applications will be assessed based on evaluation of the quality of the PI and his or her potential for continued superb performance as a cancer researcher. **Also, of critical importance is the strength of the institutional commitment to the PI. Recruitment efforts are not likely to be successful unless there is a strong commitment from both CPRIT and the host institution.** It is not necessary that a PI agrees to accept the recruitment offer at the time an application is submitted. However, applicant institutions should have an expectation that the recruitment will be successful if an award is granted by CPRIT. It is the expectation that the nominating institution provides CPRIT with a status of the award acceptance as soon as status is known.

Review criteria will focus on the overall impression of the PI, his or her proposed research program, and his or her long-term potential for contributions to, and impact on, the field of cancer research. Questions to be considered by the reviewers are as follows:

Quality of the PI: Has the PI demonstrated academic excellence? Has the PI received excellent predoctoral and postdoctoral training? Does the PI show exceptional potential for achieving future impact on basic, translational, clinical, or population-based cancer research in the future? Has the PI demonstrated a commitment to cancer research? Has the PI demonstrated independence or the potential for independence?

Scientific Merit of Proposed Research: Is the research plan comprehensive and well thought out? Does the proposed research program demonstrate innovation, creativity, and feasibility? Will it have a significant impact on the field of cancer research? Will the proposed research generate preliminary data that can be used for the preparation of applications for future independent research project grants?

Relevance of PI's Research: Is the proposed research likely to have a significant impact on reducing the burden of cancer in the near term or address unique aspects of the burden of cancer

in Texas? Does the research contribute to basic, translational, clinical, or population-based cancer research?

Letters of Recommendation: Do the letters of recommendation detail the PI's academic and clinical research accomplishments, potential for high-impact research, and ability to make a significant contribution to the field of cancer research?

Research Environment: Does the institution have the necessary facilities, expertise, and resources to support the PI's research? Is there evidence of strong institutional support? Will the PI be free of major administrative/clinical responsibilities so that he or she can focus on growing his or her research? Has the institution identified a mentor who will design and execute a faculty career development plan for the PI?

10. KEY DATES

RFA

RFA Release June 21, 2023

11. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Awards made under this RFA are not transferable to another institution. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov.

Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the specific aims and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. CPRIT requires funding acknowledgement to include the award grant ID on all print and visual materials that are funded in whole or in part by CPRIT grants. Examples of print and visual materials include, but are not limited to, publications, brochures, pamphlets, project websites, videos, and media materials. Grantees must have written approval from CPRIT prior to the purchase of any equipment. If the equipment is clearly defined in the grantee's budget submitted with the initiating award requirements, then approval of the grant award constitutes "prior approval" for the purchase. Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of "CPRIT Scholar in Cancer Research," and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must

be made at the time the award contract is executed and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#), for specific requirements regarding the demonstration of available funding.

13. CONTACT INFORMATION

13.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff members are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

13.2. Scientific and Programmatic Questions

Questions regarding the CPRIT Program, including questions regarding this or other funding opportunities, should be directed to the CPRIT Director of Academic Research.

Email: Research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)
Academic Research Review Panel – Recruitment Review
Panel 24.3-4 (REC 24.3-4)
Observation Report

Report No. 2023-11-16 REC_24.3-4
Program Name: Academic Research
Panel Name: Academic Research Review Panel – Recruitment Review Panel
24.3-4 (REC_24.3-4)
Panel Date: November 16, 2023
Report Date: November 17, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the Academic Research Review Panel – Recruitment Review Panel 24.3-4 (REC_24.3-4) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on November 16, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer(s) participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Nine (9) applications were discussed
- Panelists: One (1) panel chair, and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Three (3)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.5 Academic Research Recruitment Review Panel (24.5

REC) Observation Report

Report No. 2023-12-14 24.5_REC
Program Name: Academic Research
Panel Name: 24.5 Academic Research Recruitment Review Panel (24.5 _REC)
Panel Date: December 14, 2023
Report Date: January 17, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.5 Academic Research Recruitment Review Panel (24.5_REC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 14, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Five (5) applications were discussed; one (1) application was provisionally approved in the 24.3-4_REC meeting
- Panelists: One (1) panel chair, and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COIs) identified prior to the meeting. However, application RR240007 from 24.3-4_REC was discussed during this meeting. No additional information pertaining to COIs or the discussion of this application was received prior to, during or after the meeting. Please note, 24.3-4_REC meeting information indicated no COI's existed for this application, and panel members were the same for both meetings.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Recruitment Cycles 24.3-24.5

Awards Announced at the February 21, 2024, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Recruitment Cycles 24.3 through 24.5 include: *Recruitment of Established Investigators*, *Recruitment of First-Time, Tenure-Track Faculty Members*; and *Recruitment of Rising Stars*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|--|------------------------|--------------|----------------------------|
| Applications considered by the PIC and Oversight Committee: | | | |
| No reported COIs. | | | |
| Applications not considered by the PIC and Oversight Committee: | | | |
| No reported COIs. | | | |

De-Identified Overall Evaluation Scores

Recruitment of First-Time, Tenure-Track Faculty Members

Academic Research Recruitment Cycles 24.3-24.5

| Application ID | Final Overall Evaluation Score |
|----------------|--------------------------------|
| RR240013* | 1.2 |
| RR240016* | 1.3 |
| RR240027* | 1.4 |
| ab | 3.8 |

* Recommended for funding.

Final Overall Evaluation Scores and Rank Order Scores

UC San Diego

SCHOOL OF MEDICINE

January 3, 2024

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Dr. Cummings and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Individual Investigator Research Awards, Individual Investigator Research Awards for Childhood and Adolescent Cancers, Individual Investigator Research Awards for Computational Systems Biology of Cancer, Individual Investigator Research Awards for Clinical Translation, Individual Investigator Research Awards for Prevention and Early Detection, Recruitment of Established Investigators, Recruitment of Rising Stars and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on December 14, 2023 to consider the FY24.1 applications recommended by the peer review panels following their meetings held October 11, 2023 to October 20, 2023. The SRC met on November 16, 2023 to review recruitment applications submitted for Cycle FY24.3-4 and then on December 14, 2023 to review recruitment applications submitted for Cycle FY24.5.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$83,180,142.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

| Recommended for Funding by Mechanism (Ranked by Overall Score) | | | | | | | |
|--|----------|-----------------|-----------------------|---|-----------------|--|--------------------|
| Rank | ID | Award Mechanism | Meeting Overall Score | Application Title | PI | PI Organization | Recommended Budget |
| 1 | RP240068 | IIRA | 1.0 | Understanding the Mechanism of Linker Histone Mutations in Malignancy | Soshnev, Alexey | The University of Texas at San Antonio | \$997,770 |
| 2 | RP240293 | IIRACSBC | 1.0 | Therapeutic Vulnerabilities and Predictors of Response to Chemo(immuno)therapy in Patients With High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC) | Korkut, Anil | The University of Texas M. D. Anderson Cancer Center | \$1,199,999 |
| 3 | RR240019 | RRS | 1.0 | Development of Chemotherapeutics Inspired by Natural Products | Sarlah, David | Rice University | 4,000,000.00 |
| 4 | RP240137 | IIRACSBC | 1.1 | Charting TCR-Tumor Antigen Interactions to Foster Novel Immunotherapeutic Approaches for Triple-Negative Breast Cancer | Zhang, Bing | Baylor College of Medicine | \$1,200,000 |
| 5 | RR240013 | RFTFM | 1.2 | Regulation of gene expression and tumorigenesis by ubiquitin-mediated protein quality control | Mark, Kevin | The University of Texas Southwestern Medical Center | 2,000,000.00 |
| 6 | RR240016 | RFTFM | 1.3 | Impact of Germline Variants on Pediatric Leukemia Progression: Insights from 3D Chromatin Remodeling and Clinical Outcomes | Luan, Yu | The University of Texas Health Science Center at San Antonio | 2,000,000.00 |
| 7 | RR240030 | REI | 1.3 | Break-induced DNA Replication as a Driver of Genomic Instability in Cancer | Malkova, Anna | The University of Texas Health Science Center at San Antonio | 6,000,000.00 |
| 8 | RR240027 | RFTFM | 1.4 | Genomic and Epigenomic Mechanisms of Chemobrain | Dileep, Vishnu | Baylor College of Medicine | 2,000,000.00 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|-----------------------|--|-------------|
| 9 | RP240075 | IIRACT | 1.5 | Combination Therapy Using ATRA and Carfilzomib to Treat Proteasome Inhibitor Refractory Multiple Myeloma | Yi, Qing | The Methodist Hospital Research Institute | \$1,921,388 |
| 10 | RP240291 | IIRA | 1.6 | Targeting MYCN disruption of the molecular clock and tumor metabolism in neuroblastoma oncogenesis. | Barbieri, Eveline | Baylor College of Medicine | \$1,050,000 |
| 11 | RP240289 | IIRA | 1.6 | Real-time, label-free, micro HSI device and transformer-based attention networks for oral cancer imaging | Fei, Baowei | The University of Texas at Dallas | \$1,049,806 |
| 12 | RP240125 | IIRA | 1.8 | Immune-Related Determinants of HPV-Associated Oropharyngeal Cancer Outcomes | Li, Guojun | The University of Texas M. D. Anderson Cancer Center | \$1,049,726 |
| 13 | RP240061 | IIRA | 1.8 | Deciphering Iron Redox Cycles in Ferroptosis-based Cancer Therapy | Lu, Yi | The University of Texas at Austin | \$1,044,608 |
| 14 | RP240091 | IIRA | 1.9 | High resolution high sensitivity photoacoustic imaging molecular guided brain tumor surgery with pilot clinical deployment | Valdes Quevedo, Pablo | The University of Texas Medical Branch at Galveston | \$1,044,967 |
| 15 | RP240401 | IIRACCA | 1.9 | Lead Optimization, Target Engagement, and Efficacy Studies of Locally Bioavailable COX-2 inhibitors for Preventing Colon Cancer Progression in FAP Children | Hu, Ming | University of Houston | \$1,400,000 |
| 16 | RP240272 | IIRACCA | 1.9 | The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy for DSRCT | Ludwig, Joseph | The University of Texas M. D. Anderson Cancer Center | \$1,398,788 |
| 17 | RP240184 | IIRACT | 1.9 | Maximizing Antitumor Immunity Through Simultaneous Activation of the Innate and Adaptive Immune System | Hannan, Raquibul | The University of Texas Southwestern Medical Center | \$1,999,993 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|-------------------|--|-------------|
| 18 | RP240095 | IIRA | 2.0 | Targeting chitinase-3-like-1 as a novel therapy for hepatocellular carcinoma | ju, Cynthia | The University of Texas Health Science Center at Houston | \$1,049,388 |
| 19 | RP240035 | IIRA | 2.0 | Harnessing the metabolic dependencies of mitochondrial NADK2 as a therapeutic strategy for lung cancer | Hoxhaj, Gerta | The University of Texas Southwestern Medical Center | \$1,050,000 |
| 20 | RP240225 | IIRA | 2.0 | PARP16-mediated Ribosome MARYlation and Translation Control in Ovarian Cancer | Kraus, W. Lee | The University of Texas Southwestern Medical Center | \$1,049,743 |
| 21 | RP240259 | IIRA | 2.0 | Targeting Cancer-associated Lactobacillus iners to improve response to cancer therapy | Colbert, Lauren | MDACC/BLI | \$1,049,427 |
| 22 | RP240119 | IIRA | 2.0 | Integrating proteolysis-targeting capability into antibodies to augment therapeutic efficacy | Liu, Qingyun | The University of Texas Health Science Center at Houston | \$1,050,000 |
| 23 | RP240326 | IIRA | 2.0 | Translation of gut commensal bacteria peptidoglycan remodeling pathway for chimeric antigen receptor T-cell therapy | Saini, Neeraj | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 24 | RP240311 | IIRA | 2.0 | Treatment planning of ADC therapy for ovarian cancer with molecular photoacoustic-ultrasonic imaging | Bouchard, Richard | The University of Texas M. D. Anderson Cancer Center | \$1,049,859 |
| 25 | RP240117 | IIRA | 2.0 | Identify radiopathomics markers to guide immunotherapy for non-small cell lung cancer | Wu, Jia | The University of Texas M. D. Anderson Cancer Center | \$1,049,906 |
| 26 | RP240054 | IIRACCA | 2.0 | Myeloid Support of Refractory and Aggressive T-ALL at Distinct Tumor Sites | Ehrlich, Lauren | The University of Texas at Austin | \$1,400,000 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|---------------------|--|--------------|
| 27 | RP240237 | IIRACCA | 2.0 | The Role of EWSR1-FLI1-CENP-A Signaling in Chemoresistance in Ewing Sarcoma | Kitagawa, Katsumi | The University of Texas Health Science Center at San Antonio | \$1,400,000 |
| 28 | RR240015 | RRS | 2.0 | HyperGlio - New tools to fight brain cancer with signal-enhanced magnetic resonance | Gloeggler, Stephan | The University of Texas Southwestern Medical Center | 4,000,000.00 |
| 29 | RR240021 | RRS | 2.0 | Expansion and Single-cell Interrogation of Tumoroid Models for Precise Treatment of Diverse Rectal Cancer Patient Populations | Smith, Jesse Joshua | The University of Texas Southwestern Medical Center | 4,000,000.00 |
| 30 | RP240183 | IIRA | 2.1 | Restoring TREM2-Dependent Efferocytosis to Inhibit Obesity-Induced Liver Inflammation and Cancer Development | Liang, Shuang | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 31 | RP240263 | IIRA | 2.1 | Identifying the Biological Determinants of Aggressive Meningioma | Patel, Akash | Baylor College of Medicine | \$1,049,370 |
| 32 | RP240392 | IIRA | 2.1 | Identifying Tumor Specific Vulnerabilities in Appendiceal Adenocarcinoma: A Systems Approach | Shen, John Paul | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 33 | RP240133 | IIRA | 2.1 | Modulation of blood-spinal cord barrier for tumor treatment | Qin, Zhenpeng | The University of Texas at Dallas | \$1,050,000 |
| 34 | RP240233 | IIRACT | 2.1 | Toward Nonoperative Management of Early-Stage ER-Positive Breast Cancer | Rahimi, Asal | The University of Texas Southwestern Medical Center | \$1,999,963 |
| 35 | RP240127 | IIRA | 2.2 | Transposon Restriction, Tumor Suppression and p53 | Abrams, John | The University of Texas Southwestern Medical Center | \$1,039,356 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|----------|-----|---|------------------|--|--------------|
| 36 | RP240072 | IIRA | 2.2 | Dissection of CAMKK2's Tumor Cell-intrinsic and -extrinsic Roles in Prostate Cancer | Frigo, Daniel | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 37 | RP240288 | IIRA | 2.3 | Epigenetic mechanism and targeting during response to BRAFi/anti-EGFR therapy in BRAF-mutant colorectal cancers | Kopetz, Scott | The University of Texas M. D. Anderson Cancer Center | \$1,043,909 |
| 38 | RP240380 | IIRA | 2.3 | Clonal hematopoiesis for improving lung cancer risk assessment | Cheng, Chao | Baylor College of Medicine | \$1,040,316 |
| 39 | RP240131 | IIRACSBC | 2.3 | Computational Methods for CRISPR-Based Lineage Tracing Systems | Liu, Zhandong | Baylor College of Medicine | \$1,200,000 |
| 40 | RR240007 | REI | 2.3 | Building a multi-modal platform to enable next-generation functional precision oncology | Shen, Xiling | The University of Texas M. D. Anderson Cancer Center | 6,000,000.00 |
| 41 | RP240214 | IIRA | 2.5 | Immunoprevention of Breast Cancer Brain Metastasis by Special Dendritic Cell-derived Extracellular Vesicles | Yu, Dihua | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 42 | RP240120 | IIRA | 2.5 | JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC | ZHANG, QING | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 43 | RP240287 | IIRA | 2.5 | Investigating the Impact of Interferon Gamma Signaling on Therapeutic Resistance in Acute Myeloid Leukemia | Abbas, Hussein | The University of Texas M. D. Anderson Cancer Center | \$1,042,256 |
| 44 | RP240104 | IIRA | 2.6 | Characterization and optimization of novel allosteric KRAS inhibitors | Gorfe, Alemayehu | The University of Texas Health Science Center at Houston | \$1,050,000 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego
SCHOOL OF MEDICINE

| | | | | | | | |
|--|----------|---------|-----|---|------------------------|---|-------------|
| 45 | RP240320 | IIRA | 2.6 | Benzothiazepines as first-in-class inhibitors for the ribogenesis factor NVL and evaluation in preclinical colorectal cancer models | De Brabander, Jef | The University of Texas Southwestern Medical Center | \$1,049,754 |
| 46 | RP240143 | IIRACCA | 2.6 | Leveraging Passport for Care in a Telehealth Framework to Improve Equitable Access to Survivorship Services | Gramatges, Maria | Baylor College of Medicine | \$1,399,382 |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| 51 | RP240208 | IIRAP | 2.8 | Unidos Contra el VPH: Screening Accuracy, Preference, and Uptake of HPV Self-Sampling Among Latinxs Along the US-Mexico Border | Calderon-Mora, Jessica | The University of Texas at Austin | \$1,920,007 |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee.

Individual Investigator Research Awards (IIRA)
Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)
Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)
Individual Investigator Research Awards for Clinical Translation (IIRACT)
Individual Investigator Research Awards for Prevention and Early Detection
Recruitment of Established Investigators (REI)
Recruitment of Rising Stars (RRS)
Recruitment of First-Time, Tenure Track Faculty Members (FTTFM)



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit

Supporting Information

Academic Research Recruitment
FY 2024—Cycles 3 through 5
Recruitment of Rising Stars

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS

RFA R-24.1-RRS

Recruitment of Rising Stars

**Please also refer to the Instructions for Applicants document,
which will be posted on June 21, 2023**

Application Receipt Dates:

June 21, 2023-June 20, 2024

FY 2024

Fiscal Year Award Period

September 1, 2023-August 31, 2024

TABLE OF CONTENTS

| | |
|--|-----------|
| 1. ABOUT CPRIT | 4 |
| 1.1. ACADEMIC RESEARCH PROGRAM PRIORITIES | 4 |
| 2. RATIONALE | 5 |
| 3. RECRUITMENT OBJECTIVES | 6 |
| 4. INSTITUTIONAL COMMITMENT | 7 |
| 5. FUNDING INFORMATION | 7 |
| 6. ELIGIBILITY | 8 |
| 7. RESUBMISSION POLICY | 10 |
| 8. RESPONDING TO THIS RFA | 11 |
| 8.1. APPLICATION SUBMISSION GUIDELINES | 11 |
| 8.2. APPLICATION COMPONENTS | 12 |
| 8.2.1. <i>Summary of Nomination (2,500 characters)</i> | 12 |
| 8.2.2. <i>Layperson's Summary (2,000 characters)</i> | 12 |
| 8.2.3. <i>Summary of Specific Aims and Sub Aims (2,000 characters)</i> | 12 |
| 8.2.4. <i>Specific Aims and Sub Aims</i> | 12 |
| 8.2.5. <i>Institutional Commitment (3 pages)</i> | 13 |
| 8.2.6. <i>Letter of Support from Department Chair (up to 2 pages)</i> | 15 |
| 8.2.7. <i>Curriculum Vitae (CV)</i> | 15 |
| 8.2.8. <i>Research (4 pages)</i> | 15 |
| 8.2.9. <i>Publications/References (1 Page)</i> | 16 |
| 8.2.10. <i>Research Collaboration/Synergy Plan (2 pages)</i> | 16 |
| 8.2.11. <i>Publications</i> | 16 |
| 8.2.12. <i>Timeline (1 page)</i> | 17 |
| 8.2.13. <i>Current and Pending Support</i> | 17 |
| 8.2.14. <i>Research Environment (1 page)</i> | 17 |
| 8.2.15. <i>Descriptive Biography (Up to 2 pages)</i> | 17 |
| 9. APPLICATION REVIEW | 18 |
| 9.1. REVIEW PROCESS..... | 18 |
| 9.1.1. <i>Confidentiality of Review</i> | 18 |
| 9.2. REVIEW CRITERIA..... | 19 |
| 10. KEY DATES | 20 |
| 11. AWARD ADMINISTRATION | 20 |
| 12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS | 22 |
| 13. CONTACT INFORMATION | 23 |
| 13.1. HELPDESK..... | 23 |
| 13.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS | 23 |

RFA VERSION HISTORY

6/21/23 RFA release

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas
- Develop and implement the Texas Cancer Plan

1.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

To accomplish CPRIT's long-term vision, the Oversight Committee has identified these 2024 priorities:

- Investing in the cancer research capacity of Texas institutions through recruitment of cancer scholars, investment in core facilities, and investment in individual investigator awards in all regions of the state;
- Building the Texas cancer life science ecosystem across Texas by bridging discovery and translational research into early-stage company products with high impact on cancer patient care and creating economic development for the State of Texas; and
- Increasing the capacity for Texas to have a significant impact on cancer prevention and early detection, ultimately decreasing cancer incidence and mortality.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state

- Reducing cancer disparities

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions and population research addressing cancer disparities.
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access.

2. RATIONALE

The aim of this award mechanism is to bolster cancer research in Texas by providing financial support to attract individuals whose work has outstanding merit, who show a marked capacity for self-direction, and who demonstrate the promise for continued and enhanced contributions to the field of cancer research (“Rising Stars”). Awards are intended to provide institutions with a competitive edge in recruiting the world’s best talent in cancer research, thereby advancing cancer research and prevention efforts, and promoting economic development in the State of Texas.

The recruitment of outstanding scientists will greatly enhance programs of scientific excellence in cancer research and will position Texas as a leader in the fight against cancer. Applications may address any research topic related to cancer biology, causation, prevention, detection or screening, treatment, or survivorship. Principal Investigators (PIs) with research programs addressing CPRIT’s priority areas for research are encouraged. These include implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions, research including population-based research, computational oncology and

analytic methods, childhood and adolescent cancers, hepatocellular cancer, and expansion of access to innovative clinical trials.

3. RECRUITMENT OBJECTIVES

The goal of this award mechanism is to recruit exceptional faculty to universities and/or cancer research institutions in the State of Texas. Having already demonstrated extraordinary accomplishments during their initial years of independent research, Rising Stars represent a unique blend of scholastic aptitude, scientific rigor, and commitment to exploring transformational research through the development of creative ideas with high potential.

PIs who have not historically worked in cancer research but are proposing creative hypotheses and research plans for this field are encouraged to apply. Similarly, PIs pursuing original and potentially high-impact basic science programs that have the potential to be translated toward clinical investigations or provide “proof of principle” are also encouraged to apply. It is expected that the PI will contribute significantly to, and have a major impact on, the institution’s overall cancer research initiative. Funding will be given for exceptional PIs who will continue to develop new research methods and techniques in the life, population-based, physical, engineering, or computational sciences and apply them to solving outstanding problems in cancer research that have been inadequately addressed or for which there may be an absence of an established paradigm or technical framework.

Ideal PIs will have specific expertise in cancer-related areas needed to address an institutional priority. PIs are expected to be approximately at the career level of a late assistant/early associate professor or equivalent. This funding mechanism considers expertise, accomplishments, and breadth of experience vital metrics for guiding CPRIT’s investment in that person’s originality, insight, and potential for continued contribution. Relevance to cancer research and to CPRIT’s priority areas are important evaluation criteria for CPRIT funding.

Applications nominating individuals who carry out patient-oriented research and who have demonstrated exceptional ability to lead innovative discovery campaigns through conduct of clinical trials are appropriate for this mechanism and are encouraged.

Additionally, population research that addresses the burden of cancer in Texas is a priority for CPRIT. Applications nominating individuals who have demonstrated exceptional ability to lead

innovative research programs involving any component across the continuum of cancer prevention and control research are appropriate for this mechanism and are highly encouraged.

Applications that include purposeful collaborations with institutions eligible for a CPRIT Texas Regional Excellence in Cancer Award are highly encouraged.

Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of “CPRIT Scholar in Cancer Research,” and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

4. INSTITUTIONAL COMMITMENT

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world’s best talent in cancer research to Texas. The funds provided by CPRIT for the Recruitment of a Rising Star (RRS) Award must be complemented by a strong institutional commitment to the recruitment. The institutional commitment should be clearly documented in the application (see [section 8.2.5](#)) and include the amount and sources of salary support and all additional financial support that will be available to the PI’s research program through the course of the CPRIT award. The financial commitments made to the PI by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

5. FUNDING INFORMATION

This is a 5-year award and is not renewable. Grant funds of up to \$4,000,000 (total costs) over a 5-year period may be requested. Exceptions to this limit will be entertained only if there is compelling written justification. Annual allocations of this award are at the discretion of the awardee as long as the total award does not exceed \$4,000,000. The award request may include indirect costs of up to 5% of the total award amount (5.263% of the direct costs). CPRIT will make every effort to be flexible in the timing for disbursement of funds; recipients will be asked at the beginning of each year for an estimate of their needs for the year. Funds may not be carried over beyond 5 years except under extraordinary circumstances with strong justification for a no-

cost extension. In addition, funds for extraordinary equipment needs may be awarded in the first year of the grant if very well justified and a detailed justification is provided along with an institutional plan should the additional funds not be approved. Scholars may request funds for travel for 2 project staff to attend CPRIT's conference.

Funds from this award mechanism may be used for salary support of this PI but may not be used to construct or renovate laboratory space.

No annual limit on the number of grant application submissions by institutions has been set.

Note that the annual salary (also referred to as direct salary or institutional base salary) that an individual may be reimbursed from a CPRIT award for FY 2024 is limited to a maximum of \$200,000. In other words, an individual may request salary proportional to the percent of effort up to a maximum of \$200,000. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities.

Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

Note: In the event of insufficient funds, specific recruitment categories may be eliminated (example REI/RRS/RFTTFM) and nominations for specific categories may be closed for the remaining cycles of the fiscal year. Additionally, depending on the availability of funds, review cycles may be reduced, and/or the number of applications per institution may be capped, and recommended nominations submitted in response to this Request for Applications (RFA) during the current receipt period may be announced and awarded either in the current fiscal year (prior to August 31, 2024) or in the first quarter of the next fiscal year (starting September 1, 2024).

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism.
- PIs must be nominated by the president, provost, vice president for research, or appropriate dean of a Texas-based public or private institution of higher education,

including academic health institutions. The application must be submitted on behalf of a specific PI.

- A PI may be nominated by only 1 institution. If more than 1 institution is interested in a given PI, negotiations as to which institution will nominate him or her must be concluded before the nomination is made.
- There is no limit to the number of applications that an institution may submit during a review cycle.
- A PI who has already accepted a position at the recruiting institution prior to the time that the Scientific Review Council reviews the PI for a recruitment award is not eligible for a recruitment award, as an investment by CPRIT is obviously not necessary. No award is final until approved by the Oversight Committee at a public meeting. However, in recognition of the timeline involved with recruiting highly sought-after PIs who are often considering multiple offers, CPRIT's Academic Research program staff will notify the nominating institution of the Scientific Review Council's review decision following the Review Council meeting. If a position is offered to the PI during the period following the Scientific Review Council's review decision but prior to the Oversight Committee's final approval, the institution does so at its own risk. There is no guarantee that the recruitment award will be approved by the Oversight Committee.
- The PI must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, **and reside in Texas for the duration of the appointment**. The PI must devote at least 70% time to research activities. PIs whose major responsibilities are clinical care, teaching, or administration are not eligible.
- At the time of the application, the PI should hold an appointment at the rank of assistant or associate professor tenure track or tenured (or equivalent) at an accredited academic institution, research institution, industry, government agency, or private foundation. The PI **must not** reside in Texas at the time the application is submitted.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within

the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.

- An applicant is not eligible to receive a CPRIT grant award if the applicant nominator, any senior member, or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the nominator, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not the individuals will receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.

CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 11](#) and [section 12](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

Resubmissions will not be accepted for the RRS Award mechanism. Any nomination for the RRS Award that was previously submitted to CPRIT and reviewed but was not recommended for funding may not be resubmitted. A nomination for the RRS Award that was previously submitted to CPRIT for the Recruitment of First-Time, Tenure Track Faculty Member or RRS Award and reviewed and recommended for funding but declined by the PI may be submitted in response to this RFA if the PI meets the eligibility criteria described in [section 6](#) and the application is not in the same fiscal year as the previous application. If a nomination was administratively rejected prior to review, it can be resubmitted in the following cycles.

Applications being resubmitted according to the criteria permitted by this section should be submitted as a new application (refer to the Instructions for Applicants [IFA] for more details).

8. RESPONDING TO THIS RFA

8.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application is submitted. PIs must be nominated by the institution's president, provost, vice president for research, or appropriate dean. The individual submitting the application (nominator) must create a user account in the system (which includes the nominator's credentials and email address) to start and submit an application. Furthermore, the Application Signing Official, who is the person authorized to sign and submit the application for the organization, and the Grants Contract/Office of Sponsored Projects Official, who is the individual who will manage the grant contract if an award is made, also must create a user account in CARS.

Dependent upon available funding, applications will be accepted on a continuous basis throughout FY24.

In order to manage the timely review of nominations, it is anticipated that applications submitted by 11:59 PM central time on the 20th day of each month will be reviewed by the 15th day of the following month. For an application to be considered for review during the monthly cycle, that application must be submitted on or before 11:59 PM central time. In the event that the 20th falls on Saturday or Sunday, applications may be submitted on or before 11:59 PM central time the following Monday. CPRIT will not extend the submission deadline. During periods when CPRIT does not receive an adequate number of applications, the review may be extended into the following month. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

8.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. For details, please refer to the *Instructions for Applicants* document that will be available when the application receipt system opens.

Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

8.2.1. Summary of Nomination (2,500 characters)

Provide a brief summary of the nomination. Include the PI's name, organization from which the PI is being recruited, and also the department and/or entity within the nominator's organization where the PI will hold the faculty position.

8.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. **This section must be completed by the PI.** Describe, in simple, nontechnical terms, the overall aims of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detection, prevention, treatment, or survivorship. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. Do not include any proprietary information in the layperson's summary.

8.2.3. Summary of Specific Aims and Sub Aims (2,000 characters)

Please provide a summary of the aims of the proposal. **This section must be completed by the PI.** The specific aims summary should identify the problem or gap in our current knowledge. It should present a hypothesis and briefly describe the aims and approaches and address the proposal's innovation, novel approaches, and significance and impact on the field and cancer research.

8.2.4. Specific Aims and Sub Aims

List specific aims and sub aims to be achieved during this award. **This section must be completed by the PI.** These aims/sub aims will also be used during the submission and evaluation of progress reports and assessment of project success. Refer to the template for

specific aims and sub aims document located in [Current Funding Opportunities](#) for Academic Research in CARS.

8.2.5. Institutional Commitment (3 pages)

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research to Texas. The funds provided by CPRIT for the recruitment of a Rising Stars PI must be complemented by a strongly documented institutional commitment to the recruitment. The financial commitments made to the PI by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

The following guidelines should be followed when documenting the institutional commitment to the PI:

- The institutional commitment should be clearly documented in the form of a letter signed by the applicant institution's president, provost, or appropriate dean and include the amount and sources of salary support and all additional financial support that will be available to the PI's research program through the course of the CPRIT award. The financial commitments made to the PI by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.
- The institutional commitment letter must include the following statement regarding the institution's financial commitment required to meet the 50% match.
 - This institutional financial commitment will not be offset by funds from an investigator-initiated award received by the PI. If an award dictates that such funds must be used for salary, the corresponding amount of institutional funds committed to pay the PI's salary will be redirected to allow the PI to use them for program support.
- Institutional commitment as described above must be presented in a table (example below), that clearly identifies the salary amount, sources of salary, and any additional research support from institutional sources over the course of the CPRIT award. Sources of support for the PI's full salary, including summer salary, for the duration of the award must be documented. If the PI is expected to provide salary support from grants during

the award period, the institutional commitment must identify the source for salary support in the event grant support is not available. Note that a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the PI.

- Include a brief job description of the PI should recruitment be successful.
- Describe the institutional environment and any professional commitments to the PI including, but not limited to, dedicated personnel, access to students, space assignment, and access to shared equipment, and discuss all other agreements between the institution and the PI.
- Institutions may provide additional information in support of a PI’s research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a PI’s cancer research. This additional information is highly encouraged when proposing a PI with exceptional expertise and/or talent that can be directed to cancer research such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research.
- Note that Texas law allows an institution of higher learning to use its federal indirect cost rate credit to comply with the requirement to demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award (see [section 12](#)). However, a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the PI.

Example of an acceptable Institutional Commitment table:

PI’s Name, Institutional Commitments

| | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|------------------------|--------|--------|--------|--------|--------|
| Salary/Benefits | | | | | |
| Research Support | | | | | |
| Administrative Support | | | | | |
| Moving Expenses | | | | | |

Total =

Note: CPRIT acknowledges that the institutional commitments by category may change during the course of the award; however, the total financial commitment to the PI must remain equal to or greater than 50% of the CPRIT award.

8.2.6. Letter of Support from Department Chair (up to 2 pages)

Provide the letter of support from and signed by the chair of the department to which the PI is being recruited. The following information should be included in the letter:

Recruitment Activities: CPRIT is committed to increasing the life sciences infrastructure in Texas via the recruitment of exceptional cancer researchers, as well as expanding research resources. The letter should provide a description of the recruitment activities, strategies, and priorities that have led to the nomination of this PI. Provide the necessary context by describing the institution's vision for the cancer programs, how the work of the nominee contributes to achieving these goals—including impact on diversity, equity, and inclusion, if applicable—and the expected impact of the recruitment on the institution (or department) and the burden of cancer in Texas (if applicable).

Caliber of PI: The letter should include a description of the caliber of the PI and justification of nomination of the PI by the institution. CPRIT recognizes that there is variability in the metrics of impact applicable across the continuum of cancer research. For example, in some disciplines, research findings—although highly impactful on the field—are less likely to be published in the highest ranked journals, ie, *Science*, *Cell*, or *Nature* series. Thus, it is incumbent on the institution to describe the impact of a nominee's work, including paradigm-shifting, practice-changing, or influence on public policy, population health behavior, or cancer disparities.

Description of PI Duties and Certification of 70% Time Commitment to Research: While scholars may engage in direct patient care activities and/or have some administrative or teaching duties, at least 70% of the PI's time must be available for research. Breach of this requirement will constitute grounds for discontinuation of funding. The certification that 70% time will be spent on research must be included.

8.2.7. Curriculum Vitae (CV)

Provide a complete CV and list of publications for the PI.

8.2.8. Research (4 pages)

Summarize the key elements of the PI's research accomplishments and provide an overview of the proposed research by outlining the background and rationale, hypotheses and aims, strategies, goals, and projected impact of the focus of the research program. Highlight the

innovative aspects of this effort and place it into context with regard to what pressing problem in cancer will be addressed. **This section of the application must be prepared by the PI. References cited in this section should be included in the Publications/References Section (see [8.2.9](#)).**

PIs for CPRIT Scholar Awards must include the following signed statement at the end of this section. **Applications that do not contain this signed statement will be returned without review.**

“I understand that I do not need to have made a commitment to *<nominating institution>* before this application has been submitted. However, I also understand that only 1 Texas institution may nominate me for a CPRIT Recruitment Award, and this is the nomination that I have endorsed. I understand that requests to change the recruiting institution during the recruitment process are not allowed after the application is submitted to CPRIT.”

8.2.9. Publications/References (1 Page)

Provide a concise and relevant list of publications/references cited in the Research section of the application. Any appropriate citation format is acceptable; official journal abbreviations should be used.

8.2.10. Research Collaboration/Synergy Plan (2 pages)

Institutions may provide additional information in support of a PI’s research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a PI’s cancer research. This additional information is highly encouraged when proposing a PI with exceptional expertise and/or talent that can be directed to cancer research, such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research. Biographical sketches of collaborators established in the research collaborative plan must be uploaded as part of the application. This will be in addition to the 2-page synergy plan (see IFA).

8.2.11. Publications

Provide the 5 most significant publications that have resulted from the PI’s research efforts. Publications should be uploaded as PDFs of full-text articles. Only articles that have been published or that have been accepted for publication (“in press”) should be submitted.

8.2.12. Timeline (1 page)

Provide a general outline of anticipated major award outcomes to be tracked. Timelines will be reviewed during the evaluation of annual progress reports. If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

8.2.13. Current and Pending Support

State the funding source, duration, and title of all current and pending research support held by the PI. If the PI has no current or pending funding, a document stating this must be submitted. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

8.2.14. Research Environment (1 page)

Briefly describe the research environment available to support the PI's research program, including core facilities, training programs, and collaborative opportunities.

8.2.15. Descriptive Biography (Up to 2 pages)

Provide a brief descriptive biography of the PI, including his or her accomplishments, education and training, professional experience, awards and honors, publications relevant to cancer research, and a brief overview of the PI's goals if selected to receive the award. **This section of the application must be prepared by the PI.** If the application is approved for funding, this section will be made publicly available on CPRIT's website. PIs are advised not to include information that they consider confidential or proprietary when preparing this section.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or do not meet the eligibility requirements listed above will be administratively withdrawn without review.

9. APPLICATION REVIEW

9.1. Review Process

All eligible applications will be evaluated and scored by the CPRIT Scientific Review Council using the criteria listed in this RFA. Applications may be submitted continuously in response to this RFA but will generally be reviewed on a monthly basis by the CPRIT Scientific Review Council. Council members may seek additional ad hoc evaluations of PIs. Scientific Review Council members will review applications and provide an individual Overall Evaluation Score that conveys the members' recommendation related to the proposed recruitment. Applications recommended by the Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review, prioritization, and recommendation to the CPRIT Oversight Committee for approval and funding. Approval is based on an application receiving a positive vote from at least two-thirds of the members of the Oversight Committee. The review process is described more fully in CPRIT's Administrative Rules, in [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

The decision of the Scientific Review Council not to recommend an application is final, and such applications may not be resubmitted for a recruitment award. Notification of review decisions is sent to the nominator.

9.1.1. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Review Council members are non-Texas residents.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed conflict of interest as set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of the Department of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant applicant from further consideration for a grant award.

9.2. Review Criteria

Applications will be assessed based on evaluation of the quality of the PI and his or her potential for continued superb performance as a cancer researcher. **Also, of critical importance is the strength of the institutional commitment to the PI. Recruitment efforts are not likely to be successful unless there is a strong commitment from CPRIT and the host institution.** It is not necessary that a PI agrees to accept the recruitment offer at the time an application is submitted. However, applicant institutions should have an expectation that the recruitment will be successful if an award is granted by CPRIT. It is the expectation that the nominating institution provides CPRIT with a status of the award acceptance as soon as status is known. Review criteria will focus on the overall impression of the PI, his/her proposed research program, and his/her long-term contribution to, and impact on, the field of cancer research. Questions to be considered by the reviewers are as follows:

Quality of the PI: Has the PI demonstrated extraordinary accomplishments during his or her initial years of independent research? Does the PI show promise of making important contributions with significant impact to basic, translational, clinical, or population-based cancer research in the future? Has the PI demonstrated strong self-direction, motivation, and commitment for transformative cancer research?

Scientific Merit of Proposed Research: Is the research plan comprehensive and well thought out? Does the proposed research program demonstrate innovation, creativity, and feasibility? Will it have a significant impact on the field of cancer research? Will it expand the boundaries of

cancer research beyond traditional methodology by incorporating novel and interdisciplinary techniques?

Relevance of PI's Research: Is the proposed research likely to have a significant impact on reducing the burden of cancer in the near term, or address unique aspects of the burden of cancer in Texas. Does the research contribute to basic, translational, clinical, or population-based cancer research?

Research Environment: Does the institution have the necessary facilities, expertise, and resources to support the PI's research? Is there evidence of strong institutional support? Will the PI be free of major administrative/clinical responsibilities so that he or she can focus on maintaining and enhancing his or her research program? Will the PI be provided with adequate professional development opportunities to grow as a leader?

10. KEY DATES

RFA

RFA Release June 21, 2023

11. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Awards made under this RFA are not transferable to another institution. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract

provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov.

Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research aims and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. CPRIT requires funding acknowledgement to include the award grant ID on all print and visual materials that are funded in whole or in part by CPRIT grants. Examples of print and visual materials include, but are not limited to, publications, brochures, pamphlets, project websites, videos, and media materials. Grantees must have written approval from CPRIT prior to the purchase of any equipment. If the equipment is clearly defined in the grantee's budget submitted with the initiating award requirements, then approval of the grant award constitutes "prior approval" for the purchase. Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of "CPRIT Scholar in Cancer Research," and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must be made at the time the award contract is executed and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, Texas Administrative Code, [Title 25, Chapters 701 to 703](#), for specific requirements regarding the demonstration of available funding.

13. CONTACT INFORMATION

13.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff members are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

13.2. Scientific and Programmatic Questions

Questions regarding the CPRIT Program, including questions regarding this or other funding opportunities, should be directed to the CPRIT Director for Academic Research.

Email: Research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)
Academic Research Review Panel – Recruitment Review
Panel 24.3-4 (REC 24.3-4)
Observation Report

Report No. 2023-11-16 REC_24.3-4
Program Name: Academic Research
Panel Name: Academic Research Review Panel – Recruitment Review Panel
24.3-4 (REC_24.3-4)
Panel Date: November 16, 2023
Report Date: November 17, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the Academic Research Review Panel – Recruitment Review Panel 24.3-4 (REC_24.3-4) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on November 16, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer(s) participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Nine (9) applications were discussed
- Panelists: One (1) panel chair, and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Three (3)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.5 Academic Research Recruitment Review Panel (24.5

REC) Observation Report

Report No. 2023-12-14 24.5_REC
Program Name: Academic Research
Panel Name: 24.5 Academic Research Recruitment Review Panel (24.5 _REC)
Panel Date: December 14, 2023
Report Date: January 17, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.5 Academic Research Recruitment Review Panel (24.5_REC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 14, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Five (5) applications were discussed; one (1) application was provisionally approved in the 24.3-4_REC meeting
- Panelists: One (1) panel chair, and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COIs) identified prior to the meeting. However, application RR240007 from 24.3-4_REC was discussed during this meeting. No additional information pertaining to COIs or the discussion of this application was received prior to, during or after the meeting. Please note, 24.3-4_REC meeting information indicated no COI's existed for this application, and panel members were the same for both meetings.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Recruitment Cycles 24.3-24.5

Awards Announced at the February 21, 2024, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Recruitment Cycles 24.3 through 24.5 include: *Recruitment of Established Investigators*, *Recruitment of First-Time, Tenure-Track Faculty Members*; and *Recruitment of Rising Stars*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|--|------------------------|--------------|----------------------------|
| Applications considered by the PIC and Oversight Committee: | | | |
| No reported COIs. | | | |
| Applications not considered by the PIC and Oversight Committee: | | | |
| No reported COIs. | | | |

De-Identified Overall Evaluation Scores

Recruitment of Rising Stars

Academic Research Recruitment Cycles 24.3-24.5

| Application ID | Final Overall Evaluation Score |
|-----------------------|--------------------------------|
| RR240019* | 1.0 |
| RR240015* | 2.0 |
| RR240021 ^a | 2.0 |
| ac | 3.0 |
| ad | 3.9 |
| ae | 5.0 |

^a The SRC recommended RR240021 for funding; however, the application was withdrawn by the applicant prior to the PIC meeting.

* Recommended for funding.

Final Overall Evaluation Scores and Rank Order Scores

UC San Diego

SCHOOL OF MEDICINE

January 3, 2024

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Dr. Cummings and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Individual Investigator Research Awards, Individual Investigator Research Awards for Childhood and Adolescent Cancers, Individual Investigator Research Awards for Computational Systems Biology of Cancer, Individual Investigator Research Awards for Clinical Translation, Individual Investigator Research Awards for Prevention and Early Detection, Recruitment of Established Investigators, Recruitment of Rising Stars and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on December 14, 2023 to consider the FY24.1 applications recommended by the peer review panels following their meetings held October 11, 2023 to October 20, 2023. The SRC met on November 16, 2023 to review recruitment applications submitted for Cycle FY24.3-4 and then on December 14, 2023 to review recruitment applications submitted for Cycle FY24.5.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$83,180,142.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

| Recommended for Funding by Mechanism (Ranked by Overall Score) | | | | | | | |
|--|----------|-----------------|-----------------------|---|-----------------|--|--------------------|
| Rank | ID | Award Mechanism | Meeting Overall Score | Application Title | PI | PI Organization | Recommended Budget |
| 1 | RP240068 | IIRA | 1.0 | Understanding the Mechanism of Linker Histone Mutations in Malignancy | Soshnev, Alexey | The University of Texas at San Antonio | \$997,770 |
| 2 | RP240293 | IIRACSBC | 1.0 | Therapeutic Vulnerabilities and Predictors of Response to Chemo(immuno)therapy in Patients With High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC) | Korkut, Anil | The University of Texas M. D. Anderson Cancer Center | \$1,199,999 |
| 3 | RR240019 | RRS | 1.0 | Development of Chemotherapeutics Inspired by Natural Products | Sarlah, David | Rice University | 4,000,000.00 |
| 4 | RP240137 | IIRACSBC | 1.1 | Charting TCR-Tumor Antigen Interactions to Foster Novel Immunotherapeutic Approaches for Triple-Negative Breast Cancer | Zhang, Bing | Baylor College of Medicine | \$1,200,000 |
| 5 | RR240013 | RFTFM | 1.2 | Regulation of gene expression and tumorigenesis by ubiquitin-mediated protein quality control | Mark, Kevin | The University of Texas Southwestern Medical Center | 2,000,000.00 |
| 6 | RR240016 | RFTFM | 1.3 | Impact of Germline Variants on Pediatric Leukemia Progression: Insights from 3D Chromatin Remodeling and Clinical Outcomes | Luan, Yu | The University of Texas Health Science Center at San Antonio | 2,000,000.00 |
| 7 | RR240030 | REI | 1.3 | Break-induced DNA Replication as a Driver of Genomic Instability in Cancer | Malkova, Anna | The University of Texas Health Science Center at San Antonio | 6,000,000.00 |
| 8 | RR240027 | RFTFM | 1.4 | Genomic and Epigenomic Mechanisms of Chemobrain | Dileep, Vishnu | Baylor College of Medicine | 2,000,000.00 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|-----------------------|--|-------------|
| 9 | RP240075 | IIRACT | 1.5 | Combination Therapy Using ATRA and Carfilzomib to Treat Proteasome Inhibitor Refractory Multiple Myeloma | Yi, Qing | The Methodist Hospital Research Institute | \$1,921,388 |
| 10 | RP240291 | IIRA | 1.6 | Targeting MYCN disruption of the molecular clock and tumor metabolism in neuroblastoma oncogenesis. | Barbieri, Eveline | Baylor College of Medicine | \$1,050,000 |
| 11 | RP240289 | IIRA | 1.6 | Real-time, label-free, micro HSI device and transformer-based attention networks for oral cancer imaging | Fei, Baowei | The University of Texas at Dallas | \$1,049,806 |
| 12 | RP240125 | IIRA | 1.8 | Immune-Related Determinants of HPV-Associated Oropharyngeal Cancer Outcomes | Li, Guojun | The University of Texas M. D. Anderson Cancer Center | \$1,049,726 |
| 13 | RP240061 | IIRA | 1.8 | Deciphering Iron Redox Cycles in Ferroptosis-based Cancer Therapy | Lu, Yi | The University of Texas at Austin | \$1,044,608 |
| 14 | RP240091 | IIRA | 1.9 | High resolution high sensitivity photoacoustic imaging molecular guided brain tumor surgery with pilot clinical deployment | Valdes Quevedo, Pablo | The University of Texas Medical Branch at Galveston | \$1,044,967 |
| 15 | RP240401 | IIRACCA | 1.9 | Lead Optimization, Target Engagement, and Efficacy Studies of Locally Bioavailable COX-2 inhibitors for Preventing Colon Cancer Progression in FAP Children | Hu, Ming | University of Houston | \$1,400,000 |
| 16 | RP240272 | IIRACCA | 1.9 | The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy for DSRCT | Ludwig, Joseph | The University of Texas M. D. Anderson Cancer Center | \$1,398,788 |
| 17 | RP240184 | IIRACT | 1.9 | Maximizing Antitumor Immunity Through Simultaneous Activation of the Innate and Adaptive Immune System | Hannan, Raquibul | The University of Texas Southwestern Medical Center | \$1,999,993 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660

T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|-------------------|--|-------------|
| 18 | RP240095 | IIRA | 2.0 | Targeting chitinase-3-like-1 as a novel therapy for hepatocellular carcinoma | ju, Cynthia | The University of Texas Health Science Center at Houston | \$1,049,388 |
| 19 | RP240035 | IIRA | 2.0 | Harnessing the metabolic dependencies of mitochondrial NADK2 as a therapeutic strategy for lung cancer | Hoxhaj, Gerta | The University of Texas Southwestern Medical Center | \$1,050,000 |
| 20 | RP240225 | IIRA | 2.0 | PARP16-mediated Ribosome MARYlation and Translation Control in Ovarian Cancer | Kraus, W. Lee | The University of Texas Southwestern Medical Center | \$1,049,743 |
| 21 | RP240259 | IIRA | 2.0 | Targeting Cancer-associated Lactobacillus iners to improve response to cancer therapy | Colbert, Lauren | MDACC/BLI | \$1,049,427 |
| 22 | RP240119 | IIRA | 2.0 | Integrating proteolysis-targeting capability into antibodies to augment therapeutic efficacy | Liu, Qingyun | The University of Texas Health Science Center at Houston | \$1,050,000 |
| 23 | RP240326 | IIRA | 2.0 | Translation of gut commensal bacteria peptidoglycan remodeling pathway for chimeric antigen receptor T-cell therapy | Saini, Neeraj | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 24 | RP240311 | IIRA | 2.0 | Treatment planning of ADC therapy for ovarian cancer with molecular photoacoustic-ultrasonic imaging | Bouchard, Richard | The University of Texas M. D. Anderson Cancer Center | \$1,049,859 |
| 25 | RP240117 | IIRA | 2.0 | Identify radiopathomics markers to guide immunotherapy for non-small cell lung cancer | Wu, Jia | The University of Texas M. D. Anderson Cancer Center | \$1,049,906 |
| 26 | RP240054 | IIRACCA | 2.0 | Myeloid Support of Refractory and Aggressive T-ALL at Distinct Tumor Sites | Ehrlich, Lauren | The University of Texas at Austin | \$1,400,000 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|---------|-----|---|---------------------|--|--------------|
| 27 | RP240237 | IIRACCA | 2.0 | The Role of EWSR1-FLI1-CENP-A Signaling in Chemoresistance in Ewing Sarcoma | Kitagawa, Katsumi | The University of Texas Health Science Center at San Antonio | \$1,400,000 |
| 28 | RR240015 | RRS | 2.0 | HyperGlio - New tools to fight brain cancer with signal-enhanced magnetic resonance | Gloeggler, Stephan | The University of Texas Southwestern Medical Center | 4,000,000.00 |
| 29 | RR240021 | RRS | 2.0 | Expansion and Single-cell Interrogation of Tumoroid Models for Precise Treatment of Diverse Rectal Cancer Patient Populations | Smith, Jesse Joshua | The University of Texas Southwestern Medical Center | 4,000,000.00 |
| 30 | RP240183 | IIRA | 2.1 | Restoring TREM2-Dependent Efferocytosis to Inhibit Obesity-Induced Liver Inflammation and Cancer Development | Liang, Shuang | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 31 | RP240263 | IIRA | 2.1 | Identifying the Biological Determinants of Aggressive Meningioma | Patel, Akash | Baylor College of Medicine | \$1,049,370 |
| 32 | RP240392 | IIRA | 2.1 | Identifying Tumor Specific Vulnerabilities in Appendiceal Adenocarcinoma: A Systems Approach | Shen, John Paul | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 33 | RP240133 | IIRA | 2.1 | Modulation of blood-spinal cord barrier for tumor treatment | Qin, Zhenpeng | The University of Texas at Dallas | \$1,050,000 |
| 34 | RP240233 | IIRACT | 2.1 | Toward Nonoperative Management of Early-Stage ER-Positive Breast Cancer | Rahimi, Asal | The University of Texas Southwestern Medical Center | \$1,999,963 |
| 35 | RP240127 | IIRA | 2.2 | Transposon Restriction, Tumor Suppression and p53 | Abrams, John | The University of Texas Southwestern Medical Center | \$1,039,356 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|----|----------|----------|-----|---|------------------|--|--------------|
| 36 | RP240072 | IIRA | 2.2 | Dissection of CAMKK2's Tumor Cell-intrinsic and -extrinsic Roles in Prostate Cancer | Frigo, Daniel | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 37 | RP240288 | IIRA | 2.3 | Epigenetic mechanism and targeting during response to BRAFi/anti-EGFR therapy in BRAF-mutant colorectal cancers | Kopetz, Scott | The University of Texas M. D. Anderson Cancer Center | \$1,043,909 |
| 38 | RP240380 | IIRA | 2.3 | Clonal hematopoiesis for improving lung cancer risk assessment | Cheng, Chao | Baylor College of Medicine | \$1,040,316 |
| 39 | RP240131 | IIRACSBC | 2.3 | Computational Methods for CRISPR-Based Lineage Tracing Systems | Liu, Zhandong | Baylor College of Medicine | \$1,200,000 |
| 40 | RR240007 | REI | 2.3 | Building a multi-modal platform to enable next-generation functional precision oncology | Shen, Xiling | The University of Texas M. D. Anderson Cancer Center | 6,000,000.00 |
| 41 | RP240214 | IIRA | 2.5 | Immunoprevention of Breast Cancer Brain Metastasis by Special Dendritic Cell-derived Extracellular Vesicles | Yu, Dihua | The University of Texas M. D. Anderson Cancer Center | \$1,050,000 |
| 42 | RP240120 | IIRA | 2.5 | JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC | ZHANG, QING | The University of Texas Southwestern Medical Center | \$1,049,997 |
| 43 | RP240287 | IIRA | 2.5 | Investigating the Impact of Interferon Gamma Signaling on Therapeutic Resistance in Acute Myeloid Leukemia | Abbas, Hussein | The University of Texas M. D. Anderson Cancer Center | \$1,042,256 |
| 44 | RP240104 | IIRA | 2.6 | Characterization and optimization of novel allosteric KRAS inhibitors | Gorfe, Alemayehu | The University of Texas Health Science Center at Houston | \$1,050,000 |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

| | | | | | | | |
|--|----------|---------|-----|---|------------------------|---|-------------|
| 45 | RP240320 | IIRA | 2.6 | Benzothiazepines as first-in-class inhibitors for the ribogenesis factor NVL and evaluation in preclinical colorectal cancer models | De Brabander, Jef | The University of Texas Southwestern Medical Center | \$1,049,754 |
| 46 | RP240143 | IIRACCA | 2.6 | Leveraging Passport for Care in a Telehealth Framework to Improve Equitable Access to Survivorship Services | Gramatges, Maria | Baylor College of Medicine | \$1,399,382 |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |
| 51 | RP240208 | IIRAP | 2.8 | Unidos Contra el VPH: Screening Accuracy, Preference, and Uptake of HPV Self-Sampling Among Latinxs Along the US-Mexico Border | Calderon-Mora, Jessica | The University of Texas at Austin | \$1,920,007 |
| The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee. | | | | | | | |

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
 T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

The Program Integration Committee (PIC) did not recommend this application to the Oversight Committee.

Individual Investigator Research Awards (IIRA)
Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)
Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)
Individual Investigator Research Awards for Clinical Translation (IIRACT)
Individual Investigator Research Awards for Prevention and Early Detection
Recruitment of Established Investigators (REI)
Recruitment of Rising Stars (RRS)
Recruitment of First-Time, Tenure Track Faculty Members (FTTFM)



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240035
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to Basic Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:55 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240035
APPLICATION TITLE: Harnessing the metabolic dependencies of mitochondrial NADK2 as a therapeutic strategy for lung cancer
APPLICANT NAME: Hoxhaj, Gerta
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 24.1 Basic Cancer Research 2 Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/13/2023 | 12/07/2023 | |
| | Method of submission | CARS | 12/07/2023 | |
| | Within receipt period | YES | 12/07/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/07/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/07/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/07/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/07/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/07/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/07/2023 | |
| Primary Reviewer 1 COI signed | | 07/20/2023 | 12/07/2023 | |
| Primary Reviewer 2 COI signed | | 07/21/2023 | 12/07/2023 | |
| Primary Reviewer 3 COI signed | | 07/19/2023 | 12/07/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/07/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/16/2023 | 12/07/2023 | |
| | Primary Reviewer 2 critique submitted | 08/20/2023 | 12/07/2023 | |
| | Primary Reviewer 3 critique submitted | 08/20/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/07/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/07/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/28/2023 | 12/07/2023 | |
| | Recommended for full review | YES | 12/07/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/07/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/05/2023 | 12/07/2023 | |
| | Primary Reviewer 1 COI signed | 09/05/2023 | 12/07/2023 | |
| | Primary Reviewer 2 COI signed | 09/05/2023 | 12/07/2023 | |
| | Primary Reviewer 3 COI signed | 09/07/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 09/22/2023 | 12/07/2023 | |
| | Primary Reviewer 1 critique submitted | 10/02/2023 | 12/07/2023 | |
| | Primary Reviewer 2 critique submitted | 10/04/2023 | 12/07/2023 | |
| | Primary Reviewer 3 critique submitted | 10/04/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/06/2023 | 12/07/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/07/2023 | |
| | COI recused from participation | N/A | 12/07/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/07/2023 | |
| | Peer Review Meeting | 10/11/2023 | 12/07/2023 | |
| | Post review statements signed | 10/12/2023 | 12/07/2023 | |
| | Third Party Observer Report | 10/16/2023 | 12/07/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/07/2023 | |
| Recommended for SRC review | YES | 12/07/2023 | | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | N/A | | |
| | COI recused from participation | N/A | | |
| | PIC Review Meeting | N/A | | |
| | Recommended for grant award | N/A | | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240054
Individual Investigator Research Awards for
Cancer in Children and Adolescents

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards for Cancer in Children and Adolescents* Request for Applications (RFA). CPRIT received 35 applications in response to this RFA. This application was assigned to Basic Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application that was not recommended for a grant award has a score that is more favorable than an application that was recommended for a grant award by the Scientific Review Council (SRC). Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the SRC for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

At their February 7 meeting, the PIC did not recommend one of the *Individual Investigator Research Awards for Cancer in Children and Adolescents* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed

above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:55 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Cancer in Children and Adolescents
APPLICATION ID: RP240054
APPLICATION TITLE: Myeloid support of refractory and aggressive T-ALL at distinct tumor sites
APPLICANT NAME: Ehrlich, Lauren I
ORGANIZATION: The University of Texas at Austin
PANEL NAME: 24.1 Basic Cancer Research 1 Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/06/2023 | 12/05/2023 | |
| | Method of submission | CARS | 12/05/2023 | |
| | Within receipt period | YES | 12/05/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/05/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/05/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/05/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/05/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/05/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/05/2023 | |
| Primary Reviewer 1 COI signed | | 07/14/2023 | 12/05/2023 | |
| Primary Reviewer 2 COI signed | | 07/23/2023 | 12/05/2023 | |
| Primary Reviewer 3 COI signed | | 07/14/2023 | 12/05/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/05/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/14/2023 | 12/05/2023 | |
| | Primary Reviewer 2 critique submitted | 08/20/2023 | 12/05/2023 | |
| | Primary Reviewer 3 critique submitted | 08/02/2023 | 12/05/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/05/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/05/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/28/2023 | 12/05/2023 | |
| | Recommended for full review | YES | 12/05/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/05/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/04/2023 | 12/05/2023 | |
| | Primary Reviewer 1 COI signed | 09/15/2023 | 12/05/2023 | |
| | Primary Reviewer 2 COI signed | 09/22/2023 | 12/05/2023 | |
| | Primary Reviewer 3 COI signed | 09/04/2023 | 12/05/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/05/2023 | |
| | Primary Reviewer 1 critique submitted | 10/13/2023 | 12/05/2023 | |
| | Primary Reviewer 2 critique submitted | 10/15/2023 | 12/05/2023 | |
| | Primary Reviewer 3 critique submitted | 10/02/2023 | 12/05/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/12/2023 | 12/05/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/05/2023 | |
| | COI recused from participation | N/A | 12/05/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/05/2023 | |
| | Peer Review Meeting | 10/20/2023 | 12/05/2023 | |
| | Post review statements signed | 11/09/2023 | 12/05/2023 | |
| | Third Party Observer Report | 10/26/2023 | 12/05/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/05/2023 | |
| | Recommended for SRC review | YES | 12/05/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240061
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards Request for Applications (RFA)*. CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to the Imaging Technology and Informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 8th day of February, 2024, by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:55 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240061
APPLICATION TITLE: Deciphering Iron Redox Cycles in Ferroptosis-based Cancer Therapy
APPLICANT NAME: Lu, Yi
ORGANIZATION: The University of Texas at Austin
PANEL NAME: 24.1 Imaging Technology and Informatics Full

| Category | Compliance Requirement | Information | Attestation Date | |
|---|--|--|------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/14/2023 | 12/19/2023 | |
| | Method of submission | CARS | 12/19/2023 | |
| | Within receipt period | YES | 12/19/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/19/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/19/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/19/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/19/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/19/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/19/2023 | |
| Primary Reviewer 1 COI signed | | 07/17/2023 | 12/19/2023 | |
| Primary Reviewer 2 COI signed | | 07/15/2023 | 12/19/2023 | |
| Primary Reviewer 3 COI signed | | 07/14/2023 | 12/19/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/19/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/08/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 08/05/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 08/17/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/23/2023 | 12/19/2023 | |
| | Recommended for full review | YES | 12/19/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/19/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/07/2023 | 12/19/2023 | |
| | Primary Reviewer 1 COI signed | 09/11/2023 | 12/19/2023 | |
| | Primary Reviewer 2 COI signed | 09/07/2023 | 12/19/2023 | |
| | Primary Reviewer 3 COI signed | 09/14/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/31/2023 | 12/19/2023 | |
| | Primary Reviewer 1 critique submitted | 09/13/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 10/07/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 10/12/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/12/2023 | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | COI recused from participation | N/A | 12/19/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/19/2023 | |
| | Peer Review Meeting | 10/19/2023 | 12/19/2023 | |
| | Post review statements signed | 10/19/2023 | 12/19/2023 | |
| | Third Party Observer Report | 10/26/2023 | 12/19/2023 | |
| Score report delivered to CSO | 11/03/2023 | 12/19/2023 | | |
| Recommended for SRC review | YES | 12/19/2023 | | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240068
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to Basic Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle.

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:57 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240068
APPLICATION TITLE: Understanding the Mechanism of Linker Histone Mutations in Malignancy
APPLICANT NAME: Soshnev, Alexey A
ORGANIZATION: The University of Texas at San Antonio
PANEL NAME: 24.1 Basic Cancer Research 2 Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/14/2023 | 12/07/2023 | |
| | Method of submission | CARS | 12/07/2023 | |
| | Within receipt period | YES | 12/07/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/07/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/07/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/07/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/07/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/07/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/07/2023 | |
| Primary Reviewer 1 COI signed | | 07/14/2023 | 12/07/2023 | |
| Primary Reviewer 2 COI signed | | 07/25/2023 | 12/07/2023 | |
| Primary Reviewer 3 COI signed | | 07/20/2023 | 12/07/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/07/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/21/2023 | 12/07/2023 | |
| | Primary Reviewer 2 critique submitted | 08/21/2023 | 12/07/2023 | |
| | Primary Reviewer 3 critique submitted | 08/14/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/07/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/07/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/28/2023 | 12/07/2023 | |
| | Recommended for full review | YES | 12/07/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/07/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/05/2023 | 12/07/2023 | |
| | Primary Reviewer 1 COI signed | 09/15/2023 | 12/07/2023 | |
| | Primary Reviewer 2 COI signed | 09/22/2023 | 12/07/2023 | |
| | Primary Reviewer 3 COI signed | 09/05/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 09/06/2023 | 12/07/2023 | |
| | Primary Reviewer 1 critique submitted | 10/05/2023 | 12/07/2023 | |
| | Primary Reviewer 2 critique submitted | 10/07/2023 | 12/07/2023 | |
| | Primary Reviewer 3 critique submitted | 10/03/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 09/28/2023 | 12/07/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/07/2023 | |
| | COI recused from participation | N/A | 12/07/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/07/2023 | |
| | Peer Review Meeting | 10/11/2023 | 12/07/2023 | |
| | Post review statements signed | 10/12/2023 | 12/07/2023 | |
| | Third Party Observer Report | 10/16/2023 | 12/07/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/07/2023 | |
| | Recommended for SRC review | YES | 12/07/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240072
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:57 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240072
APPLICATION TITLE: Dissection of CAMKK2's Tumor Cell-intrinsic and -extrinsic Roles in Prostate Cancer
APPLICANT NAME: Frigo, Daniel E
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 24.1 Cancer Biology Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/09/2023 | 12/15/2023 | |
| | Method of submission | CARS | 12/15/2023 | |
| | Within receipt period | YES | 12/15/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/15/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/15/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/15/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/15/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/15/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/15/2023 | |
| Primary Reviewer 1 COI signed | | 07/20/2023 | 12/15/2023 | |
| Primary Reviewer 2 COI signed | | 07/14/2023 | 12/15/2023 | |
| Primary Reviewer 3 COI signed | | 07/16/2023 | 12/15/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/15/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/24/2023 | 12/15/2023 | |
| | Primary Reviewer 2 critique submitted | 08/20/2023 | 12/15/2023 | |
| | Primary Reviewer 3 critique submitted | 08/14/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/15/2023 | |
| | COI indicated by non-primary reviewer | Steffi Oesterreich | 12/15/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/25/2023 | 12/15/2023 | |
| | Recommended for full review | YES | 12/15/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/15/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/04/2023 | 12/15/2023 | |
| | Primary Reviewer 1 COI signed | 09/05/2023 | 12/15/2023 | |
| | Primary Reviewer 2 COI signed | 09/01/2023 | 12/15/2023 | |
| | Primary Reviewer 3 COI signed | 09/04/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/15/2023 | |
| | Primary Reviewer 1 critique submitted | 10/15/2023 | 12/15/2023 | |
| | Primary Reviewer 2 critique submitted | 10/05/2023 | 12/15/2023 | |
| | Primary Reviewer 3 critique submitted | 10/08/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 09/14/2023 | 12/15/2023 | |
| | COI indicated by non-primary reviewer | Steffi Oesterreich | 12/15/2023 | |
| | COI recused from participation | YES | 12/15/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/15/2023 | |
| | Peer Review Meeting | 10/18/2023 | 12/15/2023 | |
| | Post review statements signed | 10/20/2023 | 12/15/2023 | |
| | Third Party Observer Report | 10/26/2023 | 01/17/2024 | |
| | Score report delivered to CSO | 11/03/2023 | 12/15/2023 | |
| | Recommended for SRC review | YES | 12/15/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240075
Individual Investigator Research Awards for
Clinical Translation

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Clinical Translation* Request for Applications (RFA). CPRIT received 19 applications in response to this RFA, including one withdrawn application. This application was assigned to the Clinical and Translational Cancer Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.


The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 8th day of February, 2024, by WAYNE R. ROBERTS.



 Sandra Reyes
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:57 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Clinical Translation
APPLICATION ID: RP240075
APPLICATION TITLE: Combination Therapy Using ATRA and Carfilzomib to Treat Proteasome Inhibitor Refractory Multiple Myeloma
APPLICANT NAME: Yi, Qing
ORGANIZATION: The Methodist Hospital Research Institute
PANEL NAME: 24.1 Clinical and Translational Cancer Research Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 05/22/2023 | 12/19/2023 | |
| | Method of submission | CARS | 12/19/2023 | |
| | Within receipt period | YES | 12/19/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/19/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/19/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | 07/12/2023 | 12/19/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/19/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/19/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/19/2023 | |
| Primary Reviewer 1 COI signed | | 07/20/2023 | 12/19/2023 | |
| Primary Reviewer 2 COI signed | | 07/18/2023 | 12/19/2023 | |
| Primary Reviewer 3 COI signed | | 07/21/2023 | 12/19/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/19/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/18/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 08/20/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 08/20/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/23/2023 | 12/19/2023 | |
| | Recommended for full review | YES | 12/19/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/19/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/06/2023 | 12/19/2023 | |
| | Primary Reviewer 1 COI signed | 09/23/2023 | 12/19/2023 | |
| | Primary Reviewer 2 COI signed | 09/09/2023 | 12/19/2023 | |
| | Primary Reviewer 3 COI signed | 09/26/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/19/2023 | |
| | Primary Reviewer 1 critique submitted | 10/10/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 10/04/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 09/29/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/01/2023 | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | COI recused from participation | N/A | 12/19/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/19/2023 | |
| | Peer Review Meeting | 10/17/2023 | 12/19/2023 | |
| | Post review statements signed | 10/19/2023 | 12/19/2023 | |
| | Third Party Observer Report | 10/23/2023 | 12/19/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/19/2023 | |
| | Recommended for SRC review | YES | 12/19/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240091
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards Request for Applications (RFA)*. CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to the Imaging Technology and Informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:57 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240091
APPLICATION TITLE: High resolution high sensitivity photoacoustic imaging molecular guided brain tumor surgery with pilot clinical deployment
APPLICANT NAME: Valdes Quevedo, Pablo A
ORGANIZATION: The University of Texas Medical Branch at Galveston
PANEL NAME: 24.1 Imaging Technology and Informatics Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/13/2023 | 12/19/2023 | |
| | Method of submission | CARS | 12/19/2023 | |
| | Within receipt period | YES | 12/19/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/19/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/19/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | 07/12/2023 | 12/19/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/19/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/19/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/19/2023 | |
| Primary Reviewer 1 COI signed | | 07/14/2023 | 12/19/2023 | |
| Primary Reviewer 2 COI signed | | 07/20/2023 | 12/19/2023 | |
| Primary Reviewer 3 COI signed | | 07/14/2023 | 12/19/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/19/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/09/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 08/07/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 08/01/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/23/2023 | 12/19/2023 | |
| | Recommended for full review | YES | 12/19/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/19/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/07/2023 | 12/19/2023 | |
| | Primary Reviewer 1 COI signed | 08/29/2023 | 12/19/2023 | |
| | Primary Reviewer 2 COI signed | 09/14/2023 | 12/19/2023 | |
| | Primary Reviewer 3 COI signed | 09/07/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/31/2023 | 12/19/2023 | |
| | Primary Reviewer 1 critique submitted | 10/12/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 10/05/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 10/11/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/12/2023 | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | COI recused from participation | N/A | 12/19/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/19/2023 | |
| | Peer Review Meeting | 10/19/2023 | 12/19/2023 | |
| | Post review statements signed | 10/19/2023 | 12/19/2023 | |
| | Third Party Observer Report | 10/26/2023 | 12/19/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/19/2023 | |
| | Recommended for SRC review | YES | 12/19/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240095
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to Basic Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:57 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240095
APPLICATION TITLE: Targeting chitinase-3-like-1 as a novel therapy for hepatocellular carcinoma
APPLICANT NAME: ju, Cynthia
ORGANIZATION: The University of Texas Health Science Center at Houston
PANEL NAME: 24.1 Basic Cancer Research 1 Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 05/19/2023 | 12/05/2023 | |
| | Method of submission | CARS | 12/05/2023 | |
| | Within receipt period | YES | 12/05/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/05/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/05/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/05/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/05/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/05/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/05/2023 | |
| Primary Reviewer 1 COI signed | | 07/25/2023 | 12/05/2023 | |
| Primary Reviewer 2 COI signed | | 07/20/2023 | 12/05/2023 | |
| Primary Reviewer 3 COI signed | | 07/24/2023 | 12/05/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/05/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/18/2023 | 12/05/2023 | |
| | Primary Reviewer 2 critique submitted | 08/26/2023 | 12/05/2023 | |
| | Primary Reviewer 3 critique submitted | 08/21/2023 | 12/05/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/05/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/05/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/28/2023 | 12/05/2023 | |
| | Recommended for full review | YES | 12/05/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/05/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/04/2023 | 12/05/2023 | |
| | Primary Reviewer 1 COI signed | 10/13/2023 | 12/05/2023 | |
| | Primary Reviewer 2 COI signed | 10/18/2023 | 12/05/2023 | |
| | Primary Reviewer 3 COI signed | 09/04/2023 | 12/05/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/05/2023 | |
| | Primary Reviewer 1 critique submitted | 10/13/2023 | 12/05/2023 | |
| | Primary Reviewer 2 critique submitted | 11/13/2023 | 12/05/2023 | |
| | Primary Reviewer 3 critique submitted | 10/09/2023 | 12/05/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/06/2023 | 12/05/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/05/2023 | |
| | COI recused from participation | N/A | 12/05/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/05/2023 | |
| | Peer Review Meeting | 10/20/2023 | 12/05/2023 | |
| | Post review statements signed | 11/09/2023 | 12/05/2023 | |
| | Third Party Observer Report | 10/26/2023 | 12/05/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/05/2023 | |
| | Recommended for SRC review | YES | 12/05/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240104
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to Basic Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.


At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:57 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240104
APPLICATION TITLE: Characterization and optimization of novel allosteric KRAS inhibitors
APPLICANT NAME: Gorfe, Alemayehu A
ORGANIZATION: The University of Texas Health Science Center at Houston
PANEL NAME: 24.1 Basic Cancer Research 2 Full

| Category | Compliance Requirement | Information | Attestation Date | |
|---|--|--|------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/13/2023 | 12/07/2023 | |
| | Method of submission | CARS | 12/07/2023 | |
| | Within receipt period | YES | 12/07/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/07/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/07/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/07/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/07/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/07/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/07/2023 | |
| Primary Reviewer 1 COI signed | | 07/18/2023 | 12/07/2023 | |
| Primary Reviewer 2 COI signed | | 07/14/2023 | 12/07/2023 | |
| Primary Reviewer 3 COI signed | | 07/22/2023 | 12/07/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/07/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/09/2023 | 12/07/2023 | |
| | Primary Reviewer 2 critique submitted | 08/27/2023 | 12/07/2023 | |
| | Primary Reviewer 3 critique submitted | 08/16/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/07/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/07/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/28/2023 | 12/07/2023 | |
| | Recommended for full review | YES | 12/07/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/07/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/05/2023 | 12/07/2023 | |
| | Primary Reviewer 1 COI signed | 09/05/2023 | 12/07/2023 | |
| | Primary Reviewer 2 COI signed | 10/04/2023 | 12/07/2023 | |
| | Primary Reviewer 3 COI signed | 09/05/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 09/06/2023 | 12/07/2023 | |
| | Primary Reviewer 1 critique submitted | 10/03/2023 | 12/07/2023 | |
| | Primary Reviewer 2 critique submitted | 10/08/2023 | 12/07/2023 | |
| | Primary Reviewer 3 critique submitted | 10/04/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 09/29/2023 | 12/07/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/07/2023 | |
| | COI recused from participation | N/A | 12/07/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/07/2023 | |
| | Peer Review Meeting | 10/11/2023 | 12/07/2023 | |
| | Post review statements signed | 10/12/2023 | 12/07/2023 | |
| | Third Party Observer Report | 10/16/2023 | 12/07/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/07/2023 | |
| Recommended for SRC review | YES | 12/07/2023 | | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240117
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to the Imaging Technology and Informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:57 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240117
APPLICATION TITLE: Identify radiopathomics markers to guide immunotherapy for non-small cell lung cancer
APPLICANT NAME: Wu, Jia
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 24.1 Imaging Technology and Informatics Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/12/2023 | 12/19/2023 | |
| | Method of submission | CARS | 12/19/2023 | |
| | Within receipt period | YES | 12/19/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/19/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/19/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/19/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/19/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/19/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/19/2023 | |
| Primary Reviewer 1 COI signed | | 07/23/2023 | 12/19/2023 | |
| Primary Reviewer 2 COI signed | | 07/20/2023 | 12/19/2023 | |
| Primary Reviewer 3 COI signed | | 07/14/2023 | 12/19/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/19/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/20/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 08/07/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 08/09/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/19/2023 | |
| | COI indicated by non-primary reviewer | Maryellen Giger, Charles Kahn | 12/19/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/23/2023 | 12/19/2023 | |
| | Recommended for full review | YES | 12/19/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/19/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/07/2023 | 12/19/2023 | |
| | Primary Reviewer 1 COI signed | 10/12/2023 | 12/19/2023 | |
| | Primary Reviewer 2 COI signed | 09/14/2023 | 12/19/2023 | |
| | Primary Reviewer 3 COI signed | 08/29/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/31/2023 | 12/19/2023 | |
| | Primary Reviewer 1 critique submitted | 10/13/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 10/08/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 10/12/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/12/2023 | 12/19/2023 | |
| | COI indicated by non-primary reviewer | Maryellen Giger, Charles Kahn | 12/19/2023 | |
| | COI recused from participation | YES | 12/19/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/19/2023 | |
| | Peer Review Meeting | 10/19/2023 | 12/19/2023 | |
| | Post review statements signed | 10/19/2023 | 12/19/2023 | |
| | Third Party Observer Report | 10/26/2023 | 12/19/2023 | |
| Score report delivered to CSO | 11/03/2023 | 12/19/2023 | | |
| Recommended for SRC review | YES | 12/19/2023 | | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240119
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to the Clinical and Translational Cancer Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:58 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240119
APPLICATION TITLE: Integrating proteolysis-targeting capability into antibodies to augment therapeutic efficacy
APPLICANT NAME: Liu, Qingyun
ORGANIZATION: The University of Texas Health Science Center at Houston
PANEL NAME: 24.1 Clinical and Translational Cancer Research Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/14/2023 | 12/19/2023 | |
| | Method of submission | CARS | 12/19/2023 | |
| | Within receipt period | YES | 12/19/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/19/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/19/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/19/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/19/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/19/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/19/2023 | |
| Primary Reviewer 1 COI signed | | 07/14/2023 | 12/19/2023 | |
| Primary Reviewer 2 COI signed | | 07/21/2023 | 12/19/2023 | |
| Primary Reviewer 3 COI signed | | 07/18/2023 | 12/19/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/19/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/14/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 08/22/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 08/20/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/23/2023 | 12/19/2023 | |
| | Recommended for full review | YES | 12/19/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/19/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/06/2023 | 12/19/2023 | |
| | Primary Reviewer 1 COI signed | 09/22/2023 | 12/19/2023 | |
| | Primary Reviewer 2 COI signed | 09/06/2023 | 12/19/2023 | |
| | Primary Reviewer 3 COI signed | 09/09/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/19/2023 | |
| | Primary Reviewer 1 critique submitted | 10/11/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 10/10/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 10/10/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/01/2023 | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | COI recused from participation | N/A | 12/19/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/19/2023 | |
| | Peer Review Meeting | 10/17/2023 | 12/19/2023 | |
| | Post review statements signed | 10/19/2023 | 12/19/2023 | |
| | Third Party Observer Report | 10/23/2023 | 12/19/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/19/2023 | |
| Recommended for SRC review | YES | 12/19/2023 | | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240120
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to Basic Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:58 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240120
APPLICATION TITLE: JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC
APPLICANT NAME: ZHANG, QING
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 24.1 Basic Cancer Research 2 Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/13/2023 | 12/07/2023 | |
| | Method of submission | CARS | 12/07/2023 | |
| | Within receipt period | YES | 12/07/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/07/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/07/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/07/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/07/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/07/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/07/2023 | |
| Primary Reviewer 1 COI signed | | 07/20/2023 | 12/07/2023 | |
| Primary Reviewer 2 COI signed | | 07/25/2023 | 12/07/2023 | |
| Primary Reviewer 3 COI signed | | 07/14/2023 | 12/07/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/07/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/20/2023 | 12/07/2023 | |
| | Primary Reviewer 2 critique submitted | 08/21/2023 | 12/07/2023 | |
| | Primary Reviewer 3 critique submitted | 08/21/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/07/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/07/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/28/2023 | 12/07/2023 | |
| | Recommended for full review | YES | 12/07/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/07/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/05/2023 | 12/07/2023 | |
| | Primary Reviewer 1 COI signed | 10/04/2023 | 12/07/2023 | |
| | Primary Reviewer 2 COI signed | 09/22/2023 | 12/07/2023 | |
| | Primary Reviewer 3 COI signed | 10/04/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 09/22/2023 | 12/07/2023 | |
| | Primary Reviewer 1 critique submitted | 10/05/2023 | 12/07/2023 | |
| | Primary Reviewer 2 critique submitted | 10/07/2023 | 12/07/2023 | |
| | Primary Reviewer 3 critique submitted | 10/06/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/06/2023 | 12/07/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/07/2023 | |
| | COI recused from participation | N/A | 12/07/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/07/2023 | |
| | Peer Review Meeting | 10/11/2023 | 12/07/2023 | |
| | Post review statements signed | 10/12/2023 | 12/07/2023 | |
| | Third Party Observer Report | 10/16/2023 | 12/07/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/07/2023 | |
| | Recommended for SRC review | YES | 12/07/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240125
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to the Cancer Prevention Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:58 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240125
APPLICATION TITLE: Immune-Related Determinants of HPV-Associated Oropharyngeal Cancer Outcomes
APPLICANT NAME: Li, Guojun
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 24.1 Cancer Prevention Research Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/13/2023 | 12/18/2023 | |
| | Method of submission | CARS | 12/18/2023 | |
| | Within receipt period | YES | 12/18/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/18/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/18/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | 07/12/2023 | 12/18/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/18/2023 |
| Assigned to primary reviewers | | 07/31/2023 | 12/18/2023 | |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/18/2023 | |
| Primary Reviewer 1 COI signed | | 07/17/2023 | 12/18/2023 | |
| Primary Reviewer 2 COI signed | | 07/23/2023 | 12/18/2023 | |
| Primary Reviewer 3 COI signed | | 07/25/2023 | 12/18/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/18/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/18/2023 | 12/18/2023 | |
| | Primary Reviewer 2 critique submitted | 08/20/2023 | 12/18/2023 | |
| | Primary Reviewer 3 critique submitted | 08/24/2023 | 12/18/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/18/2023 | |
| | COI indicated by non-primary reviewer | Thomas Brandon, Electra Paskett | 12/18/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/23/2023 | 12/18/2023 | |
| | Recommended for full review | YES | 12/18/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/18/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/02/2023 | 12/18/2023 | |
| | Primary Reviewer 1 COI signed | 09/19/2023 | 12/18/2023 | |
| | Primary Reviewer 2 COI signed | 09/29/2023 | 12/18/2023 | |
| | Primary Reviewer 3 COI signed | 09/13/2023 | 12/18/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/18/2023 | |
| | Primary Reviewer 1 critique submitted | 10/03/2023 | 12/18/2023 | |
| | Primary Reviewer 2 critique submitted | 10/08/2023 | 12/18/2023 | |
| | Primary Reviewer 3 critique submitted | 10/09/2023 | 12/18/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/04/2023 | 12/18/2023 | |
| | COI indicated by non-primary reviewer | Thomas Brandon, Electra Paskett | 12/18/2023 | |
| | COI recused from participation | YES | 12/18/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/18/2023 | |
| | Peer Review Meeting | 10/13/2023 | 12/18/2023 | |
| | Post review statements signed | 10/14/2023 | 12/18/2023 | |
| | Third Party Observer Report | 10/16/2023 | 12/18/2023 | |
| Score report delivered to CSO | 11/03/2023 | 12/18/2023 | | |
| Recommended for SRC review | YES | 12/18/2023 | | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240127
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to Basic Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:58 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240127
APPLICATION TITLE: Transposon Restriction, Tumor Suppression and p53
APPLICANT NAME: Abrams, John M
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 24.1 Basic Cancer Research 2 Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/13/2023 | 12/07/2023 | |
| | Method of submission | CARS | 12/07/2023 | |
| | Within receipt period | YES | 12/07/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/07/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/07/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/07/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/07/2023 |
| | | Assigned to primary reviewers | 09/05/2023 | 12/07/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/07/2023 | |
| Primary Reviewer 1 COI signed | | 09/05/2023 | 12/07/2023 | |
| Primary Reviewer 2 COI signed | | 09/08/2023 | 12/07/2023 | |
| Primary Reviewer 3 COI signed | | 09/05/2023 | 12/07/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | 09/06/2023 | 12/07/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | N/A | 12/07/2023 | |
| | Primary Reviewer 2 critique submitted | N/A | 12/07/2023 | |
| | Primary Reviewer 3 critique submitted | N/A | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/07/2023 | |
| | COI indicated by non-primary reviewer | N/A | 12/07/2023 | |
| | Preliminary Evaluation score summary sent to Chair | N/A | 12/07/2023 | |
| | Recommended for full review | N/A | 12/07/2023 | |
| | Applicant notified of outcome | N/A | 12/07/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/05/2023 | 12/07/2023 | |
| | Primary Reviewer 1 COI signed | 09/05/2023 | 12/07/2023 | |
| | Primary Reviewer 2 COI signed | 09/08/2023 | 12/07/2023 | |
| | Primary Reviewer 3 COI signed | 09/05/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 09/06/2023 | 12/07/2023 | |
| | Primary Reviewer 1 critique submitted | 10/04/2023 | 12/07/2023 | |
| | Primary Reviewer 2 critique submitted | 10/04/2023 | 12/07/2023 | |
| | Primary Reviewer 3 critique submitted | 10/04/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/01/2023 | 12/07/2023 | |
| | COI indicated by non-primary reviewer | Benjamin Greenbaum | 12/07/2023 | |
| | COI recused from participation | YES | 12/07/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/07/2023 | |
| | Peer Review Meeting | 10/11/2023 | 12/07/2023 | |
| | Post review statements signed | 10/12/2023 | 12/07/2023 | |
| | Third Party Observer Report | 10/16/2023 | 12/07/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/07/2023 | |
| | Recommended for SRC review | YES | 12/07/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240131
Individual Investigator Research Awards for
Computational Systems Biology of Cancer

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Computational Systems Biology of Cancer* Request for Applications (RFA). CPRIT received 18 applications in response to this RFA. This application was assigned to Basic Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 8th day of February, 2024, by WAYNE R. ROBERTS.



 Sandra Reyes
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:58 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Computational Systems Biology of Cancer
APPLICATION ID: RP240131
APPLICATION TITLE: Computational Methods for CRISPR-based Lineage Tracing Systems
APPLICANT NAME: Liu, Zhandong
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 24.1 Basic Cancer Research 2 Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/14/2023 | 12/07/2023 | |
| | Method of submission | CARS | 12/07/2023 | |
| | Within receipt period | YES | 12/07/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/07/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/07/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/07/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/07/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/07/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/07/2023 | |
| Primary Reviewer 1 COI signed | | 07/14/2023 | 12/07/2023 | |
| Primary Reviewer 2 COI signed | | 07/21/2023 | 12/07/2023 | |
| Primary Reviewer 3 COI signed | | 07/24/2023 | 12/07/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/07/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/27/2023 | 12/07/2023 | |
| | Primary Reviewer 2 critique submitted | 08/20/2023 | 12/07/2023 | |
| | Primary Reviewer 3 critique submitted | 08/22/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/07/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/07/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/28/2023 | 12/07/2023 | |
| | Recommended for full review | YES | 12/07/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/07/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/05/2023 | 12/07/2023 | |
| | Primary Reviewer 1 COI signed | 10/04/2023 | 12/07/2023 | |
| | Primary Reviewer 2 COI signed | 09/05/2023 | 12/07/2023 | |
| | Primary Reviewer 3 COI signed | 10/04/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 09/06/2023 | 12/07/2023 | |
| | Primary Reviewer 1 critique submitted | 10/06/2023 | 12/07/2023 | |
| | Primary Reviewer 2 critique submitted | 10/04/2023 | 12/07/2023 | |
| | Primary Reviewer 3 critique submitted | 10/06/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/03/2023 | 12/07/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/07/2023 | |
| | COI recused from participation | N/A | 12/07/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/07/2023 | |
| | Peer Review Meeting | 10/11/2023 | 12/07/2023 | |
| | Post review statements signed | 10/12/2023 | 12/07/2023 | |
| | Third Party Observer Report | 10/16/2023 | 12/07/2023 | |
| Score report delivered to CSO | 11/03/2023 | 12/07/2023 | | |
| Recommended for SRC review | YES | 12/07/2023 | | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240133
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to the Imaging Technology and Informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:58 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240133
APPLICATION TITLE: Modulation of blood-spinal cord barrier for tumor treatment
APPLICANT NAME: Qin, Zhenpeng
ORGANIZATION: The University of Texas at Dallas
PANEL NAME: 24.1 Imaging Technology and Informatics Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/14/2023 | 12/19/2023 | |
| | Method of submission | CARS | 12/19/2023 | |
| | Within receipt period | YES | 12/19/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/19/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/19/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/19/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/19/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/19/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/19/2023 | |
| Primary Reviewer 1 COI signed | | 07/15/2023 | 12/19/2023 | |
| Primary Reviewer 2 COI signed | | 07/24/2023 | 12/19/2023 | |
| Primary Reviewer 3 COI signed | | 07/14/2023 | 12/19/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/19/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/21/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 08/10/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 08/17/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/23/2023 | 12/19/2023 | |
| | Recommended for full review | YES | 12/19/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/19/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/07/2023 | 12/19/2023 | |
| | Primary Reviewer 1 COI signed | 09/11/2023 | 12/19/2023 | |
| | Primary Reviewer 2 COI signed | 09/07/2023 | 12/19/2023 | |
| | Primary Reviewer 3 COI signed | 09/07/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/31/2023 | 12/19/2023 | |
| | Primary Reviewer 1 critique submitted | 10/13/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 10/09/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 10/11/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/12/2023 | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | COI recused from participation | N/A | 12/19/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/19/2023 | |
| | Peer Review Meeting | 10/19/2023 | 12/19/2023 | |
| | Post review statements signed | 10/19/2023 | 12/19/2023 | |
| | Third Party Observer Report | 10/26/2023 | 12/19/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/19/2023 | |
| | Recommended for SRC review | YES | 12/19/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | N/A | | |
| | COI recused from participation | N/A | | |
| | PIC Review Meeting | N/A | | |
| | Recommended for grant award | N/A | | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240137
Individual Investigator Research Awards for
Computational Systems Biology of Cancer

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Computational Systems Biology of Cancer* Request for Applications (RFA). CPRIT received 18 applications in response to this RFA. This application was assigned to Basic Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 8th day of February, 2024, by WAYNE R. ROBERTS.



 Sandra Reyes
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:58 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Computational Systems Biology of Cancer
APPLICATION ID: RP240137
APPLICATION TITLE: Charting TCR-Tumor Antigen Interactions to Foster Novel Immunotherapeutic Approaches for Triple- Negative Breast Cancer
APPLICANT NAME: Zhang, Bing
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 24.1 Basic Cancer Research 1 Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/13/2023 | 12/05/2023 | |
| | Method of submission | CARS | 12/05/2023 | |
| | Within receipt period | YES | 12/05/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/05/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/05/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/05/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/05/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/05/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/05/2023 | |
| Primary Reviewer 1 COI signed | | 07/18/2023 | 12/05/2023 | |
| Primary Reviewer 2 COI signed | | 07/15/2023 | 12/05/2023 | |
| Primary Reviewer 3 COI signed | | 07/20/2023 | 12/05/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/05/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/20/2023 | 12/05/2023 | |
| | Primary Reviewer 2 critique submitted | 08/16/2023 | 12/05/2023 | |
| | Primary Reviewer 3 critique submitted | 08/22/2023 | 12/05/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/05/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/05/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/28/2023 | 12/05/2023 | |
| | Recommended for full review | YES | 12/05/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/05/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/04/2023 | 12/05/2023 | |
| | Primary Reviewer 1 COI signed | 09/16/2023 | 12/05/2023 | |
| | Primary Reviewer 2 COI signed | 09/10/2023 | 12/05/2023 | |
| | Primary Reviewer 3 COI signed | 10/14/2023 | 12/05/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/05/2023 | |
| | Primary Reviewer 1 critique submitted | 10/14/2023 | 12/05/2023 | |
| | Primary Reviewer 2 critique submitted | 09/13/2023 | 12/05/2023 | |
| | Primary Reviewer 3 critique submitted | 10/16/2023 | 12/05/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/06/2023 | 12/05/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/05/2023 | |
| | COI recused from participation | N/A | 12/05/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/05/2023 | |
| | Peer Review Meeting | 10/20/2023 | 12/05/2023 | |
| | Post review statements signed | 11/09/2023 | 12/05/2023 | |
| | Third Party Observer Report | 10/26/2023 | 12/05/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/05/2023 | |
| | Recommended for SRC review | YES | 12/05/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240143
Individual Investigator Research Awards for
Cancer in Children and Adolescents

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Cancer in Children and Adolescents* Request for Applications (RFA). CPRIT received 35 applications in response to this RFA. This application was assigned to the Cancer Prevention Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application that was not recommended for a grant award has a score that is more favorable than an application that was recommended for a grant award by the Scientific Review Council (SRC). Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the SRC for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend one of the *Individual Investigator Research Awards for Cancer in Children and Adolescents* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed

above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:58 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Cancer in Children and Adolescents
APPLICATION ID: RP240143
APPLICATION TITLE: Leveraging Passport for Care in a telehealth framework to improve equitable access to survivorship services
APPLICANT NAME: Gramatges, Maria M
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 24.1 Cancer Prevention Research Full

| Category | Compliance Requirement | Information | Attestation Date | |
|---|--|--|------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/12/2023 | 12/18/2023 | |
| | Method of submission | CARS | 12/18/2023 | |
| | Within receipt period | YES | 12/18/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/18/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/18/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/18/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/18/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/18/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/18/2023 | |
| Primary Reviewer 1 COI signed | | 07/17/2023 | 12/18/2023 | |
| Primary Reviewer 2 COI signed | | 07/20/2023 | 12/18/2023 | |
| Primary Reviewer 3 COI signed | | 07/18/2023 | 12/18/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/18/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/12/2023 | 12/18/2023 | |
| | Primary Reviewer 2 critique submitted | 08/19/2023 | 12/18/2023 | |
| | Primary Reviewer 3 critique submitted | 08/13/2023 | 12/18/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/18/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/18/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/23/2023 | 12/18/2023 | |
| | Recommended for full review | YES | 12/18/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/18/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/02/2023 | 12/18/2023 | |
| | Primary Reviewer 1 COI signed | 09/08/2023 | 12/18/2023 | |
| | Primary Reviewer 2 COI signed | 09/05/2023 | 12/18/2023 | |
| | Primary Reviewer 3 COI signed | 09/29/2023 | 12/18/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/18/2023 | |
| | Primary Reviewer 1 critique submitted | 09/26/2023 | 12/18/2023 | |
| | Primary Reviewer 2 critique submitted | 09/30/2023 | 12/18/2023 | |
| | Primary Reviewer 3 critique submitted | 09/30/2023 | 12/18/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 09/30/2023 | 12/18/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/18/2023 | |
| | COI recused from participation | N/A | 12/18/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/18/2023 | |
| | Peer Review Meeting | 10/13/2023 | 12/18/2023 | |
| | Post review statements signed | 10/14/2023 | 12/18/2023 | |
| | Third Party Observer Report | 10/16/2023 | 12/18/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/18/2023 | |
| Recommended for SRC review | YES | 12/18/2023 | | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240183
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:08 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240183
APPLICATION TITLE: Restoring TREM2-Dependent Efferocytosis to Inhibit Obesity-Induced Liver Inflammation and Cancer Development
APPLICANT NAME: Liang, Shuang
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 24.1 Cancer Biology Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/13/2023 | 12/15/2023 | |
| | Method of submission | CARS | 12/15/2023 | |
| | Within receipt period | YES | 12/15/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/15/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/15/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/15/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/15/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/15/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/15/2023 | |
| Primary Reviewer 1 COI signed | | 07/19/2023 | 12/15/2023 | |
| Primary Reviewer 2 COI signed | | 07/14/2023 | 12/15/2023 | |
| Primary Reviewer 3 COI signed | | 07/14/2023 | 12/15/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/15/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/23/2023 | 12/15/2023 | |
| | Primary Reviewer 2 critique submitted | 08/21/2023 | 12/15/2023 | |
| | Primary Reviewer 3 critique submitted | 08/11/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/15/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/15/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/25/2023 | 12/15/2023 | |
| | Recommended for full review | YES | 12/15/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/15/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/04/2023 | 12/15/2023 | |
| | Primary Reviewer 1 COI signed | 09/29/2023 | 12/15/2023 | |
| | Primary Reviewer 2 COI signed | 09/05/2023 | 12/15/2023 | |
| | Primary Reviewer 3 COI signed | 09/01/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/15/2023 | |
| | Primary Reviewer 1 critique submitted | 10/16/2023 | 12/15/2023 | |
| | Primary Reviewer 2 critique submitted | 10/15/2023 | 12/15/2023 | |
| | Primary Reviewer 3 critique submitted | 10/05/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 09/15/2023 | 12/15/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/15/2023 | |
| | COI recused from participation | N/A | 12/15/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/15/2023 | |
| | Peer Review Meeting | 10/18/2023 | 12/15/2023 | |
| | Post review statements signed | 10/20/2023 | 12/15/2023 | |
| | Third Party Observer Report | 10/26/2023 | 01/17/2024 | |
| Score report delivered to CSO | 11/03/2023 | 12/15/2023 | | |
| Recommended for SRC review | YES | 12/15/2023 | | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240184
Individual Investigator Research Awards for
Clinical Translation

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Clinical Translation* Request for Applications (RFA). CPRIT received 19 applications in response to this RFA, including one withdrawn application. This application was assigned to the Clinical and Translational Cancer Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 8th day of February, 2024, by WAYNE R. ROBERTS.



 Sandra Reyes
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:08 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Clinical Translation
APPLICATION ID: RP240184
APPLICATION TITLE: Maximizing Anti-tumor Immunity through Simultaneous Activation of the Innate and Adaptive Immune System
APPLICANT NAME: Hannan, Raquibul
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 24.1 Clinical and Translational Cancer Research Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/13/2023 | 12/19/2023 | |
| | Method of submission | CARS | 12/19/2023 | |
| | Within receipt period | YES | 12/19/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/19/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/19/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/19/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/19/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/19/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/19/2023 | |
| Primary Reviewer 1 COI signed | | 07/21/2023 | 12/19/2023 | |
| Primary Reviewer 2 COI signed | | 07/14/2023 | 12/19/2023 | |
| Primary Reviewer 3 COI signed | | 07/21/2023 | 12/19/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/19/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/13/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 08/17/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 08/20/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/23/2023 | 12/19/2023 | |
| | Recommended for full review | YES | 12/19/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/19/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/06/2023 | 12/19/2023 | |
| | Primary Reviewer 1 COI signed | 08/31/2023 | 12/19/2023 | |
| | Primary Reviewer 2 COI signed | 09/24/2023 | 12/19/2023 | |
| | Primary Reviewer 3 COI signed | 09/26/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/19/2023 | |
| | Primary Reviewer 1 critique submitted | 10/06/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 10/08/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 09/29/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 09/18/2023 | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | COI recused from participation | N/A | 12/19/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/19/2023 | |
| | Peer Review Meeting | 10/17/2023 | 12/19/2023 | |
| | Post review statements signed | 10/19/2023 | 12/19/2023 | |
| | Third Party Observer Report | 10/23/2023 | 12/19/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/19/2023 | |
| Recommended for SRC review | YES | 12/19/2023 | | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240208
Individual Investigator Research Awards for
Prevention and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Prevention and Early Detection* Request for Applications (RFA). CPRIT received 15 applications in response to this RFA. This application was assigned to the Cancer Prevention Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’


- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

At their February 7 meeting, the PIC did not recommend six applications recommended by the Scientific Review Council (SRC): five *Individual Investigator Research Awards* and one *Individual Investigator Research Award for Cancer in Children and Adolescents*. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available. To determine which applications would not receive funding, the Chief Scientific Officer suggested imposing a cut off score of 2.6 on the two above mentioned mechanisms. This resulted in six applications with scores less favorable than 2.6 falling outside of the PIC’s recommendation to the Oversight Committee.

Of the six applications that the PIC did not recommend, four have scores that are more favorable or the same as this application, RP240208, that was recommended by the PIC to the Oversight Committee. RP240208 was the only *Individual Investigator Research Award for Prevention and Early Detection (IIRAP)* application during this cycle to receive a recommendation from the SRC to the PIC. The SRC recommended this application to the PIC after the peer review panels scored it with the highest score of all the *IIRAP* applications reviewed during this cycle.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 20th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:09 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Prevention and Early Detection
APPLICATION ID: RP240208
APPLICATION TITLE: Unidos contra el VPH: Screening accuracy, preference, and uptake of HPV self-sampling among Latinxs along the US-Mexico border
APPLICANT NAME: Calderon-Mora, Jessica A
ORGANIZATION: The University of Texas at Austin
PANEL NAME: 24.1 Cancer Prevention Research Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/13/2023 | 12/18/2023 | |
| | Method of submission | CARS | 12/18/2023 | |
| | Within receipt period | YES | 12/18/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/18/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/18/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/18/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/18/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/18/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/18/2023 | |
| Primary Reviewer 1 COI signed | | 07/17/2023 | 12/18/2023 | |
| Primary Reviewer 2 COI signed | | 07/20/2023 | 12/18/2023 | |
| Primary Reviewer 3 COI signed | | 07/16/2023 | 12/18/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/18/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/12/2023 | 12/18/2023 | |
| | Primary Reviewer 2 critique submitted | 08/20/2023 | 12/18/2023 | |
| | Primary Reviewer 3 critique submitted | 08/15/2023 | 12/18/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/18/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/18/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/23/2023 | 12/18/2023 | |
| | Recommended for full review | YES | 12/18/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/18/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/02/2023 | 12/18/2023 | |
| | Primary Reviewer 1 COI signed | 09/08/2023 | 12/18/2023 | |
| | Primary Reviewer 2 COI signed | 09/29/2023 | 12/18/2023 | |
| | Primary Reviewer 3 COI signed | 09/04/2023 | 12/18/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/18/2023 | |
| | Primary Reviewer 1 critique submitted | 10/02/2023 | 12/18/2023 | |
| | Primary Reviewer 2 critique submitted | 09/30/2023 | 12/18/2023 | |
| | Primary Reviewer 3 critique submitted | 09/22/2023 | 12/18/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 09/30/2023 | 12/18/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/18/2023 | |
| | COI recused from participation | N/A | 12/18/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/18/2023 | |
| | Peer Review Meeting | 10/13/2023 | 12/18/2023 | |
| | Post review statements signed | 10/14/2023 | 12/18/2023 | |
| | Third Party Observer Report | 10/16/2023 | 12/18/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/18/2023 | |
| | Recommended for SRC review | YES | 12/18/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240214
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to Basic Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:09 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240214
APPLICATION TITLE: Immunoprevention of Breast Cancer Brain Metastasis by Special Dendritic Cell-derived Extracellular Vesicles
APPLICANT NAME: Yu, Dihua
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 24.1 Basic Cancer Research 1 Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/13/2023 | 12/05/2023 | |
| | Method of submission | CARS | 12/05/2023 | |
| | Within receipt period | YES | 12/05/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/05/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/05/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | 07/12/2023 | 12/05/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/05/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/05/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/05/2023 | |
| Primary Reviewer 1 COI signed | | 07/15/2023 | 12/05/2023 | |
| Primary Reviewer 2 COI signed | | 07/18/2023 | 12/05/2023 | |
| Primary Reviewer 3 COI signed | | 07/20/2023 | 12/05/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/05/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/16/2023 | 12/05/2023 | |
| | Primary Reviewer 2 critique submitted | 08/20/2023 | 12/05/2023 | |
| | Primary Reviewer 3 critique submitted | 08/22/2023 | 12/05/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/05/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/05/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/28/2023 | 12/05/2023 | |
| | Recommended for full review | YES | 12/05/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/05/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/04/2023 | 12/05/2023 | |
| | Primary Reviewer 1 COI signed | 09/10/2023 | 12/05/2023 | |
| | Primary Reviewer 2 COI signed | 09/16/2023 | 12/05/2023 | |
| | Primary Reviewer 3 COI signed | 10/14/2023 | 12/05/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/05/2023 | |
| | Primary Reviewer 1 critique submitted | 09/12/2023 | 12/05/2023 | |
| | Primary Reviewer 2 critique submitted | 10/14/2023 | 12/05/2023 | |
| | Primary Reviewer 3 critique submitted | 10/16/2023 | 12/05/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/06/2023 | 12/05/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/05/2023 | |
| | COI recused from participation | N/A | 12/05/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/05/2023 | |
| | Peer Review Meeting | 10/20/2023 | 12/05/2023 | |
| | Post review statements signed | 11/09/2023 | 12/05/2023 | |
| | Third Party Observer Report | 10/26/2023 | 12/05/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/05/2023 | |
| | Recommended for SRC review | YES | 12/05/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240225
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to Basic Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:09 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240225
APPLICATION TITLE: PARP16-mediated Ribosome MARYlation and Translation Control in Ovarian Cancer
APPLICANT NAME: Kraus, W. Lee
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 24.1 Basic Cancer Research 2 Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/13/2023 | 12/07/2023 | |
| | Method of submission | CARS | 12/07/2023 | |
| | Within receipt period | YES | 12/07/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/07/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/07/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/07/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/07/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/07/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/07/2023 | |
| Primary Reviewer 1 COI signed | | 07/14/2023 | 12/07/2023 | |
| Primary Reviewer 2 COI signed | | 07/25/2023 | 12/07/2023 | |
| Primary Reviewer 3 COI signed | | 07/15/2023 | 12/07/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/07/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/21/2023 | 12/07/2023 | |
| | Primary Reviewer 2 critique submitted | 08/21/2023 | 12/07/2023 | |
| | Primary Reviewer 3 critique submitted | 08/24/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/07/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/07/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/28/2023 | 12/07/2023 | |
| | Recommended for full review | YES | 12/07/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/07/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/05/2023 | 12/07/2023 | |
| | Primary Reviewer 1 COI signed | 09/15/2023 | 12/07/2023 | |
| | Primary Reviewer 2 COI signed | 09/22/2023 | 12/07/2023 | |
| | Primary Reviewer 3 COI signed | 09/06/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 09/22/2023 | 12/07/2023 | |
| | Primary Reviewer 1 critique submitted | 10/05/2023 | 12/07/2023 | |
| | Primary Reviewer 2 critique submitted | 10/07/2023 | 12/07/2023 | |
| | Primary Reviewer 3 critique submitted | 10/07/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/06/2023 | 12/07/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/07/2023 | |
| | COI recused from participation | N/A | 12/07/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/07/2023 | |
| | Peer Review Meeting | 10/11/2023 | 12/07/2023 | |
| | Post review statements signed | 10/12/2023 | 12/07/2023 | |
| | Third Party Observer Report | 10/16/2023 | 12/07/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/07/2023 | |
| | Recommended for SRC review | YES | 12/07/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240233
Individual Investigator Research Awards for
Clinical Translation

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Clinical Translation* Request for Applications (RFA). CPRIT received 19 applications in response to this RFA, including one withdrawn application. This application was assigned to the Clinical and Translational Cancer Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 8th day of February, 2024, by WAYNE R. ROBERTS.



 Sandra Reyes
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:09 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Clinical Translation
APPLICATION ID: RP240233
APPLICATION TITLE: Towards non-operative management of early stage ER-positive breast cancer
APPLICANT NAME: Rahimi, Asal
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 24.1 Clinical and Translational Cancer Research Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/13/2023 | 12/19/2023 | |
| | Method of submission | CARS | 12/19/2023 | |
| | Within receipt period | YES | 12/19/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/19/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/19/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/19/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/19/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/19/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/19/2023 | |
| Primary Reviewer 1 COI signed | | 07/22/2023 | 12/19/2023 | |
| Primary Reviewer 2 COI signed | | 07/21/2023 | 12/19/2023 | |
| Primary Reviewer 3 COI signed | | 07/18/2023 | 12/19/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/19/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/19/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 08/13/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 08/16/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/23/2023 | 12/19/2023 | |
| | Recommended for full review | YES | 12/19/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/19/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/06/2023 | 12/19/2023 | |
| | Primary Reviewer 1 COI signed | 10/04/2023 | 12/19/2023 | |
| | Primary Reviewer 2 COI signed | 09/24/2023 | 12/19/2023 | |
| | Primary Reviewer 3 COI signed | 09/15/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/19/2023 | |
| | Primary Reviewer 1 critique submitted | 10/11/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 10/08/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 10/09/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 09/16/2023 | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | COI recused from participation | N/A | 12/19/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/19/2023 | |
| | Peer Review Meeting | 10/17/2023 | 12/19/2023 | |
| | Post review statements signed | 10/19/2023 | 12/19/2023 | |
| | Third Party Observer Report | 10/23/2023 | 12/19/2023 | |
| Score report delivered to CSO | 11/03/2023 | 12/19/2023 | | |
| Recommended for SRC review | YES | 12/19/2023 | | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240237
Individual Investigator Research Awards for
Cancer in Children and Adolescents

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards for Cancer in Children and Adolescents* Request for Applications (RFA). CPRIT received 35 applications in response to this RFA. This application was assigned to Basic Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application that was not recommended for a grant award has a score that is more favorable than an application that was recommended for a grant award by the Scientific Review Council (SRC). Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the SRC for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.


At their February 7 meeting, the PIC did not recommend one of the *Individual Investigator Research Awards for Cancer in Children and Adolescents* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed

above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:09 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Cancer in Children and Adolescents
APPLICATION ID: RP240237
APPLICATION TITLE: The Role of EWSR1-FLI1-CENP-A Signaling in Chemoresistance in Ewing Sarcoma
APPLICANT NAME: Kitagawa, Katsumi
ORGANIZATION: The University of Texas Health Science Center at San Antonio
PANEL NAME: 24.1 Basic Cancer Research 2 Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/13/2023 | 12/07/2023 | |
| | Method of submission | CARS | 12/07/2023 | |
| | Within receipt period | YES | 12/07/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/07/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/07/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/07/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/07/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/07/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/07/2023 | |
| Primary Reviewer 1 COI signed | | 07/25/2023 | 12/07/2023 | |
| Primary Reviewer 2 COI signed | | 07/21/2023 | 12/07/2023 | |
| Primary Reviewer 3 COI signed | | 07/14/2023 | 12/07/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/07/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/21/2023 | 12/07/2023 | |
| | Primary Reviewer 2 critique submitted | 08/20/2023 | 12/07/2023 | |
| | Primary Reviewer 3 critique submitted | 08/01/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/07/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/07/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/28/2023 | 12/07/2023 | |
| | Recommended for full review | YES | 12/07/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/07/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/05/2023 | 12/07/2023 | |
| | Primary Reviewer 1 COI signed | 09/22/2023 | 12/07/2023 | |
| | Primary Reviewer 2 COI signed | 09/05/2023 | 12/07/2023 | |
| | Primary Reviewer 3 COI signed | 09/05/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 09/06/2023 | 12/07/2023 | |
| | Primary Reviewer 1 critique submitted | 10/07/2023 | 12/07/2023 | |
| | Primary Reviewer 2 critique submitted | 10/06/2023 | 12/07/2023 | |
| | Primary Reviewer 3 critique submitted | 10/04/2023 | 12/07/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/04/2023 | 12/07/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/07/2023 | |
| | COI recused from participation | N/A | 12/07/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/07/2023 | |
| | Peer Review Meeting | 10/11/2023 | 12/07/2023 | |
| | Post review statements signed | 10/12/2023 | 12/07/2023 | |
| | Third Party Observer Report | 10/16/2023 | 12/07/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/07/2023 | |
| | Recommended for SRC review | YES | 12/07/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240259
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to the Clinical and Translational Cancer Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:09 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240259
APPLICATION TITLE: Targeting Cancer-associated Lactobacillus iners to improve response to cancer therapy
APPLICANT NAME: Colbert, Lauren E
ORGANIZATION: MDACC/BLI
PANEL NAME: 24.1 Clinical and Translational Cancer Research Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/09/2023 | 12/19/2023 | |
| | Method of submission | CARS | 12/19/2023 | |
| | Within receipt period | YES | 12/19/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/19/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/19/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/19/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/19/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/19/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/19/2023 | |
| Primary Reviewer 1 COI signed | | 07/19/2023 | 12/19/2023 | |
| Primary Reviewer 2 COI signed | | 07/14/2023 | 12/19/2023 | |
| Primary Reviewer 3 COI signed | | 07/21/2023 | 12/19/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/19/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/20/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 08/10/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 08/13/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/23/2023 | 12/19/2023 | |
| | Recommended for full review | YES | 12/19/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/19/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/06/2023 | 12/19/2023 | |
| | Primary Reviewer 1 COI signed | 09/26/2023 | 12/19/2023 | |
| | Primary Reviewer 2 COI signed | 09/24/2023 | 12/19/2023 | |
| | Primary Reviewer 3 COI signed | 09/24/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/19/2023 | |
| | Primary Reviewer 1 critique submitted | 09/30/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 10/10/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 10/08/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 09/17/2023 | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | COI recused from participation | N/A | 12/19/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/19/2023 | |
| | Peer Review Meeting | 10/17/2023 | 12/19/2023 | |
| | Post review statements signed | 10/19/2023 | 12/19/2023 | |
| | Third Party Observer Report | 10/23/2023 | 12/19/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/19/2023 | |
| | Recommended for SRC review | YES | 12/19/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240263
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:09 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240263
APPLICATION TITLE: Identifying the Biological Determinants of Aggressive Meningioma
APPLICANT NAME: Patel, Akash J
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 24.1 Cancer Biology Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/14/2023 | 12/15/2023 | |
| | Method of submission | CARS | 12/15/2023 | |
| | Within receipt period | YES | 12/15/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/15/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/15/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | 07/12/2023 | 12/15/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/15/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/15/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/15/2023 | |
| Primary Reviewer 1 COI signed | | 07/20/2023 | 12/15/2023 | |
| Primary Reviewer 2 COI signed | | 07/19/2023 | 12/15/2023 | |
| Primary Reviewer 3 COI signed | | 07/15/2023 | 12/15/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/15/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/20/2023 | 12/15/2023 | |
| | Primary Reviewer 2 critique submitted | 08/11/2023 | 12/15/2023 | |
| | Primary Reviewer 3 critique submitted | 08/20/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/15/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/15/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/25/2023 | 12/15/2023 | |
| | Recommended for full review | YES | 12/15/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/15/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/04/2023 | 12/15/2023 | |
| | Primary Reviewer 1 COI signed | 09/27/2023 | 12/15/2023 | |
| | Primary Reviewer 2 COI signed | 09/11/2023 | 12/15/2023 | |
| | Primary Reviewer 3 COI signed | 09/04/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/15/2023 | |
| | Primary Reviewer 1 critique submitted | 10/10/2023 | 12/15/2023 | |
| | Primary Reviewer 2 critique submitted | 10/09/2023 | 12/15/2023 | |
| | Primary Reviewer 3 critique submitted | 10/10/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 09/16/2023 | 12/15/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/15/2023 | |
| | COI recused from participation | N/A | 12/15/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/15/2023 | |
| | Peer Review Meeting | 10/18/2023 | 12/15/2023 | |
| | Post review statements signed | 10/20/2023 | 12/15/2023 | |
| | Third Party Observer Report | 10/26/2023 | 01/17/2024 | |
| Score report delivered to CSO | 11/03/2023 | 12/15/2023 | | |
| Recommended for SRC review | YES | 12/15/2023 | | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240272
Individual Investigator Research Awards for
Cancer in Children and Adolescents

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Cancer in Children and Adolescents* Request for Applications (RFA). CPRIT received 35 applications in response to this RFA. This application was assigned to the Clinical and Translational Cancer Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application that was not recommended for a grant award has a score that is more favorable than an application that was recommended for a grant award by the Scientific Review Council (SRC). Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the SRC for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend one of the *Individual Investigator Research Awards for Cancer in Children and Adolescents* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed

above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:09 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Cancer in Children and Adolescents
APPLICATION ID: RP240272
APPLICATION TITLE: The epigenetic impact and therapeutic opportunity of AR directed therapy for DSRCT
APPLICANT NAME: Ludwig, Joseph A
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 24.1 Clinical and Translational Cancer Research Full

| Category | Compliance Requirement | Information | Attestation Date |
|--|---|---|------------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 |
| | Date application submitted | 06/09/2023 | 12/19/2023 |
| | Method of submission | CARS | 12/19/2023 |
| | Within receipt period | YES | 12/19/2023 |
| | Request for extension to submit application after CARS closed | N/A | 12/19/2023 |
| | Request for extension for late application submission accepted | N/A | 12/19/2023 |
| Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/19/2023 |
| | Donation(s) made to CPRIT / foundation | NO | 12/19/2023 |
| | Assigned to primary reviewers | 07/31/2023 | 12/19/2023 |
| | Applicant notified of review panel assignment | 07/13/2023 | 12/19/2023 |
| | Primary Reviewer 1 COI signed | 07/21/2023 | 12/19/2023 |
| | Primary Reviewer 2 COI signed | 07/14/2023 | 12/19/2023 |
| | Primary Reviewer 3 COI signed | 07/22/2023 | 12/19/2023 |
| | Primary (Advocate) Reviewer 4 COI signed | N/A | 12/19/2023 |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/20/2023 | 12/19/2023 |
| | Primary Reviewer 2 critique submitted | 08/19/2023 | 12/19/2023 |
| | Primary Reviewer 3 critique submitted | 08/20/2023 | 12/19/2023 |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/19/2023 |
| | COI indicated by non-primary reviewer | Richard O'Reilly | 12/19/2023 |
| | Preliminary Evaluation score summary sent to Chair | 08/23/2023 | 12/19/2023 |
| | Recommended for full review | YES | 12/19/2023 |
| Peer Review Meeting | Applicant notified of outcome | 09/28/2023 | 12/19/2023 |
| | Assigned to primary reviewers | 09/06/2023 | 12/19/2023 |
| | Primary Reviewer 1 COI signed | 09/26/2023 | 12/19/2023 |
| | Primary Reviewer 2 COI signed | 09/22/2023 | 12/19/2023 |
| | Primary Reviewer 3 COI signed | 10/04/2023 | 12/19/2023 |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/19/2023 |
| | Primary Reviewer 1 critique submitted | 09/29/2023 | 12/19/2023 |
| | Primary Reviewer 2 critique submitted | 10/10/2023 | 12/19/2023 |
| | Primary Reviewer 3 critique submitted | 10/11/2023 | 12/19/2023 |
| | Primary (Advocate) Reviewer 4 critique submitted | 09/18/2023 | 12/19/2023 |
| | COI indicated by non-primary reviewer | Richard O'Reilly | 12/19/2023 |
| | COI recused from participation | YES | 12/19/2023 |
| | Discussed at Peer Review Meeting | YES | 12/19/2023 |
| | Peer Review Meeting | 10/17/2023 | 12/19/2023 |
| | Post review statements signed | 10/19/2023 | 12/19/2023 |
| | Third Party Observer Report | 10/23/2023 | 12/19/2023 |
| | Score report delivered to CSO | 11/03/2023 | 12/19/2023 |
| | Recommended for SRC review | YES | 12/19/2023 |
| Final SRC Recommendation | COI indicated by SRC member | Joseph Ludwig | 01/04/2024 |
| | COI recused from participation | Other: Present at SRC meeting per FY2024 Waiver for Review Council Members | 01/04/2024 |
| | SRC Meeting | 12/14/2023 | 01/04/2024 |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 |
| | Recommended for grant award | YES | 01/04/2024 |
| PIC Review | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 |
| | COI indicated by PIC member | None | 02/07/2024 |
| | COI recused from participation | N/A | 02/07/2024 |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 |
| Oversight Committee Approval | Recommended for grant award | YES | 02/07/2024 |
| | CEO Notification to Oversight Committee | N/A | |
| | COI Indicated by Oversight Committee member | N/A | |
| | COI Recused from participation | N/A | |
| | Donation(s) made to CPRIT / foundation | N/A | |
| | Presented to CPRIT Oversight Committee | N/A | |
| | Award approved by Oversight Committee | N/A | |
| | Authority to advance funds requested | N/A | |
| Advance authority approved by Oversight Committee | N/A | | |
| Comments: | | | |
| Comment | | | |

Joseph Ludwig present at SRC meeting per FY2024 Waiver for Review Council Members.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240287
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:09 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240287
APPLICATION TITLE: Investigating the Impact of Interferon Gamma Signaling on Therapeutic Resistance in Acute Myeloid Leukemia
APPLICANT NAME: Abbas, Hussein
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 24.1 Cancer Biology Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/12/2023 | 12/15/2023 | |
| | Method of submission | CARS | 12/15/2023 | |
| | Within receipt period | YES | 12/15/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/15/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/15/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/15/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/15/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/15/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/15/2023 | |
| Primary Reviewer 1 COI signed | | 07/20/2023 | 12/15/2023 | |
| Primary Reviewer 2 COI signed | | 07/14/2023 | 12/15/2023 | |
| Primary Reviewer 3 COI signed | | 07/14/2023 | 12/15/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/15/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/17/2023 | 12/15/2023 | |
| | Primary Reviewer 2 critique submitted | 08/21/2023 | 12/15/2023 | |
| | Primary Reviewer 3 critique submitted | 08/11/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/15/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/15/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/25/2023 | 12/15/2023 | |
| | Recommended for full review | YES | 12/15/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/15/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/04/2023 | 12/15/2023 | |
| | Primary Reviewer 1 COI signed | 10/09/2023 | 12/15/2023 | |
| | Primary Reviewer 2 COI signed | 09/05/2023 | 12/15/2023 | |
| | Primary Reviewer 3 COI signed | 09/05/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 09/09/2023 | 12/15/2023 | |
| | Primary Reviewer 1 critique submitted | 10/12/2023 | 12/15/2023 | |
| | Primary Reviewer 2 critique submitted | 10/09/2023 | 12/15/2023 | |
| | Primary Reviewer 3 critique submitted | 10/15/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/07/2023 | 12/15/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/15/2023 | |
| | COI recused from participation | N/A | 12/15/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/15/2023 | |
| | Peer Review Meeting | 10/18/2023 | 12/15/2023 | |
| | Post review statements signed | 10/20/2023 | 12/15/2023 | |
| | Third Party Observer Report | 10/26/2023 | 01/17/2024 | |
| | Score report delivered to CSO | 11/03/2023 | 12/15/2023 | |
| | Recommended for SRC review | YES | 12/15/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240288
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to Basic Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.


At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:10 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240288
APPLICATION TITLE: Epigenetic mechanism and targeting during response to BRAFi/anti-EGFR therapy in BRAF-mutant colorectal cancers
APPLICANT NAME: Kopetz, Scott
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 24.1 Basic Cancer Research 1 Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/08/2023 | 12/05/2023 | |
| | Method of submission | CARS | 12/05/2023 | |
| | Within receipt period | YES | 12/05/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/05/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/05/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/05/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/05/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/05/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/05/2023 | |
| Primary Reviewer 1 COI signed | | 07/14/2023 | 12/05/2023 | |
| Primary Reviewer 2 COI signed | | 07/14/2023 | 12/05/2023 | |
| Primary Reviewer 3 COI signed | | 07/14/2023 | 12/05/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/05/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/03/2023 | 12/05/2023 | |
| | Primary Reviewer 2 critique submitted | 08/15/2023 | 12/05/2023 | |
| | Primary Reviewer 3 critique submitted | 08/20/2023 | 12/05/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/05/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/05/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/28/2023 | 12/05/2023 | |
| | Recommended for full review | YES | 12/05/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/05/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/04/2023 | 12/05/2023 | |
| | Primary Reviewer 1 COI signed | 09/04/2023 | 12/05/2023 | |
| | Primary Reviewer 2 COI signed | 09/05/2023 | 12/05/2023 | |
| | Primary Reviewer 3 COI signed | 09/09/2023 | 12/05/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/05/2023 | |
| | Primary Reviewer 1 critique submitted | 10/04/2023 | 12/05/2023 | |
| | Primary Reviewer 2 critique submitted | 10/04/2023 | 12/05/2023 | |
| | Primary Reviewer 3 critique submitted | 10/15/2023 | 12/05/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/06/2023 | 12/05/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/05/2023 | |
| | COI recused from participation | N/A | 12/05/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/05/2023 | |
| | Peer Review Meeting | 10/20/2023 | 12/05/2023 | |
| | Post review statements signed | 11/09/2023 | 12/05/2023 | |
| | Third Party Observer Report | 10/26/2023 | 12/05/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/05/2023 | |
| | Recommended for SRC review | YES | 12/05/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240289
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to the Imaging Technology and Informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:10 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240289
APPLICATION TITLE: Real-time, label-free, micro HSI device and transformer-based attention networks for oral cancer imaging
APPLICANT NAME: Fei, Baowei
ORGANIZATION: The University of Texas at Dallas
PANEL NAME: 24.1 Imaging Technology and Informatics Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/12/2023 | 12/19/2023 | |
| | Method of submission | CARS | 12/19/2023 | |
| | Within receipt period | YES | 12/19/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/19/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/19/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/19/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/19/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/19/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/19/2023 | |
| Primary Reviewer 1 COI signed | | 07/14/2023 | 12/19/2023 | |
| Primary Reviewer 2 COI signed | | 07/27/2023 | 12/19/2023 | |
| Primary Reviewer 3 COI signed | | 07/20/2023 | 12/19/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/19/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/20/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 07/31/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 08/07/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/23/2023 | 12/19/2023 | |
| | Recommended for full review | YES | 12/19/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/19/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/07/2023 | 12/19/2023 | |
| | Primary Reviewer 1 COI signed | 09/04/2023 | 12/19/2023 | |
| | Primary Reviewer 2 COI signed | 09/26/2023 | 12/19/2023 | |
| | Primary Reviewer 3 COI signed | 09/14/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 09/05/2023 | 12/19/2023 | |
| | Primary Reviewer 1 critique submitted | 10/05/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 10/14/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 10/02/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/12/2023 | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | COI recused from participation | N/A | 12/19/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/19/2023 | |
| | Peer Review Meeting | 10/19/2023 | 12/19/2023 | |
| | Post review statements signed | 10/19/2023 | 12/19/2023 | |
| | Third Party Observer Report | 10/26/2023 | 12/19/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/19/2023 | |
| | Recommended for SRC review | YES | 12/19/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240291
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to Basic Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:10 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240291
APPLICATION TITLE: Targeting MYCN disruption of the molecular clock and tumor metabolism in neuroblastoma oncogenesis.
APPLICANT NAME: Barbieri, Eveline
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 24.1 Basic Cancer Research 1 Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/14/2023 | 12/05/2023 | |
| | Method of submission | CARS | 12/05/2023 | |
| | Within receipt period | YES | 12/05/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/05/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/05/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/05/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/05/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/05/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/05/2023 | |
| Primary Reviewer 1 COI signed | | 07/21/2023 | 12/05/2023 | |
| Primary Reviewer 2 COI signed | | 07/14/2023 | 12/05/2023 | |
| Primary Reviewer 3 COI signed | | 07/14/2023 | 12/05/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/05/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/09/2023 | 12/05/2023 | |
| | Primary Reviewer 2 critique submitted | 08/03/2023 | 12/05/2023 | |
| | Primary Reviewer 3 critique submitted | 08/23/2023 | 12/05/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/05/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/05/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/28/2023 | 12/05/2023 | |
| | Recommended for full review | YES | 12/05/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/05/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/04/2023 | 12/05/2023 | |
| | Primary Reviewer 1 COI signed | 09/05/2023 | 12/05/2023 | |
| | Primary Reviewer 2 COI signed | 09/04/2023 | 12/05/2023 | |
| | Primary Reviewer 3 COI signed | 09/04/2023 | 12/05/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/05/2023 | |
| | Primary Reviewer 1 critique submitted | 10/13/2023 | 12/05/2023 | |
| | Primary Reviewer 2 critique submitted | 10/04/2023 | 12/05/2023 | |
| | Primary Reviewer 3 critique submitted | 10/09/2023 | 12/05/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/12/2023 | 12/05/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/05/2023 | |
| | COI recused from participation | N/A | 12/05/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/05/2023 | |
| | Peer Review Meeting | 10/20/2023 | 12/05/2023 | |
| | Post review statements signed | 11/09/2023 | 12/05/2023 | |
| | Third Party Observer Report | 10/26/2023 | 12/05/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/05/2023 | |
| | Recommended for SRC review | YES | 12/05/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240293
Individual Investigator Research Awards for
Computational Systems Biology of Cancer

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Computational Systems Biology of Cancer* Request for Applications (RFA). CPRIT received 18 applications in response to this RFA. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 8th day of February, 2024, by WAYNE R. ROBERTS.



 Sandra Reyes
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:10 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Computational Systems Biology of Cancer
APPLICATION ID: RP240293
APPLICATION TITLE: Therapeutic vulnerabilities and predictors of response to chemo(immuno)therapy in patients with high-risk, early stage triple-negative breast cancer (TNBC)
APPLICANT NAME: Korkut, Anil
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 24.1 Cancer Biology Full

| Category | Compliance Requirement | Information | Attestation | |
|---|--|--|-------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/08/2023 | 12/15/2023 | |
| | Method of submission | CARS | 12/15/2023 | |
| | Within receipt period | YES | 12/15/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/15/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/15/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/15/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/15/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/15/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/15/2023 | |
| Primary Reviewer 1 COI signed | | 07/15/2023 | 12/15/2023 | |
| Primary Reviewer 2 COI signed | | 07/20/2023 | 12/15/2023 | |
| Primary Reviewer 3 COI signed | | 07/14/2023 | 12/15/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/15/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/21/2023 | 12/15/2023 | |
| | Primary Reviewer 2 critique submitted | 08/24/2023 | 12/15/2023 | |
| | Primary Reviewer 3 critique submitted | 08/20/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/15/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/15/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/25/2023 | 12/15/2023 | |
| | Recommended for full review | YES | 12/15/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/15/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/04/2023 | 12/15/2023 | |
| | Primary Reviewer 1 COI signed | 10/04/2023 | 12/15/2023 | |
| | Primary Reviewer 2 COI signed | 09/05/2023 | 12/15/2023 | |
| | Primary Reviewer 3 COI signed | 09/01/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/15/2023 | |
| | Primary Reviewer 1 critique submitted | 10/11/2023 | 12/15/2023 | |
| | Primary Reviewer 2 critique submitted | 10/15/2023 | 12/15/2023 | |
| | Primary Reviewer 3 critique submitted | 10/05/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 09/13/2023 | 12/15/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/15/2023 | |
| | COI recused from participation | N/A | 12/15/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/15/2023 | |
| | Peer Review Meeting | 10/18/2023 | 12/15/2023 | |
| | Post review statements signed | 10/20/2023 | 12/15/2023 | |
| | Third Party Observer Report | 10/26/2023 | 01/17/2024 | |
| | Score report delivered to CSO | 11/03/2023 | 12/15/2023 | |
| | Recommended for SRC review | YES | 12/15/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240320
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:11 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240320
APPLICATION TITLE: Benzothiazepines as first-in-class inhibitors for the ribogenesis factor NVL and evaluation in preclinical colorectal cancer models
APPLICANT NAME: De Brabander, Jef K
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 24.1 Cancer Biology Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/13/2023 | 12/15/2023 | |
| | Method of submission | CARS | 12/15/2023 | |
| | Within receipt period | YES | 12/15/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/15/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/15/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/15/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/15/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/15/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/15/2023 | |
| Primary Reviewer 1 COI signed | | 07/23/2023 | 12/15/2023 | |
| Primary Reviewer 2 COI signed | | 07/20/2023 | 12/15/2023 | |
| Primary Reviewer 3 COI signed | | 08/01/2023 | 12/15/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/15/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/11/2023 | 12/15/2023 | |
| | Primary Reviewer 2 critique submitted | 08/20/2023 | 12/15/2023 | |
| | Primary Reviewer 3 critique submitted | 08/22/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/15/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/15/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/25/2023 | 12/15/2023 | |
| | Recommended for full review | YES | 12/15/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/15/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/04/2023 | 12/15/2023 | |
| | Primary Reviewer 1 COI signed | 09/05/2023 | 12/15/2023 | |
| | Primary Reviewer 2 COI signed | 09/27/2023 | 12/15/2023 | |
| | Primary Reviewer 3 COI signed | 10/10/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 09/09/2023 | 12/15/2023 | |
| | Primary Reviewer 1 critique submitted | 10/13/2023 | 12/15/2023 | |
| | Primary Reviewer 2 critique submitted | 10/10/2023 | 12/15/2023 | |
| | Primary Reviewer 3 critique submitted | 10/13/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/07/2023 | 12/15/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/15/2023 | |
| | COI recused from participation | N/A | 12/15/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/15/2023 | |
| | Peer Review Meeting | 10/18/2023 | 12/15/2023 | |
| | Post review statements signed | 10/20/2023 | 12/15/2023 | |
| | Third Party Observer Report | 10/26/2023 | 01/17/2024 | |
| | Score report delivered to CSO | 11/03/2023 | 12/15/2023 | |
| | Recommended for SRC review | YES | 12/15/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240326
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:11 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240326
APPLICATION TITLE: Translation of gut commensal bacteria peptidoglycan remodeling pathway for chimeric antigen receptor T-cell therapy
APPLICANT NAME: Saini, Neeraj Y
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 24.1 Cancer Biology Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/12/2023 | 12/15/2023 | |
| | Method of submission | CARS | 12/15/2023 | |
| | Within receipt period | YES | 12/15/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/15/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/15/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/15/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/15/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/15/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/15/2023 | |
| Primary Reviewer 1 COI signed | | 07/20/2023 | 12/15/2023 | |
| Primary Reviewer 2 COI signed | | 07/14/2023 | 12/15/2023 | |
| Primary Reviewer 3 COI signed | | 07/20/2023 | 12/15/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/15/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/17/2023 | 12/15/2023 | |
| | Primary Reviewer 2 critique submitted | 08/11/2023 | 12/15/2023 | |
| | Primary Reviewer 3 critique submitted | 08/24/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/15/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/15/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/25/2023 | 12/15/2023 | |
| | Recommended for full review | YES | 12/15/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/15/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/04/2023 | 12/15/2023 | |
| | Primary Reviewer 1 COI signed | 10/10/2023 | 12/15/2023 | |
| | Primary Reviewer 2 COI signed | 08/30/2023 | 12/15/2023 | |
| | Primary Reviewer 3 COI signed | 10/09/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/15/2023 | |
| | Primary Reviewer 1 critique submitted | 10/13/2023 | 12/15/2023 | |
| | Primary Reviewer 2 critique submitted | 09/09/2023 | 12/15/2023 | |
| | Primary Reviewer 3 critique submitted | 10/12/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 09/17/2023 | 12/15/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/15/2023 | |
| | COI recused from participation | N/A | 12/15/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/15/2023 | |
| | Peer Review Meeting | 10/18/2023 | 12/15/2023 | |
| | Post review statements signed | 10/20/2023 | 12/15/2023 | |
| | Third Party Observer Report | 10/26/2023 | 01/17/2024 | |
| | Score report delivered to CSO | 11/03/2023 | 12/15/2023 | |
| | Recommended for SRC review | YES | 12/15/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240380
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to the Cancer Prevention Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:11 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240380
APPLICATION TITLE: Clonal hematopoiesis for improving lung cancer risk assessment
APPLICANT NAME: Cheng, Chao
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 24.1 Cancer Prevention Research Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/13/2023 | 12/18/2023 | |
| | Method of submission | CARS | 12/18/2023 | |
| | Within receipt period | YES | 12/18/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/18/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/18/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | 07/12/2023 | 12/18/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/18/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/18/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/18/2023 | |
| Primary Reviewer 1 COI signed | | 07/31/2023 | 12/18/2023 | |
| Primary Reviewer 2 COI signed | | 07/17/2023 | 12/18/2023 | |
| Primary Reviewer 3 COI signed | | 07/20/2023 | 12/18/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/18/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/21/2023 | 12/18/2023 | |
| | Primary Reviewer 2 critique submitted | 08/18/2023 | 12/18/2023 | |
| | Primary Reviewer 3 critique submitted | 08/20/2023 | 12/18/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/18/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/18/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/23/2023 | 12/18/2023 | |
| | Recommended for full review | YES | 12/18/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/18/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/02/2023 | 12/18/2023 | |
| | Primary Reviewer 1 COI signed | 09/29/2023 | 12/18/2023 | |
| | Primary Reviewer 2 COI signed | 09/19/2023 | 12/18/2023 | |
| | Primary Reviewer 3 COI signed | 09/25/2023 | 12/18/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/18/2023 | |
| | Primary Reviewer 1 critique submitted | 10/09/2023 | 12/18/2023 | |
| | Primary Reviewer 2 critique submitted | 10/05/2023 | 12/18/2023 | |
| | Primary Reviewer 3 critique submitted | 10/05/2023 | 12/18/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/03/2023 | 12/18/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/18/2023 | |
| | COI recused from participation | N/A | 12/18/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/18/2023 | |
| | Peer Review Meeting | 10/13/2023 | 12/18/2023 | |
| | Post review statements signed | 10/14/2023 | 12/18/2023 | |
| | Third Party Observer Report | 10/16/2023 | 12/18/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/18/2023 | |
| | Recommended for SRC review | YES | 12/18/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240392
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 228 applications in response to this RFA, including four withdrawn applications. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend five of the *Individual Investigator Research Awards* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:11 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP240392
APPLICATION TITLE: Identifying Tumor Specific Vulnerabilities in Appendiceal Adenocarcinoma: A Systems Approach
APPLICANT NAME: Shen, John Paul Y
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 24.1 Cancer Biology Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/12/2023 | 12/15/2023 | |
| | Method of submission | CARS | 12/15/2023 | |
| | Within receipt period | YES | 12/15/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/15/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/15/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/15/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/15/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/15/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/15/2023 | |
| Primary Reviewer 1 COI signed | | 07/15/2023 | 12/15/2023 | |
| Primary Reviewer 2 COI signed | | 07/16/2023 | 12/15/2023 | |
| Primary Reviewer 3 COI signed | | 07/23/2023 | 12/15/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/15/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/20/2023 | 12/15/2023 | |
| | Primary Reviewer 2 critique submitted | 08/14/2023 | 12/15/2023 | |
| | Primary Reviewer 3 critique submitted | 08/11/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/15/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/15/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/25/2023 | 12/15/2023 | |
| | Recommended for full review | YES | 12/15/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/15/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/04/2023 | 12/15/2023 | |
| | Primary Reviewer 1 COI signed | 09/04/2023 | 12/15/2023 | |
| | Primary Reviewer 2 COI signed | 09/04/2023 | 12/15/2023 | |
| | Primary Reviewer 3 COI signed | 09/05/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 09/09/2023 | 12/15/2023 | |
| | Primary Reviewer 1 critique submitted | 10/10/2023 | 12/15/2023 | |
| | Primary Reviewer 2 critique submitted | 10/08/2023 | 12/15/2023 | |
| | Primary Reviewer 3 critique submitted | 10/13/2023 | 12/15/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 10/07/2023 | 12/15/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/15/2023 | |
| | COI recused from participation | N/A | 12/15/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/15/2023 | |
| | Peer Review Meeting | 10/18/2023 | 12/15/2023 | |
| | Post review statements signed | 10/20/2023 | 12/15/2023 | |
| | Third Party Observer Report | 10/26/2023 | 01/17/2024 | |
| | Score report delivered to CSO | 11/03/2023 | 12/15/2023 | |
| | Recommended for SRC review | YES | 12/15/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240401
Individual Investigator Research Awards for
Cancer in Children and Adolescents

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Cancer in Children and Adolescents* Request for Applications (RFA). CPRIT received 35 applications in response to this RFA. This application was assigned to the Clinical and Translational Cancer Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that one application that was not recommended for a grant award has a score that is more favorable than an application that was recommended for a grant award by the Scientific Review Council (SRC). Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the SRC for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

At their February 7 meeting, the PIC did not recommend one of the *Individual Investigator Research Awards for Cancer in Children and Adolescents* applications recommended by the SRC. The PIC made this decision based on the recommendation from the Chief Scientific Officer who explained that the total award recommendations from the SRC exceeded the amount of agency funds available.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed

above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:11 AM CT

FY: 2024
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Cancer in Children and Adolescents
APPLICATION ID: RP240401
APPLICATION TITLE: Lead Optimization, Target Engagement and Efficacy Studies of Locally Bioavailable COX-2 inhibitors for Preventing Colon Cancer Progression in FAP Children
APPLICANT NAME: Hu, Ming
ORGANIZATION: University of Houston
PANEL NAME: 24.1 Clinical and Translational Cancer Research Full

| Category | Compliance Requirement | Information | Attestation Date | |
|--|---|---|-------------------|------------|
| Pre-Receipt | RFA Approved by CSO | 02/16/2023 | 11/21/2023 | |
| | RFA Approved by CSO (revised) | 05/16/2023 | 11/21/2023 | |
| | RFA published in Texas.gov eGrants | 02/21/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 03/15/2023 | 11/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 06/14/2023 | 11/21/2023 | |
| | Date application submitted | 06/14/2023 | 12/19/2023 | |
| | Method of submission | CARS | 12/19/2023 | |
| | Within receipt period | YES | 12/19/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/19/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/19/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/19/2023 |
| | | Donation(s) made to CPRIT / foundation | NO | 12/19/2023 |
| | | Assigned to primary reviewers | 07/31/2023 | 12/19/2023 |
| Applicant notified of review panel assignment | | 07/13/2023 | 12/19/2023 | |
| Primary Reviewer 1 COI signed | | 07/19/2023 | 12/19/2023 | |
| Primary Reviewer 2 COI signed | | 07/14/2023 | 12/19/2023 | |
| Primary Reviewer 3 COI signed | | 07/21/2023 | 12/19/2023 | |
| Primary (Advocate) Reviewer 4 COI signed | | N/A | 12/19/2023 | |
| Preliminary Evaluation | Primary Reviewer 1 critique submitted | 08/20/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 08/20/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 08/20/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | N/A | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | Preliminary Evaluation score summary sent to Chair | 08/23/2023 | 12/19/2023 | |
| | Recommended for full review | YES | 12/19/2023 | |
| | Applicant notified of outcome | 09/28/2023 | 12/19/2023 | |
| Peer Review Meeting | Assigned to primary reviewers | 09/06/2023 | 12/19/2023 | |
| | Primary Reviewer 1 COI signed | 09/24/2023 | 12/19/2023 | |
| | Primary Reviewer 2 COI signed | 09/22/2023 | 12/19/2023 | |
| | Primary Reviewer 3 COI signed | 09/26/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 COI signed | 08/30/2023 | 12/19/2023 | |
| | Primary Reviewer 1 critique submitted | 10/10/2023 | 12/19/2023 | |
| | Primary Reviewer 2 critique submitted | 10/11/2023 | 12/19/2023 | |
| | Primary Reviewer 3 critique submitted | 09/29/2023 | 12/19/2023 | |
| | Primary (Advocate) Reviewer 4 critique submitted | 09/26/2023 | 12/19/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/19/2023 | |
| | COI recused from participation | N/A | 12/19/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/19/2023 | |
| | Peer Review Meeting | 10/17/2023 | 12/19/2023 | |
| | Post review statements signed | 10/19/2023 | 12/19/2023 | |
| | Third Party Observer Report | 10/23/2023 | 12/19/2023 | |
| | Score report delivered to CSO | 11/03/2023 | 12/19/2023 | |
| | Recommended for SRC review | YES | 12/19/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 01/04/2024 | |
| | COI recused from participation | N/A | 01/04/2024 | |
| | SRC Meeting | 12/14/2023 | 01/04/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/26/2024 | |
| | Recommended for grant award | YES | 01/04/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR240007
Recruitment of Established Investigators
Nomination of Xiling Shen, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of Established Investigators* Request for Applications (RFA). CPRIT received three applications in response to this RFA during cycles 24.3 through 24.5. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 8th day of February, 2024,
 by WAYNE R. ROBERTS.



 Sandra Reyes
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 11:11 AM CT

| FF: | 2024 | | | |
|---|---|--|------------------|------------|
| CYCLE: | 1 | | | |
| PROGRAM: | Recruitment | | | |
| MECHANISM: | Recruitment of Established Investigators | | | |
| APPLICATION ID: | RR240007 | | | |
| APPLICATION TITLE | Building a multi-modal platform to enable next-generation functional precision oncology | | | |
| APPLICANT NAME: | Shen, Xiling | | | |
| ORGANIZATION: | The University of Texas M. D. Anderson Cancer Center | | | |
| PANEL NAME: | Recruitment FY24 Cycle 3 and 4 | | | |
| Category | Compliance Requirement | Information | Attestation Date | |
| Pre-Receipt | RFA Approved by CSO | 06/20/2023 | 09/29/2023 | |
| | RFA published in Texas.gov eGrants | 06/22/2023 | 09/29/2023 | |
| | CPRIT Application Receipt Cycle opened | 08/22/2023 | 12/04/2023 | |
| | CPRIT Application Receipt Cycle closed | 09/20/2023 | 12/04/2023 | |
| | CPRIT Application Receipt Cycle opened - 24.4 | 09/21/2023 | 12/04/2023 | |
| | CPRIT Application Receipt Cycle closed - 24.4 | 10/20/2023 | 12/04/2023 | |
| | Date application submitted | 10/19/2023 | 12/04/2023 | |
| | Method of submission | CARS | 12/04/2023 | |
| | Within receipt period | YES | 12/04/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | 10/31/2023 | 12/04/2023 |
| Donation(s) made to CPRIT / foundation | | NO | 12/04/2023 | |
| Assigned to primary reviewers | | 11/03/2023 | 12/04/2023 | |
| Applicant notified of review panel assignment | | N/A | 12/04/2023 | |
| Primary Reviewer 1 COI signed | | 10/28/2023 | 12/04/2023 | |
| Primary Reviewer 2 COI signed | | 10/24/2023 | 12/04/2023 | |
| Peer Review Meeting | | Primary Reviewer 1 critique submitted | 11/12/2023 | 12/04/2023 |
| | | Primary Reviewer 2 critique submitted | 11/12/2023 | 12/04/2023 |
| | COI indicated by non-primary reviewer | NONE | 12/04/2023 | |
| | COI recused from participation | N/A | 12/04/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/04/2023 | |
| | Peer Review Meeting | 11/16/2023 | 12/04/2023 | |
| | Post review statements signed | 11/16/2023 | 12/04/2023 | |
| | Third Party Observer Report | 11/17/2023 | 12/04/2023 | |
| | Score report delivered to CSO | 11/20/2023 | 12/04/2023 | |
| | Recommended for SRC review | YES | 12/04/2023 | |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 12/04/2023 | |
| | COI recused from participation | N/A | 12/04/2023 | |
| | SRC Meeting | 11/16/2023 | 12/04/2023 | |
| | Third Party Observer Report | 11/17/2023 | 12/04/2023 | |
| | Recommended for grant award | Other: Recommendation of funding contingent on additional information requested from the PI. | 01/03/2024 | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 | |
| | COI indicated by SRC member (2nd Meeting) | NONE | 01/03/2024 | |
| | COI recused from participation (2nd Meeting) | N/A | 01/03/2024 | |
| | 2nd SRC Meeting | 12/14/2023 | 01/03/2024 | |
| | Third Party Observer Report (2nd Meeting) | 01/17/2024 | 01/24/2024 | |
| PIC Review | Recommended for grant award | YES | 01/03/2024 | |
| | Candidate not accepted position prior to SRC date | YES | 02/07/2024 | |
| | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | NO | | |
| | Authority to advance funds requested | N/A | | |
| Advance authority approved by Oversight Committee | N/A | | | |
| Comments: | | | | |
| Comment | | | Created Date | |
| No Comment | | | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR240013
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Kevin Mark, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received four applications in response to this RFA during cycles 24.3 through 24.5. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 8th day of February, 2024,
 by WAYNE R. ROBERTS.



 Sandra Reyes
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 02/09/2024 11:11 AM CT

| | | | |
|-----------------------------------|---|--------------|------------------|
| FY: | 2024 | | |
| CYCLE: | 1 | | |
| PROGRAM: | Recruitment | | |
| MECHANISM: | Recruitment of First-Time, Tenure-Track Faculty Members | | |
| APPLICATION ID: | RR240013 | | |
| APPLICATION TITLE | Regulation of gene expression and tumorigenesis by ubiquitin-mediated protein quality control | | |
| APPLICANT NAME: | Mark, Kevin | | |
| ORGANIZATION: | The University of Texas Southwestern Medical Center | | |
| PANEL NAME: | Recruitment FY24 Cycle 3 and 4 | | |
| Category | Compliance Requirement | Information | Attestation Date |
| Pre-Receipt | RFA Approved by CSO | 06/20/2023 | 09/29/2023 |
| | RFA published in Texas.gov eGrants | 06/22/2023 | 09/29/2023 |
| | CPRIT Application Receipt Cycle opened | 08/22/2023 | 12/04/2023 |
| | CPRIT Application Receipt Cycle closed | 09/20/2023 | 12/04/2023 |
| | Date application submitted | 09/19/2023 | 12/04/2023 |
| | Method of submission | CARS | 12/04/2023 |
| | Within receipt period | YES | 12/04/2023 |
| | | N/A | 12/04/2023 |
| | | NO | 12/04/2023 |
| | | 11/03/2023 | 12/04/2023 |
| Receipt, Referral, and Assignment | Administrative review notification | | |
| | Assigned to primary reviewers | | |
| | Applicant notified of review panel assignment | N/A | 12/04/2023 |
| | Primary Reviewer 1 COI signed | 10/26/2023 | 12/04/2023 |
| | Primary Reviewer 2 COI signed | 10/24/2023 | 12/04/2023 |
| | | 11/13/2023 | 12/04/2023 |
| | Peer Review Meeting | | |
| | Primary Reviewer 1 critique submitted | 11/12/2023 | 12/04/2023 |
| | Primary Reviewer 2 critique submitted | NONE | 12/04/2023 |
| | COI indicated by non-primary reviewer | N/A | 12/04/2023 |
| Peer Review Meeting | COI recused from participation | | |
| | Discussed at Peer Review Meeting | YES | 12/04/2023 |
| | Peer Review Meeting | 11/16/2023 | 12/04/2023 |
| | Post review statements signed | 11/16/2023 | 12/04/2023 |
| | Third Party Observer Report | 11/17/2023 | 12/04/2023 |
| | Score report delivered to CSO | 11/20/2023 | 12/04/2023 |
| | Recommended for SRC review | YES | 12/04/2023 |
| | | NONE | 12/04/2023 |
| | | N/A | 12/04/2023 |
| | | 11/16/2023 | 12/04/2023 |
| Final SRC Recommendation | SRC Meeting | 11/17/2023 | 12/04/2023 |
| | Third Party Observer Report | YES | 12/04/2023 |
| | Recommended for grant award | | |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 |
| | Candidate not accepted asst. prof. tenure track position prior to SRC date | YES | 02/07/2024 |
| | PIC Review | | |
| | COI indicated by PIC member | None | 02/07/2024 |
| | COI recused from participation | N/A | 02/07/2024 |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 |
| | Recommended for grant award | YES | 02/07/2024 |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | |
| | COI Indicated by Oversight Committee member | N/A | |
| | COI Recused from participation | N/A | |
| | Donation(s) made to CPRIT / foundation | N/A | |
| | Presented to CPRIT Oversight Committee | N/A | |
| | Award approved by Oversight Committee | NO | |
| | Authority to advance funds requested | N/A | |
| | Advance authority approved by Oversight Committee | N/A | |
| | | | |
| | | | |
| Comments: | | | |
| Comment | | Created Date | |
| No Comment | | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR240015
Recruitment of Rising Stars
Nomination of Stephan Gloeggler, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of Rising Stars* Request for Applications (RFA). CPRIT received six applications in response to this RFA during cycles 24.3 through 24.5, including one withdrawn application. This application was assigned to the Scientific Review Council (SRC) for review. The SRC recommended three applications from this mechanism to the PIC; however, one application was withdrawn by the nominating institution prior to the PIC meeting. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle

- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 02/09/2024 11:12 AM CT

| | | | |
|-----------------------------------|---|---|------------------|
| FY: | 2024 | | |
| CYCLE: | 1 | | |
| PROGRAM: | Recruitment | | |
| MECHANISM: | Recruitment of Rising Stars | | |
| APPLICATION ID: | RR240015 | | |
| APPLICATION TITLE | HyperGlio - New tools to fight brain cancer with signal-enhanced magnetic resonance | | |
| APPLICANT NAME: | Gloeggler, Stephan | | |
| ORGANIZATION: | The University of Texas Southwestern Medical Center | | |
| PANEL NAME: | Recruitment FY24 Cycle 3 and 4 | | |
| Category | Compliance Requirement | Information | Attestation Date |
| Pre-Receipt | RFA Approved by CSO | 06/20/2023 | 09/29/2023 |
| | RFA published in Texas.gov eGrants | 06/22/2023 | 09/29/2023 |
| | CPRIT Application Receipt Cycle opened | 08/22/2023 | 12/04/2023 |
| | CPRIT Application Receipt Cycle closed | 09/20/2023 | 12/04/2023 |
| | Date application submitted | 09/18/2023 | 12/04/2023 |
| | Method of submission | CARS | 12/04/2023 |
| | Within receipt period | YES | 12/04/2023 |
| | | N/A | 12/04/2023 |
| | | NO | 12/04/2023 |
| | | 11/03/2023 | 12/04/2023 |
| Receipt, Referral, and Assignment | Administrative review notification | | |
| | Assigned to primary reviewers | | |
| | Applicant notified of review panel assignment | N/A | 12/04/2023 |
| | Primary Reviewer 1 COI signed | 11/01/2023 | 12/04/2023 |
| | Primary Reviewer 2 COI signed | 10/31/2023 | 12/04/2023 |
| | | 11/14/2023 | 12/04/2023 |
| | Peer Review Meeting | 11/10/2023 | 12/04/2023 |
| | Primary Reviewer 1 critique submitted | | |
| | Primary Reviewer 2 critique submitted | NONE | 12/04/2023 |
| | COI indicated by non-primary reviewer | N/A | 12/04/2023 |
| Peer Review Meeting | COI recused from participation | | |
| | Discussed at Peer Review Meeting | YES | 12/04/2023 |
| | Peer Review Meeting | 11/16/2023 | 12/04/2023 |
| | Post review statements signed | 11/16/2023 | 12/04/2023 |
| | Third Party Observer Report | 11/17/2023 | 12/04/2023 |
| | Score report delivered to CSO | 11/20/2023 | 12/04/2023 |
| | Recommended for SRC review | YES | 12/04/2023 |
| | | NONE | 12/04/2023 |
| | | N/A | 12/04/2023 |
| | | 11/16/2023 | 12/04/2023 |
| Final SRC Recommendation | SRC Meeting | 11/17/2023 | 12/04/2023 |
| | Third Party Observer Report | | |
| | Recommended for grant award | YES | 12/04/2023 |
| | | 01/03/2024 | 01/24/2024 |
| | SRC Chair Notification to PIC and OC | | |
| | Candidate not accepted position prior to SRC date | YES | 02/07/2024 |
| | | None | 02/07/2024 |
| | PIC Review | N/A | 02/07/2024 |
| | COI indicated by PIC member | | |
| | COI recused from participation | 02/07/2024 | 02/07/2024 |
| PIC Review | PIC Review Meeting | YES | 02/07/2024 |
| | Recommended for grant award | | |
| | | N/A | |
| | Oversight Committee Approval | CEO Notification to Oversight Committee | |
| | | COI Indicated by Oversight Committee member | N/A |
| | | COI Recused from participation | N/A |
| | | Donation(s) made to CPRIT / foundation | N/A |
| | | Presented to CPRIT Oversight Committee | N/A |
| | | Award approved by Oversight Committee | NO |
| | | Authority to advance funds requested | N/A |
| | Advance authority approved by Oversight Committee | N/A | |
| Comments: | | | |
| Comment | | Created Date | |
| No Comment | | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR240016
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Yu Luan, BS, MS, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received four applications in response to this RFA during cycles 24.3 through 24.5. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 02/09/2024 11:12 AM CT

| | | | |
|--|--|--------------------|-------------------------|
| FY: | 2024 | | |
| CYCLE: | 1 | | |
| PROGRAM: | Recruitment | | |
| MECHANISM: | Recruitment of First-Time, Tenure-Track Faculty Members | | |
| APPLICATION ID: | RR240016 | | |
| APPLICATION TITLE | Impact of Germline Variants on Pediatric Leukemia Progression: Insights from 3D Chromatin Remodeling and Clinical Outcomes | | |
| APPLICANT NAME: | Luan, Yu | | |
| ORGANIZATION: | The University of Texas Health Science Center at San Antonio | | |
| PANEL NAME: | Recruitment FY24 Cycle 3 and 4 | | |
| Category | Compliance Requirement | Information | Attestation Date |
| Pre-Receipt | RFA Approved by CSO | 06/20/2023 | 09/29/2023 |
| | RFA published in Texas.gov eGrants | 06/22/2023 | 09/29/2023 |
| | CPRIT Application Receipt Cycle opened | 08/22/2023 | 12/04/2023 |
| | CPRIT Application Receipt Cycle closed | 09/20/2023 | 12/04/2023 |
| | Date application submitted | 09/20/2023 | 12/04/2023 |
| | Method of submission | CARS | 12/04/2023 |
| | Within receipt period | YES | 12/04/2023 |
| | Administrative review notification | N/A | 12/04/2023 |
| | Donation(s) made to CPRIT / foundation | NO | 12/04/2023 |
| | Assigned to primary reviewers | 11/03/2023 | 12/04/2023 |
| Receipt, Referral, and Assignment | Applicant notified of review panel assignment | N/A | 12/04/2023 |
| | Primary Reviewer 1 COI signed | 10/24/2023 | 12/04/2023 |
| | Primary Reviewer 2 COI signed | 11/01/2023 | 12/04/2023 |
| | Primary Reviewer 1 critique submitted | 11/12/2023 | 12/04/2023 |
| | Primary Reviewer 2 critique submitted | 11/14/2023 | 12/04/2023 |
| | COI indicated by non-primary reviewer | NONE | 12/04/2023 |
| | COI recused from participation | N/A | 12/04/2023 |
| | Discussed at Peer Review Meeting | YES | 12/04/2023 |
| Peer Review Meeting | Peer Review Meeting | 11/16/2023 | 12/04/2023 |
| | Post review statements signed | 11/16/2023 | 12/04/2023 |
| | Third Party Observer Report | 11/17/2023 | 12/04/2023 |
| | Score report delivered to CSO | 11/20/2023 | 12/04/2023 |
| | Recommended for SRC review | YES | 12/04/2023 |
| | COI indicated by SRC member | NONE | 12/04/2023 |
| | COI recused from participation | N/A | 12/04/2023 |
| | SRC Meeting | 11/16/2023 | 12/04/2023 |
| | Third Party Observer Report | 11/17/2023 | 12/04/2023 |
| | Recommended for grant award | YES | 12/04/2023 |
| Final SRC Recommendation | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 |
| | Candidate not accepted asst. prof. tenure track position prior to SRC date | YES | 02/07/2024 |
| | COI indicated by PIC member | None | 02/07/2024 |
| | COI recused from participation | N/A | 02/07/2024 |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 |
| | Recommended for grant award | YES | 02/07/2024 |
| | COI indicated by Oversight Committee member | N/A | |
| | COI Recused from participation | N/A | |
| PIC Review | Donation(s) made to CPRIT / foundation | N/A | |
| | Presented to CPRIT Oversight Committee | N/A | |
| | Award approved by Oversight Committee | NO | |
| | Authority to advance funds requested | N/A | |
| | Advance authority approved by Oversight Committee | N/A | |
| | Comments: | | |
| | Comment | | Created Date |
| | No Comment | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR240019
Recruitment of Rising Stars
Nomination of David Sarlah, BS, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of Rising Stars* Request for Applications (RFA). CPRIT received six applications in response to this RFA during cycles 24.3 through 24.5, including one withdrawn application. This application was assigned to the Scientific Review Council (SRC) for review. The SRC recommended three applications from this mechanism to the PIC; however, one application was withdrawn by the nominating institution prior to the PIC meeting. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle

- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 02/09/2024 11:12 AM CT

| | | | |
|-----------------------------------|---|-------------|------------------|
| FY: | 2024 | | |
| CYCLE: | 1 | | |
| PROGRAM: | Recruitment | | |
| MECHANISM: | Recruitment of Rising Stars | | |
| APPLICATION ID: | RR240019 | | |
| APPLICATION TITLE | Development of Chemotherapeutics Inspired by Natural Products | | |
| APPLICANT NAME: | Sarlah, David | | |
| ORGANIZATION: | Rice University | | |
| PANEL NAME: | Recruitment FY24 Cycle 5 | | |
| Category | Compliance Requirement | Information | Attestation Date |
| Pre-Receipt | RFA Approved by CSO | 06/20/2023 | 09/29/2023 |
| | RFA published in Texas.gov eGrants | 06/22/2023 | 09/29/2023 |
| | CPRIT Application Receipt Cycle opened | 10/21/2023 | 12/20/2023 |
| | CPRIT Application Receipt Cycle closed | 11/20/2023 | 12/20/2023 |
| | Date application submitted | 11/17/2023 | 12/20/2023 |
| | Method of submission | CARS | 12/20/2023 |
| | Within receipt period | YES | 12/20/2023 |
| | | N/A | 12/20/2023 |
| | | NO | 12/20/2023 |
| | | 12/05/2023 | 12/20/2023 |
| Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/20/2023 |
| | Donation(s) made to CPRIT / foundation | NO | 12/20/2023 |
| | Assigned to primary reviewers | 12/05/2023 | 12/20/2023 |
| | Applicant notified of review panel assignment | N/A | 12/20/2023 |
| | Primary Reviewer 1 COI signed | 11/28/2023 | 12/20/2023 |
| | Primary Reviewer 2 COI signed | 12/04/2023 | 12/20/2023 |
| | | 12/11/2023 | 12/20/2023 |
| | | 12/11/2023 | 12/20/2023 |
| | | NONE | 12/20/2023 |
| | | N/A | 12/20/2023 |
| Peer Review Meeting | Primary Reviewer 1 critique submitted | N/A | 12/20/2023 |
| | Primary Reviewer 2 critique submitted | 12/11/2023 | 12/20/2023 |
| | COI indicated by non-primary reviewer | NONE | 12/20/2023 |
| | COI recused from participation | N/A | 12/20/2023 |
| | Discussed at Peer Review Meeting | YES | 12/20/2023 |
| | Peer Review Meeting | 12/14/2023 | 12/20/2023 |
| | Post review statements signed | 12/14/2023 | 12/20/2023 |
| | Third Party Observer Report | 01/17/2024 | 01/24/2024 |
| | Score report delivered to CSO | 12/18/2023 | 12/20/2023 |
| | Recommended for SRC review | YES | 12/20/2023 |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 12/20/2023 |
| | COI recused from participation | N/A | 12/20/2023 |
| | SRC Meeting | 12/14/2023 | 12/20/2023 |
| | Third Party Observer Report | 01/17/2024 | 01/24/2024 |
| | Recommended for grant award | YES | 12/20/2023 |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 |
| | Candidate not accepted position prior to SRC date | YES | 02/07/2024 |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 |
| | COI recused from participation | N/A | 02/07/2024 |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 |
| | Recommended for grant award | YES | 02/07/2024 |
| | | N/A | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | |
| | COI Indicated by Oversight Committee member | N/A | |
| | COI Recused from participation | N/A | |
| | Donation(s) made to CPRIT / foundation | N/A | |
| | Presented to CPRIT Oversight Committee | N/A | |
| | Award approved by Oversight Committee | NO | |
| | Authority to advance funds requested | N/A | |
| | Advance authority approved by Oversight Committee | N/A | |
| Comments: | | | |
| Comment | | | Created Date |
| No Comment | | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR240027
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Vishnu Dileep, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received four applications in response to this RFA during cycles 24.3 through 24.5. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 02/09/2024 11:12 AM CT

| | | | |
|-----------------------------------|--|--------------|------------------|
| FY: | 2024 | | |
| CYCLE: | 1 | | |
| PROGRAM: | Recruitment | | |
| MECHANISM: | Recruitment of First-Time, Tenure-Track Faculty Members | | |
| APPLICATION ID: | RR240027 | | |
| APPLICATION TITLE: | Genomic and Epigenomic Mechanisms of Chemobrain | | |
| APPLICANT NAME: | Dileep, Vishnu | | |
| ORGANIZATION: | Baylor College of Medicine | | |
| PANEL NAME: | Recruitment FY24_Cycle 5 | | |
| Category | Compliance Requirement | Information | Attestation Date |
| Pre-Receipt | RFA Approved by CSO | 06/20/2023 | 09/29/2023 |
| | RFA published in Texas.gov eGrants | 06/22/2023 | 09/29/2023 |
| | CPRIT Application Receipt Cycle opened | 10/21/2023 | 12/20/2023 |
| | CPRIT Application Receipt Cycle closed | 11/20/2023 | 12/20/2023 |
| | Date application submitted | 11/20/2023 | 12/20/2023 |
| | Method of submission | CARS | 12/20/2023 |
| | Within receipt period | YES | 12/20/2023 |
| | | N/A | 12/20/2023 |
| | | NO | 12/20/2023 |
| | | 12/05/2023 | 12/20/2023 |
| Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/20/2023 |
| | Donation(s) made to CPRIT / foundation | NO | 12/20/2023 |
| | Assigned to primary reviewers | 12/05/2023 | 12/20/2023 |
| | Applicant notified of review panel assignment | N/A | 12/20/2023 |
| | Primary Reviewer 1 COI signed | 11/28/2023 | 12/20/2023 |
| | Primary Reviewer 2 COI signed | 11/29/2023 | 12/20/2023 |
| | | 12/11/2023 | 12/20/2023 |
| | | 12/12/2023 | 12/20/2023 |
| | | NONE | 12/20/2023 |
| | | N/A | 12/20/2023 |
| Peer Review Meeting | Primary Reviewer 1 critique submitted | 12/11/2023 | 12/20/2023 |
| | Primary Reviewer 2 critique submitted | 12/12/2023 | 12/20/2023 |
| | COI indicated by non-primary reviewer | NONE | 12/20/2023 |
| | COI recused from participation | N/A | 12/20/2023 |
| | Discussed at Peer Review Meeting | YES | 12/20/2023 |
| | Peer Review Meeting | 12/14/2023 | 12/20/2023 |
| | Post review statements signed | 12/14/2023 | 12/20/2023 |
| | Third Party Observer Report | 01/17/2024 | 01/24/2024 |
| | Score report delivered to CSO | 12/18/2023 | 12/20/2023 |
| | Recommended for SRC review | YES | 12/20/2023 |
| Final SRC Recommendation | COI indicated by SRC member | NONE | 12/20/2023 |
| | COI recused from participation | N/A | 12/20/2023 |
| | SRC Meeting | 12/14/2023 | 12/20/2023 |
| | Third Party Observer Report | 01/17/2024 | 01/24/2024 |
| | Recommended for grant award | YES | 12/20/2023 |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 |
| | Candidate not accepted asst. prof. tenure track position prior to SRC date | YES | 02/07/2024 |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 |
| | COI recused from participation | N/A | 02/07/2024 |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 |
| | Recommended for grant award | YES | 02/07/2024 |
| | | N/A | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | |
| | COI Indicated by Oversight Committee member | N/A | |
| | COI Recused from participation | N/A | |
| | Donation(s) made to CPRIT / foundation | N/A | |
| | Presented to CPRIT Oversight Committee | N/A | |
| | Award approved by Oversight Committee | NO | |
| | Authority to advance funds requested | N/A | |
| | Advance authority approved by Oversight Committee | N/A | |
| Comments: | | | |
| Comment | | Created Date | |
| No Comment | | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR240030
Recruitment of Established Investigators
Nomination of Anna Malkova, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of Established Investigators* Request for Applications (RFA). CPRIT received three applications in response to this RFA during cycles 24.3 through 24.5. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 02/09/2024 11:12 AM CT

| | | | |
|-----------------------------------|--|-------------|------------------|
| FY: | 2024 | | |
| CYCLE: | 1 | | |
| PROGRAM: | Recruitment | | |
| MECHANISM: | Recruitment of Established Investigators | | |
| APPLICATION ID: | RR240030 | | |
| APPLICATION TITLE | Break-induced DNA Replication as a Driver of Genomic Instability in Cancer | | |
| APPLICANT NAME: | Malkova, Anna | | |
| ORGANIZATION: | The University of Texas Health Science Center at San Antonio | | |
| PANEL NAME: | Recruitment FY24_Cycle 5 | | |
| Category | Compliance Requirement | Information | Attestation Date |
| Pre-Receipt | RFA Approved by CSO | 06/20/2023 | 09/29/2023 |
| | RFA published in Texas.gov eGrants | 06/22/2023 | 09/29/2023 |
| | CPRIT Application Receipt Cycle opened | 10/21/2023 | 12/20/2023 |
| | CPRIT Application Receipt Cycle closed | 11/20/2023 | 12/20/2023 |
| | Date application submitted | 11/20/2023 | 12/20/2023 |
| | Method of submission | CARS | 12/20/2023 |
| | Within receipt period | YES | 12/20/2023 |
| | Administrative review notification | 12/01/2023 | 12/20/2023 |
| | Donation(s) made to CPRIT / foundation | NO | 12/20/2023 |
| | Assigned to primary reviewers | 12/05/2023 | 12/20/2023 |
| Receipt, Referral, and Assignment | Applicant notified of review panel assignment | N/A | 12/20/2023 |
| | Primary Reviewer 1 COI signed | 11/28/2023 | 12/20/2023 |
| | Primary Reviewer 2 COI signed | 11/29/2023 | 12/20/2023 |
| | Primary Reviewer 1 critique submitted | 12/12/2023 | 12/20/2023 |
| | Primary Reviewer 2 critique submitted | 12/12/2023 | 12/20/2023 |
| | COI indicated by non-primary reviewer | NONE | 12/20/2023 |
| | COI recused from participation | N/A | 12/20/2023 |
| | Discussed at Peer Review Meeting | YES | 12/20/2023 |
| | Peer Review Meeting | 12/14/2023 | 12/20/2023 |
| | Post review statements signed | 12/14/2023 | 12/20/2023 |
| Peer Review Meeting | Third Party Observer Report | 01/17/2024 | 01/24/2024 |
| | Score report delivered to CSO | 12/18/2023 | 12/20/2023 |
| | Recommended for SRC review | YES | 12/20/2023 |
| | COI indicated by SRC member | NONE | 12/20/2023 |
| | COI recused from participation | N/A | 12/20/2023 |
| | SRC Meeting | 12/14/2023 | 12/20/2023 |
| | Third Party Observer Report | 01/17/2024 | 01/24/2024 |
| | Recommended for grant award | YES | 12/20/2023 |
| | SRC Chair Notification to PIC and OC | 01/03/2024 | 01/24/2024 |
| | Candidate not accepted position prior to SRC date | YES | 02/07/2024 |
| Final SRC Recommendation | COI indicated by PIC member | None | 02/07/2024 |
| | COI recused from participation | N/A | 02/07/2024 |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 |
| | Recommended for grant award | YES | 02/07/2024 |
| | Recommended for grant award | N/A | |
| PIC Review | CEO Notification to Oversight Committee | N/A | |
| | COI Indicated by Oversight Committee member | N/A | |
| | COI Recused from participation | N/A | |
| | Donation(s) made to CPRIT / foundation | N/A | |
| | Presented to CPRIT Oversight Committee | N/A | |
| Oversight Committee Approval | Award approved by Oversight Committee | NO | |
| | Authority to advance funds requested | N/A | |
| | Advance authority approved by Oversight Committee | N/A | |
| | Comments: | | |
| | Comment | | Created Date |
| No Comment | | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

Prevention
FY 2024—Cycles 1
Cancer Screening and Early Detection

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA P-24.1-CSD

Cancer Screening and Early Detection

Please also refer to the Instructions for Applicants document

Application Receipt Opening Date: June 1, 2023
Application Receipt Closing Date: August 30, 2023

FY 2024

Fiscal Year Award Period
September 1, 2023-August 31, 2024

TABLE OF CONTENTS

| | |
|---|-----------|
| 1. ABOUT CPRIT..... | 5 |
| 1.1 PREVENTION PROGRAM PRIORITIES..... | 5 |
| 2. FUNDING OPPORTUNITY DESCRIPTION | 6 |
| 2.1 SUMMARY | 6 |
| 2.2 PROJECT OBJECTIVES | 7 |
| 2.3 AWARD DESCRIPTION..... | 7 |
| 2.4 PRIORITIES..... | 10 |
| 2.5 SPECIFIC AREAS OF EMPHASIS..... | 12 |
| 2.6 OUTCOME METRICS..... | 13 |
| 2.7 FUNDING INFORMATION | 13 |
| 2.8 ELIGIBILITY | 14 |
| 2.9 RESUBMISSION POLICY | 16 |
| 2.10 EXPANSION POLICY | 16 |
| 3. KEY DATES | 18 |
| 4. APPLICATION SUBMISSION GUIDELINES | 18 |
| 4.1 <i>INSTRUCTIONS FOR APPLICANTS</i> DOCUMENT | 18 |
| 4.2 ONLINE APPLICATION RECEIPT SYSTEM..... | 18 |
| 4.3 SUBMISSION DEADLINE EXTENSION | 18 |
| 4.4 APPLICATION COMPONENTS | 19 |
| 4.4.1 <i>Abstract and Significance (5,000 characters)</i> | 19 |
| 4.4.2 <i>Goals and Objectives (900 characters each)</i> | 20 |
| 4.4.3 <i>Project Timeline (2 pages)</i> | 20 |
| 4.4.4 <i>Project Plan (12 pages; fewer pages permissible)</i> | 20 |
| 4.4.5 <i>People Reached (Indirect Contact)</i> | 23 |
| 4.4.6 <i>Number of Unique People Served (Direct Contact)</i> | 24 |
| 4.4.7 <i>Number of Services Delivered (Direct Contact)</i> | 24 |
| 4.4.8 <i>Number of Clinical Services Delivered</i> | 24 |
| 4.4.9 <i>References</i> | 24 |
| 4.4.10 <i>Resubmission Summary</i> | 24 |
| 4.4.11 <i>Most Recently Funded Relevant CPRIT Prevention Project Summary (only if applicable) (3 pages)</i> | 25 |
| 4.4.12 <i>CPRIT Grants Summary</i> | 25 |
| 4.4.13 <i>Budget and Justification</i> | 26 |
| 4.4.14 <i>Current and Pending Support and Sources of Funding</i> | 27 |
| 4.4.15 <i>Biographical Sketches</i> | 28 |
| 4.4.16 <i>Personnel and Collaborating Organizations</i> | 28 |
| 4.4.17 <i>Letters of Commitment (10 pages)</i> | 28 |
| 5. APPLICATION REVIEW..... | 28 |
| 5.1 REVIEW PROCESS OVERVIEW | 28 |
| 5.2 REVIEW CRITERIA | 30 |
| 5.2.1 <i>Primary Evaluation Criteria</i> | 30 |
| 5.2.2 <i>Secondary Evaluation Criteria</i> | 32 |
| 6. AWARD ADMINISTRATION | 33 |

7. CONTACT INFORMATION34
7.1 HELPDESK 34
7.2 PROGRAM QUESTIONS 34
8. RESOURCES.....35
9. REFERENCES36
APPENDIX A: KEY TERMS.....37
APPENDIX B: WRITING GOALS AND OBJECTIVES.....40

RFA VERSION HISTORY

Rev 5/5/2023 RFA release

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and enhance the potential for a medical or scientific breakthrough in the prevention of or cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

1.1 Prevention Program Priorities

Legislation from the 83rd Texas Legislature requires that CPRIT's Oversight Committee establish program priorities on an annual basis. The priorities are intended to provide transparency in how the Oversight Committee directs the orientation of the agency's funding portfolio. The Prevention Program's principles and priorities will also guide CPRIT staff and the Prevention Review Council (PRC) on the development and issuance of program-specific Requests for Applications (RFAs) and the evaluation of applications submitted in response to those RFAs.

Established Principles:

- Fund evidence-based interventions and their dissemination
- Support the prevention continuum of primary, secondary, and tertiary (includes survivorship) prevention interventions

CPRIT's Cross-Program Priorities:

- Prevention and early detection initiatives
- Translation of Texas research (discoveries) to innovations
- Enhancement of Texas' research capacity and life science infrastructure

Prevention Program Priorities

- Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services
- Assess CPRIT Prevention Program to identify best practices, use as a quality improvement tool, and guide future program direction

2. FUNDING OPPORTUNITY DESCRIPTION

2.1 Summary

The ultimate goals of the CPRIT Prevention Program are to reduce overall cancer incidence and mortality and to improve the lives of individuals who have survived or are living with cancer. The ability to reduce cancer death rates depends in part on the application of currently available evidence-based technologies and strategies. CPRIT fosters the primary, secondary, and tertiary prevention of cancer in Texas by providing financial support for a wide variety of evidence-based risk reduction, early detection, and survivorship interventions.

This award mechanism seeks to support the delivery of evidence-based clinical services to screen for cancer and precancer in priority populations who do not have adequate access to screening and early detection interventions and health care, bringing together networks of public health and community partners to carry out programs tailored for their communities. Screening for cancer recurrence or a new primary cancer in the cancer survivor population is supported by this mechanism.

Projects should identify cancers that cause the most burden in the community, have nationally recommended screening methods, and use evidence-based methods to screen for these cancers. Delivery of clinical services is restricted to residents of Texas.

Partnerships with other organizations that can support and leverage resources are strongly encouraged. A coordinated submission of a collaborative partnership program in which all partners have a substantial role in the proposed project is preferred.

NOTE: The CSD award mechanism will not support cancer prevention/intervention research; projects must be focused on implementing existing, evidence-based screening approaches. Applicants interested in prevention research should review CPRIT’s Academic Research RFAs (available at <http://www.cprit.texas.gov>).

2.2 Project Objectives

CPRIT seeks to fund projects that will do the following:

- Deliver comprehensive projects comprising all of the following: public and/or professional education, outreach, delivery of clinical services, follow-up navigation to diagnosis and into cancer treatment, and system and/or policy improvements.
- Offer effective and efficient systems of delivery of screening services based on the existing body of knowledge about and evidence in ways that far exceed current performance in a given service area.
- Implement policy changes and/or system improvements that are sustainable over time (eg, decrease wait times between positive screen and diagnostic tests and treatment through improved navigation, reminder systems)
- Provide tailored, culturally appropriate outreach and accurate information on early detection and prevention to the public and health care professionals that results in a health impact that can be measured.

2.3 Award Description

The **Cancer Screening and Early Detection** RFA solicits applications for eligible projects up to 5 years in duration that will deliver evidence-based clinical services in cancer screening for breast, cervical, colorectal, liver, and lung cancers according to established and current national guidelines and criteria, inclusive of the screening and early detection of recurring or second primary cancer in the cancer survivor population. Nonmetropolitan (rural) and/or medically underserved populations must be included in the defined service area.

The following are required components of the project:

- **Geographic Area to be Served:** Clinical service delivery to nonmetropolitan/medically underserved area (MUA) counties must be included in the defined service area. Rural and MUA counties may be identified via web-based tools from the [US Department of Health](#)

[and Human Services](#). Service to urban/nonmedically underserved counties is allowable if the project proposes to also serve nonmetropolitan/medicallyunderserved counties.

- **Comprehensive Projects:** Comprehensive projects include a continuum of services and systems and policy changes and comprise all of the following: Public and professional education and training, outreach, delivery of screening and diagnostic services, follow-up navigation to treatment services for those diagnosed with cancer and precancer, data collection and tracking, and systems improvement.
- **Evidence Based:** CPRIT’s secondary prevention grants are intended to fund effective and efficient systems of delivery of early detection services based on the existing body of knowledge about and evidence for screening for both primary and secondary cancers in ways that far exceed current performance in a given service area. The provision of clinical services, including rescreening at the appropriate interval, must comply with established and current national guidelines (eg, US Preventive Services Task Force [USPSTF], American Cancer Society [ACS]).

If evidence-based strategies have not been implemented or tested for the specific population or service setting proposed, provide evidence that the proposed service is appropriate for the population and has a high likelihood of success. Baseline data (eg, availability of resources and screening coverage) for the target population and target service region are required. If no baseline data exist, the applicant must present clear plans and describe method(s) of measurement used to collect the data necessary to establish a baseline.

The National Comprehensive Cancer Network and the ACS have developed consensus-based comprehensive survivorship care guidelines to provide direction on managing the potential physical and psychosocial long-term impact of cancer/associated treatment and subsequent surveillance for recurrence and screening for second primary cancers for projects focusing on survivor care.

- **Clinical Service and Community Partner Networks:** If applicable to the proposed project, applicants are encouraged to coordinate and describe a collaboration of clinical service providers and community partners that can deliver outreach, education, clinical, and navigation services to the most counties and the most people possible in a selected

service region. Applicants should consider providing financial assistance to service providers for navigation services. Partnerships with other organizations that can support and leverage resources (eg, community-based organizations, local and voluntary agencies, nonprofit agencies, groups that represent priority populations) are encouraged. Letters of commitment or memoranda of understanding describing their specific role in the partnership will strengthen the application.

In cases where the project proposes to work with multiple clinical providers, the Program Director (PD) should facilitate the establishment of standard protocols for all clinical service providers in the network as well as standard systems, policies, and procedures for the participating clinical service providers and organizations. These may include, but are not limited to, patient tracking and timely follow-up of all abnormal screening results and/or diagnoses of cancer.

This mechanism will fund case management/patient navigation to screening, to diagnostic testing, and into treatment. Applicants must ensure that there is access to needed diagnostic testing for those with an abnormal screening exam and to treatment services for patients with precancer or cancers that are detected as a result of the project and must describe the process for ensuring access to diagnostic and treatment services.

Applicants should not request funds for any of the above components if these components are already being funded from other sources. If clinical services are being provided and paid by others, the applicant must demonstrate and report on the outcomes and services that are delivered to the people navigated by the program.

CPRIT expects measurable outcomes of supported activities, such as a significant increase over baseline (for the proposed service area) in the provision of evidence-based clinical services, changes in provider practice, systems changes, and cost-effectiveness. Applicants must demonstrate how these outcomes will ultimately impact incidence mortality, morbidity, and disparities.

Under this RFA, CPRIT **will not** consider the following:

- Projects focused solely on metropolitan counties that are not medically underserved.

- **Projects focused solely on primary cancer prevention services.** These applicants should apply under the Primary Prevention of Cancer (PPC) RFA. Primary prevention services are allowable under this RFA if combined with cancer screening/early detection services (eg, hepatitis B vaccination with hepatitis C screening, HPV vaccination with cervical cancer screening).
- Projects focusing solely on systems and/or policy change or solely on education and/or outreach that do not include the navigation to and delivery of cancer screening and early detection services.
- **Projects focusing on screening the general population for genetic disposition to cancer.**
- **Projects focusing solely on case management/patient navigation services.** Case management/patient navigation services must be paired with the delivery of a clinical cancer screening service and reported to CPRIT, including those services delivered by another provider. Furthermore, while navigation into treatment of cancer is required when cancer is discovered through a CPRIT-funded project, applications seeking funds to provide coordination of care while an individual is in treatment are not allowed under this RFA.
- Clinical tests/services proposed as part of the project that do not comply with established and current national guidelines and criteria, have not yet been approved by the FDA, and/or have not been recommended by the USPSTF due to lack of evidence available to draw reliable conclusions about benefits and harms of the tests. These include, but are not limited to, breast self-exams, clinical breast exams, HPV self-sampling tests, and prostate-specific antigen (PSA) tests.
- **Prevention/intervention research projects.** Applicants interested in prevention research should review CPRIT's Academic Research RFAs (available at <http://www.cprit.texas.gov>).
- Resources for the treatment of cancer or viral treatment for hepatitis.

2.4 Priorities

Types of Cancer: Applications addressing any cancer type(s) that can be prevented or detected early (breast, cervix, colorectal, liver, lung), are recommended by the USPSTF, and are

responsive to this RFA will be considered for funding. See [section 2.5](#) for specific areas of emphasis. All services must comply with established and current national guidelines.

Lung cancer screening projects must also meet the Centers for Medicare and Medicaid Services (CMS) eligibility criteria for radiologists and facilities. CMS also requires delivery of smoking cessation counseling if low-dose computed tomography screening is offered; for funding through this mechanism, CPRIT requires that robust evidence-based cessation interventions be delivered. Shared decision-making about the eligibility, risks, and benefits of annual lung cancer screening between the health care provider and patient is required.

The Prevention Program's priorities for funding include the following:

1) Populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence.

CPRIT-funded programs must address 1 or more of these priority populations:

- Underinsured and uninsured individuals
- Medically under resourced communities
- Racial, ethnic, and cultural minority groups
- Populations with low screening rates, high incidence rates, and high mortality rates, focusing on individuals never before screened or who are significantly out of compliance with nationally recommended screening guidelines (more than 5 years for breast/cervical cancers).

The age of the priority population and frequency of screening/rescreening for provision of clinical services described in the application must comply with established and current national guidelines (eg, USPSTF, ACS). Provide the national guideline that will be followed.

2) Geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence.

While disparities and needs exist across the state, CPRIT will also prioritize applications proposing to serve geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence. For this RFA, projects must propose to serve nonmetropolitan and/or medically underresourced areas of the state. In addition, projects addressing areas of emphasis (see [section 2.5](#)) will receive priority consideration.

Geographic and Population Balance in Current CPRIT portfolio

At the programmatic level of review conducted by the PRC ([section 5.1](#)), priority will be given to projects that target geographic regions of the state and population subgroups that are not adequately covered by the current CPRIT Prevention project portfolio (see <https://www.cprit.texas.gov/our-programs/prevention/portfolio-maps> and <https://www.cprit.texas.gov/grants-funded?search=prevention>).

2.5 Specific Areas of Emphasis

CPRIT has identified the following areas of emphasis for this cycle of awards.

| <u>Secondary Prevention – Screening and Early Detection Services</u> |
|---|
| Breast Cancer |
| <ul style="list-style-type: none"> Decreasing disparities in mortality rates of breast cancer in racial/ethnic populations. The mortality rate is significantly higher in Black women than in other populations. Increasing screening/detection rates in MUAs of the state. |
| Cervical Cancer |
| <ul style="list-style-type: none"> Decreasing disparities in incidence and mortality rates of cervical cancer in racial/ethnic populations. Hispanic women have the highest incidence rates while Black women have the highest mortality rates. Increasing screening/detection rates in MUAs of the state. |
| Colorectal Cancer |
| <ul style="list-style-type: none"> Decreasing disparities in incidence and mortality rates of colorectal cancer in racial/ethnic populations. Blacks have the highest incidence and mortality rates, followed by non-Hispanic Whites and Hispanics. Increasing screening/detection rates in Public Health Region (PHR) 1, 2, 4, 5, and 9, where the highest rates of cancer incidence and mortality are found. Decreasing incidence and mortality rates in nonmetropolitan counties. Incidence and mortality rates are higher in nonmetropolitan counties compared with metropolitan counties. |
| Liver Cancer |
| <ul style="list-style-type: none"> Screening for hepatitis C virus infection in populations at high risk of infection. Increasing screening rates in PHR 2, 6, 8, 9, 10, and 11. Incidence and mortality rates are highest in PHR 10 and 11. |
| Lung Cancer |
| <ul style="list-style-type: none"> Decreasing disparities in incidence and mortality rates of lung cancer in racial/ethnic populations. Blacks have higher mortality rates than Hispanics and non-Hispanic Whites. Increasing screening/early detection rates in PHR 2, 4, and 5, where the highest rates of cancer incidence and mortality are found. |

2.6 Outcome Metrics

Applicants are required to clearly describe their assessment and evaluation methodology. The applicant is required to describe final outcome measures for the project. Output measures that are associated with the final outcome measures should be identified in the project plan and will serve as a measure of program effectiveness. Planned policy or system changes/improvements should be identified and the plan for qualitative analysis described. **Baseline data for each measure proposed are required.** In addition, applicants should describe how funds from the CPRIT grant will improve outcomes over baseline. If the applicant is not providing baseline data for a measure, the applicant must provide a well-justified explanation and describe clear plans and method(s) of measurement to collect the data necessary to establish a baseline.

Reporting Requirements

Funded projects are required to report both qualitative and quantitative output and outcome metrics (as appropriate for each project) through the submission of quarterly progress reports, annual reports, and a final report.

If someone other than the PD will enter information in the progress reports, they must be named as an Alternate Submitter in CARS. The Alternate Submitter is an application contact designated by the PD to complete PD tasks in CARS and/or the grants management system.

If clinical services are being paid for and provided by others, the applicant is required to report on the number of clinical services and outcomes (eg, cancers detected) that are delivered to the people navigated by the program.

2.7 Funding Information

The total amount of funding that applicants may request is dependent on the project type. Use the table below to determine the maximum amount of funding and the maximum number of years that may be requested.

| Project Type | Maximum Amount of Total Funding | Maximum Duration |
|-------------------------------|---------------------------------|------------------|
| New Project | \$1.5 million | 3 years |
| Initial Expansion Project | \$2 million | 3 years |
| Maintenance Expansion Project | \$2.5 million | 5 years |

Expansion projects require **significant expansion** in the geographic area and/or clinical services provided for the initial expansion, or in the number of clinical services delivered for any subsequent expansion, as described in [section 2.10](#). Grant funds may be used to pay for clinical services, navigation services, salary and benefits, project supplies, equipment, costs for outreach and education of populations, and travel of project personnel to project site(s). Applicants must ensure that there is access to and navigation into treatment services for patients with precancers or cancers that are detected as a result of the program and must describe access to and navigation into treatment services in their application.

Requests for funds to support construction or renovation or requests to support lobbying will not be approved. Cost sharing for equipment purchases is encouraged. Grantees may request funds for travel for 2 project staff to attend CPRIT's conference.

The budget should be proportional to the number of individuals receiving programs and services, and a significant proportion of funds is expected to be used for program delivery as opposed to program development. In addition, CPRIT funding should not be used to replace existing funding, supplant funds that would normally be expended by the applicant's organization, or make up for funding reductions from other sources.

State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the **total** award amount.

2.8 Eligibility

- The applicant must be a Texas-based entity, such as a community-based organization, health institution, government organization, public or private company, college or university, or academic health institution.
- The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The designated PD will be responsible for the overall performance of the funded project. The PD must have relevant education and management experience and must reside in Texas during the project performance time.
- The evaluation of the project must be headed by a professional who has demonstrated expertise in the field and who resides in Texas during the time that the project is conducted.

- The applicant may submit more than 1 application, but each application must be for distinctly different services without overlap in the services provided. Applicants who do not meet this criterion will have all applications administratively withdrawn without peer review.
- If an organization has a current CPRIT grant that is the same or similar to the prevention intervention being proposed, the applicant must explain how the projects are non-duplicative or complementary. Duplicative applications will be administratively withdrawn.
- If the applicant or a partner is an existing Department of State Health Services contractor, CPRIT funds may not be used as a match, and the application must explain how this grant complements or leverages existing state and federal funds.
- Collaborations are permitted and encouraged, and collaborators may or may not reside in Texas. However, collaborators who do not reside in Texas are not eligible to receive CPRIT funds. Subcontracting and collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- An applicant organization is eligible to receive a grant award only if the applicant certifies that the applicant organization, including the PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation created to benefit CPRIT.
- The applicant must report whether the applicant organization, the PD, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, (whether slated to receive salary or compensation under the grant award or not), are currently ineligible to receive federal grant funds because of scientific misconduct or

fraudor have had a grant terminated for cause within 5 years prior to the submission date of the grant application.

- CPRIT grants will be awarded by contract to successful applicants. CPRIT grants are funded on a reimbursement-only basis. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 6](#). All statutory provisions and relevant administrative rules can be found [on the CPRIT website](#).

2.9 Resubmission Policy

- **One resubmission** is permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. Resubmission applications must include a Resubmission Summary (see [section 4.4.10](#)).
- Reviewers of resubmissions are asked to assess whether the resubmission adequately addresses critiques from the previous review. **Applicants should note that addressing previous critiques is advisable; however, it does not guarantee the success of the resubmission.** All resubmitted applications must conform to the structure and guidelines outlined in this RFA.

2.10 Expansion Policy

- Expansion grants are intended to fund expansion of currently or previously funded projects that have demonstrated exemplary success, as evidenced by progress reports and project evaluations, and desire to further enhance their impact on priority populations. Detailed descriptions of **results, barriers, outcomes, and impact of the currently or previously funded project are required** (see outline of Most Recently Funded Project Summary, [section 4.4.11](#)).
- Proposed expansion projects should NOT be new projects but should closely follow the intent and core elements of the currently or previously funded project. Established infrastructure/processes and fully described prior project results are required. Expansion

of current projects into geographic areas not well served by the CPRIT Prevention portfolio (see maps at [http:// www.cprit.state.tx.us/our-programs/prevention/portfolio-maps](http://www.cprit.state.tx.us/our-programs/prevention/portfolio-maps)) will receive priority consideration.

- CPRIT expects measurable outcomes of supported activities, such as a significant increase over baseline (for the proposed service area). It is expected that baselines will have already been established and that continued improvement over baseline is demonstrated in the current application. However, in the case of a proposed expansion where no baseline data exist for the priority population, the applicant must present clear plans and describe method(s) of measurement used to collect the data necessary to establish a baseline. Applicants must demonstrate how these outcomes will ultimately impact cancer incidence, mortality, morbidity, or quality of life.
- CPRIT also expects that applications for continuation **will not** require startup time, that applicants can demonstrate that they have overcome barriers encountered, and that applicants have identified **lasting systems changes** that improve results, efficiency, and sustainability. Leveraging of resources and plans for dissemination are expected and should be well described.

Requirements for Initial and Maintenance Expansion Projects

- **Initial Expansion:** For the first expansion application, eligible applicants should propose to expand their programs to include additional types of prevention clinical services or to expand current clinical services into additional counties. In either case, the expansion must include the delivery of services to nonmetropolitan (rural) and/or medically underserved counties in the state. These may be identified via web-based tools from the [Texas Department of State Health Services](#) and [US Department of Health and Human Services](#).
- **Maintenance Expansion:** For a subsequent expansion, additional clinical services and/or expansion to additional counties is optional; however, the counties and the practices offered in the first expansion should not be decreased. The number of services delivered during the maintenance expansion must be increased substantially such that the cost per clinical service is similar to the initial expansion if no further geographic or preventive service expansion is proposed.

3. KEY DATES

| | |
|---------------------------------|------------------------------------|
| RFA release | May 5, 2023 |
| Online application opens | June 1, 2023, 7 AM central time |
| Application due | August 30, 2023, 4 PM central time |
| Application review | October 2023-January 2024 |
| Award notification | February 2024 |
| Anticipated start date | March 1, 2024 |

Applicants will be notified of peer review panel assignment prior to the peer review meeting dates.

4. APPLICATION SUBMISSION GUIDELINES

4.1 *Instructions for Applicants* document

It is **imperative** that applicants read the accompanying instructions document for this RFA (<https://CPRITGrants.org>). Requirements may have changed from previous versions.

4.2 Online Application Receipt System

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The PD must create a user account in the system to start and submit an application. The Co-PD, if applicable, must also create a user account to participate in the application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (an individual who will help manage the grant contract if an award is made) also must create a useraccount in CARS. Applications will be accepted beginning at 7 AM central time on June 1, 2023, and must be submitted by 4 PM central time on August 30, 2023. Detailed instructions for submitting an application are in the *Instructions for Applicants* document, posted on CARS. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

4.3 Submission Deadline Extension

The submission deadline may be extended for grant applications upon a showing of good cause.

All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records.

4.4 Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Refer to the *Instructions for Applicants* document for details.

Submissions that are missing 1 or more components or do not meet the eligibility requirements may be administratively withdrawn without review.

4.4.1 Abstract and Significance (5,000 characters)

Clearly explain the problem(s) to be addressed, the approach(es) to the solution, and how the application is responsive to this RFA. In the event that the project is funded, the abstract will be made public; therefore, no proprietary information should be included in this statement. Initial compliance decisions are based in part upon review of this statement.

The abstract format is as follows (use headings as outlined below):

- **Need:** Include a description of need in the specific service area. Include rates of incidence, mortality, and screening in the service area compared to overall Texas rates. Describe barriers, plans to overcome these barriers, and the priority population to be served.
- **Overall Project Strategy:** Describe the project and how it will address the identified need. Clearly explain what the project is and what it will specifically do, including the services to be provided and the process/system for delivery of services and outreach to the priority population.
- **Specific Goals:** State specifically the overall goals of the proposed project, including the prepopulated navigation into diagnosis and treatment goal; include the estimated overall numbers of clinical services delivered and number of people (public and/or professionals) served.
- **Significance and Impact:** Explain how the proposed project, if successful, will have a major impact on cancer prevention and control for the population proposed to be served and for the State of Texas.

4.4.2 Goals and Objectives (900 characters each)

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within both the stated Objective **and** the Measure sections (eg, Measure: 1,500 individuals, ages 45 to 75, will be screened for colorectal cancer during the grant period). Applications may be returned for revision if the proposed metric is not included within the Measure section. Refer to the Instructions for Applicants document for details.

One goal with 2 objectives addressing navigation into diagnosis and into treatment is required for all proposals and will be prepopulated into the application. This goal is not modifiable by the applicant. Applicants may **ADD** a maximum of 3 **additional** goals with up to 3 outcome objectives each. Projects will be evaluated annually on progress toward **all** outcome goals and objectives. See [appendix B](#) for instructions on writing outcome goals and objectives.

A baseline and method(s) of measurement are required for each objective, including the prepopulated goal. Provide both raw numbers and percent changes for the baseline and target. If a baseline has not been defined, applicants are required to explain plans to establish baseline and describe method(s) of measurement. Note that character limits are inclusive of all words in each text box, including provided headings.

4.4.3 Project Timeline (2 pages)

Provide a project timeline for project activities that includes deliverables and dates. Use Years 1, 2, 3 and Months 1, 2, 3, etc, as applicable (eg, Year 1, Months 3-5). Do NOT refer to specific months or years (eg, not May 2024). Month 1 (as opposed to March 1, 2024) is the first full month of the grant award.

4.4.4 Project Plan (12 pages; fewer pages permissible)

The required project plan format follows. Applicants must use the headings outlined below.

Background: Briefly present the rationale behind the proposed services, emphasizing the critical barriers to current service delivery that will be addressed. Identify the evidence-based service to be implemented for the priority population. Describe the race, ethnicity, age, and other defining characteristics of the population to be served.

If evidence-based strategies have not been implemented or tested for the specific population or service setting proposed, provide evidence that the proposed service is appropriate for the population and has a high likelihood of success. Baseline data for the priority population and target service area are required where applicable.

Reviewers will be aware of national and state statistics, and these should be used only to compare rates for the proposed service area. Describe the geographic region of the state that the project will serve; maps are encouraged.

Goals and Objectives: Process objectives should be included in the project plan, including the process of achieving the prepopulated navigation into diagnosis and treatment goal. Outcome goals and objectives will be entered in separate fields in CARS. However, if desired, outcome goals and objectives may be fully repeated or briefly summarized here. See [appendix B](#) for instructions on writing goals and objectives.

Components of the Project: Clearly describe the need, delivery method, and evidence base (provide references) for the services, as well as anticipated results. Be explicit about the base of evidence and any necessary adaptations for the proposed project. If an organization has a current CPRIT grant that is the same or similar to the prevention intervention being proposed, the applicant must explain how the projects are nonduplicative or complementary.

It is important to distinguish between Texas counties where the project proposes to deliver services and counties of residence of population served (see [appendix A](#) for definitions and *Instructions for Applicants*). Only counties with service delivery should be listed in the Geographic Area to be Served section of the application. Projecting counties of residence of population served is not required but may be described in the project plan.

Clearly demonstrate the ability to provide the proposed service(s) and describe how results will be improved over baseline and the ability to reach the priority population. Describe the method(s) that will be used to recall for appropriate rescreening those individuals who have been screened through this project.

If clinical services are being paid for and provided by others, the applicant must explain and report on the number of clinical services and outcomes (eg, screenings/diagnostics, vaccinations, cancer precursors, cancers detected) that are delivered to the people navigated by the program.

Applicants must also clearly describe **access to and navigation into treatment services** should precancer or cancer be detected and assurances that the treatment services will be covered for those who are uninsured or underinsured. Include how and by whom any positive screening results will be delivered to a program participant.

Evaluation Strategy: A strong commitment to evaluation of the project is required. Describe the plan for outcome and output measurements, including qualitative analysis of policy and system changes. Describe data collection and management methods, data analyses, and anticipated results. Evaluation and reporting of results should be headed by a professional who has demonstrated expertise in the field. If needed, applicants may want to consider seeking expertise at Texas-based academic cancer centers, schools/programs of public health, or the like. Applicants should budget accordingly for the evaluation activity and should involve that professional during grant application preparation to ensure, among other things, that the evaluation plan is linked to the proposed goals and objectives.

Organizational Qualifications and Capabilities: Describe the organization and its track record and success in providing health programs and services. Describe the role and qualifications of the key collaborators/partners in the project. Include information on the organization's financial stability and viability. The applicant should demonstrate how the organizational environment will contribute to a successful project. If equipment or physical resources are required to carry out the project, the applicant should describe the availability of these resources and the organizational capacity to use equipment. To ensure access to preventive services and reporting of services outcomes, applicants should demonstrate that they have provider partnerships and agreements (via memoranda of understanding) or commitments (via letters of commitment) in place.

CPRIT acknowledges that full maintenance and sustainability of projects when CPRIT funding ends may not be feasible, especially in cases involving the delivery of clinical services. However, it is important to consider sustainability early in the life cycle of a project, particularly regarding organizational characteristics and processes that are modifiable.

Washington University in St Louis has developed a useful tool ([Program Sustainability Assessment Tool](#)) to assess program capacity for sustainability. The tool assesses several factors that contribute to program sustainability. These factors include environmental support, funding

stability, partnerships, organizational capacity, program evaluation, program adaptation, communication, and strategic planning. Applicants are not required to use this tool; however, it provides practical guidance on factors that should be considered and should be included in the application to describe a program's organizational capacity for sustainability.

It is expected that steps toward building capacity for the program will be taken, and plans for such should be described in the application. The applicant should describe the factors that will contribute to the organization's capacity to facilitate sustainability.

Dissemination and Replication: Dissemination of project results and outcomes, including barriers encountered and successes achieved, is critical to building the evidence base for cancer prevention and control efforts in the state. Dissemination efforts should consider the message, source, audience, and channel (Brownson, RC, et al. [J Pub Health Manag Pract. 2018;24\(2\):102-111](#)). Dissemination methods may include, but are not limited to, presentations at workshops and seminars, one-on-one meetings, publications, news media, social media, etc.

While passive dissemination methods are common (eg, publications, presentations at professional meetings), plans should include some active dissemination methods (eg, meetings with stakeholders, blogs, social media). Applicants should describe their dissemination plans. The plans should include the kinds of audiences to be targeted and methods for reaching the targeted audiences.

Replication by others is an additional way to disseminate the project. For applicable components, describe how the project or components of the project lend themselves to application by other communities and/or organizations in the state or expansion in the same communities. Describe what components of this project can be adapted to a larger or lower resource setting. Note that some programs may have unique resources and may not lend themselves to replication by others.

4.4.5 People Reached (Indirect Contact)

Provide the estimated overall number of people (members of the public and professionals) to be reached by the funded project. The applicant is required to itemize separately the types of indirect noninteractive education and outreach activities, with estimates, that led to the calculation of the overall estimates provided. Refer to [appendix A](#) for definitions.

4.4.6 Number of Unique People Served (Direct Contact)

Provide the estimated overall number of unique members of the public and professionals served by the funded project. One person may receive multiple services but should only be counted once here. Refer to [appendix A](#) for definitions.

4.4.7 Number of Services Delivered (Direct Contact)

Provide the estimated overall number of services directly delivered to members of the public and to professionals by the funded project. Each individual service should be counted, regardless of the number of services 1 person receives. The applicant is required to itemize separately the education, navigation, and clinical activities/services, with estimates, that led to the calculation of the overall estimate provided. Refer to [appendix A](#) for definitions.

4.4.8 Number of Clinical Services Delivered

Provide the estimated overall number of clinical services directly delivered to members of the public by the funded project. Each individual clinical service should be counted, regardless of the number of services 1 person receives. Separately itemize the clinical services, with estimates, that led to the calculation of the overall estimate provided. Refer to [appendix A](#) for definitions.

4.4.9 References

Provide a concise and relevant list of references cited for the application. The successful applicant will provide referenced evidence and literature support for the proposed services.

4.4.10 Resubmission Summary

Resubmission applications must include a Resubmission Summary. Use the template provided on CARS (<https://CPRITGrants.org>). Describe the approach to the resubmission and how reviewers' comments were addressed. Clearly indicate to reviewers how the application has been improved in response to the critiques. Refer the reviewers to specific sections of other documents in the application where further detail on the points in question may be found. When a resubmission is evaluated, responsiveness to previous critiques is assessed.

The summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission; the applicant is not responsible for providing this document.

4.4.11 Most Recently Funded Relevant CPRIT Prevention Project Summary (only if applicable) (3 pages)

Upload a summary that outlines the progress made with the applicant's most recently funded relevant CPRIT Prevention Award. Applicants must describe results and outcomes of the most recently funded award and demonstrate why further funding is warranted.

Please note that a different set of reviewers from those assigned to the previously funded application may evaluate this application. Applicants should make it easy for reviewers to compare the most recently funded project with the proposed project.

In the description, include the following:

- Describe the evidence-based intervention, its purpose, and how it was implemented in the priority population. Describe any adaptations made for the population served.
- List approved goals and objectives of the most recently funded grant.
- For each objective, provide milestones/target dates and target metrics as compared to actual completion dates and metrics.
- Include a discussion of objectives not fully met. Explain any barriers encountered and strategies used to overcome these.
- For the most recently funded project, describe major activities; significant results, including major findings, developments or conclusions (both positive and negative); and key outcomes.
- Describe steps taken toward sustainability for components of the project. Fully describe systems or policy improvements and enhancements.
- Describe how project results were disseminated or plans for future dissemination of results.

4.4.12 CPRIT Grants Summary

Use the template provided on CARS (<https://CPRITGrants.org>). Provide a listing of **all** projects funded by the CPRIT Prevention program for the PD and the Co-PD, regardless of their connection to this application.

4.4.13 Budget and Justification

Provide a brief outline and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, travel, equipment, supplies, contractual expenses, servicesdelivery, and other expenses. CPRIT funds will be distributed on a reimbursement basis. Applications requesting more than the maximum allowed cost (total costs) as specified in [section 2.7](#) will be administratively withdrawn.

Clearly describe any organizational cost sharing or pro bono contributions related to this project, aswell as any attempts made or successes to secure other state/federal funds.

- **Average Cost per Person:** The average cost per person will be automatically calculated from the total cost of the project divided by the total number of unique people served (referto [appendix A](#)).
- **Average Cost per Service:** The average cost per service will be automatically calculated from the total cost of the project divided by the total number of services delivered (refer to [appendix A](#)). A significant proportion of funds is expected to be used for program deliveryas opposed to program development and organizational infrastructure.
- **Average Cost per Clinical Service:** The average cost per clinical service will be automatically calculated from the total cost of the project divided by the total number of clinical services delivered (refer to [appendix A](#)).
- **Personnel:** The individual salary cap for CPRIT awards is \$200,000 per year. Describe thesource of funding for all project personnel where CPRIT funds are not requested.
- **Travel:** PDs and related project staff are expected to attend CPRIT’s conference. CPRIT funds may be used to send up to 2 people to the conference. Meals are not reimbursable for trips that do not include an overnight stay.
- **Equipment:** Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application. Justification must be provided for why funding for this equipment cannot be found elsewhere; CPRIT funding should not supplant existing funds. Cost sharing of equipment purchases is strongly encouraged.

- **Services Costs:**
 - CPRIT reimburses for services using Medicare reimbursement rates. Describe the source of funding for all services where CPRIT funds are not requested. If clinical services are being paid for and provided by others, the applicant is required to explain and report on the number of clinical services and outcomes (eg, screenings/diagnostics, vaccinations, cancer precursors, cancers detected) that are delivered to the people navigated by the program.
 - CPRIT does not allow recovery of any costs for services not related to cancer (eg, health physicals, HIV testing) other than those required prior to the clinical services proposed in the project.
 - CPRIT does not allow recovery of costs related to tests that have not been recommended by the USPSTF. In several cases (eg, breast self-exams, clinical breast exams, PSA tests), the Task Force has concluded there is not enough evidence available to draw reliable conclusions about the additional benefits and harms of these tests. (See <https://www.uspreventiveservicestaskforce.org/>)
- **Other Expenses:**
 - **Incentives:** Use of incentives or positive rewards to change or elicit behavior is allowed; however, incentives may only be used based on strong evidence of their effectiveness for the purpose and in the priority population identified by the applicant. CPRIT will not fund cash incentives. The maximum dollar value allowed for an incentive per person, per activity or session, is \$25.
- **Indirect/Shared Costs:** Texas law limits the amount of grant funds that may be spent on indirect/shared expenses to no more than 5% of the total award amount (5.263% of the direct costs). Indirect costs reimbursed to subcontractors count toward the total allowable indirect costs. Guidance regarding indirect cost recovery can be found in [CPRIT's Administrative Rules](#).

4.4.14 Current and Pending Support and Sources of Funding

Use the template provided on the CARS (<https://CPRITGrants.org>). Describe the funding source and duration of **all** current and pending support for the proposed project, including a capitalization table that reflects private investors, if any.

4.4.15 Biographical Sketches

The designated PD will be responsible for the overall performance of the funded project and must have relevant education and management experience. The PD/Co-PD(s) must provide a biographical sketch that describes his or her education and training, professional experience, awards and honors, and publications and/or involvement in programs relevant to cancer prevention and/or service delivery.

- Use the Co-PD Biographical Sketch section ONLY if a Co-PD has been identified.
- The evaluation professional must provide a biographical sketch in the Evaluation Professional Biographical Sketch section.
- Up to 3 additional biographical sketches for key personnel may be provided in the Key Personnel Biographical Sketches section.

Each biographical sketch must not exceed 5 pages and should use either the “Prevention Programs: Biographical Sketch” template provided on the CARS (<https://CPRITGrants.org>) or the NIH Biographical Sketch format. Only biographical sketches will be accepted; do not submit resumes and/or CVs. If a position is not yet filled, please upload a job description.

4.4.16 Personnel and Collaborating Organizations

List ALL personnel working on the proposed project, paid or unpaid, as well as partners, collaborators, and anyone listed under the Current & Pending Support section.

List all key participating organizations that will partner with the applicant organization to provide 1 or more components essential to the success of the program (eg, evaluation, clinical services, recruitment to screening).

4.4.17 Letters of Commitment (10 pages)

Applicants should provide letters of commitment and/or memoranda of understanding from community organizations, key faculty, or any other component essential to the success of the program. Letters should be specific to the contribution of each organization.

5. APPLICATION REVIEW

5.1 Review Process Overview

All eligible applications will be reviewed using a 2-stage peer review process: (1) evaluation of

applications by peer review panels and (2) prioritization of grant applications by the PRC. In the first stage, applications will be evaluated by an independent review panel using the criteria listed below. In the second stage, applications judged to be meritorious by review panels will be evaluated by the PRC and recommended for funding based on comparisons with applications from all of the review panels and programmatic priorities.

Programmatic considerations may include, but are not limited to, geographic distribution, cancer type, population served, and type of program or service. The peer review scores are only 1 factor considered during programmatic review. At the programmatic level of review, priority will be given to proposed projects that target geographic regions of the state or population subgroups that are not well represented in the current CPRIT Prevention project portfolio.

Applications approved by PRC will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

Each stage of application review is conducted confidentially, and all CPRIT Peer Review Panel members, PRC members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Peer Review Panel members and PRC members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer Review Panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis

for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, [chapter 703, section 703.9](#).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, a Review Panel member, or a PRC member.

Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

5.2 Review Criteria

Peer review of applications will be based on primary scored criteria and secondary unscored criteria, identified below. Review panels consisting of experts in the field and advocates will evaluate and score each primary criterion and subsequently assign an overall score that reflects an overall assessment of the application. The overall evaluation score will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application and responsiveness to the RFA priorities.

5.2.1 Primary Evaluation Criteria

Impact

- Do the proposed services address an important problem or need in cancer prevention and control? Do the proposed project strategies support desired outcomes in cancer incidence, morbidity, and/or mortality? Do the proposed project strategies reach a priority population (eg, low income, minority, rural) at high risk of cancer?
- Will the project serve and impact an appropriate number of people based on the budget allocated to providing services and the cost of providing services?

- If applicable, have partners demonstrated that the collaborative effort will provide a greater impact on cancer prevention and control than the applicant organization's effort separately?
- Does the program address adaptation, if applicable, of the evidence-based intervention to the priority population? Is the base of evidence clearly explained and referenced?

Project Strategy and Feasibility

- Does the proposed project provide services specified in the RFA?
- Are the overall program approach, strategy, and design clearly described and supported by established theory and practice? Are the proposed objectives and activities feasible within the duration of the award? Has the applicant convincingly demonstrated the short- and long-term impacts of the project?
- Has the applicant proposed policy changes and/or system improvements?
- Are possible barriers addressed and approaches for overcoming them proposed?
- Are the priority population and culturally appropriate methods to reach the priority population clearly described?
- If applicable, does the application demonstrate the availability of resources and expertise to provide case management, including follow-up for abnormal results and access to and navigation into treatment?
- Does the program leverage partners and resources to maximize the reach of the services proposed? Does the program leverage and complement other state, federal, and nonprofit grants?

Outcomes Evaluation

- Are specific goals and measurable objectives for each year of the project provided?
- Are the proposed outcome measures appropriate for the services provided, and are the expected changes clinically significant?
- If clinical services are being paid for and provided by others, does the applicant explain the methods used to collect data and report on these clinical services and outcomes?
- Does the application provide a clear and appropriate plan for data collection and management and data analyses?

- Are clear baseline data provided for the priority population, or are clear plans included to collect baseline data?
- If an evidence-based intervention is being adapted in a population where it has not been implemented or tested, are plans for evaluation of barriers, effectiveness, and fidelity to the model described?
- Is the qualitative analysis of planned policy or system changes described?

Organizational Qualifications and Capabilities

- Do the organization and its collaborators/partners demonstrate the ability to provide the proposed preventive services?
- Does the described role of each collaborating organization make it clear that each organization adds value to the project and is committed to working together to implement the project?
- Have the appropriate personnel been recruited to design, implement, evaluate, and complete the project?
- Is the organization structurally and financially stable and viable?
- Does the applicant describe the program's organizational capacity for sustainability?
- Does the applicant describe steps that will be taken toward building internal capacity and partnerships?
- Does the applicant describe a plan for systems changes that are sustainable over time (eg, improve results, provider practice, efficiency, cost-effectiveness)?

5.2.2 Secondary Evaluation Criteria

Budget

- Is the budget appropriate and reasonable for the scope and services of the proposed work?
- Is the cost per person served appropriate and reasonable?
- Is the proportion of the funds allocated for direct services reasonable?
- Is the project a good investment of Texas public funds?

Dissemination and Replication

- Are plans for dissemination of the project's results and outcomes, including target audiences and methods, clearly described?

- Are active dissemination strategies included and described in the plan?
- Does the applicant describe whether and/or how the project lends itself to replication of all or some components of the project by others in the state?

6. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in [CPRIT's Administrative Rules](#). Applicants are advised to review CPRIT's administrative rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires the PD of the award to submit quarterly, annual, and final progress reports. These reports summarize the progress made toward project goals and address plans for the upcoming year and performance during the previous year(s). In addition, quarterly fiscal reporting and reporting on selected metrics will be required per the instructions to award recipients. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract.

7. CONTACT INFORMATION

7.1 Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding the scope and focus of applications. Before contacting the Helpdesk, please refer to the *Instructions for Applicants* document, which provides a step-by-step guide to using CARS.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

7.2 Program Questions

Questions regarding the CPRIT Prevention program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Prevention Program Office.

Tel: 512-626-2358

Email: prevention@cprit.texas.gov

Website: www.cprit.texas.gov

8. RESOURCES

- The Texas Cancer Registry. <https://www.dshs.texas.gov/tcr> or contact the Texas Cancer Registry at the Department of State Health Services.
- The Community Guide. <https://www.thecommunityguide.org/>
- Evidence-Based Cancer Control Programs (EBCCP). <https://ebccp.cancercontrol.cancer.gov/>
- Guide to Clinical Preventive Services: Recommendations of the US Preventive Services Task Force. <http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/guide/>
- Brownson, RC, Colditz GA, and Proctor, EK. (Editors). *Dissemination and Implementation Research in Health: Translating Science to Practice*. Oxford University Press, March 2012
- Program Sustainability Assessment Tool, copyright 2012, Washington University, St Louis, MO. <https://www.sustaintool.org/about-us/>
- Getting the Word Out: New Approaches for Disseminating Public Health Science. Ross C. Brownson, RC; Eyster, AA; Harris, JK; Moore, JB; Tabak, RG. *Journal of Public Health Management & Practice*. 2018;24(2):102-111
(https://journals.lww.com/jphmp/Fulltext/2018/03000/Getting_the_Word_Out_New_Approaches_for.4.aspx)
- Centers for Disease Control and Prevention: The Program Sustainability Assessment Tool: A New Instrument for Public Health Programs.
http://www.cdc.gov/pcd/issues/2014/13_0184.htm
- Centers for Disease Control and Prevention: Using the Program Sustainability Tool to Assess Plan for Sustainability. http://www.cdc.gov/pcd/issues/2014/13_0185.htm
- Cancer Prevention and Control Research Network: Putting Public Health Evidence in Action Training Workshop. <http://cpcrn.org/pub/evidence-in-action/>
- Centers for Disease Control and Prevention. Distinguishing Public Health Research and Public Health Nonresearch. <https://www.cdc.gov/os/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf>

9. REFERENCES

1. <https://www.cdc.gov/hpv/hcp/answering-questions.html>
2. Texas Cancer Registry, Cancer Epidemiology and Surveillance Branch, Texas Department of State Health Services. <https://www.cancer-rates.info/tx/>

APPENDIX A: KEY TERMS

- **Activities:** A listing of the “who, what, when, where, and how” for each objective that will be accomplished
- **Capacity Building:** Any activity (eg, training, identification of alternative resources, building internal assets) that builds durable resources and enables the grantee’s setting or community to continue the delivery of some or all components of the evidence-based intervention
- **Clinical Services:** Number of clinical services such as screenings, diagnostic tests, vaccinations, counseling sessions, or other evidence-based preventive services delivered by a health care practitioner in an office, clinic, or health care system. Other examples include genetic testing or assessments, physical rehabilitation, tobacco cessation counseling or nicotine replacement therapy, case management, clinical assessments, and family history screening.
- **Counties of Residence of Population Served:** Counties where the project does not plan to have a physical presence but people who live in these counties have received services. This includes counties of residence of people or places of business of professionals who participate in or receive education, navigation or clinical services. Examples include people traveling to receive services as a result of marketing and programs accessible via the website or social media. These counties may be described in the project plan and must be reported in the quarterly progress report.
- **Counties with Service Delivery:** Counties where an activity or service will occur and the project has a physical presence for the services provided. Examples include onsite outreach and educational activities and delivery of clinical services through clinics, mobile vans, or telemedicine consults. These counties must be entered in the Geographic Area to be Served section of the application.
- **Education Services:** Number of evidence-based, culturally appropriate cancer prevention and control education and outreach services delivered to the public and to health care professionals. Examples include education or training sessions (group or individual), focus groups, and knowledge assessments. One individual may receive multiple education services.

- **Evidence-Based Program:** A program that is validated by some form of documented research or applied evidence. CPRIT’s website provides links to resources for evidence-based strategies, programs, and clinical recommendations for cancer prevention and control. To access this information, visit <https://www.cprit.state.tx.us/our-programs/prevention>.
- **Goals:** Broad statements of general purpose to guide planning. Outcome goals should be few in number and focus on aspects of highest importance to the project ([appendix B](#)).
- **Integration:** The extent the evidence-based intervention is integrated within the culture of the grantee’s setting or community through policies and practice.
- **Navigation Services:** Number of activities/services that offer assistance to help overcome health care system barriers in a timely and informative manner and facilitate cancer screening and diagnosis to improve health care access and outcomes. Examples include patient reminders, transportation assistance, and appointment scheduling assistance. One individual may receive multiple navigation services.
- **Number of Clinical Services:** Number of [clinical services](#) delivered directly to members of the public by the funded project. One individual may receive multiple clinical services.
- **Number of Services (Direct Contact):** Number of services delivered directly to members of the public and/or professionals—direct, interactive public or professional education, outreach, training, navigation service, or clinical service, such as live educational and/or training sessions, vaccine administration, screening, diagnostics, case management/navigation services, and physician consults. One individual may receive multiple services.
- **Objectives:** Specific, **measurable**, actionable, realistic, and timely projections for outcomes; example: “Increase screening service provision in X population from Y% to Z% by 20xx.” Baseline data for the priority population must be included as part of each objective ([appendix B](#)). The proposed metric should be included in **both** the objective and the measure.
- **People Reached (Indirect Contact):** Number of members of the public and/or professionals reached via indirect noninteractive public or professional education and outreach activities, such as mass media efforts, brochure distribution, public service announcements, newsletters, and journals. (This category includes individuals who would

be reached through activities that are directly funded by CPRIT as well as individuals who would be reached through activities that occur as a direct consequence of the CPRIT-funded project's leveraging of other resources/funding to implement the CPRIT-funded project).

- **Unique People Served (Direct Contact):** Number of unique members of the public and/or professionals served via direct, interactive public or professional education, outreach, training, navigation service, or clinical service. This category includes individuals who would be served through activities that are directly funded by CPRIT as well as individuals who would be served through activities that occur as a direct consequence of the CPRIT-funded project's leveraging of other resources/funding to implement the CPRIT-funded project.

APPENDIX B: WRITING GOALS AND OBJECTIVES

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within **both** the stated Objective and the Measure sections (eg, Measure: 2,000 individuals, ages 9-12, will initiate HPV vaccination during the grant period).

One goal with 2 objectives addressing navigation into diagnosis and into treatment is required for all proposals and will be prepopulated into the application. This goal is not modifiable by the applicant. As with other proposed goals and objectives, the applicant is expected to explain plans to establish a baseline and describe method(s) of measurement, if a baseline is not defined.

Applicants may add a maximum of 3 additional goals with 3 outcome objectives each.

Projects will be evaluated annually on progress toward **outcome** goals and objectives.

The following has been adapted with permission from Appalachia Community Cancer Network, NIH Grant U54 CA 153604:

Develop well-defined goals and objectives.

Goals provide a roadmap or plan for where a group wants to go. Goals can be long term (over several years) or short term (over several months). Goals should be based on needs of the community and evidence-based data.

Goals should be

- Believable – situations or conditions that the group believes can be achieved
- Attainable – possible within a designated time
- Tangible – capable of being understood or realized
- On a timetable – with a completion date
- Win-Win – beneficial to individual members and the coalition

Objectives are measurable steps toward achieving the goal. They are clear statements of specific activities required to achieve the goal. The best objectives have several characteristics in common–

S.M.A.R.T. + C:

- Specific – they tell how much (number or percent), who (participants), what (action or activity), and by when (date)
 - Example: 115 uninsured individuals age 50 and older will complete colorectal cancer screening by March 31, 2018.

- Measurable – specific measures that can be collected, detected, or obtained to determine successful attainment of the objective
 - Example: How many screened at an event? How many completed pre/post assessment?
- Achievable – not only are the objectives themselves possible, it is likely that your organization will be able to accomplish them
- Relevant to the mission – your organization has a clear understanding of how these objectives fit in with the overall vision and mission of the group
- Timed – developing a timeline is important for when your task will be achieved
- Challenging – objectives should stretch the group to aim on significant improvements that are important to members of the community

Evaluate and refine your objectives

Review your developed objectives and determine the type and level of each using the following information:

There are 2 types of objectives:

- Outcome objectives – measure the “what” of a program; should be in the Goals and Objectives form (see [section 4.4.2](#))
- Process objectives – measure the “how” of a program; should be in the project plan only (see [section 4.4.4](#))

There are 3 levels of objectives:

- Community-level – objectives measure the planned community change
- Program impact – objectives measure the impact the program will have on a specific group of people
- Individual – objectives measures participant changes resulting from a specific program, using these factors:
 - Knowledge – understanding (know screening guidelines; recall the number to call for screening)
 - Attitudes – feeling about something (will consider secondhand smoke dangerous; believe eating 5 or more fruits and vegetable is important)
 - Skills – the ability to do something (complete fecal occult blood test)

- Intentions – regarding plan for future behavior (will agree to talk to the doctor, will plan to schedule a Pap test)
- Behaviors (past or current) – to act in a particular way (will exercise 30+ minutes a day, will have a mammogram)

Well-defined outcome goals and objectives can be used to track, measure, and report progress toward achievement.

Summary Table

| | Outcome – Use in Goals and Objectives | Process – Use in Project Plan only |
|------------------------|---|---|
| Community-level | <p>WHAT will change in a community</p> <p><i>Example: As a result of CPRIT funding, fecal immunochemical tests will be available to 1,500 uninsured individuals age 50 and over through 10 participating local clinics and doctors.</i></p> | <p>HOW the community change will come about</p> <p><i>Example: Contracts will be signed with participating local providers to enable uninsured individuals over age 50 have access to free colorectal cancer screening in their communities.</i></p> |
| Program impact | <p>WHAT will change in the target group as a result of a particular program</p> <p><i>Example: As a result of this project, 200 uninsured women between 40 and 49 will receive free breast and cervical cancer screening.</i></p> | <p>HOW the program will be implemented to affect change in a group/population</p> <p><i>Example: 2,000 female clients, between 40 and 49, will receive a letter inviting them to participate in breast and cervical cancer screening.</i></p> |
| Individual | <p>WHAT an individual will learn as a result of a particular program, or WHAT change an individual will make as a result of a particular program</p> <p><i>Example: As a result of one-to-one education of 500 individuals, at least 20% of participants will participate in a smoking cessation program to quit smoking.</i></p> | <p>HOW the program will be implemented to affect change in an individual’s knowledge or actions</p> <p><i>Example: As a result of one-to-one counseling, all participants will identify at least 1 smoking cessation service and 1 smoking cessation aid.</i></p> |

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Prevention Peer Review Panel - 1 – Day One

(24.1 PRV PP-1- Day One) Observation Report

Report No. 2023-12-05 24.1_PRV_PP-1- Day One
Program Name: Prevention
Panel Name: 24.1 Prevention Peer Review Panel - 1 – Day One (24.1 _PRV_PP-1- Day One)
Panel Date: December 5, 2023
Report Date: December 12, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Prevention Peer Review Panel - 1 – Day One (24.1_PRV_PP-1- Day One) meeting. The meeting was chaired by Ross Brownson and conducted via videoconference on December 5, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: 15 of 26 applications were discussed at peer review; of the 15, twelve (12) applications were discussed on Day 1
- Panelists: One (1) panel chair, thirteen (13) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The application for which there was a COI was not discussed on Day 1.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Prevention Peer Review Panel - 1 – Day Two

(24.1 PRV PP-1 - Day Two) Observation Report

Report No. 2023-12-06 24.1_PRV_PP-1 - Day Two
Program Name: Prevention
Panel Name: 24.1 Prevention Peer Review Panel - 1 – Day Two (24.1 _PRV_PP-1 - Day Two)
Panel Date: December 6, 2023
Report Date: December 12, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Prevention Peer Review Panel - 1 – Day Two (24.1_PRV_PP-1 - Day Two) meeting. The meeting was chaired by Ross Brownson and conducted via videoconference on December 6, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: 15 of 26 applications were discussed at peer review; of the 15, three (3) applications were discussed on Day 2
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Three (3)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
24.1 Prevention Review Council – Programmatic Review
(24.1 PRV PRC)
Observation Report

Report No. 2024-01-12 24.1_PRV_PRC
Program Name: Prevention
Panel Name: 24.1 Prevention Review Council – Programmatic Review (24.1_PRV_PRC)
Panel Date: January 12, 2024
Report Date: January 17, 2024

BACKGROUND

As part of CPRIT’s ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Prevention Review Council – Programmatic Review (24.1_PRV_PRC) meeting. The meeting was chaired by Steven Wyatt and conducted via videoconference on January 12, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT’s established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twelve (12) applications were discussed and fourteen (14) applications were not discussed
- Panelists: One (1) panel chair, and two (2) expert reviewers.
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Prevention Cycle 24.1

Awards Announced at the February 21, 2024, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Prevention Cycle 24.1 include: *Cancer Screening and Early Detection* and *Primary Prevention of Cancer*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|---|------------------------|--|----------------------------|
| Applications considered by the PIC and Oversight Committee: | | | |
| No identified COIs. | | | |
| Applications not considered by the PIC or Oversight Committee: | | | |
| PP240007 | Robert Volk | The University of Texas M. D. Anderson Cancer Center | M. Mahoney |

De-Identified Overall Evaluation Scores

Cancer Screening and Early Detection

Prevention Cycle 24.1

| Application ID | Final Overall Evaluation Score |
|----------------|--------------------------------|
| PP240017* | 2.1 |
| PP240040* | 2.2 |
| PP240042* | 3.0 |
| PP240021* | 3.1 |
| PP240012* | 3.1 |
| PP240019* | 3.3 |
| PP240011* | 3.4 |
| A | 4.7 |
| B | 5.0 |
| C | 5.0 |
| D | 5.8 |
| E | 5.8 |
| F | 7.3 |
| G | 8.3 |

* Recommended for funding.

Final Overall Evaluation Scores and Rank Order Scores

Dr. David Cummings
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Dr. Cummings and Mr. Roberts,

On behalf of the Prevention Review Council (PRC), I am pleased to provide the PRC's recommendations for the FY2024 Cycle 1 Cancer Screening and Early Detection (CSD) and Primary Prevention of Cancer (PPC) grant awards.

The PRC met on January 12, 2024, to consider the applications recommended by the peer review panel following their December 5-6, 2023, meeting. The PRC recommends 12 projects totaling \$25,902,480.

The projects are numerically ranked in the order the PRC recommends the applications be funded. Recommended funding amounts and the overall evaluation score are stated for each grant application. The average score for recommended applications ranges from 2.1 to 4.3. For the three applications with average scores of 4.0, 4.1 and 4.3 the PRC spent a considerable amount of effort reviewing panel evaluations/scores and concluded that they are quality proposals with the potential for significant impact. The PRC made no changes to the goals, project objectives, or timelines of the applications.

Our recommendations meet the PRC's standards for grant award funding of projects that are evidence-based, deliver programs or services to underserved populations, and focus on primary, secondary, or tertiary prevention. In making these recommendations the PRC continued to consider the available funding, the composition of the current portfolio, and the programmatic priorities in the RFA which include potential for impact and return on investment, geographic distribution, cancer type and type of program. All the recommended grants address one or more of the Prevention Program priorities.

Sincerely,
Stephen W. Wyatt, DMD, MPH
Chair, CPRIT Prevention Review Council

Attachment



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Cycle 24.1 Recommended Prevention Program Awards

| App. ID | Mech | Application Title | PD | Organization | Score | Rank Order | Budget |
|----------|------|---|----------------------|--|-------|------------|-------------|
| PP240017 | CSD | Expanding Access to Cervical Cancer Screening through Primary HR-HPV Testing and Self-Sampling: A Multicomponent Intervention for Safety Net Health Systems | Montealegre, Jane R | The University of Texas M. D. Anderson Cancer Center | 2.1 | 1 | \$2,499,646 |
| PP240040 | CSD | Expanding Intensive Smoking Cessation and Lung Cancer Screening in Vulnerable Adult Patients in Central Texas FQHCs | Altillo, Brandon | The University of Texas at Austin | 2.2 | 2 | \$2,000,000 |
| PP240022 | PPC | Expansion of a multi-pronged intervention to increase HPV vaccination rates among adolescents from rural and medically underserved areas in Texas | Berenson, Abbey B | The University of Texas Medical Branch at Galveston | 2.3 | 3 | \$2,494,865 |
| PP240042 | CSD | Cancer Prevention and Outreach for Individuals Disproportionately Affected by Cancer in Medically Underserved Regions (C-CUR) | Esnaola, Nestor | The Methodist Hospital Research Institute | 3.0 | 4 | \$1,437,244 |
| PP240021 | CSD | Reducing Racial/Ethnic Disparities in Breast Cancer Screening: Expanding a Comprehensive EHR-Based Patient Navigation Program | Rustveld, Luis | Baylor College of Medicine | 3.1 | 5 | \$2,499,998 |
| PP240012 | CSD | Integrated Mammography and Genetic Evaluation Services (IMAGES) | Whitman, Gary J | The University of Texas M. D. Anderson Cancer Center | 3.1 | 6 | \$1,499,400 |
| PP240019 | CSD | Increasing Access to Successful Colorectal Cancer Screening, Pairing Patient Education and Outreach with Navigation | Argenbright, Keith E | The University of Texas Southwestern Medical Center | 3.3 | 7 | \$2,487,342 |
| PP240011 | CSD | The Advancing Breast Health among uninsured Women in Central Texas (ABH-CTX) 2 | Shokar, Navkiran K | The University of Texas at Austin | 3.4 | 8 | \$2,000,000 |
| PP240041 | PPC | Expansion of the evidence-based Adolescent Vaccination Program (AVP) in a safety net clinic system to increase HPV vaccination rates in underserved populations | Shegog, Ross | The University of Texas Health Science Center at Houston | 3.5 | 9 | \$1,496,194 |
| PP240005 | PPC | Preventing Tobacco Related Cancers by Expanding Capacity for Tobacco Use Interventions Within Agencies Serving Women with Behavioral Health Needs | Reitzel, Lorraine R | The University of Texas M. D. Anderson Cancer Center | 4.0 | 10 | \$2,487,822 |
| PP240014 | PPC | Tiempo De Vacunarte 3 | Molokwu, Jennifer C | Texas Tech University Health Sciences Center at El Paso | 4.1 | 11 | \$2,500,000 |
| PP240030 | PPC | All for Them: A multilevel strategy for HPV-related cancer prevention | Cuccaro, Paula | The University of Texas Health Science Center at Houston | 4.3 | 12 | \$2,499,969 |

CSD: Cancer Screening and Early Detection

PPC: Primary Prevention of Cancer



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

Prevention
FY 2024—Cycles 1
Primary Prevention of Cancer

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA P-24.1-PPC

Primary Prevention of Cancer

Please also refer to the Instructions for Applicants document

Application Receipt Opening Date: June 1, 2023

Application Receipt Closing Date: August 30, 2023

FY 2024

Fiscal Year Award Period

September 1, 2023-August 31, 2024

TABLE OF CONTENTS

| | |
|---|-----------|
| 1. ABOUT CPRIT..... | 5 |
| 1.1 PREVENTION PROGRAM PRIORITIES..... | 5 |
| 2. FUNDING OPPORTUNITY DESCRIPTION | 6 |
| 2.1 SUMMARY | 6 |
| 2.2 PROJECT OBJECTIVES | 8 |
| 2.3 AWARD DESCRIPTION..... | 8 |
| 2.4 PRIORITIES..... | 10 |
| 2.5 OUTCOME METRICS..... | 11 |
| 2.6 FUNDING INFORMATION | 12 |
| 2.7 ELIGIBILITY | 13 |
| 2.8 RESUBMISSION POLICY | 14 |
| 2.9 EXPANSION POLICY | 15 |
| 3. KEY DATES | 16 |
| 4. APPLICATION SUBMISSION GUIDELINES..... | 16 |
| 4.1 <i>INSTRUCTIONS FOR APPLICANTS</i> DOCUMENT | 16 |
| 4.2 ONLINE APPLICATION RECEIPT SYSTEM..... | 16 |
| 4.3 SUBMISSION DEADLINE EXTENSION | 17 |
| 4.4 APPLICATION COMPONENTS | 17 |
| 4.4.1 <i>Abstract and Significance (5,000 characters)</i> | 17 |
| 4.4.2 <i>Goals and Objectives (900 characters each)</i> | 18 |
| 4.4.3 <i>Project Timeline (2 pages)</i> | 18 |
| 4.4.4 <i>Project Plan (12 pages; fewer pages permissible)</i> | 18 |
| 4.4.5 <i>People Reached (Indirect Contact)</i> | 21 |
| 4.4.6 <i>Number of Unique People Served (Direct Contact)</i> | 21 |
| 4.4.7 <i>Number of Services Delivered (Direct Contact)</i> | 22 |
| 4.4.8 <i>Number of Preventive Services Delivered</i> | 22 |
| 4.4.9 <i>References</i> | 22 |
| 4.4.10 <i>Resubmission Summary</i> | 22 |
| 4.4.11 <i>Most Recently Funded Relevant CPRIT Prevention Project Summary (only if applicable)</i> (3 pages)..... | 22 |
| 4.4.12 <i>CPRIT Grants Summary</i> | 23 |
| 4.4.13 <i>Budget and Justification</i> | 23 |
| 4.4.14 <i>Current and Pending Support and Sources of Funding</i> | 25 |
| 4.4.15 <i>Biographical Sketches</i> | 25 |
| 4.4.16 <i>Personnel and Collaborating Organizations</i> | 25 |
| 4.4.17 <i>Letters of Commitment (10 pages)</i> | 26 |
| 5. APPLICATION REVIEW..... | 26 |
| 5.1 REVIEW PROCESS OVERVIEW | 26 |
| 5.2 REVIEW CRITERIA | 27 |
| 5.2.1 <i>Primary Evaluation Criteria</i> | 28 |
| 5.2.2 <i>Secondary Evaluation Criteria</i> | 29 |
| 6. AWARD ADMINISTRATION | 30 |

7. CONTACT INFORMATION 31
7.1 HELPDESK 31
7.2 PROGRAM QUESTIONS 31
8. RESOURCES..... 32
9. REFERENCES 34
APPENDIX A: KEY TERMS..... 35
APPENDIX B: WRITING GOALS AND OBJECTIVES..... 38

RFA VERSION HISTORY

| | | |
|-----|----------|-------------|
| Rev | 5/5/2023 | RFA release |
|-----|----------|-------------|

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and enhance the potential for a medical or scientific breakthrough in the prevention of or cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

1.1 Prevention Program Priorities

Legislation from the 83rd Texas Legislature requires that CPRIT's Oversight Committee establish program priorities on an annual basis. The priorities are intended to provide transparency in how the Oversight Committee directs the orientation of the agency's funding portfolio. The Prevention Program's principles and priorities will also guide CPRIT staff and the Prevention Review Council (PRC) on the development and issuance of program-specific Requests for Applications (RFAs) and the evaluation of applications submitted in response to those RFAs.

Established Principles:

- Fund evidence-based interventions and their dissemination
- Support the prevention continuum of primary, secondary, and tertiary (includes survivorship) prevention interventions

CPRIT's Cross-Program Priorities:

- Prevention and early detection initiatives
- Translation of Texas research (discoveries) to innovations
- Enhancement of Texas' research capacity and life science infrastructure

Prevention Program Priorities:

- Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services
- Assess CPRIT Prevention Program to identify best practices, use as a quality improvement tool, and guide future program direction.

2. FUNDING OPPORTUNITY DESCRIPTION

2.1 Summary

The ultimate goals of the CPRIT Prevention Program are to reduce cancer incidence and mortality, reduce cancer disparities, and improve the lives of cancer survivors. More than half of cancers can be prevented by applying prevention knowledge we already have about modifiable causes of cancer. We can prevent some cancers, including second primary cancers in cancer survivors, by promoting and providing hepatitis B and HPV vaccines, supporting environmental approaches that make healthy choices easier, and empowering people to make healthy lifestyle choices related to tobacco use, nutrition, physical activity, and sun safety. This failure to address prevention is particularly impactful for those experiencing cancer disparities (eg, minority population groups, low-income populations). When prevention programs are comprehensive and maximize the ability for all populations to participate, major changes in behaviors and morbidity and mortality can be achieved. (Colditz GA, Emmons KM. Accelerating the Pace of Cancer Prevention-Right Now. [*Cancer Prev Res \[Phila\]*](#). 2018;11[4]:171-184)

There is increasing focus on multilevel interventions for cancer prevention. (Clauser SB, Taplin SH, Foster MK, Fagan P, Kaluzny AD. Multilevel Intervention Research: Lessons Learned and Pathways Forward. [*J Natl Cancer Inst Monogr*](#). 2012;44:127-133) A multilevel intervention seeks to influence more than 1 contextual level, ie, individual, group, organization, and community. Multilevel interventions require action targeting 2 or more levels of influence at the same time or in close temporal proximity. Multilevel interventions may involve policy, systems, and

environmental change as a way of modifying the environment to make healthy choices practical and available to all community members.

The **Primary Prevention of Cancer (PPC)** award mechanism focuses on increasing implementation of evidence-based strategies to ensure that all Texans benefit from the cancer prevention knowledge that we currently have. CPRIT seeks to fund multilevel interventions to reduce cancer risk, disease burden, and cancer disparities for priority populations, including cancer survivors. Modifiable risk behaviors include tobacco use, obesity, physical inactivity, unhealthy eating, alcohol use, sun exposure, HPV vaccination, hepatitis B vaccination, and environmental/occupational cancer exposures. **NOTE: The PPC award mechanism will not support cancer prevention/intervention research;** projects must be focused on implementing existing, evidence-based prevention approaches. Applicants interested in prevention research should review CPRIT's Academic Research RFAs (available at <http://www.cprit.texas.gov>).

This award mechanism also focuses on improving health outcomes among cancer survivors. Evidence suggests that lifestyle factors such as cessation of tobacco use, weight control, dietary choices, and physical activity substantially influence overall health and survival after a cancer diagnosis. These modifiable behaviors are risk factors for second primary cancers and comorbidity among cancer survivors. Decreasing alcohol intake is associated with cardioprotective effects, which may provide some benefits among survivors who have an increased risk of cardiovascular disease.

Applications should also assess and address social determinants that contribute to cancer burden and disparities (eg, cultural factors, unmet needs, access barriers). Interventions and communications should be structured to address the unique circumstances of the population to be served.

Eligible applications must include the delivery of interventions to nonmetropolitan (rural) and/or medically underserved counties in the state. For example, cigarette smoking and smokeless tobacco use are more prevalent in rural populations. Higher rates of obesity, lower rates of physical activity, and poor diets contribute to cancer-related health disparities in rural populations and high-risk urban populations.

Partnerships with other organizations that can support and leverage resources are strongly encouraged. A coordinated submission of a collaborative partnership program in which all partners have a substantial role in the proposed project is preferred.

2.2 Project Objectives

CPRIT seeks to reduce modifiable risk behaviors via projects that will do 1 or more of the following:

- Establish collaborations and partnerships with communities to deliver multilevel, evidence-based projects to reduce disparities and achieve health equity
- Deliver multilevel, evidence-based projects that include public and/or professional education, outreach, navigation to and delivery of primary prevention interventions
- Implement policy, systems and environmental changes that are sustainable over time (See <https://www.ccnationalpartners.org/new-resource-policy-systems-and-environmental-change-resource-guide>); examples include the following:
 - Advocating for/supporting structures that provide shade, sidewalks, paths, and recreation areas in community design
 - Implementing Farm to School programs (See <https://farmtoschoolcensus.fns.usda.gov/>)
 - Increasing availability of healthy food choices in restaurants or cafeterias
 - Advocating for/supporting policies for smoke-free zones and public events
 - Implementing programs that result in sustained smoking cessation.

2.3 Award Description

The **Primary Prevention of Cancer** RFA solicits applications for eligible projects up to 3 years in duration that will deliver multilevel, evidence-based interventions that improve cancer-related health behaviors, including improving the quality of life and cancer outcomes for cancer survivors. Interventions may address tobacco use, obesity, physical inactivity, unhealthy eating, alcohol use, HPV vaccination, hepatitis B vaccination, and environmental/occupational cancer exposures. Nonmetropolitan (rural) and/or medically underserved populations must be included in the defined service area.

The following are required components of the project:

- **Evidence-Based:** CPRIT's primary prevention grants are intended to fund culturally appropriate, effective, and efficient systems of delivery of preventive services based on the existing body of knowledge about and evidence for cancer prevention. Evidence-based and promising interventions can be identified via the [Community Guide, What Works for Health, National Comprehensive Cancer Control Program, NCI Evidence-Based Cancer Control Programs](#), and other sources.

The National Comprehensive Cancer Network and the American Cancer Society have developed consensus-based comprehensive survivorship care guidelines to provide direction on managing the potential physical and psychosocial long-term impact of cancer/associated treatment and subsequent surveillance for recurrence and screening for second primary cancers for projects focusing on survivor care.

If evidence-based interventions have not been implemented or evaluated for the specific population or setting proposed, provide evidence that the proposed intervention is appropriate for the population and has a high likelihood of success (ie, an evidence-informed practice). In cases where the evidence base is still developing, the applicant should provide a strong and comprehensive evaluation plan allowing for documentation of new evidence over the life of the project.

- **Multilevel Interventions:** Health behaviors have multiple levels of influences, often including individual, group, organization, and community determinants. Influences on behaviors interact across these different levels, and multilevel interventions are the most effective in changing behavior (See <http://medbox.iiab.me/modules/en-cdc/www.cdc.gov/cancer/crccp/sem.htm>).
- **Geographic Area to be Served:** Preventive service delivery to nonmetropolitan/medically underserved area (MUA) counties must be included in the defined service area. Rural and MUA counties may be identified via web-based tools from the [Texas Department of State Health Services](#) and [US Department of Health and Human Services](#). Service to urban counties that are not medically underserved is allowable as long as the project proposes to also serve nonmetropolitan counties that are medically underserved.

- **Community Partner Networks:** Applicants are strongly encouraged to coordinate and describe a collaboration of community partners that can deliver services to the most counties and the most people possible in a selected service region. Partnerships with other organizations that can support and leverage resources (eg, community-based organizations, local and voluntary agencies, nonprofit agencies, groups that represent priority populations) are encouraged. Letters of commitment or memoranda of understanding describing their specific role in the partnership will strengthen the application.

CPRIT expects measurable outcomes of supported activities, such as a significant increase over baseline (for the proposed service area) in the provision of evidence-based interventions to modify cancer risk factors, changes in provider practice, and systems changes. Applicants must demonstrate how these outcomes will ultimately impact incidence, mortality, morbidity, disparities, or quality of life. Under this RFA, CPRIT **will not** consider the following:

- Projects focused solely on metropolitan/non-medically underserved counties.
- Projects focusing solely on systems and/or policy change or solely on education and/or outreach that do not include the navigation to and delivery of multilevel interventions to reduce cancer risk.
- Projects focusing solely on case management/patient navigation services. Case management/patient navigation services must be paired with the delivery of a cancer prevention service, including those practices delivered by another provider.
- Cancer preventive services proposed as part of the project that do not comply with established and current national guidelines.
- Projects involving prevention/intervention research. Applicants interested in prevention research should review CPRIT’s Academic Research RFAs (available at <http://www.cprit.texas.gov>).

2.4 Priorities

The Prevention Program’s priorities for funding include the following:

- (1) **Populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence.**

CPRIT-funded programs must address 1 or more of these priority populations:

- Medically underresourced communities
- Racial, ethnic, and cultural minority groups
- Underinsured and uninsured individuals

(2) Geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence.

While disparities and needs exist across the state, CPRIT will also prioritize applications proposing to serve geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence. While it is permissible to serve metropolitan areas, projects must propose to also serve nonmetropolitan and/or MUAs of the state.

Geographic and Population Balance in Current CPRIT Portfolio

At the programmatic level of review conducted by the PRC ([section 5.1](#)), priority will be given to projects that target geographic regions of the state and population subgroups that are not adequately covered by the current CPRIT Prevention Program portfolio (see <https://www.cprit.texas.gov/our-programs/prevention/portfolio-maps> and <https://www.cprit.texas.gov/grants-funded?search=prevention>).

2.5 Outcome Metrics

Applicants are required to clearly describe their assessment and evaluation methodology. Mixed-methods evaluations are encouraged (eg, qualitative, quality improvement methods). The applicant is required to describe final outcome measures for the project. These measures should be identified in the project plan (including a logic model) and will serve as a measure of program effectiveness. Planned policy, system, or environmental changes should be identified. In addition, applicants should describe how funds from the CPRIT grant will improve outcomes over baseline. If the applicant is not providing baseline data for a measure, the applicant must provide a well-justified explanation and describe clear plans and method(s) of measurement to collect the data necessary to conduct a meaningful evaluation.

Reporting Requirements

Funded projects are required to report both qualitative and quantitative output and outcome metrics (as appropriate for each project) through the submission of quarterly progress reports, annual

reports, and a final report.

If someone other than the PD will enter information in the progress reports, they must be named as an Alternate Submitter in CARS. The Alternate Submitter is an application contact designated by the PD to complete PD tasks in CARS and/or the grants management system.

If services are being paid for and provided by others, the applicant is required to report on the number and outcomes of these preventive services.

2.6 Funding Information

The amount of total funding that applicants may request is dependent on the primary focus of the project and on the type of project: New, Initial Expansion, or Maintenance Expansion (see Expansion Policy, section 2.9). Use the table below to determine the maximum amount of funding and the maximum number of years that may be requested.

| Project Type | Maximum Amount of Total Funding | Maximum Duration |
|--|--|-------------------------|
| New Project | \$1 million | 3 years |
| Initial Expansion | \$1 million | 3 years |
| Initial Expansion – Vaccination or Tobacco Cessation for Adults | \$1.5 million | 3 years |
| Maintenance Expansion | \$2 million | 5 years |
| Maintenance Expansion – Vaccination or Tobacco Cessation for Adults | \$2.5 million | 5 years |

The funding amount is inclusive of both direct and indirect costs. Grant funds may be used to pay for preventive services, navigation services, project staff salary and benefits, project supplies, equipment, costs for outreach and education of populations, and travel of project personnel to project site(s).

Requests for funds to support construction, renovation, or any other infrastructure needs or requests to support lobbying will not be approved. Grantees may request funds for travel for 2 project staff to attend CPRIT’s conference.

The budget should be proportional to the number of individuals receiving programs and services, and a significant proportion of funds is expected to be used for program delivery as opposed to program development. In addition, CPRIT seeks to fill gaps in funding rather than replace existing funding, supplant funds that would normally be expended by the applicant’s organization, or make

up for funding reductions from other sources.

State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the **total** award amount.

2.7 Eligibility

- The applicant must be a Texas-based entity, such as a community-based organization, health institution, government organization, public or private company, college or university, or academic health institution.
- The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted.
- The designated Program Director (PD) will be responsible for the overall performance of the funded project. The PD must have relevant education and management experience and must reside in Texas during the project performance time.
- The evaluation of the project must be headed by a professional who has demonstrated expertise in the field and who resides in Texas during the time that the project is conducted.
- The applicant may submit more than 1 application, but each application must be for distinctly different services without overlap in the services provided. Applicants who do not meet this criterion will have all applications administratively withdrawn without peer review.
- If an organization has a current CPRIT grant that is the same or similar to the prevention intervention being proposed, the applicant must explain how the projects are nonduplicative or complementary. Duplicative applications will be administratively withdrawn.
- Collaborations are permitted and encouraged, and collaborators may or may not reside in Texas. However, collaborators who do not reside in Texas are not eligible to receive CPRIT funds. Collaborators should have specific and well-defined roles. Subcontracting and collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PD, any senior member or key personnel listed on the grant application, or any officer or director of the

grant applicant's organization or institution is related to a CPRIT Oversight Committee member.

- An applicant organization is eligible to receive a grant award only if the applicant certifies that the applicant organization, including the PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation created to benefit CPRIT.
- The applicant must report whether the applicant organization, the PD, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, (whether slated to receive salary or compensation under the grant award or not), are currently ineligible to receive federal grant funds because of scientific misconduct or fraud or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. CPRIT grants are funded on a reimbursement-only basis. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 6](#). All statutory provisions and relevant administrative rules can be found on the CPRIT website.

2.8 Resubmission Policy

- **One resubmission** is permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. Resubmission applications must include a Resubmission Summary (see [section 4.4.10](#)).
- Reviewers of resubmissions are asked to assess whether the resubmission adequately addresses critiques from the previous review. **Applicants should note that addressing previous critiques is advisable; however, it does not guarantee the success of the resubmission.** All resubmitted applications must conform to the structure and guidelines outlined in this RFA.

2.9 Expansion Policy

- Expansion grants are intended to fund expansion of currently or previously funded projects that have demonstrated exemplary success, as evidenced by progress reports and project evaluations, and desire to further enhance their impact on priority populations. Detailed descriptions of **results, barriers, outcomes, and impact of the currently or previously funded project are required** (see outline of Most Recently Funded Project Summary, [section 4.4.11](#)).
- Proposed expansion projects should NOT be new projects but should closely follow the intent and core elements of the currently or previously funded project. Established infrastructure/processes and fully described prior project results are required. Expansion of current projects into geographic areas not well served by the CPRIT Prevention portfolio (see maps at <http://www.cprit.state.tx.us/our-programs/prevention/portfolio-maps>) will receive priority consideration.
- CPRIT expects measurable outcomes of supported activities, such as a significant increase over baseline (for the proposed service area). It is expected that baselines will have already been established and that continued improvement over baseline is demonstrated in the current application. However, in the case of a proposed expansion where no baseline data exist for the priority population, the applicant must present clear plans and describe method(s) of measurement used to collect the data necessary to establish a baseline. Applicants must demonstrate how these outcomes will ultimately impact cancer incidence, mortality, morbidity, or quality of life.
- CPRIT also expects that applications for continuation **will not** require startup time, that applicants can demonstrate that they have overcome barriers encountered, and that applicants have identified **lasting systems changes** that improve results, efficiency, and sustainability. Leveraging of resources and plans for dissemination are expected and should be well described.

Requirements for Initial and Maintenance Expansion Projects

Initial Expansion: For the first expansion application, eligible applicants should propose to expand their programs to include additional types of primary preventive practices or to expand current practices into additional counties. In either case, the expansion must include the delivery of

services to nonmetropolitan (rural) and/or medically underserved counties in the state. These may be identified via web-based tools from the [Texas Department of State Health Services](#) and [US Department of Health and Human Services](#).

Maintenance Expansion: For a subsequent expansion, additional primary preventive practices and/or expansion to additional counties are optional; however, the counties and the practices offered in the first expansion should not be decreased. The number of services delivered during the maintenance expansion must be increased substantially if no further geographic or preventive service expansion is proposed.

3. KEY DATES

| | |
|---------------------------------|------------------------------------|
| RFA release | May 5, 2023 |
| Online application opens | June 1, 2023, 7 AM central time |
| Application due | August 30, 2023, 4 PM central time |
| Application review | October 2023-January 2024 |
| Award notification | February 2024 |
| Anticipated start date | March 1, 2024 |

Applicants will be notified of peer review panel assignment prior to the peer review meeting dates.

4. APPLICATION SUBMISSION GUIDELINES

4.1 Instructions for Applicants document

It is **imperative** that applicants read the accompanying instructions document for this RFA that will be available May 5, 2023 (<https://CPRITGrants.org>). Requirements may have changed from previous versions.

4.2 Online Application Receipt System

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The PD must create a user account in the system to start and submit an application. The Co-PD, if applicable, must also create a user account to participate in the application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official

(an individual who will help manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on June 1, 2023, and must be submitted by 4 PM central time on August 30, 2023. Detailed instructions for submitting an application are in the *Instructions for Applicants* document, posted on CARS.

Submission of an application is considered an acceptance of the terms and conditions of the RFA.

4.3 Submission Deadline Extension

The submission deadline may be extended for 1 or more grant applications upon a showing of good cause. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records.

4.4 Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Refer to the *Instructions for Applicants* document for details.

Submissions that are missing 1 or more components or do not meet the eligibility requirements may be administratively withdrawn without review.

4.4.1 Abstract and Significance (5,000 characters)

Clearly explain the problem(s) to be addressed, the approach(es) to the solution, and how the application is responsive to this RFA. If the project is funded, the abstract will be made public; therefore, no proprietary information should be included in this statement. Initial compliance decisions are based in part upon review of this statement.

The abstract format is as follows (use headings as outlined below):

- **Need:** Include a description of need in the specific service area. Include rates of incidence, mortality, and screening in the service area compared to overall Texas rates. Describe barriers, plans to overcome these barriers, and the priority population to be served.
- **Overall Project Strategy:** Describe the project and how it will address the identified need. Clearly explain what the project is and what it will specifically do, including the services to

be provided and the process/system for delivery of services and outreach to the priority population.

- **Specific Goals:** State specifically the overall goals of the proposed project; include the estimated overall numbers of preventive services to be delivered and number of people (public and/or professionals) to be served.
- **Significance and Impact:** Explain how the proposed project, if successful, will have a major impact on cancer prevention and control for the population proposed to be served and for the State of Texas.

4.4.2 Goals and Objectives (900 characters each)

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within both the stated Objective **and** the Measure sections (eg, Measure: 2,000 individuals, ages 9-12, will initiate HPV vaccination during the grant period). Refer to the *Instructions for Applicants* document for details.

The maximum number is 3 goals with 3 outcome objectives each. Projects will be evaluated annually on progress toward outcome goals and objectives. See [appendix B](#) for instructions on writing outcome goals and objectives.

A baseline and method(s) of measurement are required for each objective. Provide both raw numbers and percent changes for the baseline and target. If a baseline has not been defined, applicants are required to explain plans to establish baseline and describe method(s) of measurement. Note that character limits are inclusive of all words in each text box, including provided headings.

4.4.3 Project Timeline (2 pages)

Provide a project timeline for project activities that includes deliverables and dates. Use Years 1, 2, 3, and Months 1, 2, 3, etc, as applicable (eg, Year 1, Months 3-5). Do NOT refer to specific months or years (eg, not May 2024). Month 1 (as opposed to March 1, 2024) is the first full month of the grant award.

4.4.4 Project Plan (12 pages; fewer pages permissible)

The required project plan format follows. Applicants must use the headings outlined below.

Background: Briefly present the rationale behind the proposed primary prevention services,

emphasizing the critical barriers to current service delivery that will be addressed. Identify the evidence-based service to be implemented for the priority population. Describe the race, ethnicity, age, and other defining characteristics of the population to be served.

If evidence-based strategies have not been implemented or tested for the specific population or service setting proposed, provide evidence that the proposed service is appropriate for the population and has a high likelihood of success. Baseline data for the priority population and target service area are required where applicable.

Reviewers will be aware of national and state statistics, and these should be used only to compare rates for the proposed service area. Describe the geographic region of the state that the project will serve; maps are encouraged.

Goals and Objectives: Process objectives should be included in the project plan. Outcome goals and objectives will be entered in separate fields in CARS. However, if desired, outcome goals and objectives may be fully repeated or briefly summarized here. See [appendix B](#) for instructions on writing goals and objectives.

Components of the Project: Clearly describe the need, delivery method, and evidence base (provide references) for the services, as well as anticipated results. Be explicit about the base of evidence and any necessary adaptations for the proposed project. Describe why this project is nonduplicative. If an organization has a current CPRIT grant that is the same or similar to the prevention intervention being proposed, the applicant must explain how the projects are nonduplicative or complementary.

It is important to distinguish between Texas counties where the project proposes to deliver services and counties of residence of population served (see [appendix A](#) for definitions and *Instructions for Applicants*). Only counties where service delivery occurs should be listed in the Geographic Area to be Served section of the application. Projecting counties of residence of population served is not required but may be described in the project plan.

Clearly demonstrate the ability to provide the proposed service(s) and describe how results will be improved over baseline and the ability to reach the priority population.

If preventive services are being paid for and provided by others, the applicant must explain and report on the number of these services and outcomes.

Evaluation Strategy: A strong commitment to evaluation of the project is required. Describe the plan for outcome and output measurements, including qualitative analysis of policy and system changes. Describe data collection and management methods, data analyses, and anticipated results. Evaluation and reporting of results should be headed by a professional who has demonstrated expertise in the field. If needed, applicants may want to consider seeking expertise at Texas-based academic cancer centers, schools/programs of public health, or the like. Applicants should budget accordingly for the evaluation activity and should involve that professional during grant application preparation to ensure, among other things, that the evaluation plan is linked to the proposed goals and objectives.

Organizational Qualifications and Capabilities: Describe the organization and its track record and success in providing health programs and services. Describe the role and qualifications of the key collaborators/partners in the project. Include information on the organization's financial stability and viability. The applicant should demonstrate how the organizational environment will contribute to a successful project. If equipment or physical resources are required to carry out the project, the applicant should describe the availability of these resources and the organizational capacity to use equipment. To ensure access to preventive services and reporting of services outcomes, applicants should demonstrate that they have provider partnerships and agreements (via memoranda of understanding) or commitments (via letters of commitment) in place.

CPRIT acknowledges that full maintenance and sustainability of projects when CPRIT funding ends may not be feasible, especially in cases involving the delivery of preventive services. However, it is important to consider sustainability early in the life cycle of a project, particularly regarding organizational characteristics and processes that are modifiable.

Washington University in St Louis has developed a useful tool ([Program Sustainability Assessment Tool](#)) to assess program capacity for sustainability. The tool assesses several factors that contribute to program sustainability. These factors include environmental support, funding stability, partnerships, organizational capacity, program evaluation, program adaptation, communication, and strategic planning. Applicants are not required to use this tool; however, it provides practical guidance on factors that should be considered and should be included in the application to describe a program's organizational capacity for sustainability.

It is expected that steps toward building capacity for the program will be taken, and plans for such

should be described in the application. The applicant should describe the factors that will contribute to the organization's capacity to facilitate sustainability.

Dissemination and Replication: Dissemination of project results and outcomes, including barriers encountered and successes achieved, is critical to building the evidence base for cancer prevention and control efforts in the state. Dissemination efforts should consider the message, source, audience, and channel (Brownson, RC, et al. [J Pub Health Manag Pract. 2018;24\[2\]:102-111](#)). Dissemination methods may include, but are not limited to, presentations at workshops and seminars, one-on-one meetings, publications, news media, social media, etc.

While passive dissemination methods are common (eg, publications, presentations at professional meetings), plans should include some active dissemination methods (eg, meetings with stakeholders, blogs, social media). Applicants should describe their dissemination plans. The plans should include the kinds of audiences to be targeted and methods for reaching the targeted audiences.

Replication by others is an additional way to disseminate the project. For applicable components, describe how the project or components of the project lend themselves to application by other communities and/or organizations in the state or expansion in the same communities. Describe what components of this project can be adapted to a larger or lower resource setting. Note that some programs may have unique resources and may not lend themselves to replication by others.

4.4.5 People Reached (Indirect Contact)

Provide the estimated overall number of people (members of the public and professionals) to be reached by the funded project. The applicant is required to itemize separately the types of indirect noninteractive education and outreach activities, with estimates, that led to the calculation of the overall estimates provided. Refer to appendix A for definitions.

4.4.6 Number of Unique People Served (Direct Contact)

Provide the estimated overall number of unique members of the public and professionals served by the funded project. One person may receive multiple services but should only be counted once here. Refer to [appendix A](#) for definitions.

4.4.7 Number of Services Delivered (Direct Contact)

Provide the estimated overall number of services directly delivered to members of the public and to professionals by the funded project. Each individual service should be counted, regardless of the number of services 1 person receives. The applicant is required to itemize separately the education, navigation, and cancer prevention activities/services, with estimates, that led to the calculation of the overall estimate provided. Refer to [appendix A](#) for definitions.

4.4.8 Number of Preventive Services Delivered

Provide the estimated overall number of services directly delivered to members of the public by the funded project. Each individual clinical service should be counted, regardless of the number of services 1 person receives. Separately itemize the services, with estimates, that led to the calculation of the overall estimate provided. Refer to [appendix A](#) for definitions.

4.4.9 References

Provide a concise and relevant list of references cited for the application. The successful applicant will provide referenced evidence and literature support for the proposed services.

4.4.10 Resubmission Summary

Resubmission applications must include a Resubmission Summary. Use the template provided on CARS (<https://CPRITGrants.org>). Describe the approach to the resubmission and how reviewers' comments were addressed. Clearly indicate to reviewers how the application has been improved in response to the critiques. Refer the reviewers to specific sections of other documents in the application where further detail on the points in question may be found. When a resubmission is evaluated, responsiveness to previous critiques is assessed.

The summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission; the applicant is not responsible for providing this document.

4.4.11 Most Recently Funded Relevant CPRIT Prevention Project Summary (only if applicable) (3 pages)

Upload a summary that outlines the progress made with the applicant's most recently funded relevant CPRIT Prevention Award. Applicants must describe results and outcomes of the most

recently funded award and demonstrate why further funding is warranted.

Please note that a different set of reviewers from those assigned to the previously funded application may evaluate this application. Applicants should make it easy for reviewers to compare the most recently funded project with the proposed project.

In the description, include the following:

- Describe the evidence-based intervention, its purpose, and how it was implemented in the priority population. Describe any adaptations made for the population served.
- List approved goals and objectives of the most recently funded grant.
- For each objective, provide milestones/target dates and target metrics as compared to actual completion dates and metrics.
- Include a discussion of objectives not fully met. Explain any barriers encountered and strategies used to overcome these.
- For the most recently funded project, describe major activities; significant results, including major findings, developments, or conclusions (both positive and negative); and key outcomes.
- Describe steps taken toward sustainability for components of the project. Fully describe systems or policy improvements and enhancements.
- Describe how project results were disseminated or plans for future dissemination of results.

4.4.12 CPRIT Grants Summary

Use the template provided on CARS (<https://CPRITGrants.org>). Provide a listing of **all** projects funded by the CPRIT Prevention program for the PD and the Co-PD, regardless of their connection to this application.

4.4.13 Budget and Justification

Provide a brief outline and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, travel, equipment, supplies, contractual expenses, services delivery, and other expenses. CPRIT funds will be distributed on a reimbursement basis.

Applications requesting more than the maximum allowed cost as specified in [section 2.6](#) will be administratively withdrawn.

Clearly describe any organizational cost sharing or pro bono contributions related to this project, as

well as any attempts made or successes to secure other state/federal funds.

- **Average Cost per Person:** The average cost per person will be automatically calculated from the total cost of the project divided by the total number of unique people served (refer to [appendix A](#)).
- **Average Cost per Service:** The average cost per service will be automatically calculated from the total cost of the project divided by the total number of services delivered (refer to [appendix A](#)). A significant proportion of funds is expected to be used for program delivery as opposed to program development and organizational infrastructure.
- **Average Cost per Preventive Service:** The average cost per clinical service will be automatically calculated from the total cost of the project divided by the total number of services delivered (refer to [appendix A](#)).
- **Personnel:** The individual salary cap for CPRIT awards is \$200,000 per year. Describe the source of funding for all project personnel where CPRIT funds are not requested.
- **Travel:** PDs and related project staff are expected to attend CPRIT's conference. CPRIT funds may be used to send up to 2 people to the conference. Meals are not reimbursable for trips that do not include an overnight stay.
- **Equipment:** Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application. Cost sharing of equipment purchases is strongly encouraged.
- **Services Costs:** CPRIT reimburses for services using Medicare reimbursement rates. Describe the source of funding for all services where CPRIT funds are not requested. If preventive services are being paid for and provided by others, the applicant is required to explain and report on the number of services and outcomes that are delivered to the people navigated by the program.
- **Other Expenses:**
 - **Incentives:** Use of incentives or positive rewards to change or elicit behavior is allowed; however, incentives may only be used based on strong evidence of their effectiveness for the purpose and in the priority population identified by the applicant. CPRIT will not fund cash incentives. The maximum dollar value allowed for an incentive per person, per activity or session, is \$25.

- **Indirect/Shared Costs:** Texas law limits the amount of grant funds that may be spent on indirect/shared expenses to no more than 5% of the total award amount (5.263% of the direct costs). Indirect costs reimbursed to subcontractors count toward the total allowable indirect costs. Guidance regarding indirect cost recovery can be found in [CPRIT's Administrative Rules](#).

4.4.14 Current and Pending Support and Sources of Funding

Use the template provided on the CARS (<https://CPRITGrants.org>). Describe the funding source and duration of **all** current and pending support for the proposed project.

4.4.15 Biographical Sketches

The designated PD will be responsible for the overall performance of the funded project and must have relevant education and management experience. The PD/Co-PD(s) must provide a biographical sketch that describes his or her education and training, professional experience, awards and honors, and publications and/or involvement in programs relevant to cancer prevention and/or service delivery.

- Use the Co-PD Biographical Sketch section ONLY if a Co-PD has been identified.
- The evaluation professional must provide a biographical sketch in the Evaluation Professional Biographical Sketch section.
- Up to 3 additional biographical sketches for key personnel may be provided in the Key Personnel Biographical Sketches section.

Each biographical sketch must not exceed 5 pages and should use either the “Prevention Programs: Biographical Sketch” template provided on the CARS (<https://CPRITGrants.org>) or the NIH Biographical Sketch format. If a position is not yet filled, please upload a job description.

4.4.16 Personnel and Collaborating Organizations

List ALL personnel working on the proposed project, paid or unpaid, as well as partners, collaborators, and anyone listed under the Current & Pending Support section. Include all key participating organizations that will partner with the applicant organization to provide 1 or more components essential to the success of the program (eg, evaluation, preventive practices/services, recruitment to screening).

4.4.17 Letters of Commitment (10 pages)

Applicants should provide letters of commitment and/or memoranda of understanding from community organizations, key faculty, or any other component essential to the success of the program. Letters should be specific to the contribution of each organization.

5. APPLICATION REVIEW

5.1 Review Process Overview

All eligible applications will be reviewed using a 2-stage peer review process: (1) evaluation of applications by peer review panels and (2) prioritization of grant applications by the PRC. In the first stage, applications will be evaluated by an independent review panel using the criteria listed below. In the second stage, applications judged to be meritorious by review panels will be evaluated by the PRC and recommended for funding based on comparisons with applications from all of the review panels and programmatic priorities.

Programmatic considerations may include, but are not limited to, geographic distribution, cancer type, population served, and type of program or service. The peer review scores are only 1 factor considered during programmatic review. At the programmatic level of review, priority will be given to proposed projects that target geographic regions of the state or population subgroups that are not well represented in the current CPRIT Prevention project portfolio.

Applications approved by PRC will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

Each stage of application review is conducted confidentially, and all CPRIT Peer Review Panel members, PRC members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements

regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Peer Review Panel members and PRC members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer Review Panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, [chapter 703, section 703.9](#).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, a Review Panel member, or PRC member.

Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period prior to the opening of CARS. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

5.2 Review Criteria

Peer review of applications will be based on primary scored criteria and secondary unscored criteria, identified below. Review committees will evaluate and score each primary criterion and subsequently assign an overall score that reflects an overall assessment of the application. The overall evaluation score will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application and responsiveness to the RFA.

5.2.1 Primary Evaluation Criteria

Impact

- Do the proposed approaches address an important problem or need in primary prevention of cancer? Do the proposed project strategies support desired outcomes in cancer risk and equity? Do the proposed project strategies reach a priority population (eg, low income, minority, rural) at high risk of cancer?
- Will the project serve and impact an appropriate number of people based on the budget allocated?
- If applicable, have partners demonstrated that the collaborative effort will provide a greater impact on cancer prevention and control than the applicant organization's effort separately?
- Does the program address adaptation, if applicable, of the evidence-based intervention to the priority population? Is the base of evidence clearly explained and referenced?

Project Strategy and Feasibility

- Does the proposed project provide preventive practices specified in the RFA?
- Are the overall program approach, strategy, and design clearly described and supported by established theory and practice? Are the proposed objectives and activities feasible within the duration of the award? Has the applicant convincingly demonstrated the short- and long-term impacts of the project?
- Has the applicant proposed policy changes and/or system improvements?
- Are possible barriers addressed and approaches for overcoming them proposed?
- Are the priority population and culturally appropriate methods to reach the priority population clearly described?
- Does the program leverage partners and resources to maximize the reach of the practices proposed? Does the program leverage and complement other state, federal, and nonprofit grants?

Outcomes Evaluation

- Are specific goals and measurable objectives for each year of the project provided?
- Are the proposed outcome measures appropriate for the preventive practices provided, and are the expected changes clinically significant?

- Does the application provide a clear and appropriate plan for data collection and management and data analyses?
- Are clear baseline data provided for the priority population, or are clear plans included to collect baseline data?
- If an evidence-based intervention is being adapted in a population where it has not been implemented or tested, are plans for evaluation of barriers, effectiveness, and fidelity to the model described?
- Is the qualitative analysis of planned policy or system changes described?

Organizational Qualifications and Capabilities

- Do the organization and its collaborators/partners demonstrate the ability to provide the proposed preventive practices?
- Does the described role of each collaborating organization make it clear that each organization adds value to the project and is committed to working together to implement the project?
- Have the appropriate personnel been recruited to design, implement, evaluate, and complete the project?
- Is the organization structurally and financially stable and viable?
- Does the applicant describe the program's organizational capacity for sustainability?
- Does the applicant describe steps that will be taken toward building internal capacity and partnerships?
- Does the applicant describe a plan for systems changes that are sustainable over time (eg, improve results, provider practice, efficiency, cost-effectiveness)?

5.2.2 Secondary Evaluation Criteria

Budget

- Is the budget appropriate and reasonable for the scope and preventive practices of the proposed work?
- Is the cost per person served appropriate and reasonable?
- Is the project a good investment of Texas public funds?

Dissemination and Replication

- Are plans for dissemination of the project’s results and outcomes, including target audiences and methods, clearly described?
- Are active dissemination strategies included and described in the plan?
- Does the applicant describe whether and/or how the project lends itself to replication of all or some components of the project by others in the state?

6. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT’s electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT’s electronic signature policy as set forth in Texas Administrative Code, Title 25, chapters 701 to 703. Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in [CPRIT’s Administrative Rules](#). Applicants are advised to review CPRIT’s administrative rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in Texas Administrative Code, Title 25, chapters 701 to 703.

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT’s Administrative Rules, Texas Administrative Code, Title 25, chapters 701 to 703.

CPRIT requires award recipients to submit quarterly, annual, and final progress reports. These reports summarize the progress made toward project goals and address plans for the upcoming year. In addition, quarterly fiscal reporting and reporting on selected metrics will be required per the instructions to award recipients. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract.

7. CONTACT INFORMATION

7.1 Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding the scope and focus of applications. Before contacting the Helpdesk, please refer to the *Instructions for Applicants* document, which provides a step-by-step guide to using CARS.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

7.2 Program Questions

Questions regarding the CPRIT Prevention program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Prevention Program Office.

Tel: 512-626-2358

Email: prevention@cprit.texas.gov

Website: www.cprit.texas.gov

8. RESOURCES

- Department of State Health Services. <https://www.dshs.texas.gov/tcr/data/modifiable-risk-factors.aspx>
- The Community Guide. <https://www.thecommunityguide.org/>
- Implementing Farm to School Programs. <https://farmtoschoolcensus.fns.usda.gov/>
- What Works for Health. <https://www.countyhealthrankings.org/take-action-to-improve-health/what-works-for-health>
- National Comprehensive Cancer Control Program. <https://www.cdc.gov/cancer/ncccp/index.htm>
- NCI Evidence-Based Cancer Control Program. <https://ebccp.cancercontrol.cancer.gov/index.do>
- Evidence-Based Cancer Control Programs (EBCCP). <https://ebccp.cancercontrol.cancer.gov/>
- Comprehensive Cancer Control. Policy, Systems, and Environmental Change Resource Guide. <https://www.cccnationalpartners.org/new-resource-policy-systems-and-environmental-change-resource-guide>
- Colorectal Cancer Control Program. Social Ecological Model. <http://medbox.iiab.me/modules/en-cdc/www.cdc.gov/cancer/crcp/sem.htm>
- Guide to Clinical Preventive Services: Recommendations of the U.S. Preventive Services Task Force. <http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/guide/>
- Program Sustainability Assessment Tool, copyright 2012, Washington University, St Louis, MO, <https://www.sustaintool.org/about-us/>
- Getting the Word Out: New Approaches for Disseminating Public Health Science. Ross C. Brownson, RC; Eyler, AA; Harris, JK; Moore, JB; Tabak, RG. *Journal of Public Health Management & Practice*. 2018;24(2):102-111. https://journals.lww.com/jphmp/Fulltext/2018/03000/Getting_the_Word_Out_New_Approaches_for.4.aspx

- Centers for Disease Control and Prevention: The Program Sustainability Assessment Tool: A New Instrument for Public Health Programs. http://www.cdc.gov/pcd/issues/2014/13_0184.htm
- Centers for Disease Control and Prevention: Using the Program Sustainability Tool to Assess and Plan for Sustainability. http://www.cdc.gov/pcd/issues/2014/13_0185.htm
- Cancer Prevention and Control Research Network: Putting Public Health Evidence in Action Training Workshop. <http://cpcrn.org/pub/evidence-in-action/>
- Environmental and Occupational Interventions for Primary Prevention of Cancer: A Cross-Sectorial Policy Framework. https://ehp.niehs.nih.gov/doi/10.1289/ehp.1205897?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed
- Centers for Disease Control and Prevention. Distinguishing Public Health Research and Public Health Nonresearch. <https://www.cdc.gov/os/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf>

9. REFERENCES

1. <https://www.cdc.gov/hpv/hcp/answering-questions.html>
2. Texas Cancer Registry, Cancer Epidemiology and Surveillance Branch, Texas Department of State Health Services. <https://www.cancer-rates.info/tx/>
3. Colditz GA, Emmons KM. Accelerating the Pace of Cancer Prevention- Right Now. *Cancer Prev Res (Phila)*. 2018;11(4):171-184
4. Clauser SB, Taplin SH, Foster MK, Fagan P, Kaluzny AD. Multilevel intervention research: lessons learned and pathways forward. *J Natl Cancer Inst Monogr*. 2012;(44):127-133

APPENDIX A: KEY TERMS

- **Activities:** A listing of the “who, what, when, where, and how” for each objective that will be accomplished
- **Capacity Building:** Any activity (eg, training, identification of alternative resources, building internal assets) that builds durable resources and enables the grantee’s setting or community to continue the delivery of some or all components of the evidence-based intervention
- **Preventive Practices/Services:** Number of evidence-based preventive services delivered by a health care practitioner in an office, clinic, or health care system. Examples include, but are not limited to vaccinations, physical rehabilitation, tobacco cessation counseling or nicotine replacement therapy, case management, primary prevention clinical assessments and services.
- **Counties of Residence of Population Served:** Counties where the project does not plan to have a physical presence but people who live in these counties have received services. This includes counties of residence of people or places of business of professionals who participate in or receive education, navigation or preventive practices/services. Examples include people traveling to receive services as a result of marketing and programs accessible via the website or social media. These counties may be described in the project plan and must be reported in the quarterly progress report.
- **Counties with Service Delivery:** Counties where an activity or service will occur and the project has a physical presence for the services provided. Examples include onsite outreach and educational activities and delivery of services through clinics, mobile vans, or telemedicine consults. These counties must be entered in the Geographic Area to be Served section of the application.
- **Education Services:** Number of evidence-based, culturally appropriate cancer prevention and control education and outreach services delivered to the public and to health care professionals. Examples include education or training sessions (group or individual), focus groups, and knowledge assessments. One individual may receive multiple education services.

- **Evidence-Based Program:** A program that is validated by some form of documented research or applied evidence.
- **Goals:** Broad statements of general purpose to guide planning. Outcome goals should be few in number and focus on aspects of highest importance to the project ([appendix B](#)).
- **Integration:** The extent the evidence-based intervention is integrated within the culture of the grantee’s setting or community through policies and practice.
- **Navigation Services:** Number of activities/services that offer assistance to help overcome health care system barriers in a timely and informative manner to improve health care access and outcomes. Examples include patient reminders, transportation assistance, and appointment scheduling assistance. One individual may receive multiple navigation services.
- **Number of Preventive Services/Practices:** Number of [preventive services](#) delivered directly to members of the public by the funded project. Number of evidence-based preventive services delivered by a health care practitioner in an office, clinic, or health care system. Examples include, but are not limited to vaccinations, physical rehabilitation, tobacco cessation counseling or nicotine replacement therapy, case management, primary prevention clinical assessments and services. One individual may receive multiple preventive services.
- **Number of Services (Direct Contact):** Number of services delivered directly to members of the public and/or professionals—direct, interactive public or professional education, outreach, training, navigation service, or clinical service, such as live educational and/or training sessions, vaccine administration, case management/navigation services, and physician consults. One individual may receive multiple services.
- **Objectives:** Specific, **measurable**, actionable, realistic, and timely projections for outcomes; example: “Increase screening service provision in X population from Y% to Z% by the end of Year 1.” Baseline data for the priority population must be included as part of each objective ([appendix B](#)). The proposed metric should be included in **both** the objective and the measure.
- **People Reached (Indirect Contact):** Number of members of the public and/or professionals reached via indirect noninteractive public or professional education and outreach activities, such as mass media efforts, brochure distribution, public

service announcements, newsletters, and journals. (This category includes individuals who would be reached through activities that are directly funded by CPRIT as well as individuals who would be reached through activities that occur as a direct consequence of the CPRIT-funded project's leveraging of other resources/funding to implement the CPRIT-funded project).

- **Unique People Served (Direct Contact):** Number of unique members of the public and/or professionals served via direct, interactive public or professional education, outreach, training, navigation service, or clinical service. This category includes individuals who would be served through activities that are directly funded by CPRIT as well as individuals who would be served through activities that occur as a direct consequence of the CPRIT-funded project's leveraging of other resources/funding to implement the CPRIT-funded project.

APPENDIX B: WRITING GOALS AND OBJECTIVES

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within **both** the stated Objective and the Measure sections (eg, Measure: 2,000 individuals, ages 9-12, will initiate HPV vaccination during the grant period).

The maximum number is 3 goals with 3 objectives each. Projects will be evaluated annually on progress toward **outcome** goals and objectives.

The following has been adapted with permission from Appalachia Community Cancer Network, NIH Grant U54 CA 153604:

Develop well-defined goals and objectives.

Goals provide a roadmap or plan for where a group wants to go. Goals can be long term (over several years) or short term (over several months). Goals should be based on needs of the community and evidence-based data.

Goals should be

- Believable – situations or conditions that the group believes can be achieved
- Attainable – possible within a designated time
- Tangible – capable of being understood or realized
- On a timetable – with a completion date
- Win-Win – beneficial to individual members and the coalition

Objectives are measurable steps toward achieving the goal. They are clear statements of specific activities required to achieve the goal. The best objectives have several characteristics in common – S.M.A.R.T. + C:

- Specific – they tell how much (number or percent), who (participants), what (action or activity), and by when (date)
 - Example: 115 uninsured individuals age 50 and older will complete colorectal cancer screening by March 31, 2018.
- Measurable – specific measures that can be collected, detected, or obtained to determine successful attainment of the objective

- Example: How many screened at an event? How many completed pre/post assessment?
- Achievable – not only are the objectives themselves possible, it is likely that your organization will be able to accomplish them
- Relevant to the mission – your organization has a clear understanding of how these objectives fit in with the overall vision and mission of the group
- Timed – developing a timeline is important for when your task will be achieved
- Challenging – objectives should stretch the group to aim on significant improvements that are important to members of the community

Evaluate and refine your objectives

Review your developed objectives and determine the type and level of each using the following information:

There are 2 types of objectives:

- Outcome objectives – measure the “what” of a program; should be in the Goals and Objectives form (see [section 4.4.2](#))
- Process objectives – measure the “how” of a program; should be in the project plan only (see [section 4.4.4](#))

There are 3 levels of objectives:

- Community-level – objectives measure the planned community change
- Program impact – objectives measure the impact the program will have on a specific group of people
- Individual – objectives measures participant changes resulting from a specific program, using these factors:
 - Knowledge – understanding (know screening guidelines; recall the number to call for screening)
 - Attitudes – feeling about something (will consider secondhand smoke dangerous; believe eating 5 or more fruits and vegetable is important)
 - Skills – the ability to do something (complete fecal occult blood test)
 - Intentions – regarding plan for future behavior (will agree to talk to the doctor, will plan to schedule a Pap test)

- Behaviors (past or current) – to act in a particular way (will exercise 30+ minutes a day, will have a mammogram)

Well-defined outcome goals and objectives can be used to track, measure, and report progress toward achievement.

Summary Table

| | Outcome – Use in Goals and Objectives | Process – Use in Project Plan only |
|------------------------|---|---|
| Community-level | <p>WHAT will change in a community</p> <p><i>Example: As a result of CPRIT funding, fecal immunochemical tests will be available to 1,500 uninsured individuals age 50 and over through 10 participating local clinics and doctors.</i></p> | <p>HOW the community change will come about</p> <p><i>Example: Contracts will be signed with participating local providers to enable uninsured individuals over age 50 to have access to free colorectal cancer screening in their communities.</i></p> |
| Program impact | <p>WHAT will change in the target group as a result of a particular program</p> <p><i>Example: As a result of this project, 200 uninsured women between 40 and 49 will receive free breast and cervical cancer screening.</i></p> | <p>HOW the program will be implemented to affect change in a group/population</p> <p><i>Example: 2,000 female clients, between 40 and 49, will receive a letter inviting them to participate in breast and cervical cancer screening.</i></p> |
| Individual | <p>WHAT an individual will learn as a result of a particular program, or WHAT change an individual will make as a result of a particular program</p> <p><i>Example: As a result of one-to-one education of 500 individuals, at least 20% of participants will participate in a smoking cessation program to quit smoking.</i></p> | <p>HOW the program will be implemented to affect change in an individual’s knowledge or actions</p> <p><i>Example: As a result of one-to-one counseling, all participants will identify at least 1 smoking cessation service and 1 smoking cessation aid.</i></p> |

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Prevention Peer Review Panel - 1 – Day One

(24.1 PRV PP-1- Day One) Observation Report

Report No. 2023-12-05 24.1_PRV_PP-1- Day One
Program Name: Prevention
Panel Name: 24.1 Prevention Peer Review Panel - 1 – Day One (24.1 _PRV_PP-1- Day One)
Panel Date: December 5, 2023
Report Date: December 12, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Prevention Peer Review Panel - 1 – Day One (24.1_PRV_PP-1- Day One) meeting. The meeting was chaired by Ross Brownson and conducted via videoconference on December 5, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: 15 of 26 applications were discussed at peer review; of the 15, twelve (12) applications were discussed on Day 1
- Panelists: One (1) panel chair, thirteen (13) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The application for which there was a COI was not discussed on Day 1.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

24.1 Prevention Peer Review Panel - 1 – Day Two

(24.1 PRV PP-1 - Day Two) Observation Report

Report No. 2023-12-06 24.1_PRV_PP-1 - Day Two
Program Name: Prevention
Panel Name: 24.1 Prevention Peer Review Panel - 1 – Day Two (24.1 _PRV_PP-1 - Day Two)
Panel Date: December 6, 2023
Report Date: December 12, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Prevention Peer Review Panel - 1 – Day Two (24.1_PRV_PP-1 - Day Two) meeting. The meeting was chaired by Ross Brownson and conducted via videoconference on December 6, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: 15 of 26 applications were discussed at peer review; of the 15, three (3) applications were discussed on Day 2
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Three (3)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
24.1 Prevention Review Council – Programmatic Review
(24.1 PRV PRC)
Observation Report

Report No. 2024-01-12 24.1_PRV_PRC
Program Name: Prevention
Panel Name: 24.1 Prevention Review Council – Programmatic Review (24.1_PRV_PRC)
Panel Date: January 12, 2024
Report Date: January 17, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.1 Prevention Review Council – Programmatic Review (24.1_PRV_PRC) meeting. The meeting was chaired by Steven Wyatt and conducted via videoconference on January 12, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twelve (12) applications were discussed and fourteen (14) applications were not discussed
- Panelists: One (1) panel chair, and two (2) expert reviewers.
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Prevention Cycle 24.1

Awards Announced at the February 21, 2024, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Prevention Cycle 24.1 include: *Cancer Screening and Early Detection* and *Primary Prevention of Cancer*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

| Application ID | Principal Investigator | Organization | Conflict Noted by Reviewer |
|---|------------------------|--|----------------------------|
| Applications considered by the PIC and Oversight Committee: | | | |
| No identified COIs. | | | |
| Applications not considered by the PIC or Oversight Committee: | | | |
| PP240007 | Robert Volk | The University of Texas M. D. Anderson Cancer Center | M. Mahoney |

De-Identified Overall Evaluation Scores

Primary Prevention of Cancer

Prevention Cycle 24.1

| Application ID | Final Overall Evaluation Score |
|----------------|--------------------------------|
| PP240022* | 2.3 |
| PP240041* | 3.5 |
| PP240005* | 4.0 |
| PP240014* | 4.1 |
| PP240030* | 4.3 |
| H | 5.0 |
| I | 5.0 |
| J | 5.1 |
| K | 5.3 |
| L | 5.3 |
| M | 6.0 |
| N | 8.3 |

* Recommended for funding.

Final Overall Evaluation Scores and Rank Order Scores

Dr. David Cummings
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Dr. Cummings and Mr. Roberts,

On behalf of the Prevention Review Council (PRC), I am pleased to provide the PRC's recommendations for the FY2024 Cycle 1 Cancer Screening and Early Detection (CSD) and Primary Prevention of Cancer (PPC) grant awards.

The PRC met on January 12, 2024, to consider the applications recommended by the peer review panel following their December 5-6, 2023, meeting. The PRC recommends 12 projects totaling \$25,902,480.

The projects are numerically ranked in the order the PRC recommends the applications be funded. Recommended funding amounts and the overall evaluation score are stated for each grant application. The average score for recommended applications ranges from 2.1 to 4.3. For the three applications with average scores of 4.0, 4.1 and 4.3 the PRC spent a considerable amount of effort reviewing panel evaluations/scores and concluded that they are quality proposals with the potential for significant impact. The PRC made no changes to the goals, project objectives, or timelines of the applications.

Our recommendations meet the PRC's standards for grant award funding of projects that are evidence-based, deliver programs or services to underserved populations, and focus on primary, secondary, or tertiary prevention. In making these recommendations the PRC continued to consider the available funding, the composition of the current portfolio, and the programmatic priorities in the RFA which include potential for impact and return on investment, geographic distribution, cancer type and type of program. All the recommended grants address one or more of the Prevention Program priorities.

Sincerely,
Stephen W. Wyatt, DMD, MPH
Chair, CPRIT Prevention Review Council

Attachment



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Cycle 24.1 Recommended Prevention Program Awards

| App. ID | Mech | Application Title | PD | Organization | Score | Rank Order | Budget |
|----------|------|---|----------------------|--|-------|------------|-------------|
| PP240017 | CSD | Expanding Access to Cervical Cancer Screening through Primary HR-HPV Testing and Self-Sampling: A Multicomponent Intervention for Safety Net Health Systems | Montealegre, Jane R | The University of Texas M. D. Anderson Cancer Center | 2.1 | 1 | \$2,499,646 |
| PP240040 | CSD | Expanding Intensive Smoking Cessation and Lung Cancer Screening in Vulnerable Adult Patients in Central Texas FQHCs | Altillo, Brandon | The University of Texas at Austin | 2.2 | 2 | \$2,000,000 |
| PP240022 | PPC | Expansion of a multi-pronged intervention to increase HPV vaccination rates among adolescents from rural and medically underserved areas in Texas | Berenson, Abbey B | The University of Texas Medical Branch at Galveston | 2.3 | 3 | \$2,494,865 |
| PP240042 | CSD | Cancer Prevention and Outreach for Individuals Disproportionately Affected by Cancer in Medically Underserved Regions (C-CUR) | Esnaola, Nestor | The Methodist Hospital Research Institute | 3.0 | 4 | \$1,437,244 |
| PP240021 | CSD | Reducing Racial/Ethnic Disparities in Breast Cancer Screening: Expanding a Comprehensive EHR-Based Patient Navigation Program | Rustveld, Luis | Baylor College of Medicine | 3.1 | 5 | \$2,499,998 |
| PP240012 | CSD | Integrated Mammography and Genetic Evaluation Services (IMAGES) | Whitman, Gary J | The University of Texas M. D. Anderson Cancer Center | 3.1 | 6 | \$1,499,400 |
| PP240019 | CSD | Increasing Access to Successful Colorectal Cancer Screening, Pairing Patient Education and Outreach with Navigation | Argenbright, Keith E | The University of Texas Southwestern Medical Center | 3.3 | 7 | \$2,487,342 |
| PP240011 | CSD | The Advancing Breast Health among uninsured Women in Central Texas (ABH-CTX) 2 | Shokar, Navkiran K | The University of Texas at Austin | 3.4 | 8 | \$2,000,000 |
| PP240041 | PPC | Expansion of the evidence-based Adolescent Vaccination Program (AVP) in a safety net clinic system to increase HPV vaccination rates in underserved populations | Shegog, Ross | The University of Texas Health Science Center at Houston | 3.5 | 9 | \$1,496,194 |
| PP240005 | PPC | Preventing Tobacco Related Cancers by Expanding Capacity for Tobacco Use Interventions Within Agencies Serving Women with Behavioral Health Needs | Reitzel, Lorraine R | The University of Texas M. D. Anderson Cancer Center | 4.0 | 10 | \$2,487,822 |
| PP240014 | PPC | Tiempo De Vacunarte 3 | Molokwu, Jennifer C | Texas Tech University Health Sciences Center at El Paso | 4.1 | 11 | \$2,500,000 |
| PP240030 | PPC | All for Them: A multilevel strategy for HPV-related cancer prevention | Cuccaro, Paula | The University of Texas Health Science Center at Houston | 4.3 | 12 | \$2,499,969 |

CSD: Cancer Screening and Early Detection

PPC: Primary Prevention of Cancer



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP240005
Primary Prevention of Cancer

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Primary Prevention of Cancer* Request for Applications (RFA). CPRIT received 13 applications in response to this RFA, including one withdrawn application. This application was assigned to the Prevention Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:54 AM CT

| | | | |
|------------------------------|---|------------------------------------|------------------|
| FY: | 2024 | | |
| CYCLE: | 1 | | |
| PROGRAM: | Prevention | | |
| MECHANISM: | Primary Prevention of Cancer | | |
| APPLICATION ID: | PP240005 | | |
| APPLICATION TITLE: | Preventing Tobacco Related Cancers by Expanding Capacity for Tobacco Use Interventions Within Agencies Serving Women with Behavioral Health N | | |
| APPLICANT NAME: | Reitzel, Lorraine R | | |
| ORGANIZATION: | The University of Texas M. D. Anderson Cancer Center | | |
| PANEL NAME: | 24.1 Prevention Panel-1 | | |
| Category | Compliance Requirement | Information | Attestation Date |
| Pre-Receipt | RFA Approved by CPO | 04/28/2023 | 12/21/2023 |
| | RFA published in Texas.gov eGrants | 05/05/2023 | 12/21/2023 |
| | CPRIT Application Receipt System (CARS) opened | 06/01/2023 | 12/21/2023 |
| | CPRIT Application Receipt System (CARS) closed | 08/30/2023 | 12/21/2023 |
| | Date application submitted | 08/25/2023 | 12/22/2023 |
| | Method of submission | CARS | 12/22/2023 |
| | Within receipt period | YES | 12/22/2023 |
| | Request for extension to submit application after CARS closed | N/A | 12/22/2023 |
| | Request for extension for late application submission accepted | N/A | 12/22/2023 |
| | Receipt, Referral, and Assignment | Administrative review notification | 09/13/2023 |
| | Donation(s) made to CPRIT / foundation | NO | 12/22/2023 |
| | Assigned to primary reviewers | 09/25/2023 | 12/22/2023 |
| | Applicant notified of review panel assignment | 09/25/2023 | 12/22/2023 |
| | Primary Reviewer 1 COI signed | 09/12/2023 | 12/22/2023 |
| | Primary (Advocate) Reviewer 2 COI signed | 09/12/2023 | 12/22/2023 |
| | Primary Reviewer 3 COI signed | 09/13/2023 | 12/22/2023 |
| | Primary Reviewer 4 COI signed | 09/12/2023 | 12/22/2023 |
| Peer Review Meeting | Primary Reviewer 1 critique submitted | 11/18/2023 | 12/22/2023 |
| | Primary (Advocate) Reviewer 2 critique submitted | 11/10/2023 | 12/22/2023 |
| | Primary Reviewer 3 critique submitted | 11/01/2023 | 12/22/2023 |
| | Primary Reviewer 4 critique submitted | 11/15/2023 | 12/22/2023 |
| | COI indicated by non-primary reviewer | NONE | 12/22/2023 |
| | COI recused from participation | N/A | 12/22/2023 |
| | Discussed at Peer Review Meeting | YES | 12/22/2023 |
| | Peer Review Meeting | 12/05/2023 | 12/22/2023 |
| | Peer Review Meeting end date | 12/06/2023 | 12/22/2023 |
| | Post review statements signed | 12/06/2023 | 12/22/2023 |
| Final PRC Recommendation | Third Party Observer Report | 12/12/2023 | 01/29/2024 |
| | Score report delivered to CPO | 12/11/2023 | 12/22/2023 |
| | Recommended for PRC review | YES | 12/22/2023 |
| | COI indicated by PRC member | NONE | 01/12/2024 |
| | COI recused from participation | N/A | 01/12/2024 |
| | PRC Meeting | 01/12/2024 | 01/12/2024 |
| PIC Review | Third Party Observer Report | 01/17/2024 | 01/18/2024 |
| | Recommended for grant award | YES | 01/12/2024 |
| | PRC Chair Notification to PIC and OC | 01/18/2024 | 01/18/2024 |
| | COI indicated by PIC member | None | 02/07/2024 |
| | COI recused from participation | N/A | 02/07/2024 |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 |
| Oversight Committee Approval | Recommended for grant award | YES | 02/07/2024 |
| | CEO Notification to Oversight Committee | N/A | |
| | COI Indicated by Oversight Committee member | N/A | |
| | COI Recused from participation | N/A | |
| | Donation(s) made to CPRIT / foundation | N/A | |
| | Presented to CPRIT Oversight Committee | N/A | |
| | Award approved by Oversight Committee | N/A | |
| | Authority to advance funds requested | N/A | |
| | Advance authority approved by Oversight Committee | N/A | |
| | Comments: | | |
| Comment | | | Created Date |
| No Comment | | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP240011
Cancer Screening and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Cancer Screening and Early Detection* Request for Applications (RFA). CPRIT received 16 applications in response to this RFA, including two withdrawn applications. This application was assigned to the Prevention Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 02/09/2024 10:54 AM CT

| | | | | |
|------------------------------|--|------------------------------------|------------------|------------|
| FY: | 2024 | | | |
| CYCLE: | 1 | | | |
| PROGRAM: | Prevention | | | |
| MECHANISM: | Cancer Screening and Early Detection | | | |
| APPLICATION ID: | PP240011 | | | |
| APPLICATION TITLE: | The Advancing Breast Health among uninsured Women in Central Texas (ABH-CTX) 2 | | | |
| APPLICANT NAME: | Shokar, Navkiran K | | | |
| ORGANIZATION: | The University of Texas at Austin | | | |
| PANEL NAME: | 24.1_Prevention Panel-1 | | | |
| Category | Compliance Requirement | Information | Attestation Date | |
| Pre-Receipt | RFA Approved by CPO | 04/28/2023 | 12/21/2023 | |
| | RFA published in Texas.gov eGrants | 05/05/2023 | 12/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 06/01/2023 | 12/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 08/30/2023 | 12/21/2023 | |
| | Date application submitted | 08/30/2023 | 12/22/2023 | |
| | Method of submission | CARS | 12/22/2023 | |
| | Within receipt period | YES | 12/22/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/22/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/22/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/22/2023 |
| | Donation(s) made to CPRIT / foundation | NO | 12/22/2023 | |
| | Assigned to primary reviewers | 09/25/2023 | 12/22/2023 | |
| | Applicant notified of review panel assignment | 09/25/2023 | 12/22/2023 | |
| | Primary Reviewer 1 COI signed | 09/18/2023 | 12/22/2023 | |
| | Primary (Advocate) Reviewer 2 COI signed | 09/12/2023 | 12/22/2023 | |
| | Primary Reviewer 3 COI signed | 09/12/2023 | 12/22/2023 | |
| | Primary Reviewer 4 COI signed | 09/17/2023 | 12/22/2023 | |
| Peer Review Meeting | Primary Reviewer 1 critique submitted | 11/11/2023 | 12/22/2023 | |
| | Primary (Advocate) Reviewer 2 critique submitted | 11/10/2023 | 12/22/2023 | |
| | Primary Reviewer 3 critique submitted | 11/15/2023 | 12/22/2023 | |
| | Primary Reviewer 4 critique submitted | 11/09/2023 | 12/22/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/22/2023 | |
| | COI recused from participation | N/A | 12/22/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/22/2023 | |
| | Peer Review Meeting | 12/05/2023 | 12/22/2023 | |
| | Peer Review Meeting end date | 12/06/2023 | 12/22/2023 | |
| | Post review statements signed | 12/06/2023 | 12/22/2023 | |
| | Third Party Observer Report | 12/12/2023 | 01/29/2024 | |
| | Score report delivered to CPO | 12/11/2023 | 12/22/2023 | |
| | Recommended for PRC review | YES | 12/22/2023 | |
| Final PRC Recommendation | COI indicated by PRC member | NONE | 01/12/2024 | |
| | COI recused from participation | N/A | 01/12/2024 | |
| | PRC Meeting | 01/12/2024 | 01/12/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/18/2024 | |
| | Recommended for grant award | YES | 01/12/2024 | |
| | PRC Chair Notification to PIC and OC | 01/18/2024 | 01/18/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |
| | | | | |
| | | | | |
| Comments: | | | | |
| Comment | | | Created Date | |
| No Comment | | | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP240012
Cancer Screening and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Cancer Screening and Early Detection* Request for Applications (RFA). CPRIT received 16 applications in response to this RFA, including two withdrawn applications. This application was assigned to the Prevention Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 8th day of February, 2024,
 by WAYNE R. ROBERTS.



 Sandra Reyes
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:54 AM CT

| | | | |
|------------------------------|---|------------------------------------|------------------|
| FY: | 2024 | | |
| CYCLE: | 1 | | |
| PROGRAM: | Prevention | | |
| MECHANISM: | Cancer Screening and Early Detection | | |
| APPLICATION ID: | PP240012 | | |
| APPLICATION TITLE: | Integrated Mammography and Genetic Evaluation Services (IMAGES) | | |
| APPLICANT NAME: | Whitman, Gary J | | |
| ORGANIZATION: | The University of Texas M. D. Anderson Cancer Center | | |
| PANEL NAME: | 24.1_Prevention Panel-1 | | |
| Category | Compliance Requirement | Information | Attestation Date |
| Pre-Receipt | RFA Approved by CPO | 04/28/2023 | 12/21/2023 |
| | RFA published in Texas.gov eGrants | 05/05/2023 | 12/21/2023 |
| | CPRIT Application Receipt System (CARS) opened | 06/01/2023 | 12/21/2023 |
| | CPRIT Application Receipt System (CARS) closed | 08/30/2023 | 12/21/2023 |
| | Date application submitted | 08/29/2023 | 12/22/2023 |
| | Method of submission | CARS | 12/22/2023 |
| | Within receipt period | YES | 12/22/2023 |
| | Request for extension to submit application after CARS closed | N/A | 12/22/2023 |
| | Request for extension for late application submission accepted | N/A | 12/22/2023 |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A |
| | Donation(s) made to CPRIT / foundation | NO | 12/22/2023 |
| | Assigned to primary reviewers | 09/25/2023 | 12/22/2023 |
| | Applicant notified of review panel assignment | 09/25/2023 | 12/22/2023 |
| | Primary Reviewer 1 COI signed | 09/12/2023 | 12/22/2023 |
| | Primary (Advocate) Reviewer 2 COI signed | 09/17/2023 | 12/22/2023 |
| | Primary Reviewer 3 COI signed | 09/13/2023 | 12/22/2023 |
| | Primary Reviewer 4 COI signed | 09/20/2023 | 12/22/2023 |
| Peer Review Meeting | Primary Reviewer 1 critique submitted | 11/15/2023 | 12/22/2023 |
| | Primary (Advocate) Reviewer 2 critique submitted | 11/13/2023 | 12/22/2023 |
| | Primary Reviewer 3 critique submitted | 11/10/2023 | 12/22/2023 |
| | Primary Reviewer 4 critique submitted | 11/20/2023 | 12/22/2023 |
| | COI indicated by non-primary reviewer | NONE | 12/22/2023 |
| | COI recused from participation | N/A | 12/22/2023 |
| | Discussed at Peer Review Meeting | YES | 12/22/2023 |
| | Peer Review Meeting | 12/05/2023 | 12/22/2023 |
| | Peer Review Meeting end date | 12/06/2023 | 12/22/2023 |
| | Post review statements signed | 12/06/2023 | 12/22/2023 |
| | Third Party Observer Report | 12/12/2023 | 01/29/2024 |
| | Score report delivered to CPO | 12/11/2023 | 12/22/2023 |
| | Recommended for PRC review | YES | 12/22/2023 |
| Final PRC Recommendation | COI indicated by PRC member | NONE | 01/12/2024 |
| | COI recused from participation | N/A | 01/12/2024 |
| | PRC Meeting | 01/12/2024 | 01/12/2024 |
| | Third Party Observer Report | 01/17/2024 | 01/18/2024 |
| | Recommended for grant award | YES | 01/12/2024 |
| | PRC Chair Notification to PIC and OC | 01/18/2024 | 01/18/2024 |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 |
| | COI recused from participation | N/A | 02/07/2024 |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 |
| | Recommended for grant award | YES | 02/07/2024 |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | |
| | COI Indicated by Oversight Committee member | N/A | |
| | COI Recused from participation | N/A | |
| | Donation(s) made to CPRIT / foundation | N/A | |
| | Presented to CPRIT Oversight Committee | N/A | |
| | Award approved by Oversight Committee | N/A | |
| | Authority to advance funds requested | N/A | |
| | Advance authority approved by Oversight Committee | N/A | |
| Comments: | | | |
| Comment | | | Created Date |
| No Comment | | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP240014
Primary Prevention of Cancer

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Primary Prevention of Cancer* Request for Applications (RFA). CPRIT received 13 applications in response to this RFA, including one withdrawn application. This application was assigned to the Prevention Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 02/09/2024 10:54 AM CT

| | | | | |
|---|--|--|------------------|------------|
| FY: | 2024 | | | |
| CYCLE: | 1 | | | |
| PROGRAM: | Prevention | | | |
| MECHANISM: | Primary Prevention of Cancer | | | |
| APPLICATION ID: | PP240014 | | | |
| APPLICATION TITLE: | Tiempo De Vacunarte 3 | | | |
| APPLICANT NAME: | Molokwu, Jennifer C | | | |
| ORGANIZATION: | Texas Tech University Health Sciences Center at El Paso | | | |
| PANEL NAME: | 24.1_Prevention Panel-1 | | | |
| Category | Compliance Requirement | Information | Attestation Date | |
| Pre-Receipt | RFA Approved by CPO | 04/28/2023 | 12/21/2023 | |
| | RFA published in Texas.gov eGrants | 05/05/2023 | 12/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 06/01/2023 | 12/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 08/30/2023 | 12/21/2023 | |
| | Date application submitted | 08/29/2023 | 12/22/2023 | |
| | Method of submission | CARS | 12/22/2023 | |
| | Within receipt period | YES | 12/22/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/22/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/22/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | 09/13/2023 | 12/22/2023 |
| Donation(s) made to CPRIT / foundation | | NO | 12/22/2023 | |
| Assigned to primary reviewers | | 09/25/2023 | 12/22/2023 | |
| Applicant notified of review panel assignment | | 09/25/2023 | 12/22/2023 | |
| Primary Reviewer 1 COI signed | | 09/13/2023 | 12/22/2023 | |
| Primary (Advocate) Reviewer 2 COI signed | | 09/17/2023 | 12/22/2023 | |
| Primary Reviewer 3 COI signed | | 09/13/2023 | 12/22/2023 | |
| Primary Reviewer 4 COI signed | | 09/20/2023 | 12/22/2023 | |
| Peer Review Meeting | | Primary Reviewer 1 critique submitted | 11/14/2023 | 12/22/2023 |
| | | Primary (Advocate) Reviewer 2 critique submitted | 11/14/2023 | 12/22/2023 |
| | Primary Reviewer 3 critique submitted | 11/13/2023 | 12/22/2023 | |
| | Primary Reviewer 4 critique submitted | 11/17/2023 | 12/22/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/22/2023 | |
| | COI recused from participation | N/A | 12/22/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/22/2023 | |
| | Peer Review Meeting | 12/05/2023 | 12/22/2023 | |
| | Peer Review Meeting end date | 12/06/2023 | 12/22/2023 | |
| | Post review statements signed | 12/06/2023 | 12/22/2023 | |
| Final PRC Recommendation | Third Party Observer Report | 12/12/2023 | 01/29/2024 | |
| | Score report delivered to CPO | 12/11/2023 | 12/22/2023 | |
| | Recommended for PRC review | YES | 12/22/2023 | |
| | COI indicated by PRC member | NONE | 01/12/2024 | |
| | COI recused from participation | N/A | 01/12/2024 | |
| | PRC Meeting | 01/12/2024 | 01/12/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/18/2024 | |
| | Recommended for grant award | YES | 01/12/2024 | |
| | PRC Chair Notification to PIC and OC | 01/18/2024 | 01/18/2024 | |
| | PIC Review | Recommended for PRC review | NONE | 02/07/2024 |
| COI indicated by PIC member | | None | 02/07/2024 | |
| COI recused from participation | | N/A | 02/07/2024 | |
| PIC Review Meeting | | 02/07/2024 | 02/07/2024 | |
| Oversight Committee Approval | Recommended for grant award | YES | 02/07/2024 | |
| | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |
| Comments: | | | | |
| Comment | | | Created Date | |
| No Comment | | | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP240017
Cancer Screening and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Cancer Screening and Early Detection* Request for Applications (RFA). CPRIT received 16 applications in response to this RFA, including two withdrawn applications. This application was assigned to the Prevention Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle



- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

| | |
|--|--|
| <p>State of Texas County of Travis</p> <p>SWORN to and SUBSCRIBED before me, the undersigned authority, on the <u>8th</u> day of <u>February</u>, 2024, by WAYNE R. ROBERTS.</p> <p> _____ Sandra Reyes Notary Public, State of Texas</p> |  |
|--|--|

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:54 AM CT

| | | | |
|-------------------------------|--|------------------------------------|------------------|
| FY: | 2024 | | |
| CYCLE: | 1 | | |
| PROGRAM: | Prevention | | |
| MECHANISM: | Cancer Screening and Early Detection | | |
| APPLICATION ID: | PP240017 | | |
| APPLICATION TITLE: | Expanding Access to Cervical Cancer Screening through Primary HR-HPV Testing and Self-Sampling | | |
| APPLICANT NAME: | Monteleagre, Jane R | | |
| ORGANIZATION: | The University of Texas M. D. Anderson Cancer Center | | |
| PANEL NAME: | 24.1 Prevention Panel-1 | | |
| Category | Compliance Requirement | Information | Attestation Date |
| Pre-Receipt | RFA Approved by CPO | 04/28/2023 | 12/21/2023 |
| | RFA published in Texas.gov eGrants | 05/05/2023 | 12/21/2023 |
| | CPRIT Application Receipt System (CARS) opened | 06/01/2023 | 12/21/2023 |
| | CPRIT Application Receipt System (CARS) closed | 08/30/2023 | 12/21/2023 |
| | Date application submitted | 08/29/2023 | 12/22/2023 |
| | Method of submission | CARS | 12/22/2023 |
| | Within receipt period | YES | 12/22/2023 |
| | Request for extension to submit application after CARS closed | N/A | 12/22/2023 |
| | Request for extension for late application submission accepted | N/A | 12/22/2023 |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A |
| | Donation(s) made to CPRIT / foundation | NO | 12/22/2023 |
| | Assigned to primary reviewers | 09/25/2023 | 12/22/2023 |
| | Applicant notified of review panel assignment | 09/25/2023 | 12/22/2023 |
| | Primary Reviewer 1 COI signed | 09/13/2023 | 12/22/2023 |
| | Primary (Advocate) Reviewer 2 COI signed | 09/17/2023 | 12/22/2023 |
| | Primary Reviewer 3 COI signed | 09/12/2023 | 12/22/2023 |
| | Primary Reviewer 4 COI signed | 09/12/2023 | 12/22/2023 |
| Peer Review Meeting | Primary Reviewer 1 critique submitted | 11/13/2023 | 12/22/2023 |
| | Primary (Advocate) Reviewer 2 critique submitted | 11/12/2023 | 12/22/2023 |
| | Primary Reviewer 3 critique submitted | 10/24/2023 | 12/22/2023 |
| | Primary Reviewer 4 critique submitted | 11/13/2023 | 12/22/2023 |
| | COI indicated by non-primary reviewer | NONE | 12/22/2023 |
| | COI recused from participation | N/A | 12/22/2023 |
| | Discussed at Peer Review Meeting | YES | 12/22/2023 |
| | Peer Review Meeting | 12/05/2023 | 12/22/2023 |
| | Peer Review Meeting end date | 12/06/2023 | 12/22/2023 |
| | Post review statements signed | 12/06/2023 | 12/22/2023 |
| Third Party Observer Report | 12/12/2023 | 01/29/2024 | |
| Score report delivered to CPO | 12/11/2023 | 12/22/2023 | |
| | Recommended for PRC review | YES | 12/22/2023 |
| Final PRC Recommendation | COI indicated by PRC member | NONE | 01/12/2024 |
| | COI recused from participation | N/A | 01/12/2024 |
| | PRC Meeting | 01/12/2024 | 01/12/2024 |
| | Third Party Observer Report | 01/17/2024 | 01/18/2024 |
| | Recommended for grant award | YES | 01/12/2024 |
| | PRC Chair Notification to PIC and OC | 01/18/2024 | 01/18/2024 |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 |
| | COI recused from participation | N/A | 02/07/2024 |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 |
| | Recommended for grant award | YES | 02/07/2024 |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | |
| | COI Indicated by Oversight Committee member | N/A | |
| | COI Recused from participation | N/A | |
| | Donation(s) made to CPRIT / foundation | N/A | |
| | Presented to CPRIT Oversight Committee | N/A | |
| | Award approved by Oversight Committee | N/A | |
| | Authority to advance funds requested | N/A | |
| | Advance authority approved by Oversight Committee | N/A | |
| Comments: | | | |
| Comment | | | Created Date |
| No Comment | | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP240019
Cancer Screening and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Cancer Screening and Early Detection* Request for Applications (RFA). CPRIT received 16 applications in response to this RFA, including two withdrawn applications. This application was assigned to the Prevention Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 8th day of February, 2024,
 by WAYNE R. ROBERTS.)



 Sandra Reyes
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:54 AM CT

| | | | |
|------------------------------|---|------------------------------------|------------------|
| FY: | 2024 | | |
| CYCLE: | 1 | | |
| PROGRAM: | Prevention | | |
| MECHANISM: | Cancer Screening and Early Detection | | |
| APPLICATION ID: | PP240019 | | |
| APPLICATION TITLE: | Increasing Access to Successful Colorectal Cancer Screening, Pairing Patient Education and Outreach | | |
| APPLICANT NAME: | Argenbright, Keith E | | |
| ORGANIZATION: | The University of Texas Southwestern Medical Center | | |
| PANEL NAME: | 24.1 Prevention Panel-1 | | |
| Category | Compliance Requirement | Information | Attestation Date |
| Pre-Receipt | RFA Approved by CPO | 04/28/2023 | 12/21/2023 |
| | RFA published in Texas.gov eGrants | 05/05/2023 | 12/21/2023 |
| | CPRIT Application Receipt System (CARS) opened | 06/01/2023 | 12/21/2023 |
| | CPRIT Application Receipt System (CARS) closed | 08/30/2023 | 12/21/2023 |
| | Date application submitted | 08/29/2023 | 12/22/2023 |
| | Method of submission | CARS | 12/22/2023 |
| | Within receipt period | YES | 12/22/2023 |
| | Request for extension to submit application after CARS closed | N/A | 12/22/2023 |
| | Request for extension for late application submission accepted | N/A | 12/22/2023 |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A |
| | Donation(s) made to CPRIT / foundation | 09/25/2023 | 12/22/2023 |
| | Assigned to primary reviewers | 09/25/2023 | 12/22/2023 |
| | Applicant notified of review panel assignment | 09/12/2023 | 12/22/2023 |
| | Primary Reviewer 1 COI signed | 09/19/2023 | 12/22/2023 |
| | Primary (Advocate) Reviewer 2 COI signed | 09/17/2023 | 12/22/2023 |
| | Primary Reviewer 3 COI signed | 09/13/2023 | 12/22/2023 |
| | Primary Reviewer 4 COI signed | 11/13/2023 | 12/22/2023 |
| Peer Review Meeting | Primary Reviewer 1 critique submitted | 11/14/2023 | 12/22/2023 |
| | Primary (Advocate) Reviewer 2 critique submitted | 11/14/2023 | 12/22/2023 |
| | Primary Reviewer 3 critique submitted | 11/12/2023 | 12/22/2023 |
| | Primary Reviewer 4 critique submitted | NONE | 12/22/2023 |
| | COI indicated by non-primary reviewer | N/A | 12/22/2023 |
| | COI recused from participation | YES | 12/22/2023 |
| | Discussed at Peer Review Meeting | 12/05/2023 | 12/22/2023 |
| | Peer Review Meeting | 12/06/2023 | 12/22/2023 |
| | Peer Review Meeting end date | 12/06/2023 | 12/22/2023 |
| | Post review statements signed | 12/12/2023 | 01/29/2024 |
| | Third Party Observer Report | 12/11/2023 | 12/22/2023 |
| | Score report delivered to CPO | YES | 12/22/2023 |
| | Recommended for PRC review | NONE | 01/12/2024 |
| Final PRC Recommendation | COI indicated by PRC member | N/A | 01/12/2024 |
| | COI recused from participation | 01/12/2024 | 01/12/2024 |
| | PRC Meeting | 01/17/2024 | 01/18/2024 |
| | Third Party Observer Report | YES | 01/12/2024 |
| | Recommended for grant award | 01/18/2024 | 01/18/2024 |
| | PRC Chair Notification to PIC and OC | None | 02/07/2024 |
| PIC Review | COI indicated by PIC member | N/A | 02/07/2024 |
| | COI recused from participation | 02/07/2024 | 02/07/2024 |
| | PIC Review Meeting | YES | 02/07/2024 |
| | Recommended for grant award | N/A | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | |
| | COI Indicated by Oversight Committee member | N/A | |
| | COI Recused from participation | N/A | |
| | Donation(s) made to CPRIT / foundation | N/A | |
| | Presented to CPRIT Oversight Committee | N/A | |
| | Award approved by Oversight Committee | N/A | |
| | Authority to advance funds requested | N/A | |
| | Advance authority approved by Oversight Committee | N/A | |
| Comments: | | | |
| Comment | | | Created Date |
| No Comment | | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP240021
Cancer Screening and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Cancer Screening and Early Detection* Request for Applications (RFA). CPRIT received 16 applications in response to this RFA, including two withdrawn applications. This application was assigned to the Prevention Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:54 AM CT

| | | | |
|------------------------------|---|------------------------------------|------------------|
| FY: | 2024 | | |
| CYCLE: | 1 | | |
| PROGRAM: | Prevention | | |
| MECHANISM: | Cancer Screening and Early Detection | | |
| APPLICATION ID: | PP240021 | | |
| APPLICATION TITLE: | Reducing Racial/Ethnic Disparities in Breast Cancer Screening: Expanding a Comprehensive EHR-Based Patient Navigation Program | | |
| APPLICANT NAME: | Rustveid, Luis | | |
| ORGANIZATION: | Baylor College of Medicine | | |
| PANEL NAME: | 24.1 Prevention Panel-1 | | |
| Category | Compliance Requirement | Information | Attestation Date |
| Pre-Receipt | RFA Approved by CPO | 04/28/2023 | 12/21/2023 |
| | RFA published in Texas.gov eGrants | 05/05/2023 | 12/21/2023 |
| | CPRIT Application Receipt System (CARS) opened | 06/01/2023 | 12/21/2023 |
| | CPRIT Application Receipt System (CARS) closed | 08/30/2023 | 12/21/2023 |
| | Date application submitted | 08/29/2023 | 12/22/2023 |
| | Method of submission | CARS | 12/22/2023 |
| | Within receipt period | YES | 12/22/2023 |
| | Request for extension to submit application after CARS closed | N/A | 12/22/2023 |
| | Request for extension for late application submission accepted | N/A | 12/22/2023 |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A |
| | Donation(s) made to CPRIT / foundation | NO | 12/22/2023 |
| | Assigned to primary reviewers | 09/25/2023 | 12/22/2023 |
| | Applicant notified of review panel assignment | 09/25/2023 | 12/22/2023 |
| | Primary Reviewer 1 COI signed | 09/12/2023 | 12/22/2023 |
| | Primary (Advocate) Reviewer 2 COI signed | 09/17/2023 | 12/22/2023 |
| | Primary Reviewer 3 COI signed | 09/18/2023 | 12/22/2023 |
| | Primary Reviewer 4 COI signed | 09/17/2023 | 12/22/2023 |
| Peer Review Meeting | Primary Reviewer 1 critique submitted | 11/05/2023 | 12/22/2023 |
| | Primary (Advocate) Reviewer 2 critique submitted | 11/12/2023 | 12/22/2023 |
| | Primary Reviewer 3 critique submitted | 11/09/2023 | 12/22/2023 |
| | Primary Reviewer 4 critique submitted | 11/13/2023 | 12/22/2023 |
| | COI indicated by non-primary reviewer | NONE | 12/22/2023 |
| | COI recused from participation | N/A | 12/22/2023 |
| | Discussed at Peer Review Meeting | YES | 12/22/2023 |
| | Peer Review Meeting | 12/05/2023 | 12/22/2023 |
| | Peer Review Meeting end date | 12/06/2023 | 12/22/2023 |
| | Post review statements signed | 12/06/2023 | 12/22/2023 |
| Final PRC Recommendation | Third Party Observer Report | 12/12/2023 | 01/29/2024 |
| | Score report delivered to CPO | 12/11/2023 | 12/22/2023 |
| | Recommended for PRC review | YES | 12/22/2023 |
| | COI indicated by PRC member | NONE | 01/12/2024 |
| | COI recused from participation | N/A | 01/12/2024 |
| | PRC Meeting | 01/12/2024 | 01/12/2024 |
| PIC Review | Third Party Observer Report | 01/17/2024 | 01/18/2024 |
| | Recommended for grant award | YES | 01/12/2024 |
| | PRC Chair Notification to PIC and OC | 01/18/2024 | 01/18/2024 |
| | COI indicated by PIC member | None | 02/07/2024 |
| | COI recused from participation | N/A | 02/07/2024 |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 |
| Oversight Committee Approval | Recommended for grant award | YES | 02/07/2024 |
| | CEO Notification to Oversight Committee | N/A | |
| | COI Indicated by Oversight Committee member | N/A | |
| | COI Recused from participation | N/A | |
| | Donation(s) made to CPRIT / foundation | N/A | |
| | Presented to CPRIT Oversight Committee | N/A | |
| | Award approved by Oversight Committee | N/A | |
| | Authority to advance funds requested | N/A | |
| | Advance authority approved by Oversight Committee | N/A | |
| | Comments: | | |
| Comment | | | Created Date |
| No Comment | | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP240022
Primary Prevention of Cancer

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Primary Prevention of Cancer* Request for Applications (RFA). CPRIT received 13 applications in response to this RFA, including one withdrawn application. This application was assigned to the Prevention Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 8th day of February, 2024,
 by WAYNE R. ROBERTS.



 Sandra Reyes
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:54 AM CT

| | | | |
|-------------------------------|---|------------------------------------|------------------|
| FY: | 2024 | | |
| CYCLE: | 1 | | |
| PROGRAM: | Prevention | | |
| MECHANISM: | Primary Prevention of Cancer | | |
| APPLICATION ID: | PP240022 | | |
| APPLICATION TITLE: | Expansion of a multi-pronged intervention to increase HPV vaccination rates among adolescents from rural and medically underserved areas in Texas | | |
| APPLICANT NAME: | Berenson, Abbey B | | |
| ORGANIZATION: | The University of Texas Medical Branch at Galveston | | |
| PANEL NAME: | 24.1 Prevention Panel-1 | | |
| Category | Compliance Requirement | Information | Attestation Date |
| Pre-Receipt | RFA Approved by CPO | 04/28/2023 | 12/21/2023 |
| | RFA published in Texas.gov eGrants | 05/05/2023 | 12/21/2023 |
| | CPRIT Application Receipt System (CARS) opened | 06/01/2023 | 12/21/2023 |
| | CPRIT Application Receipt System (CARS) closed | 08/30/2023 | 12/21/2023 |
| | Date application submitted | 08/14/2023 | 12/22/2023 |
| | Method of submission | CARS | 12/22/2023 |
| | Within receipt period | YES | 12/22/2023 |
| | Request for extension to submit application after CARS closed | N/A | 12/22/2023 |
| | Request for extension for late application submission accepted | N/A | 12/22/2023 |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A |
| | Donation(s) made to CPRIT / foundation | NO | 12/22/2023 |
| | Assigned to primary reviewers | 09/25/2023 | 12/22/2023 |
| | Applicant notified of review panel assignment | 09/25/2023 | 12/22/2023 |
| | Primary Reviewer 1 COI signed | 09/18/2023 | 12/22/2023 |
| | Primary (Advocate) Reviewer 2 COI signed | 09/12/2023 | 12/22/2023 |
| | Primary Reviewer 3 COI signed | 09/13/2023 | 12/22/2023 |
| | Primary Reviewer 4 COI signed | 09/13/2023 | 12/22/2023 |
| Peer Review Meeting | Primary Reviewer 1 critique submitted | 11/15/2023 | 12/22/2023 |
| | Primary (Advocate) Reviewer 2 critique submitted | 11/10/2023 | 12/22/2023 |
| | Primary Reviewer 3 critique submitted | 11/13/2023 | 12/22/2023 |
| | Primary Reviewer 4 critique submitted | 11/11/2023 | 12/22/2023 |
| | COI indicated by non-primary reviewer | NONE | 12/22/2023 |
| | COI recused from participation | N/A | 12/22/2023 |
| | Discussed at Peer Review Meeting | YES | 12/22/2023 |
| | Peer Review Meeting | 12/05/2023 | 12/22/2023 |
| | Peer Review Meeting end date | 12/06/2023 | 12/22/2023 |
| | Post review statements signed | 12/06/2023 | 12/22/2023 |
| Third Party Observer Report | 12/12/2023 | 01/29/2024 | |
| Score report delivered to CPO | 12/11/2023 | 12/22/2023 | |
| | Recommended for PRC review | YES | 12/22/2023 |
| Final PRC Recommendation | COI indicated by PRC member | NONE | 01/12/2024 |
| | COI recused from participation | N/A | 01/12/2024 |
| | PRC Meeting | 01/12/2024 | 01/12/2024 |
| | Third Party Observer Report | 01/17/2024 | 01/18/2024 |
| | Recommended for grant award | YES | 01/12/2024 |
| | PRC Chair Notification to PIC and OC | 01/18/2024 | 01/18/2024 |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 |
| | COI recused from participation | N/A | 02/07/2024 |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 |
| | Recommended for grant award | YES | 02/07/2024 |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | |
| | COI Indicated by Oversight Committee member | N/A | |
| | COI Recused from participation | N/A | |
| | Donation(s) made to CPRIT / foundation | N/A | |
| | Presented to CPRIT Oversight Committee | N/A | |
| | Award approved by Oversight Committee | N/A | |
| | Authority to advance funds requested | N/A | |
| | Advance authority approved by Oversight Committee | N/A | |
| | | | |
| Comments: | | | |
| Comment | | | Created Date |
| No Comment | | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP240030
Primary Prevention of Cancer

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Primary Prevention of Cancer* Request for Applications (RFA). CPRIT received 13 applications in response to this RFA, including one withdrawn application. This application was assigned to the Prevention Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.



This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.


Sandra Reyes
Notary Public, State of Texas

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 02/09/2024 10:55 AM CT

| | | | | |
|------------------------------|---|------------------------------------|------------------|------------|
| FY: | 2024 | | | |
| CYCLE: | 1 | | | |
| PROGRAM: | Prevention | | | |
| MECHANISM: | Primary Prevention of Cancer | | | |
| APPLICATION ID: | PP240030 | | | |
| APPLICATION TITLE: | All for Them: A multilevel strategy for HPV-related cancer prevention | | | |
| APPLICANT NAME: | Cuccaro, Paula | | | |
| ORGANIZATION: | The University of Texas Health Science Center at Houston | | | |
| PANEL NAME: | 24.1_Prevention Panel-1 | | | |
| Category | Compliance Requirement | Information | Attestation Date | |
| Pre-Receipt | RFA Approved by CPO | 04/28/2023 | 12/21/2023 | |
| | RFA published in Texas.gov eGrants | 05/05/2023 | 12/21/2023 | |
| | CPRIT Application Receipt System (CARS) opened | 06/01/2023 | 12/21/2023 | |
| | CPRIT Application Receipt System (CARS) closed | 08/30/2023 | 12/21/2023 | |
| | Date application submitted | 08/30/2023 | 12/22/2023 | |
| | Method of submission | CARS | 12/22/2023 | |
| | Within receipt period | YES | 12/22/2023 | |
| | Request for extension to submit application after CARS closed | N/A | 12/22/2023 | |
| | Request for extension for late application submission accepted | N/A | 12/22/2023 | |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A | 12/22/2023 |
| | Donation(s) made to CPRIT / foundation | NO | 12/22/2023 | |
| | Assigned to primary reviewers | 09/25/2023 | 12/22/2023 | |
| | Applicant notified of review panel assignment | 09/25/2023 | 12/22/2023 | |
| | Primary Reviewer 1 COI signed | 09/13/2023 | 12/22/2023 | |
| | Primary (Advocate) Reviewer 2 COI signed | 09/19/2023 | 12/22/2023 | |
| | Primary Reviewer 3 COI signed | 09/13/2023 | 12/22/2023 | |
| | Primary Reviewer 4 COI signed | 09/18/2023 | 12/22/2023 | |
| Peer Review Meeting | Primary Reviewer 1 critique submitted | 11/11/2023 | 12/22/2023 | |
| | Primary (Advocate) Reviewer 2 critique submitted | 11/14/2023 | 12/22/2023 | |
| | Primary Reviewer 3 critique submitted | 11/14/2023 | 12/22/2023 | |
| | Primary Reviewer 4 critique submitted | 11/14/2023 | 12/22/2023 | |
| | COI indicated by non-primary reviewer | NONE | 12/22/2023 | |
| | COI recused from participation | N/A | 12/22/2023 | |
| | Discussed at Peer Review Meeting | YES | 12/22/2023 | |
| | Peer Review Meeting | 12/05/2023 | 12/22/2023 | |
| | Peer Review Meeting end date | 12/06/2023 | 12/22/2023 | |
| | Post review statements signed | 12/06/2023 | 12/22/2023 | |
| | Third Party Observer Report | 12/12/2023 | 01/29/2024 | |
| | Score report delivered to CPO | 12/11/2023 | 12/22/2023 | |
| | Recommended for PRC review | YES | 12/22/2023 | |
| Final PRC Recommendation | COI indicated by PRC member | NONE | 01/12/2024 | |
| | COI recused from participation | N/A | 01/12/2024 | |
| | PRC Meeting | 01/12/2024 | 01/12/2024 | |
| | Third Party Observer Report | 01/17/2024 | 01/18/2024 | |
| | Recommended for grant award | YES | 01/12/2024 | |
| | PRC Chair Notification to PIC and OC | 01/18/2024 | 01/18/2024 | |
| PIC Review | COI indicated by PIC member | None | 02/07/2024 | |
| | COI recused from participation | N/A | 02/07/2024 | |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 | |
| | Recommended for grant award | YES | 02/07/2024 | |
| Oversight Committee Approval | CEO Notification to Oversight Committee | N/A | | |
| | COI Indicated by Oversight Committee member | N/A | | |
| | COI Recused from participation | N/A | | |
| | Donation(s) made to CPRIT / foundation | N/A | | |
| | Presented to CPRIT Oversight Committee | N/A | | |
| | Award approved by Oversight Committee | N/A | | |
| | Authority to advance funds requested | N/A | | |
| | Advance authority approved by Oversight Committee | N/A | | |
| | | | | |
| | | | | |
| Comments: | | | | |
| Comment | | | Created Date | |
| No Comment | | | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP240040
Cancer Screening and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Cancer Screening and Early Detection* Request for Applications (RFA). CPRIT received 16 applications in response to this RFA, including two withdrawn applications. This application was assigned to the Prevention Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:55 AM CT

| | | | |
|------------------------------|---|------------------------------------|------------------|
| FY: | 2024 | | |
| CYCLE: | 1 | | |
| PROGRAM: | Prevention | | |
| MECHANISM: | Cancer Screening and Early Detection | | |
| APPLICATION ID: | PP240040 | | |
| APPLICATION TITLE: | Expanding Intensive Smoking Cessation and Lung Cancer Screening in Vulnerable Adult Patients in Central Texas FQHCs | | |
| APPLICANT NAME: | Altillo, Brandon | | |
| ORGANIZATION: | The University of Texas at Austin | | |
| PANEL NAME: | 24.1 Prevention Panel-1 | | |
| Category | Compliance Requirement | Information | Attestation Date |
| Pre-Receipt | RFA Approved by CPO | 04/28/2023 | 12/21/2023 |
| | RFA published in Texas.gov eGrants | 05/05/2023 | 12/21/2023 |
| | CPRIT Application Receipt System (CARS) opened | 06/01/2023 | 12/21/2023 |
| | CPRIT Application Receipt System (CARS) closed | 08/30/2023 | 12/21/2023 |
| | Date application submitted | 08/30/2023 | 12/22/2023 |
| | Method of submission | CARS | 12/22/2023 |
| | Within receipt period | YES | 12/22/2023 |
| | Request for extension to submit application after CARS closed | N/A | 12/22/2023 |
| | Request for extension for late application submission accepted | N/A | 12/22/2023 |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A |
| | Donation(s) made to CPRIT / foundation | NO | 12/22/2023 |
| | Assigned to primary reviewers | 09/25/2023 | 12/22/2023 |
| | Applicant notified of review panel assignment | 09/25/2023 | 12/22/2023 |
| | Primary Reviewer 1 COI signed | 09/12/2023 | 12/22/2023 |
| | Primary (Advocate) Reviewer 2 COI signed | 09/17/2023 | 12/22/2023 |
| | Primary Reviewer 3 COI signed | 09/12/2023 | 12/22/2023 |
| | Primary Reviewer 4 COI signed | 09/12/2023 | 12/22/2023 |
| Peer Review Meeting | Primary Reviewer 1 critique submitted | 11/12/2023 | 12/22/2023 |
| | Primary (Advocate) Reviewer 2 critique submitted | 11/12/2023 | 12/22/2023 |
| | Primary Reviewer 3 critique submitted | 11/15/2023 | 12/22/2023 |
| | Primary Reviewer 4 critique submitted | 10/31/2023 | 12/22/2023 |
| | COI indicated by non-primary reviewer | NONE | 12/22/2023 |
| | COI recused from participation | N/A | 12/22/2023 |
| | Discussed at Peer Review Meeting | YES | 12/22/2023 |
| | Peer Review Meeting | 12/05/2023 | 12/22/2023 |
| | Peer Review Meeting end date | 12/06/2023 | 12/22/2023 |
| | Post review statements signed | 12/06/2023 | 12/22/2023 |
| Final PRC Recommendation | Third Party Observer Report | 12/12/2023 | 01/29/2024 |
| | Score report delivered to CPO | 12/11/2023 | 12/22/2023 |
| | Recommended for PRC review | YES | 12/22/2023 |
| | COI indicated by PRC member | NONE | 01/12/2024 |
| | COI recused from participation | N/A | 01/12/2024 |
| | PRC Meeting | 01/12/2024 | 01/12/2024 |
| PIC Review | Third Party Observer Report | 01/17/2024 | 01/18/2024 |
| | Recommended for grant award | YES | 01/12/2024 |
| | PRC Chair Notification to PIC and OC | 01/18/2024 | 01/18/2024 |
| | COI indicated by PIC member | None | 02/07/2024 |
| | COI recused from participation | N/A | 02/07/2024 |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 |
| Oversight Committee Approval | Recommended for grant award | YES | 02/07/2024 |
| | CEO Notification to Oversight Committee | N/A | |
| | COI Indicated by Oversight Committee member | N/A | |
| | COI Recused from participation | N/A | |
| | Donation(s) made to CPRIT / foundation | N/A | |
| | Presented to CPRIT Oversight Committee | N/A | |
| | Award approved by Oversight Committee | N/A | |
| | Authority to advance funds requested | N/A | |
| | Advance authority approved by Oversight Committee | N/A | |
| | Comments: | | |
| Comment | | | Created Date |
| No Comment | | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP240041
Primary Prevention of Cancer

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Primary Prevention of Cancer* Request for Applications (RFA). CPRIT received 13 applications in response to this RFA, including one withdrawn application. This application was assigned to the Prevention Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 8th day of February, 2024, by WAYNE R. ROBERTS.



 Sandra Reyes
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:55 AM CT

| FY: | 2024 | | |
|------------------------------|---|------------------------------------|------------------|
| CYCLE: | 1 | | |
| PROGRAM: | Prevention | | |
| MECHANISM: | Primary Prevention of Cancer | | |
| APPLICATION ID: | PP240041 | | |
| APPLICATION TITLE: | Expansion of the evidence-based Adolescent Vaccination Program (AVP) in a safety net clinic system to increase HPV vaccination rates in underserved | | |
| APPLICANT NAME: | Shegog, Ross | | |
| ORGANIZATION: | The University of Texas Health Science Center at Houston | | |
| PANEL NAME: | 24.1 Prevention Panel-1 | | |
| Category | Compliance Requirement | Information | Attestation Date |
| Pre-Receipt | RFA Approved by CPO | 04/28/2023 | 12/21/2023 |
| | RFA published in Texas.gov eGrants | 05/05/2023 | 12/21/2023 |
| | CPRIT Application Receipt System (CARS) opened | 06/01/2023 | 12/21/2023 |
| | CPRIT Application Receipt System (CARS) closed | 08/30/2023 | 12/21/2023 |
| | Date application submitted | 08/30/2023 | 12/22/2023 |
| | Method of submission | CARS | 12/22/2023 |
| | Within receipt period | YES | 12/22/2023 |
| | Request for extension to submit application after CARS closed | N/A | 12/22/2023 |
| | Request for extension for late application submission accepted | N/A | 12/22/2023 |
| | Receipt, Referral, and Assignment | Administrative review notification | 09/13/2023 |
| | Donation(s) made to CPRIT / foundation | NO | 12/22/2023 |
| | Assigned to primary reviewers | 09/25/2023 | 12/22/2023 |
| | Applicant notified of review panel assignment | 09/25/2023 | 12/22/2023 |
| | Primary Reviewer 1 COI signed | 09/13/2023 | 12/22/2023 |
| | Primary (Advocate) Reviewer 2 COI signed | 09/12/2023 | 12/22/2023 |
| | Primary Reviewer 3 COI signed | 09/12/2023 | 12/22/2023 |
| | Primary Reviewer 4 COI signed | 09/13/2023 | 12/22/2023 |
| Peer Review Meeting | Primary Reviewer 1 critique submitted | 11/06/2023 | 12/22/2023 |
| | Primary (Advocate) Reviewer 2 critique submitted | 11/10/2023 | 12/22/2023 |
| | Primary Reviewer 3 critique submitted | 10/25/2023 | 12/22/2023 |
| | Primary Reviewer 4 critique submitted | 11/11/2023 | 12/22/2023 |
| | COI indicated by non-primary reviewer | NONE | 12/22/2023 |
| | COI recused from participation | N/A | 12/22/2023 |
| | Discussed at Peer Review Meeting | YES | 12/22/2023 |
| | Peer Review Meeting | 12/05/2023 | 12/22/2023 |
| | Peer Review Meeting end date | 12/06/2023 | 12/22/2023 |
| | Post review statements signed | 12/06/2023 | 12/22/2023 |
| Final PRC Recommendation | Third Party Observer Report | 12/12/2023 | 01/29/2024 |
| | Score report delivered to CPO | 12/11/2023 | 12/22/2023 |
| | Recommended for PRC review | YES | 12/22/2023 |
| | COI indicated by PRC member | NONE | 01/12/2024 |
| | COI recused from participation | N/A | 01/12/2024 |
| | PRC Meeting | 01/12/2024 | 01/12/2024 |
| PIC Review | Third Party Observer Report | 01/17/2024 | 01/18/2024 |
| | Recommended for grant award | YES | 01/12/2024 |
| | PRC Chair Notification to PIC and OC | 01/18/2024 | 01/18/2024 |
| | COI indicated by PIC member | None | 02/07/2024 |
| | COI recused from participation | N/A | 02/07/2024 |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 |
| Oversight Committee Approval | Recommended for grant award | YES | 02/07/2024 |
| | CEO Notification to Oversight Committee | N/A | |
| | COI Indicated by Oversight Committee member | N/A | |
| | COI Recused from participation | N/A | |
| | Donation(s) made to CPRIT / foundation | N/A | |
| | Presented to CPRIT Oversight Committee | N/A | |
| | Award approved by Oversight Committee | N/A | |
| | Authority to advance funds requested | N/A | |
| | Advance authority approved by Oversight Committee | N/A | |
| | Comments: | | |
| Comment | | | Created Date |
| No Comment | | | |



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP240042
Cancer Screening and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Cancer Screening and Early Detection* Request for Applications (RFA). CPRIT received 16 applications in response to this RFA, including two withdrawn applications. This application was assigned to the Prevention Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.



This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 8th day of February, 2024,
by WAYNE R. ROBERTS.


Sandra Reyes
Notary Public, State of Texas

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/09/2024 10:55 AM CT

| | | | |
|------------------------------|---|------------------------------------|------------------|
| FY: | 2024 | | |
| CYCLE: | 1 | | |
| PROGRAM: | Prevention | | |
| MECHANISM: | Cancer Screening and Early Detection | | |
| APPLICATION ID: | PP240042 | | |
| APPLICATION TITLE: | Cancer Prevention and Outreach for Individuals Disproportionately Affected by Cancer in Medically Underserved Regions (C-CUR) | | |
| APPLICANT NAME: | Esnola , Nestor | | |
| ORGANIZATION: | The Methodist Hospital Research Institute | | |
| PANEL NAME: | 24.1 Prevention Panel-1 | | |
| Category | Compliance Requirement | Information | Attestation Date |
| Pre-Receipt | RFA Approved by CPO | 04/28/2023 | 12/21/2023 |
| | RFA published in Texas.gov eGrants | 05/05/2023 | 12/21/2023 |
| | CPRIT Application Receipt System (CARS) opened | 06/01/2023 | 12/21/2023 |
| | CPRIT Application Receipt System (CARS) closed | 08/30/2023 | 12/21/2023 |
| | Date application submitted | 08/30/2023 | 12/22/2023 |
| | Method of submission | CARS | 12/22/2023 |
| | Within receipt period | YES | 12/22/2023 |
| | Request for extension to submit application after CARS closed | N/A | 12/22/2023 |
| | Request for extension for late application submission accepted | N/A | 12/22/2023 |
| | Receipt, Referral, and Assignment | Administrative review notification | N/A |
| | Donation(s) made to CPRIT / foundation | NO | 12/22/2023 |
| | Assigned to primary reviewers | 09/25/2023 | 12/22/2023 |
| | Applicant notified of review panel assignment | 09/25/2023 | 12/22/2023 |
| | Primary Reviewer 1 COI signed | 09/17/2023 | 12/22/2023 |
| | Primary (Advocate) Reviewer 2 COI signed | 09/19/2023 | 12/22/2023 |
| | Primary Reviewer 3 COI signed | 09/20/2023 | 12/22/2023 |
| | Primary Reviewer 4 COI signed | 09/18/2023 | 12/22/2023 |
| Peer Review Meeting | Primary Reviewer 1 critique submitted | 11/12/2023 | 12/22/2023 |
| | Primary (Advocate) Reviewer 2 critique submitted | 11/13/2023 | 12/22/2023 |
| | Primary Reviewer 3 critique submitted | 11/14/2023 | 12/22/2023 |
| | Primary Reviewer 4 critique submitted | 11/09/2023 | 12/22/2023 |
| | COI indicated by non-primary reviewer | NONE | 12/22/2023 |
| | COI recused from participation | N/A | 12/22/2023 |
| | Discussed at Peer Review Meeting | YES | 12/22/2023 |
| | Peer Review Meeting | 12/05/2023 | 12/22/2023 |
| | Peer Review Meeting end date | 12/06/2023 | 12/22/2023 |
| | Post review statements signed | 12/06/2023 | 12/22/2023 |
| Final PRC Recommendation | Third Party Observer Report | 12/12/2023 | 01/29/2024 |
| | Score report delivered to CPO | 12/11/2023 | 12/22/2023 |
| | Recommended for PRC review | YES | 12/22/2023 |
| | COI indicated by PRC member | NONE | 01/12/2024 |
| | COI recused from participation | N/A | 01/12/2024 |
| | PRC Meeting | 01/12/2024 | 01/12/2024 |
| PIC Review | Third Party Observer Report | 01/17/2024 | 01/18/2024 |
| | Recommended for grant award | YES | 01/12/2024 |
| | PRC Chair Notification to PIC and OC | 01/18/2024 | 01/18/2024 |
| | COI indicated by PIC member | None | 02/07/2024 |
| | COI recused from participation | N/A | 02/07/2024 |
| | PIC Review Meeting | 02/07/2024 | 02/07/2024 |
| Oversight Committee Approval | Recommended for grant award | YES | 02/07/2024 |
| | CEO Notification to Oversight Committee | N/A | |
| | COI Indicated by Oversight Committee member | N/A | |
| | COI Recused from participation | N/A | |
| | Donation(s) made to CPRIT / foundation | N/A | |
| | Presented to CPRIT Oversight Committee | N/A | |
| | Award approved by Oversight Committee | N/A | |
| | Authority to advance funds requested | N/A | |
| | Advance authority approved by Oversight Committee | N/A | |
| | Comments: | | |
| Comment | | | Created Date |
| No Comment | | | |